



20.10.2023

10:15 - 11:45	<p>Type: Industry Satellite Symposium Title: AstraZeneca - Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates Chair(s): Javier Cortés, ES</p>	<p>Salamanca Auditorium - Hall 3</p>
10:15 - 10:20	<p>Welcome and Introduction <u>J. Cortés</u>, Hospital Ruber Internacional, Madrid, ES</p>	
10:20 - 10:45	<p>Antibody-Drug Conjugates for HR-Positive Breast Cancer: Where Are We Today? <u>P. Fasching</u>, University Hospital Erlangen, Erlangen, DE</p>	
10:45 - 11:10	<p>Next-Generation Antibody-Drug Conjugates in Practice: A Case-Based Discussion <u>S. Hurvitz</u>, University of Washington, Seattle, US</p>	
11:10 - 11:30	<p>New Antibody-Drug Conjugates on the Horizon <u>P. Schmid</u>, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB</p>	
11:30 - 11:40	<p>Audience Q&A <u>J. Cortés</u>¹, <u>P. Fasching</u>², <u>S. Hurvitz</u>³, <u>P. Schmid</u>⁴, ¹Hospital Ruber Internacional, Madrid, ES, ²University Hospital Erlangen, Erlangen, DE, ³University of Washington, Seattle, US, ⁴Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB</p>	
11:40 - 11:45	<p>Concluding Remarks <u>J. Cortés</u>, Hospital Ruber Internacional, Madrid, ES</p>	



10:15 - 11:45	Type: Industry Satellite Symposium Title: Seagen - HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift? Chair(s): Salvatore Siena, IT	Málaga Auditorium - Hall 10
10:15 - 10:20	Welcome and Introduction <u>S. Siena</u> , UNIMI - Università degli Studi di Milano Statale, Milan, IT	
10:20 - 10:35	HER2 as an Actionable Target in HER2+ mCRC <u>K. Ng</u> , Dana Farber Cancer Institute, Boston, US	
10:35 - 10:55	The Role of HER2 Testing in mCRC <u>R. Adams</u> , Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB	
10:55 - 11:15	Exploring New Opportunities to Improve Outcomes in Patients with HER2+ mCRC <u>S. Siena</u> , UNIMI - Università degli Studi di Milano Statale, Milan, IT	
11:15 - 11:40	Panel Discussion and Interactive Q&A <u>S. Siena</u> ¹ , <u>K. Ng</u> ² , <u>R. Adams</u> ³ , ¹ UNIMI - Università degli Studi di Milano Statale, Milan, IT, ² Dana Farber Cancer Institute, Boston, US, ³ Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB	
11:40 - 11:45	Closing Remarks <u>S. Siena</u> , UNIMI - Università degli Studi di Milano Statale, Milan, IT	



10:15 - 11:40 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 9**
Title: Deciphera - Expert perspectives: management of advanced GIST -now and in the future
Chair(s): Cesar Serrano, ES

10:15 - 10:20 **Welcome and introduction**
C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

10:20 - 10:40 **Overview of advanced GIST: understanding the pathogenesis for this rare cancer**
A. Napolitano, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

10:40 - 11:00 **Reviewing advanced GIST management and addressing current challenges to care**
S. Watson, Institut Curie, Paris, FR

11:00 - 11:20 **Individualising treatment, ctDNA and future advanced GIST management**
C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

11:20 - 11:40 **Discussion and conclusions**
C. Serrano, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES



10:15 - 11:45	Type: Industry Satellite Symposium Title: Astellas Pharma Europe Ltd - The evolving treatment landscape in LA/mUC Chair(s): Ignacio Duran Martinez, ES	Toledo Auditorium - Hall 3
10:15 - 10:20	Housekeeping and introductions <u>I. Duran Martinez</u> , HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES	
10:20 - 10:30	First-line therapy for patients with LA/mUC: The transformation of the treatment landscape and current unmet needs <u>I. Duran Martinez</u> , HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES	
10:30 - 10:50	Overview of current trials investigating first-line treatment of LA/mUC <u>T. Friedlander</u> , UCSF - University of California San Francisco, San Francisco, US	
10:50 - 11:30	Clinical experiences with first-line treatment of LA/mUC <u>F. Schlürmann</u> ¹ , <u>T. Friedlander</u> ² , ¹ CHRU Brest - Hopital Augustin Morvan, Brest, FR, ² UCSF - University of California San Francisco, San Francisco, US	
11:30 - 11:40	Panel discussion <u>I. Duran Martinez</u> ¹ , <u>F. Schlürmann</u> ² , <u>T. Friedlander</u> ³ , ¹ HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES, ² CHRU Brest - Hopital Augustin Morvan, Brest, FR, ³ UCSF - University of California San Francisco, San Francisco, US	
11:40 - 11:45	Summary and close <u>I. Duran Martinez</u> , HUMV - Hospital Universitario Marques de Valdecilla, Santander, ES	



10:15 - 11:45	Type: Industry Satellite Symposium	Oviedo
	Title: Bristol Myers Squibb - Immuno-Oncology Landscape for GI Cancers: Perspectives on Current Practices and Recent Advances	Auditorium - Hall 7
	Chair(s): John Bridgewater, GB	
10:15 - 10:20	Immuno-Oncology Landscape for GI Cancers: Perspectives on Current Practices and Recent Advances	
	<u>J. Bridgewater</u> , UCL Cancer Institute - Paul O'Gorman Building, London, GB	
10:20 - 10:40	Immunotherapeutic Advances in the Treatment of Esophageal Cancer	
	<u>P. Thuss-Patience</u> , Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE	
10:40 - 11:00	Update on Immuno-Oncology for the Treatment of Gastric Cancer	
	<u>T. Fleitas</u> , Hospital Clinico Universitario de Valencia, Valencia, ES	
11:00 - 11:20	Advances in Immuno-Oncology for the Treatment of Colorectal Cancer	
	<u>M.E. Elez Fernandez</u> , Vall d'Hebron University Hospital, Barcelona, ES	
11:20 - 11:40	Roundtable Case Discussion, Q&A	
	<u>J. Bridgewater</u> ¹ , <u>M.E. Elez Fernandez</u> ² , <u>P. Thuss-Patience</u> ³ , <u>T. Fleitas</u> ⁴ , ¹ UCL Cancer Institute - Paul O'Gorman Building, London, GB, ² Vall d'Hebron University Hospital, Barcelona, ES, ³ Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, DE, ⁴ Hospital Clinico Universitario de Valencia, Valencia, ES	
11:40 - 11:45	Summary and Close	
	<u>J. Bridgewater</u> , UCL Cancer Institute - Paul O'Gorman Building, London, GB	



10:15 - 11:45	Type: Industry Satellite Symposium Title: Servier - Are brain cancer patients finally able to benefit from precision medicine approaches? Chair(s): Carmen Balana, ES	León Auditorium - Hall 7
10:15 - 10:25	Introduction: The Sword of Damocles hanging over each patient <u>C. Balana</u> , ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES	
10:25 - 10:45	IDH Mutated Glioma: A Decade's journey from bench to bedside <u>T. Cloughesy</u> , Ronald Reagan UCLA Medical Center University of California, Los Angeles, US	
10:45 - 11:00	Connecting the dots: Understanding recent clinical evidence in the framework of previous studies and current practice <u>M. Van Den Bent</u> , Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL	
11:00 - 11:15	The evolving paradigm for clinical management of glioma <u>S. Erridge</u> , Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, GB	
11:15 - 11:30	Navigating the paradigm shift: Thriving in the new era glioma care <u>G. Tabatabai</u> , Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE	
11:30 - 11:45	Q&A Session <u>C. Balana</u> ¹ , <u>G. Tabatabai</u> ² , <u>T. Cloughesy</u> ³ , <u>M. Van Den Bent</u> ⁴ , <u>S. Erridge</u> ⁵ , ¹ ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ² Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE, ³ Ronald Reagan UCLA Medical Center University of California, Los Angeles, US, ⁴ Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL, ⁵ Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, GB	



12:00 - 13:45 **Type: Opening session** **Madrid Auditorium - Hall 6**
Title: Opening session

12:00 - 12:17 **Welcome and Presidential address**
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

12:17 - 12:22 **Scientific Chair address**
S. Gillessen, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

12:22 - 12:27 **Presentation of the ESMO awards 2023**

12:27 - 12:46 **ESMO Award 2023**
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

12:46 - 13:05 **ESMO Award for Translational Research 2023**
N. Turner, The Royal Marsden Hospital - Chelsea, London, GB

13:05 - 13:24 **ESMO Women for Oncology Award 2023**
G. Long, University of Sydney, Sydney, AU

13:24 - 13:43 **ESMO Lifetime Achievement Award 2023**
A.T.C. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

13:43 - 13:45 **Closure of the Opening Ceremony**
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

14:00 - 15:40 **Type: Proffered Paper session** **Barcelona Auditorium**
Title: Proffered Paper session 1 - Gastrointestinal **- Hall 9**
tumours, upper digestive

Chair(s): Elizabeth Smyth, GB; Magnus Nilsson, SE

14:00 - 14:10 **LBA74 - Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The Phase 3 KEYNOTE-585 study**
K. Shitara¹, S.Y. Rha², L. Wyrwicz³, T. Oshima⁴, N. Karaseva⁵, M. Osipov⁶, H. Yasui⁷, H. Yabusaki⁸, S. Afanasyev⁹, Y.-K. Park¹⁰, S.-E. Al-Batran¹¹, T. Yoshikawa¹², P. Yanez Weber¹³, M. Di Bartolomeo¹⁴, S. Lonardi¹⁵, X. Fang¹⁶, C.-S. Shih¹⁶, P. Bhagia¹⁶, Y.-J. Bang¹⁷, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Yonsei Cancer Center, Yonsei University Health System & Songdang Institute for Clinical Research, Seoul, KR, ³Maria Sklodowska-Curie National Cancer Research Institute, Warsaw, PL, ⁴Kanagawa Cancer Center, Yokohama, JP, ⁵SPb SBHI Clinical Oncology Dispensary, Saint-Petersburg, RU, ⁶Leningrad Regional Clinical Hospital, Saint-Petersburg, RU, ⁷Kobe City Medical Center General Hospital, Kobe, JP, ⁸Niigata Cancer Center Hospital, Niigata, JP, ⁹Cancer Research Institute, Siberian Branch of the Russian Academy of Medical Sciences, Tomsk,



RU, ¹⁰Chonnam National University Hwasun Hospital, Hwasun, KR, ¹¹Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, DE, ¹²National Cancer Center Hospital, Tokyo, JP, ¹³Universidad de La Frontera, James Lind Cancer Research Center, Temuco, CL, ¹⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹⁵IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Seoul National University College of Medicine, Seoul, KR

14:10 - 14:20

LBA73 - Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): interim results of the global, Phase 3 MATTERHORN study

Y. Janjigian¹, S.-E. Al-Batran², Z. Wainberg³, E. Van Cutsem⁴, D. Molena¹, K. Muro⁵, W.J. Hyung⁶, L. Wyrwicz⁷, D.-Y. Oh⁸, T. Omori⁹, M. Moehler¹⁰, M. Garrido¹¹, S. Cunha Sousa Oliveira¹², M. Liberman¹³, V. Castro Oviden¹⁴, M. Bilici¹⁵, J. Kurland¹⁶, I. Xynos¹⁷, H. Mann¹⁷, J. Tabernero¹⁸, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Krankenhaus Nordwest, University Cancer Center, Frankfurt, DE, ³David Geffen School of Medicine at UCLA, Los Angeles, US, ⁴University Hospitals Leuven and KU Leuven, Leuven, BE, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶Yonsei University College of Medicine, Seoul, KR, ⁷Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁸Seoul National University Hospital; Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ⁹Osaka International Cancer Institute, Osaka, JP, ¹⁰Johannes Gutenberg-University Clinic, Mainz, DE, ¹¹SAGA Clinical Trial Centre and Universidad Mayor, Santiago, CL, ¹²Northern Riograndense League Against Cancer, Natal, Rio Grande do Norte, BR, ¹³Centre Hospitalier de l'Université de Montréal, Centre de Recherche du CHUM, Montreal, CA, ¹⁴National Institute of Neoplastic Diseases (INEN), Lima, PE, ¹⁵Atatürk University Faculty of Medicine, Erzurum, TR, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸Vall d'Hebron Hospital Campus & Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, ES

14:20 - 14:30

Invited Discussant LBA74 and LBA73

E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB

14:30 - 14:40

Q&A

14:40 - 14:50

LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial

B. Van Der Wilk¹, B.M. Eyck¹, B. Wijnhoven², S. Lagarde³, C. Rosman⁴, B.J. Noordman⁵, M. Valkema¹, P.-P. Coene⁶, J.-W. Dekker⁷, H. Hartgrink⁸, J. Heisterkamp⁹, E. Kouwenhoven¹⁰, G. Nieuwenhuijzen¹¹, J.-P. Pierie¹², J. Van Sandick¹³, M. Sosef¹⁴, M. Spaander², E. Van Der Zaag¹⁵, E. Steyerberg⁸, J. Van Lanschot¹, ¹Erasmus MC - Erasmus University Rotterdam, Rotterdam, NL, ²Erasmus MC, Rotterdam, NL, ³Erasmus Medical Center, Rotterdam, NL, ⁴Radboud University Medical Center, Nijmegen, NL, ⁵Erasmus University Medical Center, Rotterdam, NL, ⁶Maasstad Ziekenhuis, Rotterdam, NL, ⁷Reinier de Graaf Hospital (Gasthuis), Delft, NL, ⁸LUMC-Leiden University Medical Center, Leiden, NL, ⁹ETZ - Elisabeth-TweeSteden Hospital, Tilburg, NL,



¹⁰Ziekenhuisgroep Twente (ZGT), Almelo, NL, ¹¹Catharina Hospital Eindhoven, Eindhoven, NL, ¹²MCL - Medisch Centrum Leeuwarden, Leeuwarden, NL, ¹³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹⁴Zuyderland Medical Center, Heerlen, NL, ¹⁵Gelre Ziekenhuizen, Apeldoorn, NL

14:50 - 15:00 **Invited Discussant LBA75**

M. Nilsson, Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE

15:00 - 15:10 **Q&A**

15:10 - 15:20 **15110 - Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study**

Y. Janjigian¹, A. Kawazoe², Y. Bai³, J. Xu⁴, S. Lonardi⁵, J.-P. Metges⁶, P. Yanez Weber⁷, L. Wyrwicz⁸, L. Shen⁹, Y. Ostapenko¹⁰, M. Bilici¹¹, H.C. Chung¹², K. Shitara¹³, S. Qin¹⁴, E. Van Cutsem¹⁵, J. Tabernero¹⁶, K. Li¹⁷, C.-S. Shih¹⁸, P. Bhagia¹⁸, S.Y. Rha¹², ¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ²National Cancer Center Hospital East, Kashiwa, JP, ³Harbin Medical University Hospital, Harbin, CN, ⁴Fifth Medical Center, Chinese PLA General Hospital, Beijing, CN, ⁵Istituto Oncologico Veneto IOV-IRCCS, Padova, IT, ⁶University Hospital of Brest, Brest, FR, ⁷Universidad de La Frontera, James Lind Cancer Research Center, Temuco, CL, ⁸Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, PL, ⁹Peking University Cancer Hospital & Institute, Beijing, CN, ¹⁰Clinic of National Cancer Institute, Kyiv, UA, ¹¹Atatürk University, Erzurum, TR, ¹²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ¹³National Cancer Hospital East, Kashiwa, JP, ¹⁴Cancer Center of People's Liberation Army, Nanjing, CN, ¹⁵University Hospitals Gasthuisberg and KU Leuven, Leuven, BE, ¹⁶Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, ES, ¹⁷Merck & Co. Inc., Rahway, US, ¹⁸Merck & Co., Inc., Rahway, US

15:20 - 15:30 **Invited Discussant 15110**

F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE

15:30 - 15:40 **Q&A**

14:00 - 15:45 **Type: Proffered Paper session** **Sevilla Auditorium**
Title: Proffered Paper session - Non-metastatic NSCLC and **- Hall 9**
other thoracic malignancies
 Chair(s): Rafal Dziadziuszko, PL; Fiona Blackhall, GB

14:00 - 14:10 **12610 - Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial**



M. Awad¹, P. Forde², N. Girard³, J. Spicer⁴, C. Wang⁵, S. Lu⁶, T. Mitsudomi⁷, E. Felip⁸, S. Broderick², S.J. Swanson¹, J. Brahmer², K. Kerr⁹, G. Saylor¹⁰, K.-N. Chen¹¹, J.L. Cai¹², J. Mahmood¹², J. Neely¹², D. Balli¹², N. Hu¹², M. Provencio Pulla¹³, ¹Dana-Farber Cancer Institute, Boston, US, ²The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ³Institut Curie, Paris, FR, ⁴McGill University Health Centre, Montreal, CA, ⁵Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ⁶Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN, ⁷Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, JP, ⁸Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁹Aberdeen Royal Infirmary, Aberdeen, GB, ¹⁰Charleston Oncology, Charleston, US, ¹¹Peking University School of Oncology, Beijing Cancer Hospital, Beijing, CN, ¹²Bristol Myers Squibb, Princeton, US, ¹³Hospital Universitario Puerta de Hierro, Madrid, ES

14:10 - 14:20

LBA56 - Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)

J. Spicer¹, S. Gao², M. Liberman³, T. Kato⁴, M. Tsuboi⁵, S.-H. Lee⁶, K.-N. Chen⁷, C. Dooms⁸, M. Majem⁹, E. Eigendorff¹⁰, G. Martinengo¹¹, O. Bylicki¹², M. Garassino¹³, D. Rodriguez Abreu¹⁴, J. Chaft¹⁵, S. Novello¹⁶, J. Yang¹⁷, S. Keller¹⁸, A. Samkari¹⁸, H. Wakelee¹⁹, ¹McGill University, Montréal, CA, ²National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ³Centre Hospitalier de Université de Montréal (CHUM), Montreal, CA, ⁴Kanagawa Cancer Center, Yokohama, JP, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, KR, ⁷Peking University Cancer Hospital and Institute, Beijing, CN, ⁸UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹⁰Zentralklinik Bad Berka GmbH, Bad Berka, DE, ¹¹Sanatorio Parque, Rosario, AR, ¹²Hôpital d'Instruction des Armées Sainte Anne Toulon, Toulon, Cedex, FR, ¹³Knapp Center for Biomedical Discovery, The University of Chicago, Chicago, US, ¹⁴Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES, ¹⁵Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, US, ¹⁶University of Turin, A.O.U. San Luigi Gonzaga di Orbassano, Orbassano, IT, ¹⁷Merck & Co., Inc. - Rahway, Rahway, US, ¹⁸Merck & Co., Inc., Rahway, US, ¹⁹Stanford University School of Medicine, Stanford Cancer Institute, Stanford, US

14:20 - 14:30

Invited Discussant 12610 and LBA56

J. Naidoo, Beaumont Hospital, Dublin, IE

14:30 - 14:35

Q&A

14:35 - 14:45

LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer

Z.-R. Zhao¹, S. Liu², T. Zhou¹, G. Chen¹, Z.-H. Ye³, Z.-C. Li¹, J.-D. Wu¹, Y. Yang¹, M. Xi¹, Y.-B. Lin¹, H. Yang¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen



University Cancer Center, Guangzhou, CN, ³The University of Hong Kong - Shenzhen Hospital, Shenzhen, CN

- 14:45 - 14:55 **12910 - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial**
- P. Vera¹, F. Le Tinier², P. Chaumet-Riffaud³, E. Martin⁴, N. Pourel⁵, P. Boisselier⁶, N. Salem⁷, C. Le Pechoux⁸, E. Giroux-Leprieur⁹, S. Guillermin¹⁰, C. Audigier Valette¹¹, D. Lerouge¹², C. Massabeau¹³, P. Moisson¹⁴, A. Larrouy¹⁵, S. Hapdey¹, A. Langlais¹⁶, E. Amour¹⁶, G. Zalcman¹⁷, P. Giraud¹⁸, S. Thureau¹, ¹Centre Henri Becquerel, ROUEN, FR, ²Centre Oscar Lambret, Lille, FR, ³Hôpital National des 15-20, Paris, FR, ⁴Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁵Institut Sainte-Catherine, Avignon, Cedex, FR, ⁶ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁷Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁸Institut Gustave Roussy, Villejuif, Cedex, FR, ⁹University Paris-Saclay, UVSQ, APHP - Ambroise Paré Hospital, Boulogne-Billancourt, FR, ¹⁰Université Paris Cité, Assistance Publique - Hôpitaux de Paris, Paris, FR, ¹¹CHITS Toulon Sainte-Musse, Toulon, FR, ¹²Centre François Baclesse, Caen, Cedex, FR, ¹³Institut Claudius Regaud - IUCT Oncopole, Toulouse, Cedex, FR, ¹⁴Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, ¹⁵ICPN - Centre de Cancerologie Paris Nord, Sarcelles, FR, ¹⁶French Cooperative Thoracic Intergroup, Paris, FR, ¹⁷Hopital Bichat - Claude-Bernard AP-HP, Paris, FR, ¹⁸HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR
- 14:55 - 15:05 **Invited Discussant LBA60 and 12910**
- R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL
- 15:05 - 15:10 **Q&A**
- 15:10 - 15:20 **LBA98 - Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVANT phase II trial**
- C. Proto¹, S. Manglaviti¹, G. Galli¹, M. Imbimbo², M.F. Alvisi³, F. Zollo³, M. Perrino⁴, M. Giuliano⁵, E. Pietrolungo⁵, Z. Ballatore⁶, A. Chella⁷, A. Fabbri¹, R. Vigorito¹, F.G.M. De Braud⁸, G. Pasello⁹, I. Petrini⁷, R. Berardi¹⁰, P. Zucali⁴, M. Ganzinelli¹, M. Garassino¹¹, G. Lo Russo¹, ¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ²Fondazione IRCCS Istituto Nazionale dei Tumori, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ³Istituto Di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, IT, ⁴IRCCS Humanitas Research Hospital, Rozzano, IT, ⁵AOU "Federico II", Napoli, IT, ⁶AOU delle Marche, Torrette di Ancona, IT, ⁷AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ⁸Fondazione IRCCS Istituto Nazionale dei Tumori, Università di Milano, Milan, IT, ⁹University of Padova Medical School, Padova, Italy; Medical Oncology 2, Veneto Institute of Oncology IOV-IRCCS, Padova, IT, ¹⁰Università Politecnica delle Marche, AOU delle Marche, Ancona, IT, ¹¹Fondazione IRCCS Istituto Nazionale dei Tumori, The University of Chicago, Chicago, US
- 15:20 - 15:30 **LBA92 - Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase 2 DeLLphi-301 study**



L. Paz-Ares¹, M.-J. Ahn², E. Felip³, S. Handzhiev⁴, I. Korantzis⁵, H. Izumi⁶, K. Ohashi⁷, M. Majem⁸, J. Wolf⁹, M. Reck¹⁰, H.-D. Hummel¹¹, F. Blackhall¹², A.-M. Dingemans¹³, T. Owonikoko¹⁴, S. Ramalingam¹⁵, J. Sands¹⁶, T. Jiang¹⁷, S. Mukherjee¹⁷, E. Anderson¹⁷, B.C. Cho¹⁸, ¹Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO-H12o Lung Cancer Unit and Ciberonc, Madrid, ES, ²Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Universitätsklinikum Krems, Krems an der Donau, AT, ⁵St Luke's Hospital-Agios Loukas Clinic, Thessaloniki, GR, ⁶National Cancer Center Hospital East, Kashiwa, JP, ⁷Okayama University Hospital, Okayama, JP, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁹Universitätsklinikum Köln (AöR), Cologne, DE, ¹⁰Airway Research Center North, German Center for Lung Research, LungenClinic Grosshansdorf, Grosshansdorf, DE, ¹¹Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken, Wuerzburg, DE, ¹²The Christie NHS Foundation Trust, Manchester, GB, ¹³Erasmus MC Cancer Institute, University Medical Center, Rotterdam, NL, ¹⁴UPMC Hillman Cancer Center, Pittsburgh, US, ¹⁵Winship Cancer Institute of Emory University, Atlanta, US, ¹⁶Dana-Farber Cancer Institute, Harvard Medical School, Boston, US, ¹⁷Amgen Inc., Thousand Oaks, US, ¹⁸Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, KR

15:30 - 15:40 **Invited Discussant LBA98 and LBA92**

P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

15:40 - 15:45 **Q&A**

14:00 - 15:40	Type: Proffered Paper session Title: Proffered Paper session - Breast cancer, early stage Chair(s): Stephen Johnston, GB; Sara Tolaney, US	Bilbao Auditorium - NCC
---------------	--	--------------------------------

14:00 - 14:10 **LBA17 - Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes**

N. Harbeck¹, P. Rastogi², J. O'Shaughnessy³, F. Boyle⁴, J. Cortés⁵, H. Rugo⁶, M. Goetz⁷, E. Hamilton⁸, C. Huang⁹, E. Senkus-Konefka¹⁰, A. Tryakin¹¹, P. Neven¹², J. Huober¹³, R.J. Wei¹⁴, V. Andre¹⁴, M. Muñoz¹⁴, B. San Antonio¹⁴, A. Shahir¹⁴, M. Martin Jimenez¹⁵, S. Johnston¹⁶, ¹Ludwig Maximilians University Hospital, Munich, DE, ²University of Pittsburgh Medical Center, Pittsburgh, US, ³Baylor University Medical Center, Dallas, US, ⁴University of Sydney, Sydney, AU, ⁵Hospital Ruber Internacional, Madrid, ES, ⁶UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁷Mayo Clinic, Rochester, US, ⁸Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁹NTUH - National Taiwan University Hospital, Taipei City, TW, ¹⁰Medical University of Gdansk, Gdansk, PL, ¹¹Altai Branch of N. N. Blokhin Russian Cancer Research Centre, Barnaul, RU, ¹²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹³Kantonsspital St. Gallen, St. Gallen, CH, ¹⁴Eli Lilly and Company, Indianapolis, US, ¹⁵Gregorio Marañón General University Hospital, Madrid, ES, ¹⁶Royal Marsden NHS Foundation Trust, London, GB

14:10 - 14:20 **LBA18 - Pembrolizumab or placebo plus chemotherapy followed by**



pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study

P. Schmid¹, J. Cortés², R. Dent³, L. Pusztai⁴, H. Mcarthur⁵, S. Kummel⁶, C. Denkert⁷, Y.H. Park⁸, R. Hui⁹, N. Harbeck¹⁰, M. Takahashi¹¹, T. Foukakis¹², M.A. Mouret Reynier¹³, M. Ferreira¹⁴, S.-A. Im¹⁵, F. Cardoso¹⁶, Y. Ding¹⁷, W. Pan¹⁷, K. Tryfonidis¹⁷, J. O'Shaughnessy¹⁸, ¹Barts Cancer Institute, Queen Mary University of London, London, GB, ²Quironsalud Group, Barcelona, Spain and Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, ES, ³Duke - National University of Singapore Medical School, Singapore, SG, ⁴Yale Cancer Center, New Haven, US, ⁵University of Texas Southwestern Medical Center, Dallas, US, ⁶Kliniken Essen-Mitte, Essen, Germany and Charité - Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, DE, ⁷Philipps-University Marburg and University Hospital Marburg, Marburg, DE, ⁸Sungkyunkwan University School of Medicine, Seoul, KR, ⁹Westmead Hospital and the University of Sydney, Sydney, NSW, Australia and Centre of Cancer Medicine, School of Clinical Medicine, University of Hong Kong, Hong Kong, HK, ¹⁰LMU University Hospital, Munich, DE, ¹¹Hokkaido University Hospital, Sapporo, JP, ¹²Karolinska Institutet and Breast Cancer Centre, Cancer theme, Karolinska University Hospital, Solna, SE, ¹³Centre Jean Perrin, Clermont-Ferrand, FR, ¹⁴Instituto Português de Oncologia do Porto Francisco Gentil (IPO-Porto), Porto, PT, ¹⁵Seoul National University Hospital, Seoul, KR, ¹⁶Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, PT, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸Texas Oncology, US Oncology Network, Dallas, US

14:20 - 14:30

LBA19 - Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study

L. Gianni¹, C. Huang², D. Egle³, B. Bermejo⁴, C. Zamagni⁵, M. Thill⁶, A. Anton Torres⁷, G. Bianchini⁸, E. Sevillano Fernandez⁹, S. Russo¹⁰, E. Ciruelos¹¹, R. Greil¹², V. Semiglazov¹³, M. Colleoni¹⁴, C. Kelly¹⁵, G. Mariani¹⁶, L. Del Mastro¹⁷, R. Spezia¹, H. Ali¹⁸, G. Viale¹⁴, ¹Fondazione Michelangelo, Milan, IT, ²National Taiwan University Hospital and Taiwan Breast Cancer Consortium, Taipei, TW, ³BrustGesundheitZentrum Tirol, Medical University, Innsbruck, AT, ⁴Hospital Clínico Universitario de Valencia, INCLIVA; Department of Medicine, Universidad de Valencia; CIBERONC-ISCI, Madrid, ES, ⁵IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, ⁶Agaplesion Markus Krankenhaus,, Frankfurt am Main, DE, ⁷Hospital Universitario Miguel Servet Instituto Investigación Sanitaria de Aragon Universidad de Zaragoza, Zaragoza, ES, ⁸IRCCS San Raffaele Hospital, Milan, IT, ⁹Hospital Universitario HM Sanchinarro, Centro Integral Oncológico Clara Campal, Unidad Central de Ensayos Clínicos, Madrid, ES, ¹⁰Azienda Sanitaria Friuli Centrale, Udine, IT, ¹¹Hospital Universitario 12 de octubre, Madrid, ES, ¹²Paracelsus Medical University; Salzburg Cancer Research Institute-CCCIT and Cancer cluster, Salzburg, AT, ¹³NN Petrov Research Inst of Oncology, Saint-Petersburg, RU, ¹⁴IEO Istituto Europeo di Oncologia IRCCS, Milan, IT, ¹⁵Cancer Trials Ireland & Mater Misericordiae University Hospital, Dublin, IE, ¹⁶IRCCS Istituto Nazionale Tumori, Milan, IT, ¹⁷IRCCS Ospedale Policlinico San Martino, Università degli Studi di Genova, Genova, IT, ¹⁸Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, GB

14:30 - 14:45

Invited Discussant LBA17, LBA18 and LBA19

K. Kalinsky, Winship Cancer Institute of Emory University, Atlanta, US



14:45 - 14:55 **Q&A**

14:55 - 15:05 **LBA20 - A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2- primary breast cancer (BC)**

S. Loi¹, G. Curigliano², R. Salgado³, R.I. Romero Diaz⁴, S. Delaloge⁵, C. Rojas⁶, M. Kok⁷, C. Saura Manich⁸, N. Harbeck⁹, E. Mittendorf¹⁰, D. Yardley¹¹, L. Pusztai¹², A. Suarez Zaizar¹³, A. Ungureanu¹⁴, F. Ades¹⁵, R. Chandra¹⁶, R. Nathani¹⁷, M. Pacius¹⁶, J. Wu¹⁶, H. Mcarthur¹⁸, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²European Institute of Oncology, IRCCS; University of Milano, Milan, IT, ³GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE, ⁴Consultorio de Oncólogo Médico, Tlalnepantla de Baz, MX, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶Bradford Hill, Independencia, CL, ⁷Netherlands Cancer Institute, Amsterdam, NL, ⁸Vall d'Hebron University Hospital, Barcelona, ES, ⁹Ludwig Maximilians University Hospital, Munich, DE, ¹⁰Dana Farber/Brigham and Women's Cancer Center, Boston, US, ¹¹Sarah Cannon Research Center and Tennessee Oncology, Chattanooga, US, ¹²Smilow Cancer Hospital at Yale University School of Medicine, New Haven, US, ¹³CENEIT Oncologicos, Ciudad de Mexico, MX, ¹⁴Amethyst Radiotherapy Center Cluj, Floresti, RO, ¹⁵Bristol-Myers Squibb, Lawrenceville, US, ¹⁶BMS - Bristol-Myers Squibb, Cambridge, US, ¹⁷Bristol Myers Squibb, Cambridge, US, ¹⁸University of Texas Southwestern Medical Center, Dallas, US

15:05 - 15:15 **LBA21 - KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2- breast cancer**

F. Cardoso¹, H. Mcarthur², P. Schmid³, J. Cortés⁴, N. Harbeck⁵, M. Telli⁶, D. Cescon⁷, J. O'Shaughnessy⁸, P. Fasching⁹, Z. Shao¹⁰, D. Loirat¹¹, Y.H. Park¹², M. González Fernández¹³, Z. Liu¹⁴, H. Yasojima¹⁵, Y. Ding¹⁶, L. Jia¹⁶, V. Karantza¹⁶, K. Tryfonidis¹⁶, A. Bardia¹⁷, ¹Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, PT, ²University of Texas Southwestern Medical Center, Dallas, US, ³Barts Cancer Institute, Queen Mary University of London, London, GB, ⁴Quironsalud Group, Barcelona, Spain and Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, ES, ⁵LMU University Hospital, Munich, DE, ⁶Stanford University School of Medicine, Stanford, US, ⁷Princess Margaret Cancer Centre, Toronto, CA, ⁸Texas Oncology, US Oncology Network, Dallas, US, ⁹Comprehensive Cancer Center Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Erlangen, DE, ¹⁰Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, CN, ¹¹Institut Curie, Paris, FR, ¹²Sungkyunkwan University School of Medicine, Seoul, KR, ¹³IMAT-Oncomedica, Montería, CO, ¹⁴Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, CN, ¹⁵NHO Osaka National Hospital, Osaka, JP, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Harvard Medical School, Boston, US

15:15 - 15:25 **Invited Discussant LBA20 and LBA21**

S. Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

15:25 - 15:40 **Q&A**



14:00 - 15:30	Type: Educational session Title: Optimising overall survival in advanced renal cancer Chair(s): Cristina Suarez Rodriguez, ES; Thomas Powles, GB	Granada Auditorium - Hall 3
14:00 - 14:25	Evolving frontline treatment paradigms <u>T. Choueiri</u> , Dana Farber Cancer Institute, Boston, US	
14:25 - 14:50	What is the role of localised therapies in metastatic RCC? <u>A. Bex</u> , Royal Free London NHS Foundation Trust, London, GB	
14:50 - 15:15	Data from sequencing trials and new therapeutic targets <u>C. Suarez Rodriguez</u> , Vall d'Hebron University Hospital, Barcelona, ES	
15:15 - 15:30	Discussion	
14:00 - 15:30	Type: Educational session Title: Therapeutic view on tumour immune microenvironment: It's TIME Chair(s): Tanja de Gruijl, NL; Gary Middleton, GB	Burgos Auditorium - Hall 3
14:00 - 14:20	Immune suppressive cell populations in TME <u>V. Bronte</u> , IOV - Istituto Oncologico Veneto IRCCS, Padova, IT	
14:20 - 14:40	Site specific TME <u>W. Zou</u> , Michigan Medicine University of Michigan, Ann Arbor, US	
14:40 - 15:00	How tumour-draining lymph nodes inform the content of the TME and vice versa <u>T. De Gruijl</u> , Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL	
15:00 - 15:20	Modulating TME to overcome primary and acquired resistance <u>S. Zelenay</u> , Cancer Research UK Manchester Institute, Manchester, GB	
15:20 - 15:30	Q&A and Discussion	



14:00 - 15:30 **Type: Educational session** **Salamanca Auditorium**
Title: First-line therapy in advanced melanoma: What is my preferred choice? **- Hall 3**
 Chair(s): Teresa Petrella, CA; Reinhard Dummer, CH

14:00 - 14:25 **My preferred choice is PD-1 monotherapy, and these are the reasons why**
T. Petrella, Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA

14:25 - 14:50 **My preferred choice is combined immunotherapy with PD1+CTLA-4, and these are the reasons why**
A.M. Arance Fernandez, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

14:50 - 15:15 **I prefer the combination of anti-PD-1 and anti-LAG-3, and these are the reasons why**
R. Dummer, USZ - University Hospital Zürich, Zurich, CH

15:15 - 15:30 **Q&A and Discussion**

14:00 - 15:30 **Type: Educational session** **Santander Auditorium - Hall 9**
Title: Neuro-Oncology 101: All you need to know to take care of brain tumour patients
 Chair(s): Matthias Holdhoff, US; Emeline Tabouret, FR

14:00 - 14:20 **WHO classification simplified for the busy clinician**
M. Holdhoff, Johns Hopkins University, Baltimore, US

14:20 - 14:40 **Glioma beyond TMZ/RT**
E. Galanis, Mayo Clinic - Rochester, Rochester, US

14:40 - 15:00 **Brain metastases: When radiation is (not!) indicated**
S. Lukacova, Aarhus University Hospital, Aarhus, DK

15:00 - 15:20 **Supportive care: Antiepileptics, steroids and anticoagulation**
A. Pace, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

15:20 - 15:30 **Q&A and Discussion**



14:00 - 15:30 **Type: Special session** **León Auditorium**
Title: In collaboration with SIOG: Fundamentals in geriatric **- Hall 7**
oncology in clinical practice
Chair(s): Ravindran Kaneshvaran, SG; Etienne Brain, FR

14:00 - 14:20 **Geriatric assessment: It is primetime now?**
L. Biganzoli, Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT

14:20 - 14:40 **Optimizing oncologic care in older patients with advanced lung cancer**
E. Quoix, Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR

14:40 - 15:00 **Optimizing oncologic care in older patients with advanced breast cancer**
E. Brain, Hopital René Huguenin - Institut Curie, Saint-Cloud, FR

15:00 - 15:20 **Optimizing oncologic care in older patients with advanced colorectal cancer**
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY

15:20 - 15:30 **Discussion**



14:00 - 15:30	Type: Patient Advocacy session Title: The importance to address the caregivers' needs: The perspective of the caregivers Chair(s): Bettina Ryll, SE; Katie Rizvi, RO	Cádiz Auditorium - NCC
14:00 - 14:15	Caregiver? Carer? Who are they? <u>S. Yghemonos</u> , Eurocarers, Brussels, BE	
14:15 - 14:30	Caregivers' needs along the patient journey: What do oncologists need to know? <u>B. Ryll</u> , Melanoma Patient Network Europe MPNE, Uppsala, SE	
14:30 - 14:45	Caregivers' needs along the patient journey: What do nurses need to know? <u>K. Rizvi</u> , YCE - Youth Cancer Europe, Cluj-Napoca, RO	
14:45 - 15:00	Caregivers after patient end of life: The caregivers' role continues...as do their needs! <u>S. Chaturvedi</u> , King's College Hospital - NHS Foundation Trust, London, GB	
15:00 - 15:15	Cancer patient groups and their help to support caregivers: Guide for healthcare professionals <u>M. Leal</u> , Portuguese League Against Cancer, Lisbon, PT	
15:15 - 15:25	Discussion	
15:25 - 15:45	Conclusion	



14:00 - 15:30 **Type: Special session** **Ávila Auditorium - NCC**
Title: ESMO-MCBS: 2023 revolution
 Chair(s): Nathan Cherny, IL; Dario Trapani, IT

14:00 - 14:05 **Introduction**
D. Trapani, Università degli Studi di Milano, Milan, IT

14:05 - 14:30 **A guide through the new ESMO-MCBS v2.0**
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

14:30 - 14:55 **ESMO-Magnitude of Clinical Scale for Haematological Malignancies (ESMO-MCBS:H)**
B. Kiesewetter-Wiederkehr, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

14:55 - 15:20 **Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints (SISAQOL-IMI): Two years update**
M. Pe, EORTC, Brussels, BE

15:20 - 15:30 **Conclusions and perspectives, discussion and Q&A**
D. Trapani, Università degli Studi di Milano, Milan, IT

14:15 - 15:00 **Type: Challenge your Expert** **Valencia Auditorium**
Title: First-line treatment of EGFR mutated NSCLC: Choosing between many options **- Hall 10**
 Chair(s): Enriqueta Felip, ES

14:15 - 14:30 **Presentation by Expert EGFR**
Z. Piotrowska, MGH - Massachusetts General Hospital, Boston, US

14:30 - 14:45 **Presentation by Expert ALK**
G. Pasello, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

14:45 - 15:00 **Discussion led by Chair**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES



14:15 - 15:30 **Type: Multidisciplinary session** **Málaga Auditorium - Hall 10**
Title: Integrating locoregional strategies into the management of metastatic breast cancer (mBC) patients
 Chair(s): Lisa Carey, US; Adam Sonabend, US

14:15 - 14:20 **Presentation of case with extra cranial met / condition**
M. Banys-Paluchowski, UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE

14:20 - 14:35 **Integrating locoregional and systemic therapies for non-CNS metastatic disease**
A. Kirby, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

14:35 - 14:40 **Presentation of case with CNS met / condition**
A. Fitzpatrick, King's College London, London, GB

14:40 - 14:55 **Integrating locoregional and systemic therapies for CNS metastatic disease**
T. Bachelot, Centre Léon Bérard, Lyon, FR

14:55 - 15:10 **Beyond medical oncology in the management of metastatic disease: When to involve a surgeon or a radiation doctor or interventional radiologist**
L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US

15:10 - 15:30 **Discussion**

14:15 - 15:00 **Type: Challenge your Expert** **Toledo Auditorium - Hall 3**
Title: East meets West in the management of head and neck cancer: Learning from each other
 Chair(s): Jean-Pascal Machiels, BE

14:15 - 14:35 **Presentation by Expert**
B. Keam, Seoul National University Hospital, Seoul, KR

14:35 - 15:00 **Discussion led by Chair**
J.-P. Machiels, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE

16:00 - 17:30 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 9**
Title: Proffered Paper session - NSCLC, metastatic
 Chair(s): Marina Garassino, US; Yi-Long Wu, CN

16:00 - 16:10 **LBA63 - SAPPHIRE: Phase 3 Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Squamous Non-**



Small Cell Lung Cancer (NSCLC)

H. Borghaei¹, M. Johnson², E. Garon³, K. He⁴, D. Planchard⁵, M. Reck⁶, S. Popat⁷, R.S. Herbst⁸, T. Leal⁹, D. Dumoulin¹⁰, F. De Marinis¹¹, C. Reynolds¹², W. Theelen¹³, I. Percent¹⁴, V. Gutierrez Calderon¹⁵, A.-C. Madroszyk Flandin¹⁶, R. Shazer¹⁷, X. Yan¹⁷, R. Harrigan¹⁷, S. Peters¹⁸, ¹Fox Chase Cancer Center, Philadelphia, US, ²Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, ³University of California, Los Angeles, US, ⁴The Ohio State University, Columbus, US, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶LungenClinic Grosshansdorf, Grosshansdorf, DE, ⁷The Royal Marsden Hospital NHS Foundation Trust, London, GB, ⁸Yale University, New Haven, US, ⁹Emory University, Atlanta, US, ¹⁰Erasmus Medisch Centrum, Rotterdam, NL, ¹¹European Institute of Oncology, IRCC, Milan, IT, ¹²Florida Cancer Specialists and Research Institute - North Region (SCRI), Ocala, US, ¹³Netherlands Cancer Institute, Amsterdam, NL, ¹⁴Florida Cancer Specialists and Research Institute - South Region (SCRI), Fort Myers, US, ¹⁵Hospital Regional Universitario de Malaga, Malaga, ES, ¹⁶Institut Paoli-Calmettes, Marseille, FR, ¹⁷Mirati Therapeutics, Inc., San Diego, US, ¹⁸Centre Hospitalier Universitaire Vaudois, Lausanne, CH

16:10 - 16:20

LBA64 - Overall Survival from a Phase II Randomised Double-Blind Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC

S. Peters¹, A.L. Ortega Granados², F. De Marinis³, G. Lo Russo⁴, M. Schenker⁵, E. Arriola⁶, J. Puig⁷, D.H. Lee⁸, M. Reck⁹, Z. Szigyarto¹⁰, E. Buss¹¹, N. Stjepanovic¹¹, S.M. Lim¹², ¹Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, CH, ²Hospital Universitario de Jaén, Jaén, ES, ³Istituto Europeo di Oncologia (IRCCS), Milan, IT, ⁴Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁵Policlinica Sf. Nectarie, Centrul de Oncologie, Craiova, RO, ⁶Hospital del Mar, Parc de Salut Mar, Barcelona, ES, ⁷Centro Polivalente de Asistencia e Investigación Clínica, CER San Juan, San Juan, AR, ⁸University of Ulsan, College of Medicine, Asan Medical Center, Seoul, KR, ⁹Lungen Clinic, Airway Research Center North, Center for Lung Research, Grosshansdorf, DE, ¹⁰GSK, Stevenage, GB, ¹¹GSK, Baar, CH, ¹²Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, KR

16:20 - 16:30

Invited Discussant LBA63 and LBA64

N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

16:30 - 16:40

Q&A

16:40 - 16:50

LBA65 - KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

M. Garassino¹, W. Theelen², R. Jotte³, J. Laskin⁴, F. De Marinis⁵, C. Aguado⁶, F. Badin⁷, I. Chmielewska⁸, M. Hochmair⁹, S. Lu¹⁰, E. Nadal¹¹, G. Ostoros¹², E. Felip¹³, A. Spira¹⁴, C. Lane¹⁵, J. He¹⁵, R. Chao¹⁵, P. Jänne¹⁶, ¹The University of Chicago, Chicago, US, ²The Netherlands Cancer Institute, Amsterdam, NL, ³Rocky Mountain Cancer Centers, Greenwood Village, US, ⁴BC Cancer Vancouver Centre, University of British Columbia, Vancouver, CA, ⁵Istituto Europeo di Oncologia, Milan, IT, ⁶Hospital Universitario Clínico San Carlos, Madrid, ES, ⁷Baptist Health Medical Group, Lexington, US, ⁸Medical



University of Lublin, Lublin, PL, ⁹Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Vienna, AT, ¹⁰Shanghai Lung Cancer Center, Shanghai Jiao Tong University, Shanghai, CN, ¹¹Institut Català d'Oncologia (ICO), Barcelona, ES, ¹²National Korányi Institute of Pulmonology, Budapest, HU, ¹³Vall d'Hebron University Hospital, Barcelona, ES, ¹⁴Virginia Cancer Specialists, Fairfax, VA; US Oncology Research, The Woodlands, US, ¹⁵Mirati Therapeutics, Inc., San Diego, US, ¹⁶Dana Farber Cancer Institute, Boston, US

16:50 - 17:00

LBA66 - Afatinib versus chemotherapy for treatment-naïve non-small cell lung cancer with a sensitizing uncommon epidermal growth factor receptor mutation: a phase III study (ACHILLES/TORG1834)

S. Miura¹, H. Tanaka¹, T. Misumi², H. Yoshioka³, T. Kurata³, T. Tokito⁴, T. Fukuhara⁵, Y. Sato⁶, Y. Shiraishi⁷, S. Kusuhara⁸, S. Teraoka⁹, T. Kato¹⁰, H. Horinouchi¹¹, Y. Takiguchi¹², Y. Goto¹³, K. Tanaka¹⁴, M. Kanazu¹⁵, S. Ikeda¹⁶, E. Ichihara¹⁷, H. Okamoto¹⁸, ¹Niigata Cancer Center Hospital, Niigata, JP, ²Yokohama City University Hospital, Yokohama, JP, ³Kansai Medical University, Hirakata, JP, ⁴Kurume University, Kurume, JP, ⁵Miyagi Cancer Center, Natori, JP, ⁶Kobe City Medical Center General Hospital, Kobe, JP, ⁷Kyushu University Hospital, Fukuoka, JP, ⁸Kitasato University Hospital, Sagamihara, JP, ⁹Wakayama Medical University, Wakayama, JP, ¹⁰Kanagawa Cancer Center, Yokohama, JP, ¹¹National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ¹²Chiba University, School of Medicine, Chiba, JP, ¹³Fujita Health University, Toyoake, JP, ¹⁴Kyushu university hospital, Fukuoka, JP, ¹⁵National Hospital Organization Toneyama Hospital, Toyonaka, JP, ¹⁶Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, ¹⁷Okayama University Hospital, Okayama, JP, ¹⁸Yokohama Municipal Citizen's Hospital, Yokohama, JP

17:00 - 17:10

LBA67 - A Phase 3, Randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATLAS, KCSG-LU19-04)

M.-J. Ahn¹, S. Park², T.M. Kim³, J.-Y. Han⁴, G.-W. Lee⁵, B. Shim⁶, Y.-G. Lee⁷, S.-W. Kim⁸, I.-H. Kim⁹, S. Lee¹⁰, Y.J. Kim¹¹, J.H. Park¹², S.G. Park¹³, K. Lee¹⁴, E.J. Kang¹⁵, J.W. Kim¹⁶, S.-H. Shin¹⁷, ¹Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ²Samsung Medical Center, Seoul, KR, ³Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR, ⁴National Cancer Center - Graduate School of Cancer Science and Policy, Goyang, KR, ⁵Gyeongsang National University Hospital and Gyeongsang National University School of Medicine, Jinju, KR, ⁶The Catholic University of Korea - St. Vincent's Hospital, Suwon, KR, ⁷Samsung Medical Center (SMC)-Kangbuk Samsung Hospital, Seoul, KR, ⁸Asan Medical Center - University of Ulsan, Seoul, KR, ⁹Inje University Haeundae Paik Hospital, Busan, KR, ¹⁰Dong-A University Medical Center, Busan, KR, ¹¹SNUBH - Seoul National University Bundang Hospital, Seongnam, KR, ¹²Konkuk University Medical Center, Seoul, KR, ¹³Chosun University Hospital, Gwangju, KR, ¹⁴Chungbuk National University Hospital, Cheongju, KR, ¹⁵Korea University Guro Hospital, Seoul, KR, ¹⁶Korea University Anam Hospital, Seoul, KR, ¹⁷Kosin Univeristy Gospel Hospital, Busan, KR

17:10 - 17:20

Invited Discussant LBA65, LBA66 and LBA67

F. Blackhall, The Christie NHS Foundation Trust, Manchester, GB

17:20 - 17:30

Q&A



16:00 - 17:30 **Type: Proffered Paper session** **Sevilla Auditorium - Hall 9**
Title: Proffered Paper session 1 - Gynaecological cancers
 Chair(s): David SP Tan, SG; Ana Oaknin, ES

16:00 - 16:10 **LBA36 - Efficacy and Safety of Senaparib as Maintenance Treatment in Patients with Newly Diagnosed Advanced Ovarian Cancer (FLAMES Study): A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial**

X. Wu¹, J. Liu², X. Wang³, J. Wang⁴, L. Wang⁵, J. Zhu⁶, B. Kong⁷, J. Fei⁸, Y. Tang⁹, B. Xia¹⁰, Z. Liang¹¹, K. Wang¹², Z. Lin¹³, Y. Huang¹⁴, H. Zheng¹⁵, A. Lin¹⁶, K. Jiang¹⁷, W. Wang¹⁸, X. Wang¹⁹, G. Lou²⁰, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁴Hunan Cancer Hospital, Changsha, CN, ⁵Henan Cancer Hospital, Zhengzhou, CN, ⁶Cancer hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, CN, ⁷Qilu Hospital of Shandong University, Jinan, CN, ⁸The First Hospital of Jilin University, Changchun, CN, ⁹Chongqing University Cancer Hospital, Chongqing, CN, ¹⁰Anhui Provincial Cancer Hospital aka West Branch of Anhui Province Hospital, Hefei, CN, ¹¹South West Hospital, Third Military Medical University, Chongqing, CN, ¹²TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ¹³The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN, ¹⁴Hubei Cancer Hospital, Wuhan, CN, ¹⁵Beijing Cancer Hospital, Beijing, CN, ¹⁶Fujian Provincial Cancer Hospital, Fuzhou, CN, ¹⁷The Second Affiliated Hospital of Dalian Medical University, Dalian, CN, ¹⁸The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ¹⁹Zhongshan Hospital Xiamen University, Xiamen, CN, ²⁰Harbin Medical University Cancer Hospital, Harbin, CN

16:10 - 16:20 **LBA37 - Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial**

A. Gonzalez Martin¹, M.J. Rubio Perez², F. Heitz³, R.D. Christensen⁴, N. Colombo⁵, T. Van Gorp⁶, A. Oaknin⁷, A. Leary⁸, L. Gaba Garcia⁹, C. Lebreton¹⁰, L.M. De Sande González¹¹, M. Romeo Marin¹², A. Redondo¹³, M.P. Barretina Ginesta¹⁴, J.A. Perez Fidalgo¹⁵, A. Santaballa Bertran¹⁶, M.J. Bermejo-Pérez¹⁷, I. Bruchim¹⁸, I. Ray-Coquard¹⁹, F. Selle²⁰, ¹Cima-Universidad de Navarra, Cancer Center Clínica Universidad de Navarra (CCUN), Madrid, ES, ²Reina Sofía University Hospital of Cordoba, Cordoba, ES, ³KEM | Evang. Kliniken Essen-Mitte gGmbH, Essen, DE, ⁴Copenhagen University Hospital, Copenhagen, DK, ⁵Department of Medicine and Surgery, University of Milan-Bicocca, Milan, IT, ⁶University Hospital Leuven, Leuven Cancer Institute, Leuven, BE, ⁷Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, ES, ⁸Gustave Roussy, Villejuif, FR, ⁹Hospital Clinic and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, ES, ¹⁰Institut Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ¹¹Complejo Asistencial Universitario de León - Hospital de León, León, ES, ¹²Institut Català d'Oncologia, Badalona, ES, ¹³Hospital Universitario La Paz-IdiPAZ, Madrid, ES, ¹⁴Institut Català d'Oncologia, IDIBGI, Girona, ES, ¹⁵Hospital Clínico Universitario de Valencia, Valencia, ES, ¹⁶Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹⁷Hospitales Universitarios Regional y Virgen Victoria,



Málaga, ES, ¹⁸Hillel Yaffe Medical Center Israel, affiliated with the Ruth and Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Hadera, IL, ¹⁹Centre Léon Bérard, Lyon, FR, ²⁰Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, FR

16:20 - 16:30 **Invited Discussant LBA36 and LBA37**

C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB

16:30 - 16:45 **Q&A**

16:45 - 16:55 **LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study**

D. Lorusso¹, Y. Xiang², K. Hasegawa³, G. Scambia⁴, M. Leiva Galves⁵, P. Ramos Elias⁶, A. Acevedo⁷, J. Vizkeleti⁸, A.J. Gomes⁹, F. Contreras Mejia¹⁰, A. Reiss¹¹, A. Ayhan¹², J.-Y. Lee¹³, V. Saevets¹⁴, F. Zagouri¹⁵, K. Li¹⁶, K. Ussui Yamada¹⁶, S. Toker¹⁶, S. Pignata¹⁷, L. Duska¹⁸, ¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of Sacred Heart, Rome, IT, ²Peking Union Medical College Hospital, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, CN, ³Saitama Medical University International Medical Center, Hidaka, Saitama, JP, ⁴Fondazione Policlinico Universitario Agostino Gemelli IRCCS and Catholic University of the Sacred Heart, Rome, IT, ⁵Instituto de Oncologia y Radioterapia Clinica Ricardo Palma, Lima, PE, ⁶Edificio Integra Medical Center, Guatemala City, GT, ⁷Oncocentro, Valparaiso, CL, ⁸Centre of Radiotherapy, Budapest, HU, ⁹Liga Norte Riograndense Contra o Câncer Rio Grande do Norte, Natal, BR, ¹⁰Instituto Nacional de Cancerologia, Bogota, CO, ¹¹Gyneco-oncology Unit, Haifa, IL, ¹²Başkent University, Ankara, TR, ¹³Yonsei University College of Medicine, Seoul, KR, ¹⁴Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine, Chelyabinsk, RU, ¹⁵Alexandra Hospital, Athens, GR, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, IT, ¹⁸University of Virginia School of Medicine, Charlottesville, US

16:55 - 17:05 **LBA39 - Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase 3 trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)**

A. Oaknin¹, L. Gladieff², J. Martinez-Garcia³, G. Villacampa⁴, M. Takekuma⁵, U. De Giorgi⁶, K. Lindemann⁷, L. Woelber⁸, N. Colombo⁹, L. Duska¹⁰, A. Leary¹¹, A. Godoy Ortiz¹², S. Nishio¹³, A. Angelergues¹⁴, M.J. Rubio Perez¹⁵, L. Fariñas Madrid¹⁶, S. Yamaguchi¹⁷, D. Lorusso¹⁸, V. D'Hondt¹⁹, L. Randall²⁰, ¹Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron University Hospital, Barcelona, ES, ²Oncopole Claudius Regaud, IUCT, Toulouse, FR, ³Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO) and SOLTI Breast Cancer Research Group, Barcelona, ES, ⁵Shizuoka Cancer Center, Shizuoka, JP, ⁶IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, IT, ⁷Oslo University Hospital, Oslo, NO, ⁸Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, ⁹Department of Medicine and Surgery, University of Milan-Bicocca, Milan, IT, ¹⁰University of Virginia Cancer Center, Charlottesville, US, ¹¹Gustave Roussy, Villejuif,



FR, ¹²Hospital Regional Universitario Málaga Carlos Haya, Málaga, ES, ¹³Kurume University, Kurume, JP, ¹⁴Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, FR, ¹⁵Hospital Universitario Reina Sofía, Cordoba, ES, ¹⁶Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹⁷Hyogo Cancer Center, Akashi, JP, ¹⁸Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, ¹⁹Institut du Cancer de Montpellier, Montpellier, FR, ²⁰VCUHealth, Richmond, US

17:05 - 17:15 **Invited Discussant LBA38 and LBA39**
B. Monk, The University of Arizona, Tucson, US

17:15 - 17:30 **Q&A**

16:00 - 17:30 **Type: Special symposium** **Bilbao Auditorium - NCC**
Title: HER2 positive gastroesophageal cancer
 Chair(s): Elizabeth Smyth, GB; Sylvie Lorenzen, DE

16:00 - 16:05 **Introduction and scientific background**
E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB

16:05 - 16:20 **Novel therapies in HER2 in advanced gastroesophageal cancer**
Y. Janjigian, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

16:20 - 16:35 **Targeting HER2 in operable gastroesophageal cancer**
F. Lordick, Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE

16:35 - 16:50 **Lessons from the biology of HER2 positive gastroesophageal cancer**
H. Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, NL

16:50 - 17:05 **HER2 and beyond: What's next?**
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

17:05 - 17:25 **Discussion**

17:25 - 17:30 **Conclusions and perspectives**
S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

16:00 - 17:20 **Type: Proffered Paper session** **Granada Auditorium - Hall 3**
Title: Proffered Paper session - Genitourinary tumours, prostate
 Chair(s): Karim Fizazi, FR; Shahneen Sandhu, AU



- 16:00 - 16:10 **17640 - Timing of radiotherapy (RT) after radical prostatectomy (RP): Final results of RADICALS RT randomised controlled trial**
- C. Parker¹, N. Clarke², A. Cook³, H. Kynaston⁴, P. Meidahl Petersen⁵, W. Cross⁶, R. Persad⁷, C. Catton⁸, J. Logue⁹, H. Payne¹⁰, F. Saad¹¹, K. Brasso¹², C. Heath¹³, H. Lindberg¹⁴, R. Raman¹⁵, M.A. Røder¹², A. Zarkar¹⁶, W. Parulekar¹⁷, M. Parmar¹⁸, M. Sydes³, ¹The Royal Marsden Hospital (Sutton) - NHS Foundation Trust, Sutton, GB, ²The University of Manchester, Manchester, GB, ³Medical Research Council Clinical Trials Unit, London, GB, ⁴Cardiff & Vale UHB, Cardiff, GB, ⁵Copenhagen University, Copenhagen, DK, ⁶University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB, ⁷University Hospitals Bristol NHS Foundation Trust, Bristol, GB, ⁸Princess Margaret Cancer Center, Toronto, CA, ⁹The Christie NHS Foundation Trust, Manchester, GB, ¹⁰University College London Hospitals NHS Foundation Trust, London, GB, ¹¹Hospital St. Luc du CHUM, Montreal, CA, ¹²Rigshospitalet, Copenhagen, DK, ¹³Southampton General Hospital - University Hospital Southampton NHS Trust, Southampton, GB, ¹⁴Herlev and Gentofte Hospital, Herlev, DK, ¹⁵Kent Oncology Centre - Maidstone and Tunbridge NHS Trust, Maidstone, GB, ¹⁶Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, ¹⁷Canadian Cancer Trials Group, Kingston, CA, ¹⁸MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB
- 16:10 - 16:20 **17650 - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2#x2b;1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)**
- W. Kelly¹, D. Danila², C.-C. Lin³, J.-L. Lee⁴, N. Matsubara⁵, P. Ward⁶, A. Armstrong⁷, D. Pook⁸, M. Kim⁹, T. Dorff¹⁰, S. Fischer¹¹, Y.-C. Lin¹², L. Horvath¹³, C. Sumey¹⁴, Z. Yang¹⁵, G. Jurida¹⁵, J. Connarn¹⁵, H. Penny¹⁵, J. Stieglmaier¹⁶, L. Appleman¹⁷, ¹Thomas Jefferson University, Philadelphia, US, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³NTUH - National Taiwan University Hospital, Taipei City, TW, ⁴Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Oncology Hematology Care, Cincinnati, US, ⁷Duke Cancer Center, Durham, US, ⁸Monash Health - Monash Cancer Centre, Bentleigh East, AU, ⁹SNUH - Seoul National University Hospital, Seoul, KR, ¹⁰City of Hope Comprehensive Cancer Center, Duarte, US, ¹¹Kantonsspital St. Gallen, St. Gallen, CH, ¹²Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, ¹³Chris O'Brien Lifecare, Camperdown, AU, ¹⁴Sanford Cancer Center, Sioux Falls, US, ¹⁵AMGEN (Headquarters) - USA, Thousand Oaks, US, ¹⁶AMGEN Research (Munich) GmbH, Munich, DE, ¹⁷UPMC Hillman Cancer Center, Pittsburgh, US
- 16:20 - 16:30 **Invited Discussant 17640 and 17650**
- S. Sandhu, Peter MacCallum Cancer Centre, Melbourne, AU
- 16:30 - 16:40 **Q&A**
- 16:40 - 16:50 **LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)**
- L. Emmett¹, S. Subramaniam², M. Crumbaker³, A. Joshua⁴, A. Weickhardt⁵, S.T. Lee⁶, S.



Ng⁷, R. Francis⁸, J. Goh⁹, D. Pattison⁹, H. Tan¹⁰, I. Kirkwood¹⁰, S. Sandhu¹¹, A. Nguyen¹, C. Gedye¹², N. Rutherford¹³, M. Hofman¹⁴, A. Martin², M. Stockler¹⁵, I. Davis¹⁶, ¹St. Vincent's Hospital, Darlinghurst, AU, ²University of Sydney, Sydney, AU, ³The Kinghorn Cancer Centre, Sydney, AU, ⁴St Vincents Hospital Sydney, Sydney, AU, ⁵Austin Health, Melbourne, AU, ⁶Austin Health - Austin Hospital, Heidelberg, AU, ⁷Sir Charles Gairdner Hospital, Nedlands, AU, ⁸University of Western Australia, Perth, AU, ⁹Royal Brisbane and Women's Hospital, Herston, AU, ¹⁰Royal Adelaide Hospital, Adelaide, AU, ¹¹Peter MacCallum Cancer Centre, Melbourne, AU, ¹²Calvary Mater Hospital Newcastle, Newcastle, AU, ¹³Hunter New England Health Imaging Service, New Lambton, AU, ¹⁴Victorian Comprehensive Cancer Centre, Melbourne, AU, ¹⁵University of Sydney, Camperdown, AU, ¹⁶Monash University and Eastern Health, Box Hill, AU

16:50 - 17:00 **17700 - Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium**

P. Ravi¹, W. Xie¹, M. Buyse², S. Halabi³, P. Kantoff⁴, O. Sartor⁵, G. Attard⁶, N. Clarke⁷, A. D'Amico¹, J. Dignam⁸, N. James⁹, K. Fizazi¹⁰, S. Gillessen¹¹, W. Parulekar¹², H. Sandler¹³, D. Spratt¹⁴, M. Sydes¹⁵, B. Tombal¹⁶, S. Williams¹⁷, C. Sweeney¹⁸, ¹Dana Farber Cancer Institute, Boston, US, ²International Drug Development Institute, Louvain-la-Neuve, BE, ³Duke University Medical Center, Durham, US, ⁴Convergent Therapeutics, Inc., Cambridge, US, ⁵Mayo Clinic - Rochester, Rochester, US, ⁶University College London, London, GB, ⁷The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, ⁸NRG Oncology Statistics and Data Management Center, Philadelphia, US, ⁹ICR - Institute of Cancer Research, London, GB, ¹⁰Institut Gustave Roussy, Villejuif, Cedex, FR, ¹¹EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, ¹²Canadian Cancer Trials Group, Kingston, CA, ¹³Cedars Sinai Medical Center, Los Angeles, US, ¹⁴Case Western Reserve University / University Hospitals, Cleveland, US, ¹⁵Medical Research Council Clinical Trials Unit, London, GB, ¹⁶Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE, ¹⁷Peter MacCallum Cancer Center, Melbourne, AU, ¹⁸The University of Adelaide, Adelaide, AU

17:00 - 17:10 **Invited Discussant LBA84 and 17700**

D. Heinrich, Sykehuset Innlandet HF, Brumunddal, NO

17:10 - 17:20 **Q&A**

16:00 - 17:20 Type: Proffered Paper session **Burgos Auditorium - Hall 3**
Title: Proffered Paper session - Supportive and palliative care

Chair(s): Anne Letsch, DE; Christina Ruhlmann, DK

16:00 - 16:10 **20300 - Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for metastatic cancer: Results from the PRO-TECT trial (Alliance AFT-39)**

E. Basch¹, D. Schrag², J. Jansen³, B. Ginos⁴, P. Spears⁵, M. Jonsson³, P. Carr³, A. Deal³, G.



Thanarajasingam⁶, B. Reeve⁷, C. Snyder⁸, D. Bruner⁹, D. Cella¹⁰, V. Blinder¹¹, L. Kottschade¹², J. Perlmutter¹³, C. Geoghegan¹³, G. Mazza⁶, A. Weiss¹⁴, A. Dueck⁴, ¹UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³University of North Carolina - Chapel Hill, Chapel Hill, US, ⁴Mayo Clinic Cancer Center, Phoenix, US, ⁵UNC - Lineberger Cancer Center, Chapel Hill, US, ⁶Mayo Clinic - Rochester, Rochester, US, ⁷Duke Cancer Center - Duke University Medical Center, Durham, US, ⁸Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ⁹Winship Cancer Institute of Emory University, Atlanta, US, ¹⁰Northwestern University, Chicago, US, ¹¹Memorial Sloan Kettering Cancer Center, Commack, US, ¹²Mayo Clinic, Jacksonville, US, ¹³Independent, Philadelphia, US, ¹⁴University of Rochester Cancer Center, Rochester, US

- 16:10 - 16:20 **20310 - Randomized trial of a telephone-based weight loss intervention in overweight and obese patients (pts) with breast cancer (BC): The MEDEA trial**
I. Vaz Luis¹, A. Di Meglio¹, E. Martin¹, L. Vanlemmens², C. Segura-Djezzar³, C. Bouleuc⁴, O. Tredan⁵, B. Pistilli¹, T. Crane⁶, D. Soldato¹, C. Charles¹, A. Barbier¹, B. Raynard⁷, A. Mangin¹, B. Coquet⁸, G. Jacob⁹, J. Bonastre¹⁰, S. Michiels¹, D. Chaltiel¹, J. Ligibel¹¹, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Centre Oscar Lambret, Lille, FR, ³Centre Francois Baclesse, Caen, Cedex, FR, ⁴Institut Curie, Paris, FR, ⁵Centre Léon Bérard, Lyon, FR, ⁶University of Miami, Sylvester Comprehensive Cancer Center, Deerfield Beach, US, ⁷Gustave Roussy - Cancer Campus, Villejuif, FR, ⁸Ligue Nationale Contre le Cancer, Paris, FR, ⁹Seintinelles, Paris, FR, ¹⁰Institut Gustave Roussy, Villejuif, FR, ¹¹Dana Farber Cancer Institute, Boston, US
- 16:20 - 16:30 **Invited Discussant 20300 and 20310**
A. Letsch, Universitätsklinikum Schleswig Holstein Campus Kiel II, Kiel, DE
- 16:30 - 16:40 **Q&A**
- 16:40 - 16:50 **LBA94 - Effects of short-term fasting on quality of life as an add-on option during chemotherapy**
D. Koppold¹, C. Kessler¹, M. Wischnewsky², I.M. Alvarado-Rupflin¹, C. Kempter³, M. Paul⁴, B. Brueckner³, D. Fischer⁵, N. Steckhan⁶, M. Jeitler¹, E. Hanslian¹, B. Kunz¹, A. Michalsen¹, ¹Charité - Universitätsmedizin Berlin, Berlin, DE, ²University of Bremen, Bremen, DE, ³Waldfriede Krankenhaus, Berlin, DE, ⁴Vivantes Klinikum am Urban, Berlin, DE, ⁵Klinikum Ernst von Bergmann, Potsdam, DE, ⁶Hasso-Plattner-Institut, Potsdam, DE
- 16:50 - 17:00 **LBA95 - Anamorelin and weight gain in patients with advanced Non Small Cell Lung Cancer (NSCLC) and cachexia: efficacy and safety in the multinational phase 3 SCALA program**
D. Currow¹, S. Chessari², P. Bonomi³, R. Giorgino⁴, R. Skipworth⁵, ¹University of Wollongong, Wollongong, AU, ²Helsinn Healthcare SA, Pazzallo-Lugano, CH, ³Rush University, Chicago, US, ⁴Triallism GmbH, Allschwill, CH, ⁵University of Edinburgh, Edinburgh, GB



17:00 - 17:10 **Invited Discussant LBA94 and LBA95**

J. Arends, Universitätsklinikum Freiburg - Klinik für Innere Medizin I/Klinik für Tumorbiologie, Freiburg im Breisgau, DE

17:10 - 17:20 **Q&A**

16:00 - 17:30 Type: Proffered Paper session Santander Auditorium - Hall 9
Title: Proffered Paper session - CNS tumours

Chair(s): Dieta Brandsma, NL; Evanthia Galanis, US

16:00 - 16:10 **4980 - INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma**

D. Blumenthal¹, I. Mellinohoff², M. Van Den Bent³, M. Touat⁴, K. Peters⁵, J. Clarke⁶, J. Mendez⁷, L. Welsh⁸, W. Mason⁹, A. Hottinger¹⁰, J.M. Sepulveda Sanchez¹¹, W. Wick¹², R. Soffietti¹³, A. Tron¹⁴, D. Zhao¹⁴, S. Pandya¹⁴, L. Steelman¹⁴, I. Hassan¹⁴, P. Wen¹⁵, T. Cloughesy¹⁶, ¹Tel-Aviv Medical Center, Tel-Aviv University, Tel Aviv, IL, ²Memorial Sloan-Kettering Cancer Center, New York, US, ³Brain Tumor Center at Erasmus MC Cancer Institute, Rotterdam, NL, ⁴Sorbonne Université, Institut du Cerveau, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière, Charles Foix, Paris, FR, ⁵Duke University Medical Center, Durham, US, ⁶University of California, San Francisco, US, ⁷Huntsman Cancer Institute at the University of Utah, Salt Lake City, US, ⁸The Royal Marsden Hospital, London, GB, ⁹Princess Margaret Cancer Centre, and University of Toronto, Toronto, CA, ¹⁰Lundin Family Brain Tumor Research Center, University Hospital of Lausanne, and University of Lausanne, Lausanne, CH, ¹¹Hospital Universitario 12 de Octubre, Madrid, ES, ¹²Universitätsklinikum Heidelberg, Heidelberg, DE, ¹³University of Turin, Torino, IT, ¹⁴Servier Pharmaceuticals, Boston, US, ¹⁵Dana-Farber Cancer Institute, Boston, US, ¹⁶University of California, Los Angeles, US

16:10 - 16:20 **Invited Discussant 4980**

D. Brandsma, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:20 - 16:30 **Q&A**

16:30 - 16:40 **4990 - A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated**

W. Li¹, Y. Mao², Z. Kang¹, W. Hua², S. Li¹, Z. Wu³, H. Liu⁴, J. Hu⁴, J. Guo⁴, W. Zhong⁴, X. Wang⁵, ¹Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, ²Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, CN, ³Beijing Fosun Pharmaceutical Research and Development Co., Ltd., Beijing, CN, ⁴Beijing Fosun Pharmaceutical Research and Development Co., Ltd., Shanghai, CN, ⁵Shanghai Fosun Pharmaceutical Development Co.,Ltd, Shanghai, CN

16:40 - 16:50 **5000 - Trotaresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed**



primary glioblastoma (ndGBM): Updated results from a phase Ib/II study

M. Vieito Villar¹, J.M. Sepúlveda Sánchez², V. Moreno Garcia³, G. Lombardi⁴, A. Stradella⁵, R.H. Dahlrot⁶, C. Haslund⁷, M. Geurts⁸, E. Pineda⁹, P. Brandal¹⁰, F. De Vos¹¹, M.A. Vaz Salgado¹², M. Martinez Garcia¹³, M. Macchini¹⁴, B. Amoroso¹⁵, T. Sanchez¹⁵, B. Hanna¹⁶, X. Li¹⁶, Z. Nikolova¹⁵, M. Simonelli¹⁷, ¹Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ⁴Istituto Oncologico Veneto, Oncologia 1, IOV-IRCCS, Padua, IT, ⁵Institut Català d'Oncologia, Hospitalet de Llobregat, Barcelona, ES, ⁶Odense University Hospital, Odense, DK, ⁷Aalborg University Hospital, Aalborg, DK, ⁸Erasmus MC Cancer Institute, Rotterdam, NL, ⁹Hospital Clínic de Barcelona, Barcelona, ES, ¹⁰Oslo University Hospital, Oslo, NO, ¹¹University Medical Center Utrecht, Utrecht, NL, ¹²Hospital Universitario Ramon y Cajal, Madrid, ES, ¹³Hospital del Mar, Barcelona, ES, ¹⁴IRCCS San Raffaele Scientific Institute, Milan, IT, ¹⁵Centre for Innovation and Translational Research Europe, a Bristol Myers Squibb Company, Seville, ES, ¹⁶Bristol Myers Squibb, Princeton, US, ¹⁷IRCCS Humanitas Research Hospital and Department of Biomedical Sciences, Humanitas University, Milan, IT

16:50 - 17:00 **5010 - Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial**

M.A. Vaz Salgado¹, S. Del Barco², J.M. Sepúlveda³, M. Alonso⁴, E. Pineda⁵, C. Balana⁶, M. Martínez-García⁷, R. Gironés⁸, ¹Hospital Universitario Ramón y Cajal, Madrid, ES, ²Institut Català d'Oncologia Girona, Girona, ES, ³Hospital Universitario 12 de Octubre, Madrid, ES, ⁴Hospital Virgen del Rocío, Sevilla, ES, ⁵Hospital Clínic de Barcelona, Barcelona, ES, ⁶Institut Català d'Oncologia, Badalona, ES, ⁷Hospital del Mar, Barcelona, ES, ⁸Hospital Universitario y Politécnico la Fe de Valencia, Valencia, ES

17:00 - 17:15 **Invited Discussant 4990, 5000 and 5010**

A.S. Berghoff, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

17:15 - 17:30 **Q&A**



16:00 - 17:30	Type: Educational session Title: Harnessing innate immunity to fight cancer Chair(s): Adrian Hayday, GB; Daniela Thommen, NL	León Auditorium - Hall 7
16:00 - 16:25	Are Gamma Delta T cells the protagonists of cancer attack by the innate immune system? <u>A. Hayday</u> , King's College London Guy's Hospital - NHS Foundation Trust, London, GB	
16:25 - 16:50	DNA sensing by innate immunity <u>A. Ablasser</u> , EPFL - Ecole Polytechnique Federale de Lausanne - Interfaculty (EPFL-SV-IBI), Lausanne, CH	
16:50 - 17:15	The Type 2 immune axis in the marrow directs pro-tumorigenic myelopoiesis <u>T. Marron</u> , Icahn School of Medicine at Mount Sinai, New York, US	
17:15 - 17:30	Q&A and Discussion	



16:00 - 17:30	Type: Patient Advocacy session Title: How to improve access to medicines through patient engagement? Chair(s): Jana Pelouchova, CZ; André Deschamps, BE	Cádiz Auditorium - NCC
16:00 - 16:15	The improvement of the regulatory process through the consideration of patients' reported outcomes during the medicines' development <u>A. Deschamps</u> , Europa Uomo - The European Prostate Cancer Coalition, Antwerpen, BE	
16:15 - 16:30	A gap analysis on access to modern medicines and treatments: A comparison between West and Eastern Europe <u>K.E. Morgan</u> , Myeloma Patients Europe AISBL, Brussels, BE	
16:30 - 16:45	Incorporating patient organizations' expertise into the healthcare legislation <u>J. Pelouchova</u> , Diagnóza leukemie, z.s, Prague, CZ	
16:45 - 17:00	Patient engagement and collaboration with national regulatory agencies <u>L.-L. Eriksson</u> , The Swedish Blood Cancer Association, Sundbyberg, SE	
17:00 - 17:15	Leukaemia care and the collaboration with NICE <u>Z. Pemberton-Whiteley</u> , Leukaemia Care - National Worcester, Worcester, GB	
17:15 - 17:25	Discussion	
17:25 - 17:30	Conclusion	



16:00 - 18:00	<p>Type: Special session Title: 8th ESMO Designated Centres of Integrated Oncology and Palliative Care Session and Awards: Approaches to the integration of palliative care in oncology services Chair(s): Jayne Wood, GB; Anna Reyners, NL</p>	<p>Ávila Auditorium - NCC</p>
16:00 - 16:05	<p>Introduction <u>J. Wood</u>, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB</p>	
16:05 - 16:20	<p>Importance of integration of palliative care into mainstream oncology <u>J. Wood</u>, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB</p>	
16:20 - 16:35	<p>Designated centres virtual visits pilot <u>A. Reyners</u>, UMCG - University Medical Center Groningen, Groningen, NL</p>	
16:35 - 16:50	<p>MyPath update and introduction to the JANE network <u>S. Kaasa</u>, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO</p>	
16:50 - 17:05	<p>Symptom screening with Targeted Early Palliative care (STEP) intervention <u>C. Zimmermann</u>, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA</p>	
17:05 - 17:25	<p>Q&A</p>	
17:25 - 17:30	<p>Conclusion and next steps <u>A. Reyners</u>, UMCG - University Medical Center Groningen, Groningen, NL</p>	
17:30 - 18:00	<p>Designated Centres Awards <u>J. Wood</u>¹, <u>A. Reyners</u>², ¹The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ²UMCG - University Medical Center Groningen, Groningen, NL</p>	



16:00 - 17:30 **Type: Young Oncologists session** **Pamplona Auditorium - Hall 9**
Title: YO Mentorship sessions

16:00 - 16:00 **Table 1: Clinical research in the general oncology practice setting**
J. Cortés¹, H. Zhu², ¹Hospital Ruber Internacional, Madrid, ES, ²Fudan University Shanghai Cancer Center, Shanghai, CN

16:00 - 16:00 **Table 2: How to build your own lab and research group in academia**
C. Saura Manich¹, R. Pihlak², ¹Vall d'Hebron University Hospital, Barcelona, ES, ²St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

16:00 - 16:00 **Table 3: How to build your own lab and research group in academia**
J. Haanen¹, M. Moutafi², ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Attikon University Hospital, Haidari, GR

16:00 - 16:00 **Table 4: Career opportunities for oncologists in the pharmaceutical industry**
L. Mühlhoff¹, E. Kocakavuk², ¹AstraZeneca GmbH, Wedel, DE, ²University Hospital Essen, Essen, DE

16:00 - 16:00 **Table 5: A career in supportive and palliative care**
K. Jordan¹, D.C. Guven², ¹Ernst von Bergmann Klinikum Potsdam, Potsdam, DE, ²Hacettepe University Oncology Hospital, Ankara, TR

16:00 - 16:00 **Table 6: Leadership and management in oncology**
T. Amaral¹, K. Punie², ¹Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE, ²UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:00 - 16:00 **Table 7: A career in neuro-oncology for medical oncologists**
R. Stupp¹, A. Starzer², ¹Northwestern University Feinberg School of Medicine, Chicago, US, ²Medizinische Universitaet Wien, Vienna, AT

16:15 - 17:00 **Type: Challenge your Expert** **Valencia Auditorium**
Title: Immunotherapy in colorectal cancer: Where do we stand and what do we expect? **- Hall 10**
Chair(s): Chiara Cremolini, IT

16:15 - 16:35 **Presentation by Expert**
G. Argiles Martinez, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

16:35 - 17:00 **Discussion led by Chair**
C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT



16:15 - 17:00 **Type: Challenge your Expert** **Salamanca Auditorium - Hall 3**
Title: When does targeted therapy outperform immunotherapy in patients with advanced melanoma?
 Chair(s): Ryan Sullivan, US

16:15 - 16:35 **Presentation by Expert**
C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

16:35 - 17:00 **Discussion led by Chair**
R. Sullivan, MGH - Massachusetts General Hospital, Boston, US

16:15 - 17:00 **Type: Challenge your Expert** **Málaga Auditorium - Hall 10**
Title: Is there still a place for anthracyclines in early breast cancer?
 Chair(s): Evandro de Azambuja, BE

16:15 - 16:35 **Presentation by Expert**
S. Hurvitz, University of Washington, Seattle, US

16:35 - 17:00 **Discussion led by Chair**
E. De Azambuja, Institute Jules Bordet, Brussels, BE

16:15 - 17:00 **Type: Challenge your Expert** **Toledo Auditorium - Hall 3**
Title: When can we cure patients with metastatic sarcoma?
 Chair(s): Silvia Stacchiotti, IT

16:15 - 16:35 **Presentation by Expert**
W. Van Houdt, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:35 - 17:00 **Discussion led by Chair**
S. Stacchiotti, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT



16:15 - 17:30 **Type: Multidisciplinary session** **Oviedo Auditorium - Hall 7**
Title: Building an academic cell therapy programme
 Chair(s): Elena Garralda, ES; Inge-Marie Svane, DK

16:15 - 16:20 **Presentation of case/condition**
E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES

16:20 - 16:40 **Lab requirements and translational opportunities**
I.-M. Svane, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK

16:40 - 17:00 **Clinical requirements**
A. Furness, The Royal Marsden Hospital - Chelsea, London, GB

17:00 - 17:20 **Regulatory requirements**
A. Hidalgo-Simon, EMA - European Medicines Agency, Amsterdam, NL

17:20 - 17:30 **Q&A and Discussion**

17:30 - 18:30 **Type: Young Oncologists session** **Networking Hub - NCC**
Title: YO Vesalius talk: Diversity, equity and inclusion: Tips to move forward in your career
 Chair(s): Kok Haw Jonathan Lim, GB; Elene Mariamidze, GE

17:30 - 17:40 **Intorduction by the Chair**
K.H.J. Lim¹, E. Mariamidze², ¹The Francis Crick Institute, London, GB, ²Todua Clinic, Tbilisi, GE

17:40 - 18:30 **Diversity, equity and inclusion: Tips to move forward in your career**
P. Vuylsteke¹, S. Peters², P. Garrido Lopez³, T.S.K. Mok⁴, ¹University of Botswana, Gaborone, BW, ²CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ³Hospital Universitario Ramon y Cajal, Madrid, ES, ⁴Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK



18:00 - 19:30	Type: Industry Satellite Symposium Title: AstraZeneca - Clinical Perspectives in mCRPC: Practical Considerations on Incorporating PARPi plus Next-generation Hormonal Agents into the Clinic Chair(s): Elena Castro, ES	Salamanca Auditorium - Hall 3
----------------------	---	--------------------------------------

18:00 - 18:05 **Welcome and introduction**
 E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

18:05 - 18:20 **Examining the evidence: PARPi plus NHA combination therapy in mCRPC**
 G. Von Amsberg, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

18:20 - 19:00 **Clinical considerations: case-based scenarios for patient selection and AE management with combination PARPi plus NHAs**
 E. Castro¹, F. Saad², ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Hospital St. Luc du CHUM, Montreal, CA

19:00 - 19:25 **Exploring the patient perspective: practical approaches for shared decision making**
 R. Mckay, University of California San Diego - UCSD, La Jolla, US

19:25 - 19:30 **Summary and close**
 E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES



18:00 - 19:30	Type: Industry Satellite Symposium Title: Janssen Pharmaceutica N.V. - Targeted therapy optimising the future of GU cancer care - realising the value, exploring the evidence Chair(s): Aurelius Omlin, CH; Alison Birtle, GB	Málaga Auditorium - Hall 10
18:00 - 18:05	Opening remarks & introduction <u>A. Omlin</u> ¹ , <u>A. Birtle</u> ² , ¹ OnkoZentrum Zürich, Zurich, CH, ² Royal Preston Hospital, Preston, GB	
18:05 - 18:25	How can we balance efficacy and QoL in mHSPC treatment? Why it's time to tailor treatments <u>F. Schlürmann</u> ¹ , <u>L.-M. Krabbe</u> ² , ¹ CHRU Brest - Hopital Augustin Morvan, Brest, FR, ² UKM - University Hospital Muenster, Muenster, DE	
18:25 - 18:45	Germ line testing and genomic profiling - isn't it time for personalised prostate cancer care? <u>D. Olmos</u> ¹ , <u>N. Mehra</u> ² , ¹ Hospital Universitario 12 de Octubre, Madrid, ES, ² Radboud University Medical Center, Nijmegen, Nijmegen, NL	
18:45 - 19:05	Revolutionising urothelial carcinoma care: Discovering the value of targeted therapy <u>G.A. De Velasco Oria</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
19:05 - 19:25	Interactive Q&A session <u>A. Omlin</u> ¹ , <u>A. Birtle</u> ² , <u>F. Schlürmann</u> ³ , <u>D. Olmos</u> ⁴ , <u>N. Mehra</u> ⁵ , <u>L.-M. Krabbe</u> ⁶ , <u>G.A. De Velasco Oria</u> ⁴ , ¹ OnkoZentrum Zürich, Zurich, CH, ² Royal Preston Hospital, Preston, GB, ³ CHRU Brest - Hopital Augustin Morvan, Brest, FR, ⁴ Hospital Universitario 12 de Octubre, Madrid, ES, ⁵ Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁶ UKM - University Hospital Muenster, Muenster, DE	
19:25 - 19:30	Closing remarks <u>A. Omlin</u> ¹ , <u>A. Birtle</u> ² , ¹ OnkoZentrum Zürich, Zurich, CH, ² Royal Preston Hospital, Preston, GB	



18:00 - 19:30	<p>Type: Industry Satellite Symposium Title: Servier - A journey through IDH1mutated Cholangiocarcinoma - Unveiling clinical and therapeutic perspectives Chair(s): Michel Ducreux, FR</p>	<p>Santander Auditorium - Hall 9</p>
18:00 - 18:10	<p>Introduction <u>M. Ducreux</u>, Gustave Roussy - Cancer Campus, Villejuif, FR</p>	
18:10 - 18:15	<p>Introducing a patient case with IDH1 mutated CCA <u>T. Macarulla</u>, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES</p>	
18:15 - 18:35	<p>CCA diagnosis: current practice and challenges <u>T. Macarulla</u>¹, <u>E. Martinelli</u>², ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT</p>	
18:35 - 18:55	<p>Molecular profiling in CCA: where do we stand? <u>T. Macarulla</u>¹, <u>A. Stenzinger</u>², ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE</p>	
18:55 - 19:15	<p>Treatment landscape in CCA and future perspectives <u>B. Westphalen</u>¹, <u>T. Macarulla</u>², ¹LMU Klinikum der Universität München, Munich, DE, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES</p>	
19:15 - 19:25	<p>Panel discussion Q&A <u>M. Ducreux</u>¹, <u>T. Macarulla</u>², <u>E. Martinelli</u>³, <u>A. Stenzinger</u>⁴, <u>B. Westphalen</u>⁵, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ³Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁴University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, ⁵LMU Klinikum der Universität München, Munich, DE</p>	
19:25 - 19:30	<p>Conclusion <u>M. Ducreux</u>, Gustave Roussy - Cancer Campus, Villejuif, FR</p>	



18:00 - 19:30	Type: Industry Satellite Symposium Title: Bayer - Delivering on the Promise of Precision Oncology: From the Big Bang to Tangible Impact on Patients' Lives Chair(s): Vivek Subbiah, US	Toledo Auditorium - Hall 3
18:00 - 18:05	Welcome <u>V. Subbiah</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
18:05 - 18:10	The Voice That Matters - A Patient Perspective <u>V. Subbiah</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
18:10 - 18:25	The Big Bang of Precision Oncology: Creating Milestones in Medicine <u>V. Subbiah</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
18:25 - 18:40	Theory to Reality: Overcoming Challenges and Raising the Value of Precision Oncology <u>V. Subbiah</u> ¹ , <u>J. Hernandez-Losa</u> ² , ¹ The University of Texas M. D. Anderson Cancer Center, Houston, US, ² Vall d'Hebron University Hospital, Barcelona, ES	
18:40 - 19:05	Making It Stick: Implementing the Advances in Precision Oncology into Clinical Practice <u>V. Subbiah</u> ¹ , <u>J. Naidoo</u> ² , <u>D.S.W. Tan</u> ³ , ¹ The University of Texas M. D. Anderson Cancer Center, Houston, US, ² Beaumont Hospital, Dublin, IE, ³ NCCS - National Cancer Centre Singapore, Singapore, SG	
19:05 - 19:15	Open Panel Audience Q&A <u>V. Subbiah</u> ¹ , <u>J. Naidoo</u> ² , <u>D.S.W. Tan</u> ³ , <u>J. Hernandez-Losa</u> ⁴ , ¹ The University of Texas M. D. Anderson Cancer Center, Houston, US, ² Beaumont Hospital, Dublin, IE, ³ NCCS - National Cancer Centre Singapore, Singapore, SG, ⁴ Vall d'Hebron University Hospital, Barcelona, ES	
19:15 - 19:25	Impact From Within: Patient Advocacy and the Voices That Bring Progress <u>A. Moore</u> , LUNGevery Foundation, Chicago, US	
19:25 - 19:30	Closing Remarks <u>V. Subbiah</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	



18:00 - 19:30	Type: Industry Satellite Symposium Title: Boehringer Ingelheim - Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer	Oviedo Auditorium - Hall 7
	Chair(s): Charles Rudin, US	
18:00 - 18:05	Welcome and Introduction of Agenda and Speakers	
	<u>C. Rudin</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
18:05 - 18:25	Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma	
	<u>P. Schoeffski</u> , KU Leuven - Laboratory of Experimental Oncology, Leuven, BE	
18:25 - 18:50	Improving HER2 Targeting in NSCLC with Selective TKI	
	<u>Z. Piotrowska</u> , MGH - Massachusetts General Hospital, Boston, US	
18:50 - 19:15	T-cell Engagers: Fighting Solid Tumors from Within	
	<u>C. Rudin</u> , MSKCC - Memorial Sloan Kettering Cancer Center, New York, US	
19:15 - 19:30	Panel Discussion and Audience Q&A, Key Takeaways and Closing Remarks	
	<u>C. Rudin</u> ¹ , <u>P. Schoeffski</u> ² , <u>Z. Piotrowska</u> ³ , ¹ MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ² KU Leuven - Laboratory of Experimental Oncology, Leuven, BE, ³ MGH - Massachusetts General Hospital, Boston, US	



18:00 - 19:30	Type: Industry Satellite Symposium Title: Regeneron Pharmaceuticals, Inc. - Putting the Patient First: The Value of Personalized Medicine for Nonmelanoma Skin Cancers Chair(s): Vishal Patel, GB	León Auditorium - Hall 7
18:00 - 18:05	Welcome and Introduction <u>V. Patel</u> , Birmingham City University - City South Campus, Birmingham, GB	
18:05 - 18:20	The CSCC and BCC Essentials <u>D.M. Miller</u> , Beth Israel Deaconess Medical Center, Boston, US	
18:20 - 18:50	Navigating the Patient Journey for CSCC <u>V. Patel</u> ¹ , <u>D.M. Miller</u> ² , <u>T. Guo</u> ³ , ¹ Birmingham City University - City South Campus, Birmingham, GB, ² Beth Israel Deaconess Medical Center, Boston, US, ³ University of California San Diego - UCSD, La Jolla, US	
18:50 - 19:20	Leveraging the Patient Voice in BCC <u>V. Patel</u> ¹ , <u>D.M. Miller</u> ² , <u>T. Guo</u> ³ , ¹ Birmingham City University - City South Campus, Birmingham, GB, ² Beth Israel Deaconess Medical Center, Boston, US, ³ University of California San Diego - UCSD, La Jolla, US	
19:20 - 19:30	Audience Q&A <u>V. Patel</u> ¹ , <u>D.M. Miller</u> ² , <u>T. Guo</u> ³ , ¹ Birmingham City University - City South Campus, Birmingham, GB, ² Beth Israel Deaconess Medical Center, Boston, US, ³ University of California San Diego - UCSD, La Jolla, US	



21.10.2023

08:30 - 09:50 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 9**
Title: Proffered Paper session 1 - Genitourinary tumours, non-prostate

Chair(s): Thomas Powles, GB; Srikala Sridhar, CA

08:30 - 08:40 **23590 - Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)**

A. Siefker-Radtke¹, N. Matsubara², S.H. Park³, R. Huddart⁴, E. Burgess⁵, M. Ozguroglu⁶, B. Perez Valderrama⁷, S. Triantos⁸, S. Akapame⁸, Y. Kean⁸, K. Deprince⁹, S. Mukhopadhyay¹⁰, Y. Loriot¹¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²National Cancer Center Hospital East, Chiba, JP, ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, GB, ⁵Levine Cancer Institute, Charlotte, US, ⁶Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TR, ⁷Hospital Universitario Virgen del Rocío, Seville, ES, ⁸Janssen Research & Development, Spring House, US, ⁹Janssen Research & Development, Beerse, BE, ¹⁰Janssen Research & Development, Lexington, US, ¹¹INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex, FR

08:40 - 08:50 **LBA102 - THOR-2 cohort 1: Results of erdafitinib (ERDA) vs intravesical chemotherapy (chemo) in patients (pts) with high-risk non-muscle-invasive bladder cancer (HR NMIBC) with select fibroblast growth factor receptor alterations (FGFRALT) who received prior bacillus calmette-guérin (BCG) treatment**

J. Catto¹, B. Tran², M. Roupret³, J. Gschwend⁴, Y. Loriot⁵, H. Nishiyama⁶, J. Palou⁷, S. Daneshmand⁸, S. Hussain¹, H. Cutuli⁹, G. Procopio¹⁰, V. Guadalupi¹⁰, N. Vasdev¹¹, V. Naini¹², L. Crow¹³, S. Triantos¹³, M. Baig¹³, G. Steinberg¹⁴, ¹University of Sheffield; Sheffield Teaching Hospitals NHS Trust, Sheffield, GB, ²Peter MacCallum Cancer Centre, Melbourne, AU, ³GRC 5 Predictive Onco-Uro, Hôpital Pitié-Salpêtrière, Sorbonne University, Paris, Cedex, FR, ⁴Rechts der Isar Hospital, Technical University of Munich, Munich, DE, ⁵INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex, FR, ⁶University of Tsukuba, Tsukuba, JP, ⁷Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, ES, ⁸Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, US, ⁹Sirio Libanes Hospital, Buenos Aires, AR, ¹⁰Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ¹¹Hertfordshire and Bedfordshire Urological Cancer Centre, Lister Hospital, East and North Herts NHS Trust, Stevenage, UK; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, GB, ¹²Janssen Research & Development, San Diego, US, ¹³Janssen Research & Development, Spring House, US, ¹⁴Rush University Medical Center, Chicago, US

08:50 - 09:00 **Invited Discussant 23590 and LBA102**

M. Van Der Heijden, Netherlands Cancer Institute, Amsterdam, NL

09:00 - 09:10 **Q&A**



- 09:10 - 09:20 **23600 - The double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) as second-line therapy for metastatic urothelial carcinoma (mUC)**
- B. Mcgregor¹, G. Sonpavde², L. Kwak¹, X. Gao³, C. Mantia¹, X. Wei¹, J. Berchuck¹, P. Ravi¹, M.D. Michaelson⁴, T. Choueiri¹, J. Bellmunt¹, ¹Dana Farber Cancer Institute, Boston, US, ²AdventHealth Medical Group - Internal Medicine at Orlando, Orlando, US, ³Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ⁴MGH - Massachusetts General Hospital, Boston, US
- 09:20 - 09:30 **LBA103 - ICRA: efficacy of paclitaxel with tremelimumab +/- durvalumab in metastatic urothelial carcinoma after progression on platinum chemotherapy and anti-PD-(L)1**
- S.M.H. Einerhand¹, J. Van Dorp¹, J. De Feijter¹, A. Daletzakis¹, S. Oosting², C. Bruijnen³, B. Suelmann³, M. Van Der Heijden¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²UMCG - University Medical Center Groningen, Groningen, NL, ³UMC - University Medical Center Utrecht, Utrecht, NL
- 09:30 - 09:40 **Invited Discussant 23600 and LBA103**
- T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB
- 09:40 - 09:50 **Q&A**



08:30 - 10:00 **Type: Special symposium** **Sevilla Auditorium - Hall 9**
Title: Advancing strategies for cancer immunotherapy
 Chair(s): Inge-Marie Svane, DK; Ignacio Melero, ES

08:30 - 08:35 **Introduction and scientific background**
I.-M. Svane, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK

08:35 - 08:50 **Activation of innate cells through Treg targeting**
S. Quezada, University College London, London, GB

08:50 - 09:05 **CAR-T and TCR-T approaches for solid cancers**
S. Kobold, LMU Klinikum der Universität München, Munich, DE

09:05 - 09:20 **Intra-tumoural immunotherapy**
I. Melero, Clinica Universidad de Navarra, Pamplona, ES

09:20 - 09:35 **New approaches in cancer vaccines**
S. Van Der Burg, LUMC - Leids Universitair Medisch Centrum, Leiden, NL

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**

08:30 - 10:00 **Type: Mini Oral session** **Granada Auditorium - Hall 3**
Title: Mini oral session 1 - NSCLC, metastatic
 Chair(s): Daniel Shao Weng Tan, SG; Yi-Long Wu, CN; Lizza Hendriks, NL; Jordi Remon Masip, FR

08:30 - 08:35 **LBA68 - FLAURA2: safety and CNS outcomes of first-line (1L) osimertinib (osi) ± chemotherapy (CTx) in EGFRm advanced NSCLC**
D. Planchard¹, P. Jänne², Y. Cheng³, C. Lee⁴, K. Laktionov⁵, T.-Y. Yang⁶, Y. Yu⁷, T. Kato⁸, L. Jiang⁹, B. Chewaskulyong¹⁰, S. Lucien Geater¹¹, J.-M. Maurel¹², C. Rojas¹³, L. Havel¹⁴, F.A. Shepherd¹⁵, K. Tanaka¹⁶, D. Ghiorghiu¹⁷, E. Armenteros Monterroso¹⁷, X. Huang¹⁷, J.C.-H. Yang¹⁸, ¹Institut Gustave Roussy, Thoracic Unit, Villejuif, Paris, FR, ²Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, US, ³Jilin Cancer Hospital, Changchun, CN, ⁴Cancer Care Centre, St. George Hospital, Kogarah, AU, ⁵Ministry of Health of the Russian Federation, Moscow, RU, ⁶Taichung Veterans General Hospital, Taichung, TW, ⁷Harbin Medical University Cancer Hospital, Harbin, CN, ⁸Kanagawa Cancer Center, Asahi Ward, Yokohama, JP, ⁹Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ¹⁰Faculty of Medicine, Chiang Mai University, Chiang Mai, TH, ¹¹Prince of Songkla University, Hat Yai District, Songkhla, TH, ¹²Cancercare, Rondebosch Oncology Centre, Rondebosch, Cape Town, ZA, ¹³Bradford Hill Clinical



Research Center, Santiago, CL, ¹⁴First Faculty of Medicine, Charles University, Thomayer Hospital, Prague, CZ, ¹⁵University Health Network, Princess Margaret Cancer Centre, Toronto, CA, ¹⁶Graduate School of Medical Sciences, Kyushu University, Fukuoka, JP, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW

08:35 - 08:40

LBA69 - Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): a randomized multicenter study

Y. Hu¹, F. Zhang¹, M. Zhao², Z. Zheng³, H. Zhang⁴, T. Jiang⁵, Z. Liu⁶, J. Wen⁷, X. Gan⁸, H. Wang⁹, L. Wu¹⁰, S. Cang¹¹, J. Zhao¹², X. Li¹³, L. Peng¹⁴, Z. Fan¹⁵, G. Shen¹⁶, Q. Zhou¹⁷, J. Zou¹⁸, ¹Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, ²The First Affiliated Hospital of China Medical University, Shenyang, CN, ³General Hospital of Northern Theater Command, Shenyang, CN, ⁴Air Force Medical University, xi'an, CN, ⁵The Second Affiliate Hospital of Air Force Medical University/Tangdu Hospital, Xi'an, CN, ⁶The Third Medical Center of Chinese PLA General Hospital, Beijing, CN, ⁷The Sixth Medical Center of Chinese PLA General Hospital, Beijing, CN, ⁸The First Affiliated Hospital of Nanchang University, Nanchang, CN, ⁹The Affiliated Hospital of Qingdao University, Qingdao, CN, ¹⁰Hunan Cancer Hospital, Changsha, CN, ¹¹Henan Province People's Hospital, Zhengzhou, CN, ¹²Changzhi People's Hospital of Changzhi Medical College, Changzhi, CN, ¹³The Seventh Medical Center of Chinese PLA General Hospital, Beijing, CN, ¹⁴The Fourth Medical Center of Chinese PLA General Hospital, Beijing, CN, ¹⁵Air Force General Hospital (PLA), Beijing, CN, ¹⁶Beijing Fengtai Youanmen Hospital, Beijing, CN, ¹⁷Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, CN, ¹⁸Renmin Hospital of Wuhan University/ Hubei General Hospital, Wuhan, CN

08:40 - 08:50

Invited Discussant LBA68 and LBA69

D.S.W. Tan, NCCS - National Cancer Centre Singapore, Singapore, SG

08:50 - 08:55

LBA70 - OSIRAM-1: A multicenter, open label, randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer (TORG1833)

Y. Nakahara¹, T. Kato², R. Isomura², T. Misumi³, M. Tamiya⁴, K. Yoh³, N. Furuya⁵, A. Ono⁶, Y. Takiguchi⁷, K. Koyama⁸, S. Ikeda⁹, K. Watanabe¹⁰, T. Tokito¹¹, N. Seki¹², H. Imai¹³, T. Shukuya¹⁴, Y. Shibata¹⁵, S. Hosokawa¹⁶, T. Kozuki¹⁷, H. Okamoto¹⁸, ¹Kitasato University School of Medicine, Sagamihara, JP, ²Kanagawa Cancer Center, Yokohama, JP, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Osaka International Cancer Institute, Osaka, JP, ⁵St.Marianna University School of Medicine, Kawasaki, JP, ⁶Shizuoka Cancer Center, Shizuoka, JP, ⁷Chiba University Hospital, Chiba, JP, ⁸Niigata Cancer Center Hospital, Niigata, JP, ⁹Kanagawa Cardiovascular and Respiratory Center, Yokohama, JP, ¹⁰Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JP, ¹¹Kurume University Hospital, Kurume, JP, ¹²Teikyo University Hospital, Tokyo, JP, ¹³Gunma Prefectural Cancer Center, Ota, JP, ¹⁴Juntendo University Hospital, Tokyo, JP, ¹⁵National Hospital Organization Yokohama Medical Center, Yokohama, JP, ¹⁶Japanese Red Cross Okayama Hospital, Okayama, JP, ¹⁷National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ¹⁸Yokohama Municipal Citizen's Hospital, Yokohama, JP



- 08:55 - 09:00 **LBA71 - A Multi-Centre Open-Label Randomized Phase II Study of Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC (RAMOSE trial interim analysis)**
- X. Le¹, J. Patel², E. Shum³, R. Sanborn⁴, C. Baik⁵, C.A. Shu⁶, C. Kim⁷, M. Fidler⁸, R. Hall⁹, N. Hanna¹⁰, N. Mohindra¹¹, J. Sabari¹², S. Heeke¹³, M. Hernandez¹⁴, J. Gray¹⁵, J. Heymach¹⁴, A. Saltos¹⁵, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Northwestern University Feinberg School of Medicine, Chicago, US, ³New York University Medical Center, New York, US, ⁴Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, ⁵University of Washington Seattle Cancer Care Alliance, Seattle, US, ⁶Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁷Lombardi Cancer Center Georgetown University, Washington, US, ⁸Rush Cancer Institute, Chicago, US, ⁹The University of Virginia, Charlottesville, US, ¹⁰Indiana University Simon Cancer Center, Indianapolis, US, ¹¹Northwestern University, Chicago, US, ¹²NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, ¹³University of Texas MD Anderson Cancer Center, Houston, US, ¹⁴MD Anderson Cancer Center, Houston, US, ¹⁵H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US
- 09:00 - 09:10 **Invited Discussant LBA70 and LBA71**
- Y.-L. Wu, Guangdong Province People's Hospital, Guangzhou, CN
- 09:10 - 09:15 **1312MO - Combining the antigen-presenting cell activator efitlagimod alpha (soluble LAG-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)**
- E. Carcereny¹, E. Felip², M. Majem³, B. Doger De Spéville⁴, T. Clay⁵, I. Bondarenko⁶, J. Peguero⁷, M. Cobo Dols⁸, M. Forster⁹, G. Ursol¹⁰, E. Kalinka¹¹, G. Garcia Ledo¹², L. Vila Martinez¹³, W. Iams¹⁴, M. Krebs¹⁵, J. Kefas¹⁶, K. Efthymiadis¹⁷, S. Perera¹⁸, C. Mueller¹⁹, F. Triebel²⁰, ¹ICO - Institut Català d'Oncologia Badalona -Hospital Germans Trias i Pujol, Badalona, ES, ²Vall d'Hebron University Hospital (VHIO), Barcelona, ES, ³Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁴Fundacion Jimenez Díaz, Madrid, ES, ⁵Saint John of God Subiaco Hospital, Subiaco, AU, ⁶City Clinical hospital Nr. 4, Dnipro, UA, ⁷Oncology Consultants, Houston, US, ⁸Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ⁹University College London Cancer Institute and University College London Hospital NHS Trust, London, GB, ¹⁰St. Luke's Hospital - Medical and Diagnostic Center "Acinus", Kropyvnytskyi, UA, ¹¹Instytut Centrum Zdrowia Matki Polki, Łódź, PL, ¹²HM Universitario Sanchinarro, Madrid, ES, ¹³Parc Taulí Sabadell Hospital Universitari, Barcelona, ES, ¹⁴Vanderbilt Ingram Cancer Center, Nashville, US, ¹⁵The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB, ¹⁶University College London Hospitals NHS Trust, London, GB, ¹⁷UCLH NHS Foundation Trust, London, GB, ¹⁸Immutep GmbH - Berlin, Berlin, DE, ¹⁹Immutep GmbH, Leipzig, DE, ²⁰Immutep S.A.S, SAINT-AUBIN, FR
- 09:15 - 09:20 **1313MO - Safety and preliminary efficacy of AZD7789, a bispecific antibody targeting PD-1 and TIM-3, in patients (pts) with stage IIIB–IV non-small-cell lung cancer (NSCLC) with previous anti-PD-(L)1 therapy**
- B. Besse¹, A. Italiano², S. Cousin², G. Ruiter³, E. Felip⁴, E. Castanon Alvarez⁵, S. Ramalingam⁶, C. Rolfo⁷, D.R. Spigel⁸, D. Andrew⁹, S. Cho¹⁰, T. Collins⁹, A. Hansen¹⁰, G.



Hawkins⁹, R. Kurek⁹, N. Ceaicovscaia¹⁰, M. Petruzzelli⁹, E. Dean⁹, A. Sacher¹¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Institute Bergonié, Bordeaux, FR, ³The Netherlands Cancer Institute, Amsterdam, NL, ⁴Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁵Clínica Universidad de Navarra, Madrid, ES, ⁶Emory University - Winship Cancer Institute, Atlanta, US, ⁷Mount Sinai Hospital, New York, US, ⁸Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US, ⁹AstraZeneca, Cambridge, GB, ¹⁰AstraZeneca, Gaithersburg, US, ¹¹Princess Margaret Cancer Centre, Toronto, CA

09:20 - 09:30

Invited Discussant 1312MO and 1313MO

L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL

09:30 - 09:35

1314MO - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

L. Paz-Ares¹, M.-J. Ahn², A. Lisberg³, S. Kitazono⁴, B.C. Cho⁵, G. Blumenschein⁶, E. Shum⁷, E. Pons-Tostivint⁸, Y. Goto⁹, K. Yoh¹⁰, R. Heist¹¹, P. Baas¹², D. Planchard¹³, M. Pérol¹⁴, E. Felip¹⁵, W.-C. Su¹⁶, H. Zebger-Gong¹⁷, L. Lan¹⁸, C. Liu¹⁸, J. Sands¹⁹, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³David Geffen School of Medicine at UCLA, Los Angeles, US, ⁴The Cancer Institute Hospital of JFCR, Tokyo, JP, ⁵Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁶University of Texas MD Anderson Cancer Center, Houston, US, ⁷NYU Perlmutter Cancer Center, New York, US, ⁸University Hospital Nantes, Nantes, FR, ⁹National Cancer Center Hospital, Tokyo, JP, ¹⁰National Cancer Center Hospital East, Kashiwa, JP, ¹¹Massachusetts General Hospital Cancer Center, Boston, US, ¹²The Netherlands Cancer Institute, Amsterdam, NL, ¹³Institut Gustave Roussy, Villejuif, FR, ¹⁴Léon Bérard Cancer Center, Lyon, FR, ¹⁵Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁶National Cheng Kung University Hospital, Tainan City, TW, ¹⁷Daiichi Sankyo Europe GmbH, Munich, DE, ¹⁸Daiichi Sankyo, Inc, Basking Ridge, US, ¹⁹Dana-Farber Cancer Institute, Harvard Medical School, Boston, US

09:35 - 09:40

1315MO - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

A. Schram¹, K. Goto², D.-W. Kim³, A. Hollebecque⁴, S.Y. Rha⁵, K. Nishino⁶, M. Duruisseaux⁷, K. Umemoto⁸, J.O. Park⁹, N. Leigh¹⁰, T. Macarulla¹¹, S. Liu¹², M.N. Al-Hallak¹³, J. Cleary¹⁴, C. Neuzillet¹⁵, Y. Goto¹⁶, A.K. Joe¹⁷, S. Adeyemi¹⁷, S. Jauhari¹⁷, A. Drilon¹⁸, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²National Cancer Center Hospital East, Kashiwa, JP, ³Seoul National University Hospital and Seoul National University College of Medicine, Seoul, KR, ⁴Gustave Roussy Cancer Campus, Villejuif, FR, ⁵Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ⁶Osaka International Cancer Institute, Osaka, JP, ⁷Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute; Cancer Research Centre of Lyon, UMR INSERM 1052 CNRS 5286; Claude Bernard University Lyon 1, University of Lyon, Lyon, FR, ⁸St. Marianna University School of Medicine, Kawasaki, JP, ⁹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁰Princess Margaret Cancer Centre, Toronto, CA, ¹¹Vall d'Hebrón University Hospital, Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, ES, ¹²Lombardi Comprehensive Cancer Center, Georgetown University, Washington, US, ¹³Barbara Ann Karmanos Cancer Institute, Wayne State University



School of Medicine, Detroit, US, ¹⁴Dana-Farber Cancer Institute, Boston, MA, United States of America, Harvard Medical School, Boston, US, ¹⁵Versailles-Saint Quentin University, Saint-Cloud, FR, ¹⁶National Cancer Center Hospital, Tokyo, JP, ¹⁷Merus N.V, Utrecht, NL, ¹⁸Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US

09:40 - 09:45 **1316MO - BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate, in patients with non-small cell lung cancer: Updated results from first-in-human phase I study**
L. Zhang¹, Y. Ma¹, Y. Zhao², W.F. Fang¹, H. Zhao¹, Y. Huang¹, Y. Yang¹, X. Hou¹, Z. Wen³, S. Zhang³, J. Wang³, S. Xiao³, H. Wang⁴, H. Zhu⁴, M. Olivo⁴, Y. Zhu⁴, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²The Affiliated Hospital of Qingdao University, Qingdao, CN, ³Baili-Bio (Chengdu) Pharmaceutical Co., Ltd., Chengdu, CN, ⁴SystImmune Inc., Redmond, US

09:45 - 10:00 **Invited Discussant 1314MO, 1315MO and 1316MO**
J. Remon Masip, Institut Gustave Roussy, Villejuif, Cedex, FR

08:30 - 10:00	Type: Educational session Title: Fight the enemy as soon as possible: News and views in the management of early stages colorectal cancer (CRC) Chair(s): <u>Jenny Seligmann</u> , GB; <u>Dominik Modest</u> , DE	Burgos Auditorium - Hall 3
----------------------	--	-----------------------------------

08:30 - 08:50 **Screening programmes 20 years later: Lessons learned and how to move on?**
M. Van Leerdam, LUMC-Leiden University Medical Center, Leiden, NL

08:50 - 09:05 **How do we optimise imaging?**
E. Dresen, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

09:05 - 09:25 **Current systemic treatment of locally advanced colon cancer**
J. Seligmann, The University of Leeds, Leeds, GB

09:25 - 09:45 **Future directions neoadjuvant versus adjuvant**
D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE

09:45 - 10:00 **Q&A and Discussion**



08:30 - 10:00 **Type: Special symposium** **Valencia Auditorium - Hall 10**
Title: Open questions in the management of mesothelioma
Chair(s): Jean Yannis Perentes, CH; Kenneth Rosenzweig, US

08:30 - 08:35 **Introduction and scientific background**
P. Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

08:35 - 08:50 **When and when not to operate**
J.Y. Perentes, UNIL - University of Lausanne, Lausanne, CH

08:50 - 09:05 **What is the optimal first-line treatment?**
A. Scherpereel, DRC / CHRU of Lille, Lille, FR

09:05 - 09:20 **Biomarker-selected therapy: Progress or delusion?**
P. Baas, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

09:20 - 09:35 **Preoperative or postoperative radiation for mesothelioma**
K. Rosenzweig, Mount Sinai Hospital, New York, US

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**



08:30 - 10:00 **Type: Educational session** **Salamanca Auditorium - Hall 3**
Title: Unravelling choices for adjuvant endocrine therapy in HR+ early breast cancer
Chair(s): Stephen Johnston, GB; Nadia Harbeck, DE

08:30 - 08:50 **Risk assessment stratification**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

08:50 - 09:10 **ER positive breast cancer: What endocrine therapy is needed in premenopausal patients?**
S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL

09:10 - 09:30 **ER positive breast cancer: What endocrine therapy is needed in menopausal patients?**
P. Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

09:30 - 09:50 **Beyond chemo and endocrine therapy**
S. Johnston, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

09:50 - 10:00 **Q&A and Discussion**



08:30 - 10:00 **Type: Special symposium** **Málaga Auditorium - Hall 10**
Title: New targets on the horizon
Chair(s): Ruth Plummer, GB; Alexander Drilon, US

- 08:30 - 08:35 **Introduction and scientific background**
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 08:35 - 08:50 **POLTheta inhibitors and USP1 inhibitors for BRCA-deficient cancers**
A. D'Andrea, Dana Farber Cancer Institute, Boston, US
- 08:50 - 09:05 **Innovative/novel delivery of immunotherapeutics**
A. Marabelle, Institut Gustave Roussy, Villejuif, FR
- 09:05 - 09:20 **Peptide-based cancer vaccines**
J. Walz, University Clinic Tübingen, Tuebingen, DE
- 09:20 - 09:35 **Mutant specific inhibitors**
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 09:35 - 09:55 **Discussion**
- 09:55 - 10:00 **Conclusions and perspectives**
R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB



08:30 - 09:50 **Type: Special symposium** **Santander Auditorium**
Title: Protein degrading cancer drugs: The promises of **- Hall 9**
the new generation
Chair(s): Madelon Maurice, NL; David Spiegel, US

08:30 - 08:35 **Introduction and scientific background**
M. Maurice, UMC - University Medical Center Utrecht, Utrecht, NL

08:35 - 08:50 **Degrading oncogenic transcription factors**
N. Thomä, Friedrich Miescher Institute for Biomedical Research, Basel, CH

08:50 - 09:05 **Degrading cancer targets on the cell surface (SureTACs)**
M. Maurice, UMC - University Medical Center Utrecht, Utrecht, NL

09:05 - 09:20 **Bifunctional small molecules that mediate the degradation of extracellular proteins**
D. Spiegel, Yale University School of Medicine - Yale Cancer Center, New Haven, US

09:20 - 09:45 **Discussion**

09:45 - 09:50 **Conclusions and perspectives**
D. Spiegel, Yale University School of Medicine - Yale Cancer Center, New Haven, US



08:30 - 10:00	Type: Special symposium Title: Next generation diagnostics of blood cancer: An optimistic view on the future of cancer testing Chair(s): Thorsten Zenz, CH; Iñaki Martin Subero, ES	Oviedo Auditorium - Hall 7
08:30 - 08:35	Introduction and scientific background <u>I. Martin Subero</u> , IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES	
08:35 - 08:50	Liquid biopsy in lymphoma <u>D. Kurtz</u> , Stanford University, Stanford, US	
08:50 - 09:05	Multi-omic profiling in lymphoid neoplasms <u>I. Martin Subero</u> , IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES	
09:05 - 09:20	Drug sensitivity testing in blood cancer <u>T. Zenz</u> , USZ - University Hospital Zürich, Zurich, CH	
09:20 - 09:35	How novel profiling methods impact trial design <u>R. Schlenk</u> , NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE	
09:35 - 09:55	Discussion	
09:55 - 10:00	Conclusions and perspectives <u>T. Zenz</u> , USZ - University Hospital Zürich, Zurich, CH	



08:30 - 10:00	Type: Educational session Title: Making essential cancer drugs affordable Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL	Cádiz Auditorium - NCC
08:30 - 08:50	Insights in essential medicine availability and accessibility from ESMO antineoplastic medicines study 2.0 <u>N. Cherny</u> , Shaare Zedek Medical Center, Jerusalem, IL	
08:50 - 09:05	Policy and intellectual property regulatory instruments as tools to enhance access to expensive essential cancer medicines <u>E. 'T Hoen</u> , Medicines Law & Policy, Amsterdam, NL	
09:05 - 09:20	Governmental policies to control cancer medicine prices <u>K. Tay-Teo</u> , WHO - World Health Organization, Geneva, CH	
09:20 - 09:35	India's approach to advance access to cancer medicines <u>M. Sengar</u> , Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN	
09:35 - 10:00	Q&A and Discussion	



08:30 - 10:00 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Opening session & Keynote lectures
 Chair(s): Virpi Sulosaari, FI

08:30 - 08:35 **Welcome address**
V. Sulosaari, Turku University of Applied Sciences, Turku, FI

08:35 - 08:40 **Welcome from Spanish Oncology Nursing Society (Sociedad Española de Enfermería Oncológica, SEEO)**
J. De La Torre-Montero, Universidad Pontificia Comillas, Madrid, ES

08:40 - 08:45 **Welcome from ESMO**
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

08:45 - 09:05 **Keynote lecture: The effectiveness of nurse-led interventions for cancer symptom management**
D. Kelly, Cardiff University - School of Healthcare Sciences, Cardiff, GB

09:05 - 09:25 **Keynote lecture: Priorities for future research in cancer nursing**
G. Bagcivan, Koc University - School of Nursing, Istanbul, TR

09:25 - 09:40 **CN1 - Integrating an electronic patient reported outcome measure (ePROM) into a nurse-led rare cancer pathway**
J. Ireson¹, T. Holch², D. Greenfield³, K. Singh¹, S. Gillett¹, S. Rollins¹, S. Radley³, J. Tidy¹, G. Jones², ¹Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ²Leeds Beckett University, Leeds, GB, ³Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB

09:40 - 09:50 **Lifetime Achievement Award, RECaN Award, NRDA Award**

09:50 - 10:00 **Q&A and discussion**

08:45 - 10:00 **Type: Proffered Paper session** **Bilbao Auditorium - NCC**
Title: Proffered Paper session 2 - Gynaecological cancers
 Chair(s): Domenica Lorusso, IT; Sven Mahner, DE

08:45 - 08:55 **LBA40 - Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma.**
N. Colombo¹, K. Harano², E. Hudson³, F. Galli⁴, Y. Antill⁵, C.H. Choi⁶, M. Rabaglio⁷, F. Marmé⁸, E. Petru⁹, C.-H. Lai¹⁰, E. Biagioli¹¹, L. Fariñas Madrid¹², K. Takehara¹³, K.



Allan¹⁴, Y.C. Lee¹⁵, E. Piovano¹⁶, C. Zamagni¹⁷, G. Tasca¹⁸, A. Ferrero¹⁹, M.P. Barretina Ginesta²⁰, ¹European Institute of Oncology IRCCS, Milan, IT, ²National Cancer Center Hospital East, Kashiwa, JP, ³Velindre Cancer Centre, Cardiff, GB, ⁴Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, IT, ⁵Frankston Hospital, Melbourne, AU, ⁶Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Inselspital - Universitatsspital, Bern, CH, ⁸UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, ⁹Medical University of Graz Division of Gynecology, Graz, AT, ¹⁰Chang Gung Memorial Hospital, Linkou Branch, Taoyuan City, TW, ¹¹Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, IT, ¹²Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹³National Hospital Organization Shikoku Cancer Center, Matsuyama, JP, ¹⁴University of Glasgow, Glasgow, GB, ¹⁵The University of Sydney, Sydney, AU, ¹⁶AOU Città della Salute e della Scienza - Presidio Sant'Anna, Torino, IT, ¹⁷IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT, ¹⁸Istituto Oncologico Veneto IOV, IRCCS, Padova, IT, ¹⁹Azienda Ospedaliera Ordine Mauriziano - Presidio Umberto I, Torino, IT, ²⁰Institut Català d'Oncologia & IDIBGI, Girona, ES

08:55 - 09:05 **Invited Discussant LBA40**

D.S. Tan, NUHS - National University Health System, Singapore, SG

09:05 - 09:15 **Q&A**

09:15 - 09:25 **LBA41 - Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): results from the Phase III DUO-E/GOG-3041/ENGOT-EN10 trial**

S. Westin¹, K. Moore², H.S. Chon³, J.-Y. Lee⁴, J. Thomes Pepin⁵, M. Sundborg⁶, J. De La Garza⁷, S. Nishio⁸, K. Wang⁹, K. Mcintyre¹⁰, T. Tillmanns¹¹, F. Contreras Mejia¹², A. De Melo¹³, D. Klasa-Mazurkiewicz¹⁴, C. Papadimitriou¹⁵, M. Gil Martín¹⁶, B. Brasiuniene¹⁷, C. Donnelly¹⁸, X. Liu¹⁹, E. Van Nieuwenhuysen²⁰, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Stephenson Cancer Center, University of Oklahoma Medical Center, Oklahoma City, US, ³University of South Florida, Tampa, US, ⁴Yonsei University College of Medicine, Seoul, KR, ⁵Minnesota Oncology, Maplewood, US, ⁶FirstHealth Moore Regional Hospital, Pinehurst, US, ⁷Texas Oncology-San Antonio Medical Center, San Antonio, US, ⁸Kurume University School of Medicine, Kurume, JP, ⁹Medical University Cancer Institute & Hospital, Tianjin, CN, ¹⁰Texas Health Presbyterian Hospital, Dallas, US, ¹¹West Cancer Center & Research Institute, Germantown, US, ¹²National Cancer Institute of Colombia, Bogotá, CO, ¹³Brazilian National Cancer Institute, Rio de Janeiro, BR, ¹⁴Medical University of Gdańsk, and PGOG, Gdańsk, PL, ¹⁵The National and Kapodistrian University of Athens, and HeCOG, Athens, GR, ¹⁶Catalan Institute of Oncology-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Hospital Duran i Reynals, L'Hospitalet-Barcelona, and GEICO, Barcelona, ES, ¹⁷National Cancer Institute of Lithuania, Faculty of Medicine of Vilnius University, and NSGO, Vilnius, LT, ¹⁸AstraZeneca, Cambridge, GB, ¹⁹AstraZeneca, Gaithersburg, US, ²⁰UZ Leuven, and BGOG, Leuven, BE

09:25 - 09:35 **LBA42 - Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO**

**randomized phase Iib UTOLA trial**

F. Joly Lobbedez¹, A. Leary², I. Ray-Coquard³, B. Asselain⁴, M. Rodrigues⁵, L. Gladiéff⁶, F. Bazan⁷, S. Abadie Lacourtoisie⁸, C. Lebreton⁹, L. Bengrine Lefevre¹⁰, K. Leroy¹¹, R. Leman¹, P. Fournel¹², R. Largillier¹³, F. Selle¹⁴, J.-S. Frenel¹⁵, Y. Fernandez¹⁶, C. Foa¹⁷, B. You¹⁸, J. Alexandre¹⁹, ¹Centre Francois Baclesse, Caen, Cedex, FR, ²Gustave Roussy, Villejuif, FR, ³Centre Léon Bérard and University of Lyon, Lyon, FR, ⁴ARCAGY-GINECO, Paris, FR, ⁵Institut Curie, Paris, FR, ⁶Institut Claudius Régaud, IUCT Oncopole, Toulouse, FR, ⁷CHRU BESANCON - Hôpital Jean Minjot, BESANCON, FR, ⁸Institut de Cancérologie de l'Ouest - ICO - Site Paul Papin, Angers, FR, ⁹Institut Bergonié, Bordeaux, FR, ¹⁰Centre Georges-François Leclerc, Dijon, FR, ¹¹Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, Paris, FR, ¹²Centre Hospitalier Universitaire de Saint-Etienne, pôle de cancérologie, Saint-Étienne, FR, ¹³Centre Azuréen de Cancérologie, MOUGINS, FR, ¹⁴Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, FR, ¹⁵Institut de Cancérologie de l'Ouest - Site René Gauducheau, Saint-Herblain, FR, ¹⁶Institut de Cancérologie de Lorraine - Centre Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹⁷Hôpital Saint-Joseph, Marseille, FR, ¹⁸Hospices Civil de Lyon - Centre Hospitalier Lyon Sud, PIERRE BENITE, Pierre-Bénite, FR, ¹⁹Université de Paris Cité, AP-HP, Cochin Port-Royal, Paris, FR

09:35 - 09:45 **Invited Discussant LBA41 and LBA42**

D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT

09:45 - 10:00 **Q&A**



08:45 - 10:00	Type: Multidisciplinary session Title: Relieving complex suffering in women with advanced cervical cancer Chair(s): Snezana Bosnjak, RS; Giovanni Aletti, IT	Toledo Auditorium - Hall 3
08:45 - 08:50	Presentation of case/condition <u>S. Bosnjak</u> , Institute for Oncology and Radiology of Serbia, Belgrade, RS	
08:50 - 09:05	Refractory pain <u>J. Paice</u> , Northwestern University, Chicago, US	
09:05 - 09:20	Ureteral and bowel obstruction, haemorrhage: A surgical perspective <u>G. Aletti</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
09:20 - 09:35	A psycho-oncologist's perspective <u>M. Die-Trill</u> , Atrium: Psycho-Oncology & Clinical Psychology, Madrid, ES	
09:35 - 09:50	Nausea and vomiting in advanced cervical cancer <u>A. Baptista Capela</u> , Centro Hospitalar Vila Nova de Gaia / Espinho, Vila Nova de Gaia, PT	
09:50 - 10:00	Discussion	



08:45 - 10:00	Type: Multidisciplinary session Title: Interdisciplinary management of advanced and functional digestive neuroendocrine tumours Chair(s): Rachel Riechelmann, BR; Stefano Partelli, IT	León Auditorium - Hall 7
08:45 - 08:50	Presentation of case/condition <u>S. De Dosso</u> , EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH	
08:50 - 09:10	Role of surgery in advanced disease <u>S. Partelli</u> , UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT	
09:10 - 09:30	Role of locoregional and ablative therapies <u>R. Riechelmann</u> , A.C. Camargo Cancer Center - Unidade Antonio Prudente, Sao Paulo, BR	
09:30 - 09:50	Role of systemic therapies in the control of hormone-release <u>S. Singh</u> , Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA	
09:50 - 10:00	Q&A and Discussion	



08:45 - 09:45 **Type: Young Oncologists session** **Ávila Auditorium - NCC**
Title: YO Boxing session
Chair(s): Maria Kfoury, FR; Emre Kocakavuk, DE

08:45 - 08:55 **Do you need a basic science rotation for your career in oncology? Yes**
J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

08:55 - 09:05 **Do you need a basic science rotation for your career in oncology? No**
S. Pilotto, University of Verona, Verona, IT

09:05 - 09:15 **Discussion led by Chairs**

09:15 - 09:25 **Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours - Yes**
B. Kiesewetter-Wiederkehr, Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT

09:25 - 09:35 **Off-label molecular-guided treatments are a reasonable approach for refractory advanced solid tumours - No**
Y. Metaxas, Spital Thurgau AG - Kantonsspital Muensterlingen, Muensterlingen, CH

09:35 - 09:45 **Discussion led by Chairs**



10:00 - 11:00	Type: Special session Title: Climate Change Task Force - How to build more sustainable and environment-friendly oncology care Chair(s): Mathilde Jalving, NL; Rebecca Lee, GB	Pamplona Auditorium - Hall 9
10:00 - 10:10	Moving towards a sustainable academic society: Update from the ESMO Climate Change Task Force <u>R. Lee</u> , The University of Manchester, Manchester, GB	
10:10 - 10:20	Climate toxicity of cancer care <u>S. O'Reilly</u> , CUH - Cork University Hospital, Cork, IE	
10:20 - 10:30	A sustainable oncology department: Practical tips and tricks <u>M. Wolodarski</u> , Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE	
10:30 - 10:40	Rationale drug prescribing to reduce environmental impact <u>M. Van De Poll</u> , Maxima Medisch Centrum -Veldhoven, Veldhoven, NL	
10:40 - 11:00	Discussion	
10:15 - 11:35	Type: Proffered Paper session Title: Proffered Paper session - Breast cancer, metastatic Chair(s): Hervé Bonnefoi, FR; Janice Wing-Hang Tsang, HK	Barcelona Auditorium - Hall 9
10:15 - 10:25	3810 - First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors J. Wu ¹ , <u>J. Zhang</u> ² , H. Li ³ , X. Wang ⁴ , Q.Y. Zhang ⁵ , Y. Shi ⁶ , M. Yan ⁷ , Y. Pan ⁸ , A. Shen ⁹ , Q. Chen ¹⁰ , Q. Rao ¹⁰ , H. Wei ¹¹ , C. Li ¹¹ , L. Yang ¹¹ , Q. Huang ¹¹ , Z. Cao ¹¹ , Q. Wu ¹¹ , ¹ Fudan University Cancer Institute, Shanghai, CN, ² Fudan University Shanghai Cancer Center, Shanghai, CN, ³ Peking University Cancer Hospital and Institute, Beijing, CN, ⁴ Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, ⁵ 3rd Affiliated Hospital of Harbin Medical University, Harbin, CN, ⁶ TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁷ Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁸ Anhui Provincial Hospital, Hefei, CN, ⁹ The First Affiliated Hospital of USTC/ Anhui Provincial Hospital, Hefei, CN, ¹⁰ Sun Yat-Sen Memorial Hospital, Guangzhou, CN, ¹¹ Hansoh Pharma Group CO.,LTD., Shanghai, CN	
10:25 - 10:35	3760 - Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study <u>S. Modi</u> ¹ , W. Jacot ² , H. Iwata ³ , Y.H. Park ⁴ , M.J. Vidal Losada ⁵ , W. Li ⁶ , J. Tsurutani ⁷ , K. Zaman ⁸ , N. Ueno ⁹ , A. Prat ¹⁰ , K. Papazisis ¹¹ , H. Rugo ¹² , N. Harbeck ¹³ , S.-A. Im ¹⁴ , M. De Laurentiis ¹⁵ , C. Orbegoso ¹⁶ , L. Yung ¹⁷ , F.-C. Cheng ¹⁷ , Y. Cheng ¹⁷ , D. Cameron ¹⁸ , ¹ Memorial Sloan Kettering Cancer Center, New York, US, ² Institut du Cancer de	



Montpellier, Montpellier, FR, ³Aichi Cancer Center Hospital, Nagoya, JP, ⁴Samsung Medical Center, Seoul, KR, ⁵Hospital Clínic de Barcelona, Barcelona, ES, ⁶The First Hospital of Jilin University, Changchun, CN, ⁷Showa University, Shinagawa, JP, ⁸Lausanne University Hospital CHUV, Lausanne, CH, ⁹University of Hawaii Cancer Center, Honolulu, US, ¹⁰Translational Genomics and Targeted Therapies Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, ES, ¹¹Euromedica General Clinic, Thessaloniki, GR, ¹²UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ¹³LMU University Hospital, Munich, DE, ¹⁴Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR, ¹⁵Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, IT, ¹⁶Daiichi Sankyo, Inc., Rueil-Malmaison, FR, ¹⁷Daiichi Sankyo, Inc., Basking Ridge, US, ¹⁸University of Edinburgh, Edinburgh, GB

10:35 - 10:45 **Invited Discussant 3810 and 3760**

G. Bianchini, IRCCS Ospedale San Raffaele, Milan, IT

10:45 - 10:55 **Q&A**

10:55 - 11:05 **3770 - A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2⁺) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03**

S. Hurvitz¹, S. Modi², W. Li³, Y.H. Park⁴, W. Chung⁵, S.-B. Kim⁶, J. Cortés⁷, T. Yamashita⁸, J. Pedrini⁹, S.-A. Im¹⁰, L.-M. Tseng¹¹, N. Harbeck¹², I. Krop¹³, G. Curigliano¹⁴, E. Mathias¹⁵, J. Cathcart¹⁶, A. Cagnazzo¹⁵, S. Ashfaq¹⁵, A. Egorov¹⁵, F. André¹⁷, ¹David Geffen School of Medicine at UCLA, Los Angeles, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³The First Hospital of Jilin University, Changchun, CN, ⁴Samsung Medical Center, Seoul, KR, ⁵National Cheng Kung University, Tainan City, TW, ⁶Asan Medical Center, Seoul, KR, ⁷International Breast Cancer Center, Barcelona, ES, ⁸Kanagawa Cancer Center, Yokohama, JP, ⁹Hospital Nossa Senhora da Conceicao, Porto Alegre, BR, ¹⁰Seoul National University Hospital, Seoul, KR, ¹¹Taipei Veterans General Hospital, Taipei City, TW, ¹²LMU University Hospital, Munich, DE, ¹³Yale Cancer Center, New Haven, US, ¹⁴European Institute of Oncology, IRCCS, and University of Milan, Milan, IT, ¹⁵Daiichi Sankyo, Inc., Basking Ridge, US, ¹⁶Daiichi Sankyo Inc., Basking Ridge, US, ¹⁷Institiut Gustave Roussy, Villejuif, FR

11:05 - 11:15 **3780 - Persistence under abemaciclib and endocrine treatment (ABA⁺ET) in patients with advanced breast cancer (aBC): First results of the randomized IMPACT trial comparing patient coaching with the MASCC oral agent teaching tool (MOATT) versus local routine patient coaching (LC)**

M. Welslau¹, P. Fasching², L. Mueller³, E. Belleville⁴, L. Rieger⁵, M.-O. Zahn⁶, B. Lex⁷, L. Häberle⁸, H. Tesch¹, ¹Klinikum Aschaffenburg, Aschaffenburg, DE, ²Universitätsklinikum Erlangen, Erlangen, DE, ³Onkologie Untere Ems - Leer Papenburg Emden, Leer, DE, ⁴ClinSol, wuerzburg, DE, ⁵Praxis Dr. Vehling-Kaiser, Landshut, DE, ⁶MVZ Onkologische Kooperation Harz, Goslar, DE, ⁷Department of Gynecology and Obstetrics, Kulmbach, DE, ⁸Universitätsklinik Erlangen, Erlangen, DE



11:15 - 11:25 **Invited Discussant 3770 and 3780**
J.W.-H. Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK

11:25 - 11:35 **Q&A**

<p>10:15 - 11:45</p>	<p>Type: Special symposium Title: Open questions in immunotherapy for advanced NSCLC: Duration of IO, combinations and rechallenge Chair(s): Raffaele Califano, GB; Sanjay Popat, GB</p>	<p>Sevilla Auditorium - Hall 9</p>
-----------------------------	--	---

10:15 - 10:20 **Introduction and scientific background**
R. Califano, The Christie NHS Foundation Trust, Manchester, GB

10:20 - 10:35 **Duration of IO treatment**
B. Besse, Institut Gustave Roussy, Villejuif, FR

10:35 - 10:50 **Immunotherapy re-challenge: Who, when and why**
N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

10:50 - 11:05 **When and how to combine PD-1/PD-L1?**
S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

11:05 - 11:20 **How to overcome IO resistance: New approaches**
E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**
S. Popat, The Royal Marsden Hospital - NHS Foundation Trust, London, GB



10:15 - 11:45 **Type: Special symposium** **Granada Auditorium - Hall 3**
Title: Upper GI cancers: From bench to bedside
Chair(s): Nicole van Grieken, NL; Kohei Shitara, JP

10:15 - 10:20 **Introduction and scientific background**

K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

10:20 - 10:35 **Heterogeneity, evolution, and outcomes in gastroesophageal cancer**

S. Klempner, MGH - Massachusetts General Hospital, Boston, US

10:35 - 10:50 **ctDNA: From theory to clinical translation**

J. Lee, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

10:50 - 11:05 **New directions in pancreas cancer**

C. Jorgensen, Cancer Research UK Manchester Institute, Manchester, GB

11:05 - 11:20 **Evolving diagnostics in gastroesophageal cancer**

N. Van Grieken, Vrije University Medical Centre (VUMC), Amsterdam, NL

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**

N. Van Grieken, Vrije University Medical Centre (VUMC), Amsterdam, NL



10:15 - 11:45 **Type: Special symposium** **Burgos Auditorium - Hall 3**
Title: What's the future in melanoma therapy? Novel targets, new drugs, reinvented approaches
 Chair(s): Omid Hamid, US; Joanna Mangana, CH

10:15 - 10:20 **Introduction and scientific background**

10:20 - 10:40 **Revisiting old friends: New clinical developments of MEKi/BRAFi/NRASI combinations**

R. Sullivan, MGH - Massachusetts General Hospital, Boston, US

10:40 - 11:00 **Bispecific T-Cell engagers (TCE) and fusion protein carriers: Ready for prime-time in melanoma?**

O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US

11:00 - 11:20 **Clinical data, NGS, (x)-omics et al.: What is the ideal mixture to identify and overcome primary resistance to immune-checkpoint inhibitors?**

I. Pires Da Silva, Melanoma Institute Australia, Wollstonecraft, AU

11:20 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**

10:15 - 11:45 **Type: Proffered Paper session** **Salamanca Auditorium - Hall 3**
Title: Proffered Paper session 1 - Basic Science and Translational research

Chair(s): Federica Di Nicolantonio, IT; Stefan Fröhling, DE

10:15 - 10:25 **LBA55 - An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer**

J. Black¹, A. Frankell¹, S. Veeriah², M. Colopi², M. Hill¹, C. Abbott³, S. Boyle³, B. Li³, R. Chen³, M. Al Bakir¹, C. Martinez Ruiz², A. Huebner², M. Jamal-Hanjani⁴, N. Mcgranahan⁴, C. Swanton¹, ¹Francis Crick Institute, London, GB, ²University College London, London, GB, ³Personalis, Inc. - Headquarters (Office and Laboratory), Menlo Park, US, ⁴UCL Cancer Institute - Paul O'Gorman Building, London, GB

10:25 - 10:35 **12060 - Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling**

S. Baca¹, J.-H. Seo², J. Berchuck¹, T. El Zarif¹, R. Saliby¹, K. Semaan², B. Fortunato¹, M. Awad¹, C. Chau³, J.A. Decaprio², W.D. Figg³, A. Hata⁴, F.S. Hodi⁵, K. Ligon², K. Ng², M. Oser², S. Tolaney², P. Wen², M. Freedman¹, T. Choueiri¹, ¹Dana-Farber Cancer Institute, Boston, US, ²Dana Farber Cancer Institute, Boston, US, ³NIH - National Institutes of Health, Bethesda, US, ⁴MGH - Massachusetts General Hospital, Boston, US, ⁵Dana



Farber Cancer Institute - Longwood Center, Boston, US

- 10:35 - 10:45 **LBA16 - Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)**
- L. Mileskin¹, T. Bochtler², C. Pauli³, G. Durán-Pacheco⁴, C. Arslan⁵, F. Bigot⁶, N. Chalabi⁴, N. Cook⁷, A. Italiano⁸, F. Losa⁹, J. Menezes¹⁰, C. Michaud⁴, M. Ozguroglu¹¹, R. Pazo Cid¹², J. Ross¹³, K.-K. Shiu¹⁴, M. Stahl¹⁵, M. Thomas⁴, H. Moch³, A. Krämer², ¹The University of Melbourne, Melbourne, AU, ²German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, DE, ³University of Zürich and University Hospital Zürich, Zurich, CH, ⁴F. Hoffmann-La Roche Ltd, Basel, CH, ⁵Medical Park İzmir Hospital, İzmir, TR, ⁶Institut de Cancérologie de l'Ouest, Nantes-Angers, FR, ⁷The University of Manchester and the Christie NHS Foundation Trust, Manchester, GB, ⁸Institute Bergonié, Bordeaux, FR, ⁹Hospital de Sant Joan Despí Moisès Broggi, ICO Hospitalet, Barcelona, ES, ¹⁰Centro Pesquisa Integrado em Oncologia, Porto Alegre, BR, ¹¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Istanbul, TR, ¹²Miguel Servet University Hospital, Zaragoza, ES, ¹³Foundation Medicine, Inc./SUNY Upstate Medical University, Cambridge, US, ¹⁴UCL Cancer Institute, London, GB, ¹⁵Evang. Kliniken Essen-Mitte, Essen, DE
- 10:45 - 10:55 **Invited Discussant LBA55, 1206O and LBA16**
- F. Di Nicolantonio, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT
- 10:55 - 11:05 **Q&A**
- 11:05 - 11:15 **1207O - Beyond 100,000 genomes project: Whole genome sequencing for cancer patients within NHS Genomic Medicine Service**
- A. Sosinsky¹, S. Walker¹, J. Ambrose¹, R. Coleran¹, O. Yavorska¹, A. Hamblin¹, N. Murugaesu¹, P. Talley², S. `Hing², J. Starczynski², S. Deans², S. Hill², ¹Genomics England Ltd, London, GB, ²NHS England, London, GB
- 11:15 - 11:25 **2231O - Pan-cancer assessment of the impact of intronic variants on cancer development and progression**
- A. Safonov¹, M. Mehine², O. Ceyhan-Birsoy², D. Brown², C. Bandlamudi¹, A. Forbes³, A. Gazzo², P. Selenica², R. Shen², E. Khurana⁴, L. Norton⁵, D. Solit¹, S. Chandarlapaty¹, P. Razavi², M. Robson¹, B. Weigelt¹, M. Berger², M. Ladanyi¹, J. Reis-Filho¹, D. Mandelker², ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Weill Cornell Medical College, New York, US, ⁴Weill Cornell Medicine Sandra and Edward Meyer Cancer Center, New York, US, ⁵Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US
- 11:25 - 11:35 **Invited Discussant 1207O and 2231O**
- C. Swanton, Francis Crick Institute, London, GB



11:35 - 11:45 Q&A

10:15 - 11:15 Type: Mini Oral session **Málaga Auditorium - Hall 10**
 Title: Mini oral session - Head and neck cancer
 Chair(s): Panagiota Economopoulou, GR; Marc Oliva, ES

10:15 - 10:20 **855MO - Adjuvant immunotherapy after salvage surgery in head and neck cancer squamous cell carcinoma (HNSCC): Phase II trial evaluating the efficacy and the toxicity of Nivolumab (ADJORL1)**

J. Guerlain¹, N. Cozic¹, A. Daste², O. Malard³, J. Fayette⁴, F. Rolland⁵, O. Mauvais⁶, A. Johnson⁷, S. Salas⁸, M. Vinches⁹, A. Bozec¹⁰, S. Vergez¹¹, E. De Monès¹², I. Breuskin¹, M. Iacob¹³, B. Archambaud¹, F. Janot¹, C. Even¹³, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²CHU Bordeaux - Hopital St. André, Bordeaux, FR, ³Chu Nantes Hotel Dieu, Nantes, FR, ⁴Centre Léon Bérard, Lyon, FR, ⁵ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁶CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ⁷Centre Francois Baclesse, Caen, FR, ⁸AP-HM - CHU La Timone Enfants, Marseille, FR, ⁹ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ¹⁰Centre Antoine Lacassagne (CLCC), Nice, FR, ¹¹IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR, ¹²CHU - Centre Universitaire Hospitalier de Bordeaux, Bordeaux, FR, ¹³Institut Gustave Roussy, Villejuif, Cedex, FR

10:20 - 10:25 **856MO - A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis**

D. Zandberg¹, D. Clump¹, B. Isett¹, R. Bao¹, H. Wang¹, L. Vujanovic¹, H. Li¹, J. Ohr¹, M. Fenton¹, H. Skinner¹, R. Seethala¹, S. Chiosea¹, B. Jonathan², J. Bauman³, R. Ferris⁴, ¹UPMC Hillman Cancer Center, Pittsburgh, US, ²Winship Cancer Institute of Emory University, Atlanta, US, ³University of Arizona Cancer Center, Tucson, US, ⁴University of Pittsburgh Cancer Institute, Pittsburgh, US

10:25 - 10:30 **LBA46 - SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & Neck Squamous Cell Carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy.**

N. Mach¹, E. Fernandez¹, R. Vernet¹, O. Vonrohr¹, M. Urwyler¹, E. Charrier¹, M.-C. Belkouch¹, V. Saingier¹, F. Courtout¹, C. De Vito¹, O. Rubin¹, V. Ancrenaz¹, J. Grogg², J. Renaux³, K. Gysel⁴, G. Müller⁴, T. Brezina⁵, T. Rordorf⁵, M. Joerger⁶, O. Michielin¹, ¹Geneva University Hospital HUG, Geneva, CH, ²MaxiVax SA, Geneva, CH, ³MaxiVAX SA, Geneva, CH, ⁴SAKK - Swiss Group for Clinical Cancer Research, Bern, CH, ⁵University Hospital Zurich (USZ), Zurich, CH, ⁶Kantonsspital St. Gallen, St. Gallen, CH

10:30 - 10:45 **Invited Discussant 855MO, 856MO and LBA46**
P. Economopoulou, Attikon University Hospital, Haidari, GR

10:45 - 10:50 **859MO - Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial**



L. Michel¹, A. Jimeno², A. Sukari³, T. Beck⁴, J. Chiu⁵, E. Ahern⁶, J. Hilton⁷, A. Hollebecque⁸, S. Zanetta⁹, J. Patel¹⁰, S. Mekan¹⁰, T. Wu¹⁰, E. Dumbrava¹¹, ¹Memorial Sloan Kettering 64th Street Outpatient Center, New York, US, ²University of Colorado Cancer Center & Charles C. Gates Center of Stem Cell Biology, Aurora, US, ³Barbara Ann Karmanos Cancer Institute, Detroit, US, ⁴Highlands Oncology Group - Rogers, Fayetteville, US, ⁵The University of Hong Kong Queen Mary Hospital, Hong Kong, HK, ⁶Monash Medical Centre, Clayton, AU, ⁷The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ⁸Gustave Roussy, Villejuif, FR, ⁹Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹⁰Gilead Sciences, Inc., Foster City, US, ¹¹The University of Texas M. D. Anderson Cancer Center, Houston, US

10:50 - 10:55

860MO - MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma

F. Han¹, F. Wang¹, Y.-R. Shi², Y. Guo³, X.-L. Shu⁴, S. Pan⁵, S.-H. Qu⁶, P. Zhang⁷, Y. Jiang⁸, M.-J. Xu⁹, K. Lei¹⁰, S. Qu¹¹, F. Lei¹², X. Lv¹³, Y.-Q. Xiang¹, R.-H. Xu¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Hunan Cancer Hospital, Changsha, CN, ³Shanghai East Hospital, Shanghai, CN, ⁴Chongqing University Cancer Hospital, Chongqing, CN, ⁵Yuebei People's Hospital, Shaoguan, CN, ⁶The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, CN, ⁷West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ⁸Cancer Hospital of Shantou University Medical College, Shantou, CN, ⁹First Affiliated Hospital of Gannan Medical University, Ganzhou, CN, ¹⁰The Second People's Hospital of Yibin City, Yibin, CN, ¹¹Guangxi Medical University Affiliated Tumour Hospital, Nanning, CN, ¹²Zhongshan City People's Hospital, Zhongshan, CN, ¹³Sun Yat-Sen University Cancer Center, Guangzhou, CN

10:55 - 11:00

LBA47 - A phase 2 study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)

A. Ho¹, D. Adkins², G. Hanna³, J. Bruce⁴, M.-J. Ahn⁵, L. Iglesias Docampo⁶, H. Kang⁷, D. Wong⁸, A. Psyrri⁹, M. Gillison¹⁰, I. Braña¹¹, Y.C. Liu¹², C.-Y. Hsieh¹³, M.H. Hong¹⁴, Z. Zhang¹⁵, B. Balsara¹⁵, A. Saunders¹⁵, A. Gasco Hernandez¹⁵, S. Dale¹⁵, R. Haddad³, ¹Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ²Washington University School of Medicine in St. Louis, St. Louis, US, ³Dana Farber Cancer Institute, Boston, US, ⁴University of Wisconsin Carbone Cancer Center, Madison, US, ⁵Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Hospital Universitario 12 de Octubre, Madrid, ES, ⁷University of California San Francisco, San Francisco, US, ⁸UCLA - David Geffen School of Medicine, Los Angeles, US, ⁹Attikon University Hospital, Haidari, GR, ¹⁰University of Texas MD Anderson Cancer Center, Houston, US, ¹¹Vall d'Hebron University Hospital, Barcelona, ES, ¹²Taichung Veterans General Hospital, Taichung City, TW, ¹³China Medical University Hospital, Taichung City, TW, ¹⁴Severance Hospital, Yonsei University College of Medicine, Seoul, KR, ¹⁵Kura Oncology, Inc., Boston, US

11:00 - 11:15

Invited Discussant 859MO, 860MO and LBA47

M. Oliva, Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet), Barcelona, ES



- 10:15 - 11:45** **Type: Mini Oral session** **Toledo Auditorium - Hall 3**
Title: Mini oral session - Sarcoma
 Chair(s): Piotr Rutkowski, PL; Kjetil Boye, NO; Nadia Hindi, ES
- 10:15 - 10:20 **1914MO - The clinico-radiological outcome of desmoid type-fibromatosis after discontinuing the sorafenib treatment in responders: Single-arm phase II clinical trial**
 B. Bharath¹, S. Rastogi¹, V. Garg², G. Tansir¹, E. Dhamija¹, A. Barwad¹, S. Kaur¹, S. Gamanagatti¹, S. Bhorawal¹, M. Khan¹, ¹AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ²Princess Margaret Cancer Centre, Toronto, CA
- 10:20 - 10:25 **1915MO - Fear, anxiety and depression in gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study**
D. Van De Wal¹, D. Den Hollander², I. Desar², H. Gelderblom³, A. Oosten⁴, A. Reyners⁵, N. Steeghs¹, W. Van Der Graaf¹, O. Husson¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Radboud University Medical Center, Nijmegen, NL, ³LUMC - Leids University Medical Center, Leiden, NL, ⁴Erasmus MC, Rotterdam, NL, ⁵UMCG - University Medical Center Groningen, Groningen, NL
- 10:25 - 10:35 **Invited Discussant 1914MO and 1915MO**
P. Rutkowski, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL
- 10:35 - 10:40 **1916MO - A first-in-human phase I trial of NB003, a potent and selective KIT/PDGFRa inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)**
P. Chi¹, L. Shen², J. Li³, J. Zhang⁴, K. Hu⁵, L. Zhang⁵, Y. Xu⁵, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Peking University Cancer Hospital and Institute, Beijing, CN, ³Peking University Cancer Hospital and Institute, Beijing, CN, ⁴Fudan University Shanghai Cancer Center, Shanghai, CN, ⁵Ningbo Newbay Technology Development Co., Ltd., Ningbo, CN
- 10:40 - 10:45 **1917MO - CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor**
Y. Naito¹, Y. Komatsu², Y. Kurokawa³, H. Hirano⁴, T. Nishida⁵, T. Doi¹, ¹National Cancer Center Hospital East, Kashiwa, JP, ²Hokkaido University Hospital, Sapporo, JP, ³Graduate School of Medicine / Faculty of Medicine, Osaka University, Suita, JP, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵NCCH - National Cancer Center Hospital, Chuo-ku, JP
- 10:45 - 10:50 **1918MO - Circulating tumor DNA in relation to tumor volume in gastrointestinal stromal tumors**
R. Bleckman¹, C. Haag¹, R. Mathijssen², N. Steeghs³, H. Gelderblom⁴, I. Desar⁵, A. Ter Elst¹, E. Schuurin¹, A. Reyners⁶, ¹UMCG - University Medical Center Groningen, Groningen, NL, ²Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, NL, ³Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴LUMC - Leids Universitair Medisch Centrum, Leiden, NL, ⁵Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁶University Medical Center Groningen, University of



Groningen, Groningen, NL

10:50 - 11:00 **Invited Discussant 1916MO, 1917MO and 1918MO**

K. Boye, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

11:00 - 11:05 **1919MO - Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma**

B. Wilky¹, J. Trent², M. Gordon³, A. El-Khoueiry⁴, A. Bullock⁵, B. Henick⁶, G. Schwartz⁶, M. Agulnik⁷, D. Mahadevan⁸, J. Patel⁹, J. Grossman⁹, K. Rosenthal⁹, S. O'Day¹⁰, A.M. Tsimberidou¹¹, ¹UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ²Sylvester Comprehensive Cancer Center - University of Miami, Miami, US, ³HonorHealth Research Institute, Scottsdale, US, ⁴USC - University of Southern California - Keck School of Medicine, Los Angeles, US, ⁵Beth Israel Deaconess Medical Center, Boston, US, ⁶Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ⁷City of Hope Comprehensive Cancer Center, Duarte, US, ⁸UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, ⁹Agenus Inc - Corporate HQ, R&D and Vaccine Manufacturing, Lexington, US, ¹⁰Agenus Inc, Lexington, US, ¹¹The University of Texas MD Anderson Cancer Center, Houston, US

11:05 - 11:10 **1920MO - Regomune: A phase II study of regorafenib + avelumab in solid tumors - Results of the advanced or metastatic gastrointestinal stromal tumors (mGIST) cohort**

S. Cousin¹, C. Bellera², J.-P. Guegan³, T. Valentin⁴, B. Verret⁵, J.-P. Metges⁶, A. Adenis⁷, P. Cassier⁸, F. Bouteiller², M. Spalato Ceruso¹, I. Korakis⁹, A. Hollebecque¹⁰, P.G. Poureau¹¹, J. Palussiere¹², M. Kind², I. Soubeyran¹³, A. Bessedes³, A. Italiano¹³, ¹Institut Bergonie, Bordeaux, FR, ²Institut Bergonié, Bordeaux, FR, ³Explicyte, Bordeaux, FR, ⁴Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁵Institut Gustave Roussy, Villejuif, FR, ⁶CHU Morvan - Institut de Cancerologie et d'Hematologie, Brest, FR, ⁷ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁸Centre Léon Bérard, Lyon, FR, ⁹Iuct Oncopole, Toulouse, FR, ¹⁰Institut Gustave Roussy, Villejuif, Cedex, FR, ¹¹CHRU Brest - Hopital Augustin Morvan, Brest, FR, ¹²Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ¹³Institute Bergonié, Bordeaux, FR

11:10 - 11:15 **1921MO - Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies two prognostic profiles: A cohort study from the French Sarcoma Group (FSG)**

H. Vanacker¹, F. Le Loarer², M. Karanian¹, A. Meurgey¹, A. Dufresne¹, S. El Zein³, J.-Y. Blay¹, O. Collard⁴, I. Ray-Coquard¹, W. Waissi¹, D. Pissaloux¹, S. Paindavoine¹, A. Houlier¹, G. Pierron³, P. Meeus¹, F. Tirode¹, M. Brahmi¹, ¹Centre Léon Bérard, Lyon, FR, ²Institut Bergonié, Bordeaux, FR, ³Institut Curie, Paris, FR, ⁴Institute de Cancerologie de la Loire, Saint-Priest-en-Jarez, FR

11:15 - 11:25 **Invited Discussant 1919MO, 1920MO and 1921MO**

N. Hindi, Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz, Madrid, ES



10:15 - 11:45 **Type: Special session** **Oviedo Auditorium - Hall 7**
Title: Bridging the Efficacy-Effectiveness (E-E) gap for cancer therapies

Chair(s): Hendrik van Halteren, NL; John Cairns, GB

10:15 - 10:30 **Which factors can cause an E-E gap?**

H. Van Halteren, Adrz-Admiraal de Ruijter Hospital-Goes, Goes, NL

10:30 - 10:45 **How often and to which extent does the E-E gap seriously affect treatment outcome in daily practice?**

G. Sonke, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

10:45 - 11:00 **Which adaptations in trials and daily practice could bridge the E-E gap?**

M. Koopman, UMC - University Medical Center Utrecht, Utrecht, NL

11:00 - 11:15 **Under which circumstances could effectiveness data be used for clinical guidelines?**

H. Groen, UMCG - University Medical Center Groningen, Groningen, NL

11:15 - 11:30 **Should effectiveness data be taken into consideration for drug appraisal by regulatory authorities?**

J. Cairns, London School of Hygiene & Tropical Medicine, London, GB

11:30 - 11:45 **Discussion**

10:15 - 11:45 **Type: Mini Oral session** **León Auditorium - Hall 7**
Title: Mini oral session: CNS tumours

Chair(s): Joan Seoane, ES; Andreas Hottinger, CH; Emeline Tabouret, FR

10:15 - 10:20 **502MO - Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: A real-life cohort analysis from Veneto Institute of Oncology, Padua (Italy)**

G. Cerretti¹, M. Padovan¹, C. De Toni¹, M. Maccari¹, A. Bosio¹, M. Caccese¹, M. Corrà¹, I. Cestonaro¹, A. Pittaro¹, A. Guerriero², M. Coppola¹, G. Lombardi¹, ¹IIOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ²Azienda Universitaria Ospedaliera di Padova, Padova, IT

10:20 - 10:25 **503MO - Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights**

O. Mirallas¹, G. Velilla², F. Ruiz-Pace³, J. Yaringaño¹, T. Gorria⁴, D. Gomez-Puerto¹, Á. Martínez⁵, D. López Valbuena¹, M.A. Vaz Salgado⁶, A. Hernandez Gonzalez⁷, M. Aguado Sorolla⁸, K. Raskina⁹, M. Gonzalez Rodriguez¹, M. Martinez Garcia⁵, J. Carles Galceran¹, C. Balana¹⁰, E. Pineda¹¹, R. Dienstmann¹², J.M. Sepúlveda Sánchez¹³, M. Vieito Villar¹, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Instituto de Investigación Sanitaria



Hospital 12 de Octubre (i+12), Madrid, ES, ³Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ⁴Hospital Clinic of Barcelona, Barcelona, ES, ⁵Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ⁶Hospital Universitario Ramon y Cajal, Madrid, ES, ⁷Institut Catala d'Oncologia (ICO) Badalona, Badalona Applied Research Group in Oncology (B- ARGO Group), Badalona, ES, ⁸Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁹VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁰ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹²Grupo Oncoclinicas, Sao Paulo, BR, ¹³Hosp. Doce de Octubre, Madrid, ES

10:25 - 10:30

504MO - Validation of a spectroscopic liquid biopsy for the earlier detection of brain cancer

J. Cameron¹, A. Sala¹, J. Conn¹, G. Antoniou¹, D. Palmer¹, M. Baker², ¹Dxcover Limited, Glasgow, GB, ²University of Central Lancashire, Preston, GB

10:30 - 10:45

Invited Discussant 502MO, 503MO and 504MO

J. Seoane, Vall d'Hebron Institute of Oncology - Cellex Center, Barcelona, ES

10:45 - 10:50

505MO - A phase 0/Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients

N. Sanai, S. Desai, T. Margaryan, C. Lo Cascio, M. Elliott, J. Molloy, J. Harmon, A. Hong, E. Luna Melendez, J. Wanebo, K. Braun, W. Kennedy, M. Garcia, W. Yoo, A. Tovmasyan, A.-C. Tien, S. Mehta, Barrow Neurological Institute, Phoenix, US

10:50 - 10:55

506MO - A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma

W. Li¹, Z. Kang¹, Z. Wu¹, S. Li¹, M. Huang¹, W. Pu², X. Yang², J. Lin², M. Liu², ¹Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, ²CSPC Pharmaceutical Group Limited, Shijiazhuang, CN

10:55 - 11:10

Invited Discussant 505MO and 506MO

A. Hottinger, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

11:10 - 11:15

507MO - REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients

G. Lombardi¹, I. Desideri², V. Villani³, M. Simonelli⁴, M. Buglione⁵, S. Chiesa⁶, E. Franceschi⁷, P. Gaviani⁸, I. Stasi⁹, C. Caserta¹⁰, S. Brugnara¹¹, I.R. Lolli¹², E. Bennicelli¹³, P. Bini¹⁴, A. Cuccu¹⁵, S. Scoccianti¹⁶, G. Magni¹⁷, M. Caccese¹, G. De Salvo¹, V. Zagonel¹, ¹IIOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ²Università di Firenze- Dipartimento di Patologia e Oncologia Sperimentali, Firenze, IT, ³IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁴Humanitas University, Milan, IT, ⁵UNIBS - Università degli Studi di Brescia - Facoltà di Medicina e Chirurgia, Brescia, IT, ⁶Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁷Ospedale Bellaria Carlo Alberto Pizzardi, Bologna, IT, ⁸Fondazione IRCCS - Istituto Neurologico C.Besta, Milan, IT, ⁹Azienda Toscana Nord-Ovest Livorno, Livorno, IT, ¹⁰Azienda Ospedaliera Santa Maria di Terni, Terni, IT, ¹¹Ospedale Santa Chiara, Trento, IT, ¹²IRCCS



Castellana Grotte, Castellana Grotte, IT, ¹³Ospedale Policlinico San Martino, Genova, IT, ¹⁴IRCCS Mondino, Pavia, IT, ¹⁵A.O.U di Sassari, Sassari, IT, ¹⁶Ospedale Santa Maria Annunziata (Ponte a Niccheri) - USL Toscana Centro, Bagno a Ripoli, IT, ¹⁷Veneto Institute of Oncology IOV - IRCCS, padua, IT

11:15 - 11:20 **508MO - Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial**

S. Leonardelli¹, J.P. Layer¹, L.L. Friker¹, R. Turiello¹, G. Van Der Voort¹, D. Corvino¹, C. Schaub¹, W. Müller², E. Sperk³, L.C. Schmeel², K. Sahn³, S. Kebir⁴, P. Hamsch², T. Pietsch¹, K. Thurley¹, M. Glas⁵, C. Seidel², U. Herrlinger⁶, F. Giordano³, M. Hölzel¹, ¹University Hospital Bonn, Bonn, DE, ²University Hospital Leipzig, Leipzig, DE, ³Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE, ⁴University Hospital Essen, Essen, DE, ⁵University Hospital Essen - Westdeutsches Protonentherapiezentrum, Essen, DE, ⁶Institute of Experimental Immunology - UKB University of Bonn, Bonn, DE

11:20 - 11:35 **Invited Discussant 507MO and 508MO**

E. Tabouret, CHU La Timone Adultes, Marseille, FR

10:15 - 11:45 **Type: Educational session** **Cádiz Auditorium**
Title: Do we enter a new era of oncology with big data and artificial intelligence? **- NCC**

Chair(s): Rudolf Fehrmann, NL; James McKay, FR

10:15 - 10:30 **Where are we in Oncology in relation to developments in digital health, big data, artificial intelligence...? Challenges and opportunities**

R. Fehrmann, UMCG - University Medical Center Groningen, Groningen, NL

10:30 - 10:45 **Wearable medical devices in oncology: Hopes and hypes for patients and health professionals**

H. Martins, UBI - Universidade da Beira Interior - Faculdade de Ciencias da Saude, Covilha, PT

10:45 - 11:05 **AI-based therapeutic algorithms in oncology**

L. Verlingue, Centre Léon Bérard, Lyon, FR

11:05 - 11:25 **What will the European Health Data Space bring us?**

11:25 - 11:45 **Q&A and Discussion**



10:15 - 11:45 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Health promotion, prevention and screening
 Chair(s): Constantina Cloconi, CY

- 10:15 - 10:30 **Genetics and cancer nurses prevention**
C. Diez De Los Rios De La Serna, University of Glasgow, Glasgow, GB
- 10:30 - 10:45 **PrEvCan - Preventing cancer across Europe**
L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE
- 10:45 - 11:00 **Perceptions of health promotion among young people**
N. Dodlek, University Hospital Center Osijek, Osijek, HR
- 11:00 - 11:15 **Promoting cancer screening among under-represented populations**
S. Mulcahy Symmons, University College Dublin, Dublin, IE
- 11:15 - 11:25 **CN18 - Impact of the medical record-based frailty index on the health outcomes of elderly patients with colorectal cancer**
H. Lee, Yonsei University, Seoul, KR
- 11:25 - 11:35 **CN76 - Consensus views on research priorities for cancer survivorship in older adulthood: A Delphi study**
A. Drury¹, A. O'Brien², L. O'Connell³, S. Cosgrave⁴, M. Hannan⁵, C. Smyth⁶, K. Fessele⁷, S. Sheehan¹, M. Harkin⁸, L. Rogers², ¹DCU - Dublin City University, Dublin, IE, ²University College Dublin, Dublin, IE, ³Tallaght University Hospital, Dublin, IE, ⁴St. Vincent's University Hospital, Dublin, IE, ⁵University Hospital Waterford, Waterford, IE, ⁶HSE - Health Service Executive, Dublin, IE, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸Age and Opportunity, Dublin, IE
- 11:35 - 11:45 **Q&A and discussion**



10:30 - 11:45 **Type: Controversy session** **Bilbao Auditorium - NCC**
Title: Adjuvant or neoadjuvant immunotherapy or both in localised NSCLC
 Chair(s): Tony S.K. Mok, HK

10:30 - 10:35 **Welcome and “set the scene”**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

10:35 - 10:50 **Adjuvant only**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

10:50 - 11:05 **Neo adjuvant only**

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

11:05 - 11:20 **Neo adjuvant follow by adjuvant**
F. Cappuzzo, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

11:20 - 11:25 **First voting**

11:25 - 11:40 **Perspective from the Chair**
T.S.K. Mok, Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK

11:40 - 11:45 **Second voting**

10:30 - 11:15 **Type: Challenge your Expert** **Valencia Auditorium - Hall 10**
Title: Immunotherapy in dMMR/MSI-H recurrent/metastatic endometrial cancer: Monotherapy or combination?
 Chair(s): Domenica Lorusso, IT

10:30 - 10:50 **Presentation by Expert**
S. Banerjee, The Royal Marsden Hospital - Chelsea, London, GB

10:50 - 11:15 **Discussion led by Chair**
D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT



10:30 - 11:15	<p>Type: Challenge your Expert Title: All you want to know about advanced prostate cancer as we finally enter the era of biomarker-triggered treatment Chair(s): Silke Gillessen, CH</p>	Santander Auditorium - Hall 9
10:30 - 10:50	<p>Presentation by Expert <u>S. Sandhu</u>, Peter MacCallum Cancer Centre, Melbourne, AU</p>	
10:50 - 11:15	<p>Discussion led by Chair <u>S. Gillessen</u>, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH</p>	
11:00 - 11:45	<p>Type: Young Oncologists session Title: YO Brunch 1: Caring for the LGBTQ+ cancer patient Chair(s): Pawel Sobczuk, PL</p>	Ávila Auditorium - NCC
11:00 - 11:15	<p>Caring for the LGBTQ+ cancer patient <u>A. Berner</u>, Private Address - Dr. Alison Berner, Milton Keynes, GB</p>	
11:15 - 11:45	<p>Discussion led by Chair <u>P. Sobczuk</u>, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL</p>	
11:15 - 12:15	<p>Type: Special session Title: Patient Guides: Let's talk about oesophageal and stomach cancers</p>	Networking Hub - NCC
11:15 - 12:15	<p>Patient Guides: Let's talk about oesophageal and stomach cancers <u>F. Lordick</u>¹, <u>R. Obermannova</u>², <u>E. Smyth</u>³, <u>T. Gašpert</u>⁴, <u>Z. Maravic</u>⁵, 1Universitätsklinikum Leipzig - Universitäres Krebszentrum Leipzig, Leipzig, DE, 2Masaryk Memorial Cancer Institute, Brno, CZ, 3Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB, 4University Hospital KBC Rijeka, Rijeka, HR, 5DiCE - Digestive Cancers Europe vzw/asbl, Overijse, BE</p>	
12:00 - 12:30	<p>Type: Keynote lecture Title: The hallmarks of cancer in 2023 Chair(s): Charles Swanton, GB</p>	Barcelona Auditorium - Hall 9
12:00 - 12:05	<p>Introduction by the Chair <u>C. Swanton</u>, Francis Crick Institute, London, GB</p>	
12:05 - 12:30	<p>The hallmarks of cancer in 2023 <u>D. Hanahan</u>, Swiss Institute of Experimental Cancer Research, EPFL, Lausanne, CH</p>	



12:00 - 13:30 **Type: EONS Industry Satellite Symposium** **Alicante Auditorium - Hall 10**
Title: MSD - Improving health literacy across the patient pathway from screening and prevention to treatment and care
 Chair(s): Esra Urkmez Uzel, CH

12:00 - 12:05 **Opening remarks**
E. Urkmez Uzel, ESGO ENGAGE European Network of Gynecological Cancer Advocacy Group, Geneva, CH

12:05 - 12:15 **Cancer nursing's potential to address the growing cancer burden in Europe**
D. Protogiros, National Public Health Organisation, Athens, GR

12:15 - 12:25 **Role of cancer nurses in cancer screening and prevention**
L. Benito, Barcelona University, Barcelona, ES

12:25 - 12:35 **Exploring the conceptual underpinnings of cancer literacy and how it guides policy and action**
K. Sorensen, Global Health Literacy Association, Risskov, DK

12:35 - 13:25 **Panel discussion and Q&A**
E. Urkmez Uzel¹, D. Protogiros², L. Benito³, K. Sorensen⁴, ¹ESGO ENGAGE European Network of Gynecological Cancer Advocacy Group, Geneva, CH, ²National Public Health Organisation, Athens, GR, ³Barcelona University, Barcelona, ES, ⁴Global Health Literacy Association, Risskov, DK

13:25 - 13:30 **Conclusion remarks**
E. Urkmez Uzel, ESGO ENGAGE European Network of Gynecological Cancer Advocacy Group, Geneva, CH



13:00 - 14:30 **Type: Industry Satellite Symposium** **Burgos Auditorium - Hall 3**
Title: Pfizer Oncology - Focus on Individualised Care With CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
Chair(s): Javier Cortés, ES

13:00 - 13:05 **Welcome and Introductions**
J. Cortés, Hospital Ruber Internacional, Madrid, ES

13:05 - 13:15 **Beyond Therapy: How Can You Identify Women's Goals For Living with Metastatic Breast Cancer?**
J. Cortés, Hospital Ruber Internacional, Madrid, ES

13:15 - 14:25 **Leveraging Experience for a Personalised Approach in Patients with HR+/HER2-Metastatic Breast Cancer: An Interactive Discussion**
J. Cortés¹, H. Rugo², P. Fasching³, ¹Hospital Ruber Internacional, Madrid, ES, ²UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ³University Hospital Erlangen, Erlangen, DE

14:25 - 14:30 **Chair's sum up and Meeting Close**
J. Cortés, Hospital Ruber Internacional, Madrid, ES



13:00 - 14:30	Type: Industry Satellite Symposium	Valencia Auditorium - Hall 10
Title: Medscape Oncology Global - Keeping the Outcome in Mind: Applying Best Practices for Managing HR+/HER2- EBC at High Risk of Recurrence		
Chair(s): Sara Hurvitz, US		
13:00 - 13:05	Welcome and Introductions	
	<u>S. Hurvitz</u> , University of Washington, Seattle, US	
13:05 - 13:20	Keeping the Outcome in Mind: The Patient With HR-Positive, HER2-Negative Early Breast Cancer at High Risk of Recurrence	
	<u>P. Neven</u> , University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
13:20 - 13:40	Latest Developments for Oral Adjuvant Therapy: Analyzing the Latest Data, Guideline Recommendations and Best Practices	
	<u>S. Johnston</u> , The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB	
13:40 - 14:00	Managing the Patient at Risk: Which Patients Will Benefit from Adjuvant Oral Anti-Cancer Therapies?	
	<u>P. Neven</u> ¹ , <u>S. Hurvitz</u> ² , ¹ University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ² University of Washington, Seattle, US	
14:00 - 14:15	How to Approach Nonadherence in Practice: Clinical Pearls for the Multidisciplinary Team	
	<u>E. Hamilton</u> , Sarah Cannon Research Institute-Cancer Centre, Nashville, US	
14:15 - 14:30	Q&A Session	
	<u>S. Hurvitz</u> ¹ , <u>S. Johnston</u> ² , <u>P. Neven</u> ³ , <u>E. Hamilton</u> ⁴ , ¹ University of Washington, Seattle, US, ² The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB, ³ University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁴ Sarah Cannon Research Institute-Cancer Centre, Nashville, US	



13:00 - 14:20	Type: Industry Satellite Symposium Title: Bristol Myers Squibb - Clinical Perspectives on the Evolution of NSCLC Treatment With I-O and ROS1 TKIs Chair(s): Jürgen Wolf, DE	Salamanca Auditorium - Hall 3
13:00 - 13:10	Welcome and Introductions <u>J. Wolf</u> , University Hospital of Cologne, Cologne, DE	
13:10 - 13:30	A Foundation for Survivorship With I-O and Potential New Approaches for Patients With ROS1+ NSCLC <u>J. Wolf</u> , University Hospital of Cologne, Cologne, DE	
13:30 - 13:55	Multidisciplinary Approach to Managing the Expanding Options With I-O in Non-Metastatic NSCLC <u>T. Cascone</u> ¹ , <u>J.L. Campo Canaveral</u> ² , ¹ The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, ² University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES	
13:55 - 14:18	We Are NSCLC Clinicians: Ask Us Anything <u>J. Wolf</u> ¹ , <u>T. Cascone</u> ² , <u>J.L. Campo Canaveral</u> ³ , ¹ University Hospital of Cologne, Cologne, DE, ² The University of Texas MD Anderson Cancer Center - Main Building, Houston, US, ³ University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES	
14:18 - 14:20	Closing Remarks <u>J. Wolf</u> , University Hospital of Cologne, Cologne, DE	



13:00 - 14:30	Type: Industry Satellite Symposium Title: Sanofi - Novel Targets in Advanced NSCLC: Leveraging Emerging Biomarkers in an Evolving Treatment Landscape Chair(s): Silvia Novello, IT	Málaga Auditorium - Hall 10
----------------------	--	------------------------------------

13:00 - 13:05 **Welcome and Introduction**
S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

13:05 - 13:25 **Treatment in Advanced NSCLC: What Have We Learned and Where Are We Headed?**
S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

13:25 - 13:45 **Tailor-made: Guiding Treatment Choice With Emerging Biomarkers**
A. Ryska, University Hospital (Fakultni Nemocnice), Hradec Kralove, CZ

13:45 - 14:05 **What Does the Future Hold? Clinical Update on ADCs in Advanced NSCLC**
E. Nadal, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES

14:05 - 14:30 **Group Discussion**
S. Novello¹, E. Nadal², A. Ryska³, ¹Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ²ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ³University Hospital (Fakultni Nemocnice), Hradec Kralove, CZ



13:00 - 14:30 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 9**
Title: Servier - Shining the light on colorectal cancer: Advancing treatment strategies in mCRC
Chair(s): Eric Van Cutsem, BE; Julien Taieb, FR

- 13:00 - 13:10 **Introduction**
E. Van Cutsem, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 13:10 - 13:30 **New approaches in treating patients with mCRC**
J. Seligmann, The University of Leeds, Leeds, GB
- 13:30 - 13:50 **Redefining the meaning of later lines of therapy**
J. Taieb, Hopital European George Pompidou, Paris, FR
- 13:50 - 14:20 **Patient cases in mCRC and panel discussion**
F. Ciardiello, Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT
- 14:20 - 14:30 **Conclusion**
J. Taieb, Hopital European George Pompidou, Paris, FR



13:00 - 14:30	Type: Industry Satellite Symposium Title: Merck Healthcare KGaA - Putting Patients First: Cultivating Care in Bladder Cancer Chair(s): Joaquim Bellmunt, US	Toledo Auditorium - Hall 3
13:00 - 13:10	Chairman's introduction <u>J. Bellmunt</u> , Harvard Medical School, Boston, US	
13:10 - 13:25	Improving treatment standards in advanced UC: What can we learn from clinical practice? <u>P. Grivas</u> , University of Washington, Seattle, US	
13:25 - 13:40	Patient needs in UC: How to optimize treatment experience <u>E. Grande Pulido</u> , MD Anderson Cancer Center Madrid, Madrid, ES	
13:40 - 13:55	Open questions in UC: Which gaps can we address today? <u>V. Gruenwald</u> , University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	
13:55 - 14:25	Hot topics in UC: What keeps the faculty awake at night <u>J. Bellmunt</u> ¹ , <u>E. Grande Pulido</u> ² , <u>V. Gruenwald</u> ³ , <u>P. Grivas</u> ⁴ , ¹ Harvard Medical School, Boston, US, ² MD Anderson Cancer Center Madrid, Madrid, ES, ³ University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ⁴ University of Washington, Seattle, US	
14:25 - 14:30	Closing remarks <u>J. Bellmunt</u> , Harvard Medical School, Boston, US	



13:00 - 14:30 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 7**
Title: Amgen - Targeting advanced GI cancer: new approaches on the horizon?
 Chair(s): Fernando Rivera, ES

13:00 - 13:10 **Welcome and introduction**
F. Rivera, Hospital Universitario Marqués de Valdecilla, Santander, ES

13:10 - 13:30 **Optimising use of targeted therapy across the RAS WT mCRC continuum**
D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE

13:30 - 13:50 **New therapeutic approaches in GI cancers: targeting KRAS mutations**
C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

13:50 - 14:10 **The pursuit of further actionable targets in advanced gastric and GEJ cancers**
E. Smyth, Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB

14:10 - 14:30 **Panel discussion and Q&A**
F. Rivera¹, D. Modest², C. Cremolini³, E. Smyth⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, ES, ²Charité - Universitaetsmedizin Berlin, Berlin, DE, ³AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ⁴Oxford University Hospitals NHS Foundation Trust - Churchill Hospital, Oxford, GB



13:00 - 14:30	<p>Type: Industry Satellite Symposium Title: Gilead Sciences Europe Ltd - MILLIONS OF LIVES. ONE MISSION. Exploring the potential of ADCs in multiple solid tumours</p>	<p>León Auditorium - Hall 7</p>
<p>Chair(s): Peter Schmid, GB</p>		
13:00 - 13:15	<p>Welcome and introduction: ADCs - A journey across time <u>P. Schmid</u>, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB</p>	
13:15 - 13:35	<p>Improving the lives of patients with triple-negative and HR+/HER2- metastatic breast cancer <u>S. Tolaney</u>, Dana Farber Cancer Institute, Boston, US</p>	
13:35 - 13:55	<p>Unlocking the potential for the treatment of metastatic urothelial cancer <u>T. Powles</u>, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB</p>	
13:55 - 14:10	<p>Expanding opportunities in patients with metastatic NSCLC <u>E. Felip</u>, Vall d'Hebron University Hospital, Barcelona, ES</p>	
14:10 - 14:30	<p>Q&A and closing remarks <u>P. Schmid</u>¹, <u>S. Tolaney</u>², <u>T. Powles</u>³, <u>E. Felip</u>⁴, ¹Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, ²Dana Farber Cancer Institute, Boston, US, ³St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ⁴Vall d'Hebron University Hospital, Barcelona, ES</p>	



13:00 - 14:30	Type: Patient Advocacy session Title: New approaches for technologies, therapies, and surgery Chair(s): Tanja Spanic, SI; Anne-Marie Baird, IE	Cádiz Auditorium - NCC
13:00 - 13:15	How to decide which mutation to investigate and invest in <u>M.F. Mosele</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
13:15 - 13:30	Surgical therapies: What are the new robotic models and how do they support efficient processes in clinical settings? <u>S. Sandrucci</u> , AOU Città della Salute e della Scienza Torino, Torino, IT	
13:30 - 13:45	Radiation therapies: How do proton beam therapy, stereotactic radiosurgery and gamma knife surgery treat cancer? <u>P. Poortmans</u> , AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE	
13:45 - 14:00	Identification of new biomarkers in lung cancer <u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	
14:00 - 14:25	Discussion	
14:25 - 14:30	Conclusion	



14:15 - 15:45 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Supportive care
 Chair(s): Eva Pape, BE

14:15 - 14:30 **eHealth and digital innovations in supportive care: IBM Watson at your service**
A. Charalambous, Cyprus University of Technology - Nursing Science, Limassol, CY

14:30 - 14:45 **Psychosocial aspects of living long term with advanced cancer and ongoing systemic treatment**
E. Kolsteren, Radboud University Medical Center, Nijmegen, NL

14:45 - 15:00 **Cancer nurses roles in a late effect clinic**
K. Dieperink, Odense University Hospital, Odense C, DK

15:00 - 15:15 **The European Cancer Nursing Index 2020 and 2022**
L. Sharp, RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE

15:15 - 15:25 **CN36 - Current care for patients on oral anticancer therapy through a different lens: Assessment from a patient and healthcare professional perspective**
 A. Van Hecke¹, L.-M. Kinnaer², V. Foulon³, I. Kenis⁴, ¹Ghent University - University Centre for Nursing and Midwifery, GENT, BE, ²Ghent University - University Centre for Nursing and Midwifery, Ghent, BE, ³KU Leuven, Leuven, BE, ⁴Ghent University, Gent, BE

15:25 - 15:45 **Q&A and discussion**

14:45 - 16:10 **Type: Proffered Paper session** **Barcelona Auditorium - Hall 9**
Title: Proffered Paper session 2 - Genitourinary tumours, non-prostate
 Chair(s): Manuela Schmidinger, AT; Cristina Suarez Rodriguez, ES

14:45 - 14:55 **LBA87 - Phase 2 LITESPARK-003 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)**
T. Choueiri¹, T. Bauer², J. Merchan³, D. Mcdermott⁴, R. Figlin⁵, E. Arrowsmith⁶, M.D. Michaelson⁷, E. Heath⁸, A. D'Souza⁹, S. Zhao¹⁰, L. Mhamdi¹¹, R. Perini¹¹, D. Vickery¹¹, S. Tykodi¹², ¹Dana-Farber Cancer Institute, Boston, US, ²Sarah Cannon Research Institute and Tennessee Oncology, Nashville, US, ³University of Miami Health System, Miami, US, ⁴Beth Israel Deaconess Medical Center, Boston, US, ⁵Cedars-Sinai Medical Center, Los Angeles, US, ⁶Tennessee Oncology, Chattanooga, US, ⁷Massachusetts General Hospital, Boston, US, ⁸Karmanos Cancer Institute, Detroit, US, ⁹University of Southern California, Los Angeles, US, ¹⁰Swedish Medical Center, Seattle, US, ¹¹Merck & Co., Inc., Rahway, US, ¹²University of Washington and Fred Hutchinson Cancer Center, Seattle, US

14:55 - 15:05 **LBA88 - Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label**



phase 3 LITESPARK-005 study

L. Albiges¹, B. Rini², K. Peltola³, G.A. De Velasco Oria⁴, M. Burotto⁵, C. Suarez Rodriguez⁶, P. Ghatalia⁷, R. Iacovelli⁸, E. Lam⁹, E. Verzoni¹⁰, M. Gumus¹¹, W. Stadler¹², C. Kollmannsberger¹³, B. Melichar¹⁴, B. Venugopal¹⁵, A. Wang¹⁶, R. Perini¹⁷, D. Vickery¹⁸, T. Powles¹⁹, T. Choueiri²⁰, ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Vanderbilt Ingram Cancer Center, Nashville, US, ³Comprehensive Cancer Center - Helsinki University Central Hospital, Helsinki, FI, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Bradford Hill-Clinical Center, Santiago, CL, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁸Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁹UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ¹⁰Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹¹Istanbul Medeniyet University, Prof.Dr. Suleyman Yalcin City Hospital, Istanbul, TR, ¹²The University of Chicago Medical Center, Chicago, US, ¹³BC Cancer Agency - Vancouver, Vancouver, CA, ¹⁴FN Olomouc/ University Hospital Olomouc, Olomouc, CZ, ¹⁵BWSSC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ¹⁶Merck & Co., Inc., Rahway, US, ¹⁷Merck & Co., Inc. - Corporate Headquarters, Whitehouse Station, US, ¹⁸Merck & Co., Inc. - Rahway, Rahway, US, ¹⁹St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, ²⁰Dana Farber Cancer Institute, Boston, US

15:05 - 15:15

18810 - Safety and efficacy of two doses of belzutifan in patients (pts) with advanced RCC: Results of the randomized phase II LITESPARK-013 study

N. Agarwal¹, J. Brugarolas², P. Ghatalia³, S. George⁴, J. Haanen⁵, H. Gurney⁶, R. Ravilla⁷, A. Van Der Veldt⁸, B. Beuselinck⁹, I. Pokataev¹⁰, B. Suelmann¹¹, M. Tuthill¹², D. Vaena¹³, F. Zagouri¹⁴, J. Wu¹⁵, Y. Liu¹⁵, R. Perini¹⁵, J. Merchan¹⁶, M. Atkins¹⁷, ¹Huntsman Cancer Institute, Salt Lake City, US, ²University of Texas Southwestern Medical Center, Dallas, US, ³Fox Chase Cancer Center, Philadelphia, US, ⁴Roswell Park Cancer Institute, Buffalo, US, ⁵Netherlands Cancer Institute, Amsterdam, NL, ⁶Macquarie University, Sydney, AU, ⁷New York Oncology Hematology - Albany Cancer Center, Albany, US, ⁸Erasmus MC, Rotterdam, NL, ⁹UZ Leuven, Leuven, BE, ¹⁰City Clinical Oncology Hospital No. 1, Moscow, RU, ¹¹Universitair Medisch Centrum Utrecht, Utrecht, NL, ¹²Oxford University Hospitals NHS Foundation Trust, London, GB, ¹³West Cancer Center and Research Institute, Germantown, US, ¹⁴Alexandra Regional General Hospital, Athens, GR, ¹⁵Merck & Co., Inc., Rahway, US, ¹⁶University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services, Miami, US, ¹⁷Georgetown University Medical Center, Washington, US

15:15 - 15:30

Invited Discussant LBA87, LBA88 and 18810

L. Pickering, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

15:30 - 15:40

Q&A

15:40 - 15:50

18820 - RENOTORCH: Toripalimab combined with axitinib versus sunitinib in first-line treatment of advanced renal-cell carcinoma (RCC) - A randomized, open-label, phase III study

X. Sheng¹, M. Ye², Q. Zou³, P. Chen⁴, Z. He⁵, B. Wu⁶, D. He⁷, C. He⁸, X. Xue⁹, Z. Ji¹⁰, H. Chen¹¹, S. Zhang¹², Y. Liu¹³, W. Zhai¹⁴, X. Zhang¹⁵, C. Fu¹⁶, D. Xu¹⁷, M. Qiu¹⁸, Y.



Huang¹⁴, J. Guo¹, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Hunan Cancer Hospital, Changsha, CN, ³Jiangsu Cancer Hospital, Nanjing, CN, ⁴Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, CN, ⁵Peking University First Hospital, Beijing, CN, ⁶Shengjing Hospital of China Medical University - Nanhu Campus, Shenyang, CN, ⁷First Affiliated of Xian Communication University, Xian, CN, ⁸Henan Cancer Hospital, Zhengzhou, CN, ⁹The First Affiliated Hospital of Fujian Medical University, Fuzhou, CN, ¹⁰Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ¹¹Harbin Medical University Cancer Hospital, Harbin, CN, ¹²West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ¹³The First Hospital of China Medical University, Shenyang, CN, ¹⁴Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, CN, ¹⁵Beijing Chaoyang Hospital - Capital Medical University, Beijing, CN, ¹⁶Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹⁷Ruijin Hospital - Shanghai Jiao Tong University School of Medicine, Shanghai, CN, ¹⁸Sichuan Academy of Medical Sciences/Sichuan Provincial People's Hospital, Chengdu, CN

15:50 - 16:00 **Invited Discussant 18820**

A. Van Der Veldt, Erasmus MC - University Medical Center, Rotterdam, NL

16:00 - 16:10 **Q&A**

14:45 - 16:15 **Type: Proffered Paper session** **Sevilla Auditorium - Hall 9**
Title: Proffered Paper session 1 - Gastrointestinal tumours, lower digestive
 Chair(s): Chiara Cremolini, IT; Rodrigo Dienstmann, BR

14:45 - 14:55 **LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)**

T. Zhang¹, K. Tao¹, Z. Lin¹, P. Zhang¹, Y. Yin¹, P. Chi², Y. Huang², Y. Xiao³, Z. Sun³, X. Xu⁴, A. Zhang⁵, X. Qiu⁶, W. Junxin⁷, Y. Yuan⁸, Z. Wang⁹, X.J. Qu⁹, F. Zhao¹⁰, C. Ma¹⁰, F. Cheng¹⁰, Z. Hou¹⁰, ¹Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ²Fujian Medical University Union Hospital, Fuzhou, CN, ³Peking Union Medical College Hospital, Beijing, CN, ⁴Renmin Hospital of Wuhan University, Wuhan, CN, ⁵Affiliated Hospital of Hebei University, Baoding, CN, ⁶Zhongshan Hospital Xiamen University, Xiamen, CN, ⁷Fujian Cancer Hospital, Fuzhou, CN, ⁸The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁹The First Affiliated Hospital of China Medical University, Shenyang, CN, ¹⁰Jiangsu Hengrui Pharmaceutical Co., Ltd., Shanghai, CN

14:55 - 15:05 **LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial**

P.-R. Ding¹, X.-Z. Wang², Y.-F. Li³, Y.-M. Sun⁴, C.-K. Yang⁵, Z.-G. Wu⁶, R. Zhang⁷, W. Wang⁸, Y. Li⁹, Y.-Z. Zhuang¹⁰, J. Lei¹¹, Y. Ren¹², X. Wan¹³, Y. Cheng¹⁴, W.-L. Li¹⁵, Z.-Q. Wang¹⁶, Z. Pan¹, Y.H. Gao¹, Z.-F. Zeng¹⁷, D.-S. Wan¹⁷, ¹Sun Yat-sen University Cancer



Center, Guangzhou, CN, ²Shantou Central Hospital, Shantou, CN, ³Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, CN, ⁴Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ⁵Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁶Meizhou People's Hospital, Meizhou, CN, ⁷Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁸the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, ⁹Guangdong Provincial People's Hospital, Guangzhou, CN, ¹⁰Cancer Hospital of Shantou University Medical College, Shantou, CN, ¹¹The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ¹²Henan Cancer Hospital, Zhengzhou, CN, ¹³Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ¹⁴The First Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ¹⁵The First Affiliated Hospital of Kunming Medical University, Kunming, CN, ¹⁶West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ¹⁷State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN

15:05 - 15:15 **Invited Discussant LBA25 and LBA26**

K. Haustermans, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:15 - 15:25 **Q&A**

15:25 - 15:35 **5490 - Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations**

M. Pelster¹, R. Yaeger², S. Klempner³, S.-H. Ou⁴, A. Spira⁵, P. Jänne⁶, N. Uboha⁷, Y. Gaffar⁸, G. Newman⁹, C. Paweletz⁶, G. Heavey⁶, L. Alejandro¹⁰, T. Kheoh¹⁰, K. Anderes¹⁰, H. Der Torossian¹⁰, J. Christensen¹⁰, J. Weiss¹¹, ¹Sarah Cannon Research Institute, Nashville, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Massachusetts General Cancer Center, Boston, US, ⁴UCI Health Chao Family Comprehensive Cancer Center, Orange, US, ⁵Virginia Cancer Specialist, Fairfax, VA; US Oncology Research, The Woodlands, US, ⁶Dana Farber Cancer Institute, Boston, US, ⁷University of Wisconsin, Madison, US, ⁸Maryland Oncology Hematology, Columbia, US, ⁹Ridley-Tree Cancer Center, Santa Barbara, US, ¹⁰Mirati Therapeutics, Inc., San Diego, US, ¹¹University of North Carolina-Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, US

15:35 - 15:45 **5500 - Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study**

R.-H. Xu¹, Y. Xu², D. Yan³, P. Munster⁴, D. Ruan¹, Y. Deng⁵, H. Pan⁶, C. Underhill⁷, G. Richardson⁸, I. Nordman⁹, K.-W. Lee¹⁰, S. Wei¹¹, X.-Y. Li¹², J. Shan¹³, G. Han¹⁴, S. Henderson⁴, X. Xie¹⁵, Z. Xiang¹⁵, Z. Shi¹⁵, L. Zhang¹⁵, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Fudan University Shanghai Cancer Center, Shanghai, CN, ³Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, CN, ⁴UCSF, San Francisco, US, ⁵The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, ⁶Sir Run Run Shaw Hospital School of Medicine Zhejiang University, Hangzhou, CN, ⁷Border Medical Oncology, Albury, AU, ⁸Cabrini Hospital - Malvern, Malvern, AU, ⁹Calvary Mater Newcastle, Waratah, AU, ¹⁰Seoul National University College of



Medicine, Seoul National University Bundang Hospital, Seongnam-si, KR, ¹¹Hubei Cancer Hospital, Wuhan, CN, ¹²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ¹³The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ¹⁴Xi'an International Medical Center Hospital, Xi'an, CN, ¹⁵InventisBio Co., Ltd, Shanghai, CN

- 15:45 - 15:55 **5510 - Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2⁺, RAS WT metastatic CRC (mCRC) in MOUNTAINEER**
- J. Strickler¹, A. Cercek², K. Ng³, S. Siena⁴, T. André⁵, E. Van Cutsem⁶, C. Wu⁷, A. Paulson⁸, J. Hubbard⁹, A. Coveler¹⁰, C. Fountzilas¹¹, A. Kardosh¹², P. Kasi¹³, H.J. Lenz¹⁴, K. Ciombor¹⁵, M.E. Elez Fernandez¹⁶, M. Stecher¹⁷, P. Cronin¹⁷, M. Bieda¹⁷, T. Bekaii-Saab⁷, ¹Duke Cancer Center, Durham, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Dana Farber Cancer Institute, Boston, US, ⁴Università degli Studi di Milano, Milan, IT, ⁵Hopital Saint-Antoine, Paris, FR, ⁶UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁷Mayo Clinic Cancer Center, Phoenix, US, ⁸Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ⁹Mayo Clinic, Rochester, US, ¹⁰Fred Hutchinson Cancer Research Center, Seattle, US, ¹¹Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹²OHSU - Oregon Health Science University, Portland, US, ¹³Weill Cornell Medicine, New York, US, ¹⁴USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, ¹⁵Vanderbilt University Medical Center, Nashville, US, ¹⁶Vall d'Hebron University Hospital, Barcelona, ES, ¹⁷Seagen Inc., Bothell, US
- 15:55 - 16:05 **Invited Discussant 5490, 5500 and 5510**
- R. Dienstmann, Grupo Oncoclinicas, Sao Paulo, BR
- 16:05 - 16:15 **Q&A**



14:45 - 16:15 **Type: Educational session** **Bilbao Auditorium - NCC**
Title: Optimal treatment sequence in metastatic breast cancer (mBC) in 2023
 Chair(s): Hervé Bonnefoi, FR; Christoph Thomssen, DE

14:45 - 14:50 **Introduction**
C. Thomssen, MLU - Martin-Luther-University Halle-Wittenberg, Halle, DE

14:50 - 15:10 **Luminal-like breast cancer**
S. Delaloge, Institut Gustave Roussy, Villejuif, Cedex, FR

15:10 - 15:30 **HER2+ breast cancer**
I. Krop, Yale University School of Medicine - Yale Cancer Center, New Haven, US

15:30 - 15:50 **Triple-negative breast cancer**
A. Schneeweiss, German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE

15:50 - 16:15 **Discussion**

14:45 - 16:15 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Managing disease progression in oncogene-driven lung cancer
 Chair(s): Noemi Reguart Aransay, ES; Ross Soo, SG

14:45 - 15:00 **Detection: From technology to clinical practice**
C. Rolfo, Icahn School of Medicine at Mount Sinai, New York, US

15:00 - 15:15 **Mechanisms of resistance**
A.-M. Baird, St. James's Hospital, Dublin, IE

15:15 - 15:35 **Managing progression after EGFR TKIs in EGFR-mutant lung cancer**
M.-J. Ahn, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

15:35 - 15:55 **Managing progression after TKIs in oncogenic fusion-driven lung cancer**
J. Lin, MGH - Massachusetts General Hospital, Boston, US

15:55 - 16:15 **Discussion**



14:45 - 16:15 **Type: Educational session** **Valencia Auditorium**
Title: Is neoadjuvant immunotherapy a therapeutic platform for all tumour types? **- Hall 10**
 Chair(s): Myriam Chalabi, NL; Jessica Hassel, DE

14:45 - 15:10 **Is chemotherapy plus immunotherapy equal to immunotherapy alone at the neoadjuvant stage?**
 T. Cascone, The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

15:10 - 15:35 **Novel neoadjuvant combination immunotherapies**
 A. Menzies, Melanoma Institute Australia, Wollstonecraft, AU

15:35 - 16:00 **How to personalise neoadjuvant immunotherapy**
 C. Blank, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

16:00 - 16:15 **Q&A and Discussion**

14:45 - 16:15 **Type: Mini Oral session** **Salamanca Auditorium - Hall 3**
Title: Mini oral session 1 - Non-metastatic NSCLC and other thoracic malignancies
 Chair(s): Andrea Ardizzoni, IT; Joachim Aerts, NL; Kersti Oselin, EE

14:45 - 14:50 **1988MO - Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data**
 F. Bozorgmehr¹, F. Weykamp², T. Overbeck³, N. Maguire⁴, E. Buchmeier⁵, M. Hammer-Hellmig⁵, T. Gauler⁶, M. Wermke⁷, E.G.C. Troost⁸, M. Ulmer⁹, A.-C. Mueller¹⁰, K. Kokowski¹¹, B. Röper¹², T. Wehler¹³, S. Hey-Koch¹⁴, N.-S. Consdorf¹⁵, R. Behnisch¹⁶, P. Christopoulos¹, M. Thomas¹, S. Rieken¹⁷, ¹Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, DE, ²University Hospital Heidelberg, Heidelberg University, Heidelberg, DE, ³University Medical Center Göttingen, Göttingen University, Goettingen, DE, ⁴Barmherzige Brüder Krankenhaus Regensburg, Regensburg, DE, ⁵Klinikum Köln-Merheim, Köln, DE, ⁶WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ⁷University Hospital Dresden, TU Dresden, Dresden, DE, ⁸Medizinische Fakultät und Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, DE, ⁹Klinikum Ludwigsburg Medizinische Klinik I, Ludwigsburg, DE, ¹⁰Klinikum Ludwigsburg, Ludwigsburg, DE, ¹¹Krankenhaus München Bogenhausen II Med. Abteilung, Munich, DE, ¹²Strahlentherapie Klinikum Bogenhausen, München, DE, ¹³Sana Klinikum Offenbach GmbH, Offenbach am Main, DE, ¹⁴Sana Klinikum Offenbach, Offenbach am Main, DE, ¹⁵Lungenklinik Hemer des Deutschen Gemeinschafts-Diakonieverbandes GmbH, Hemer, DE, ¹⁶Heidelberg University Hospital, Heidelberg, DE, ¹⁷Universitätsmedizin Göttingen, Goettingen, DE



- 14:50 - 14:55 **1989MO - Lurbinectedin (LUR) in combination with pembrolizumab (PBL) in relapsed small cell lung cancer (SCLC): The phase I/II LUPER study**
A. Calles Blanco¹, A. Navarro Mendivil², B. Doger De Spéville³, E. Álvarez Colomé⁴, M.J. De Miguel Luken⁵, R. Alvarez¹, V. Moreno Garcia³, J. Ramon⁶, M. Arregui Valles⁷, E. Corral De La Fuente⁶, D. Alcalá⁸, M. Fernández⁸, J. Rodríguez Morató⁸, E. Calvo⁶, R. Palmero Sanchez⁹, M. Jové¹⁰, E. Felip¹¹, ¹Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, ES, ²Vall d'Hebron Hospital Universitari and Vall d'Hebron Institute of Oncology (VHIO); MEDSIR - Medica Scientia Innovation Research, Barcelona, ES, ³Hospital Universitario Fundación Jiménez Díaz, Madrid, ES, ⁴Vall d'Hebron Hospital Universitari and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, ⁶START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, ⁷Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁸MEDSIR - Medica Scientia Innovation Research, Barcelona, ES, ⁹ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat, ES, ¹⁰ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ¹¹Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES
- 14:55 - 15:00 **1990MO - Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): Preliminary results from the phase II TROPiCS-03 basket trial**
A. Dowlati¹, A. Cervantes², S. Babu³, E. Hamilton⁴, S.F. Wong⁵, A. Tazbirkova⁶, I.G. Sullivan⁷, C. Van Marcke De Lummen⁸, A. Italiano⁹, J. Patel¹⁰, S. Mekan¹⁰, T. Wu¹⁰, A. Chiang¹¹, ¹University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, US, ²INCLIVA Instituto de Investigación Sanitaria, University of Valencia, Valencia, ES, ³Fort Wayne Medical Oncology and Hematology, Fort Wayne, Fort Wayne, US, ⁴Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, ⁵Andrew Love Cancer Centre, Geelong, Geelong, AU, ⁶Pindara Private Hospital, Southport, AU, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁸Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, BE, ⁹Institute Bergonié, Bordeaux, FR, ¹⁰Gilead Sciences, Inc., Foster City, US, ¹¹Yale University School of Medicine, New Haven, US
- 15:00 - 15:15 **Invited Discussant 1988MO, 1989MO and 1990MO**
A. Ardizzoni, University of Bologna - Alma Mater Studiorum, Bologna, IT
- 15:15 - 15:20 **LBA99 - First survival data from the NIPU trial; A randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma**
A. Helland¹, V. Haakensen², A. Ojlert³, S. Thunold⁴, A. Nowak⁵, W.L. Chin⁵, O. Grundberg⁶, S. Farooqi⁷, M. Lund-Iversen⁸, W. Szejniuk⁹, S. Cedres Perez¹⁰, J. Sørensen¹¹, M. Bjaanaes¹², ¹University of Oslo, Institute of Clinical medicine, Oslo, NO, ²Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ³Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, NO, ⁴Oslo University Hospital - Radiumhospitalet, Oslo, NO, ⁵University of Western Australia, Perth, AU, ⁶Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE, ⁷Oslo University Hospital - Ullevål Hospital, Oslo, NO, ⁸Oslo University Hospital, Oslo,



NO, ⁹Aalborg University Hospital, Aalborg, DK, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Rigshospitalet, Copenhagen, DK, ¹²Oslo University Hospital - Ullevål Hospital, Oslo, NO

15:20 - 15:25

LBA93 - EXTENTORCH: a randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC)

Y. Cheng¹, Y. Liu², W. Zhang³, L. Wu⁴, C. Zhou⁵, D. Wang⁶, B. Xia⁷, M. Bi⁸, X. Fu⁹, C. Li¹⁰, G. Chen¹¹, D. Lv¹², Y. Zhao¹³, J. Huang¹⁴, M. Li¹⁵, T. Yi¹⁶, X. Huang¹⁷, R. Yang¹⁸, Z. Chen¹⁹, Y. Wang²⁰, ¹Jilin Cancer Hospital, Changchun, CN, ²Jilin Cancer Hospital, Changchun, CN, ³The First Affiliated Hospital of Nanchang University, Nanchang, CN, ⁴Hunan Cancer Hospital, Changsha, CN, ⁵Shanghai Pulmonary Hospital, Shanghai, CN, ⁶Chongqing Cancer Hospital, Chongqing, CN, ⁷Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁸The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ⁹The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CN, ¹⁰The Third Affiliated Hospital of Soochow University (The First People's Hospital of Changzhou), Changzhou, CN, ¹¹Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN, ¹²Affiliated Taizhou Hospital of Zhejiang Province of Wenzhou Medical University, Taizhou, CN, ¹³Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ¹⁴The First Affiliated Hospital Of Soochow University, Suzhou, CN, ¹⁵Xiangya Hospital of Central South University, Changsha, CN, ¹⁶Xiangyang Central Hospital, Xiangyang, CN, ¹⁷Chongqing University Three Gorges Hospital, Chongqing, CN, ¹⁸Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Center, Kunming, CN, ¹⁹The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, ²⁰West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN

15:25 - 15:35

Invited Discussant LBA99 and LBA93

J. Aerts, Erasmus MC - University Medical Center, Rotterdam, NL

15:35 - 15:40

1262MO - Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial

G. Eberst¹, J. Henriques², M. Monchatre³, E. Giroux-Leprieur⁴, E. Kelkel⁵, A. Bizieux Thamiy⁶, P. Ravier⁷, P. Thomas⁸, S. Bayle⁹, C. Audigier Valette¹⁰, H. Berard¹¹, F. Desliers¹², A. Lagrange¹³, P. Bonnefoy¹⁴, A. Langlais¹⁵, D. Vernerey², A. Anota², F. Morin¹⁵, V. Westeel¹, ¹CHRU Besançon - Hopital Jean Minjoz, Besançon, FR, ²CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ³Clinique Claude Bernard, Ermont, FR, ⁴University Paris-Saclay, UVSQ, APHP - Ambroise Paré Hospital, Boulogne-Billancourt, FR, ⁵Centre Hospitalier Metropole Savoie - Chambéry, Chambéry, FR, ⁶CHD Vendée, La Roche-sur-Yon, FR, ⁷Cabinet de Pneumologie, DIJON, FR, ⁸CHU Alpes du Sud - Site de Gap, Gap, FR, ⁹CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, ¹⁰Hopital Sainte Musse, Toulon, FR, ¹¹Hôpital d'Instruction des Armées Sainte Anne Toulon, Toulon, Cedex, FR, ¹²Cabinet de Pneumologie, Lens, FR, ¹³Centre Hospitalier Louis Pasteur, Dôle, FR, ¹⁴Hôpital de Jonzac, Jonzac, FR, ¹⁵French Cooperative Thoracic Intergroup, Paris, FR

15:40 - 15:45

1263MO - The impact of PET-CT and brain MRI for metastasis detection among



patients with T1-stage lung cancer: Findings from a large cohort study

W. Liang, Y. Feng, B. Cheng, J. Li, J. He, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN

15:45 - 15:55 **Invited Discussant 1262MO and 1263MO**

K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE

14:45 - 16:15 **Type: Educational session** **Málaga Auditorium - Hall 10**
Title: Integrating immunotherapy into the standard of care for cervical cancer

Chair(s): Nicoletta Colombo, IT; Alexandra Leary, FR

14:45 - 15:10 **IO in combination with chemoradiation therapy in locally advanced cervical cancer**

S. De Boer, LUMC - Universitair Medisch Centrum, Leiden, NL

15:10 - 15:35 **In metastatic and recurrence**

N. Colombo, IEO - Istituto Europeo di Oncologia, Milan, IT

15:35 - 16:00 **Treatment after progression on immunotherapy**

A. Leary, Institut Gustave Roussy, Villejuif, FR

16:00 - 16:15 **Discussion**

14:45 - 16:15 **Type: Proffered Paper session** **Santander Auditorium - Hall 9**
Title: Proffered Paper session 2 - Basic Science and Translational research

Chair(s): Göran Jönsson, SE; Elin Gray, AU

14:45 - 14:55 **1310 - A composite biomarker for evaluation of homologous recombination repair deficiency in a pan-cancer cohort**

M. Rübsam¹, M. Rheinnecker¹, B. Hutter¹, M. Fröhlich¹, C. Heilig¹, N. Paramasivam¹, M. Oles¹, C. Ball², H. Glimm², M. Hlevnjak¹, M. Zapatka¹, P. Lichter¹, S. Fröhling¹, R. Schlenk³, D. Hübschmann¹, ¹German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE, ²National Center for Tumor Diseases (NCT/UCC) Dresden, German Cancer Research Center (DKFZ) Heidelberg, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, DE, ³National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), and Heidelberg University Hospital, Heidelberg, DE

14:55 - 15:05 **10 - CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites**

L. Ruilin¹, Q. Li², H. Yao³, ¹2nd Affiliated Hospital/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, CN, ²The Second Affiliated Hospital of Sun Yat-Sen



University, Guangzhou, CN, ³2nd Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN

15:05 - 15:15 **Invited Discussant 1310 and 10**

E. Gray, Edith Cowan University, Perth, AU

15:15 - 15:25 **Q&A**

15:25 - 15:35 **22320 - Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031**

N. Harbeck¹, C. Duan², K. Dupree³, C.-W. Chang³, C. Barrios⁴, H. Zhang⁵, S. Saji⁶, K. Jung⁷, M. Telli⁸, M. Liste Hermoso⁹, S. Chui³, M. Dieterich⁹, E. Mittendorf¹⁰, L. Molinero³, ¹LMU Klinikum München, Munich, DE, ²Roche (China) Holding Ltd, Shanghai, CN, ³Genentech, Inc., South San Francisco, US, ⁴Hospital São Lucas, Porto Alegre, BR, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶Fukushima Medical University, Fukushima, JP, ⁷Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁸Stanford University School of Medicine, Stanford, US, ⁹F. Hoffmann-La Roche AG, Basel, CH, ¹⁰Brigham and Women's Hospital, Boston, US

15:35 - 15:45 **20 - PD-1 defines a distinct, functional, tissue-adapted state in V-delta-1⁺ T cells with implications for cancer immunotherapy**

Y. Wu¹, D. Davies¹, S. Kamdar¹, R. Woolf¹, I. Zlatareva¹, M.L. Iannito¹, C. Morton², Y. Haque¹, H. Martin³, O. O'Neill³, O. Nussbaumer¹, A. Hayday¹, ¹King's College London, London, GB, ²Guy's and St Thomas' NHS Foundation Trust, London, GB, ³The Francis Crick Institute, London, GB

15:45 - 15:55 **30 - IGSF8 is an innate immune checkpoint and cancer immunotherapy target**

K. Benhadji¹, Y. Li², X. Wu², H. Liu², X. Xiao², H. Liu², Q. Ding², B. Xie², C. Sheng², R. Zheng², Q. Yu², X. Hu¹, X.S. Liu¹, T. Xiao², ¹GV20 Therapeutics, Cambridge, US, ²GV20 Therapeutics, Shanghai, CN

15:55 - 16:05 **Invited Discussant 22320, 20 and 30**

G. Jönsson, Lund University, Lund, SE

16:05 - 16:15 **Q&A**

14:45 - 16:15 Type: Mini Oral session Toledo Auditorium - Hall 3
Title: Mini oral session - Supportive and palliative care

Chair(s): Christina Ruhlmann, DK; Karin Jordan, DE; Camilla Zimmermann, CA

14:45 - 14:50 **2032MO - Correlation of safety and efficacy in atezolizumab therapy across indications**



J. Naidoo¹, G. Durán-Pacheco², V. Maiya³, M. Socinski⁴, G. Sonpavde⁴, J. Puente⁵, L. Essioux⁶, C. Carter³, J. Cardona², R. Mohindra⁷, S. Chandler⁶, ¹Beaumont Hospital, Dublin, IE, ²F. Hoffmann-La Roche Ltd, Basel, CH, ³Genentech, Inc. - Member of the Roche Group, South San Francisco, US, ⁴AdventHealth Medical Group - Internal Medicine at Orlando, Orlando, US, ⁵Hospital Clinico Universitario San Carlos, Madrid, ES, ⁶F. Hoffmann-La Roche AG, Basel, CH, ⁷F. Hoffmann-La Roche AG - Elsaessertor II, Basel, CH

14:50 - 14:55 **1843MO - The effect of chronic psychological stress on the efficacy of first-line therapy of ICIs in advanced NSCLC (STRESS-LUNG-1 trial)**

F. Wu¹, Y. Zeng¹, Y. Li¹, J. Liu¹, C. Xiao¹, M. Liu², Z. Qiu¹, C. Deng¹, F. Ma¹, C. Xia¹, B. Zhang³, Z. Xiao⁴, C. Xu⁵, Z. Sheng⁶, P. Liu⁷, X. Zeng⁸, Y. Zhao⁸, J. Zhou¹, X. Liu¹, C. Hu¹, ¹The Second Xiangya Hospital of Central South University, Changsha, CN, ²University of Washington, Seattle, US, ³Hunan Yiyang Central Hospital, Yiyang, CN, ⁴CHANGDE City First People's Hoapital, Changsha, CN, ⁵Xiangxi Tujia and Miao Autonomous Prefecture People's Hospital, Jishou, CN, ⁶The Third Hospital of Changsha, Changsha, CN, ⁷The First Hospital of Changsha, Changsha, CN, ⁸Changsha Central Hospital, Changsha, CN

14:55 - 15:00 **2033MO - The impact of proton pump inhibitor (PPI) exposure before immune checkpoint inhibitor (ICI) therapy on overall survival (OS): A population-based study**

L. Eng¹, S. Saibil², R. Sutradhar³, V. Aghanya³, Y. Kaliwal³, Y. Niu³, N. Liu³, Y. Liu³, M. Powis⁴, G. Liu¹, J. Peppercorn⁵, P. Bedard¹, M. Krzyzanowska¹, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²UHN - University Health Network - Princess Margaret Cancer Centre, Toronto, CA, ³ICES - Institute for Clinical Evaluative Sciences, Toronto, CA, ⁴Princess Margaret Cancer Centre, Toronto, CA, ⁵Massachusetts General Hospital, Boston, US

15:00 - 15:15 **Invited Discussant 2032MO, 1843MO, 2033MO**

C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

15:15 - 15:20 **LBA96 - Roxadustat for Chemotherapy-Induced Anemia in Patients with Non-Myeloid Malignancies: A Randomized, Open-Label, Active-Controlled, Phase III Study**

S. Lu¹, J. Wu², J. Jiang³, Q. Guo⁴, Y. Yu⁵, Y. Liu⁶, H. Zhang⁷, L. Qian⁸, X. Dai⁹, Y. Xie¹⁰, T. Fu¹¹, T. Lee¹², Y. Lu¹³, R. Ma¹³, M. Eisner¹², ¹Shanghai Chest Hospital, Shanghai, CN, ²Fudan University, Shanghai, CN, ³The First Hospital of Jiaxing, Jiaxing, CN, ⁴Shandong First Medical University Cancer Hospital, Jinan, CN, ⁵Harbin Medical University Cancer Hospital, Harbin, CN, ⁶Neijiang Second People's Hospital, Neijiang, CN, ⁷The First People's Hospital of Foshan, Foshan, CN, ⁸Shanghai Fifth People's Hospital, Shanghai, CN, ⁹Xuzhou Central Hospital, Xuzhou, CN, ¹⁰The People's Hospital of Guangxi Zhuang Autononous Region, Nanning, CN, ¹¹Zhuzhou Central Hospital, Zhuzhou, CN, ¹²FibroGen, Inc., San Francisco, US, ¹³FibroGen (China) Medical Technology Development Co., Ltd., Shanghai, CN

15:20 - 15:25 **LBA97 - Olanzapine for the prevention of Chemotherapy Induced Nausea Vomiting in patients receiving moderately emetogenic chemotherapeutic (MEC) regimens - results of a prospective triple blinded phase 3 multicentric study (OMECE)**



V. Ostwal¹, S. Mandavkar¹, M. Parulekar¹, A. Ramaswamy¹, P. Bhargava², S. Srinivas¹, D. Chaugule¹, D. Naughane¹, A. Kapoor³, A. Gupta⁴, B. Sansar⁴, A. Sharma³, R. Rai⁵, P. Gupta⁵, B. Mishra³, V.K. Muddu⁶, I. Olver⁷, ¹Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, ²Tata Memorial Hospital Centre, Mumbai, IN, ³Mahamana Pandit Madan Mohan Malviya Cancer Centre and Homi Bhabha Cancer Hospital, Tata Memorial Centre, Varanasi, IN, ⁴Homi Bhabha Cancer Hospital, Varanasi, IN, ⁵Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, IN, ⁶AIG Hospitals, Hyderabad, IN, ⁷University of Adelaide, Adelaide, AU

15:25 - 15:30 **1844MO - Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive symptoms in lung cancer patients undergoing systemic therapy**

A. Starzer, J. Fuerst, E. Tomasich, L. Gottmann, J. Berger, M. Korpan, C. Englisch, M. Kleinberger, F. Moik, G. Heller, L. Carlberg, M. Preusser, A.S. Berghoff, Medical University of Vienna, Vienna, AT

15:30 - 15:45 **Invited Discussant LBA96, LBA97 and 1844MO**

K. Jordan, Ernst von Bergmann Klinikum Potsdam, Potsdam, DE

15:45 - 15:50 **1592MO - Anticancer therapy at the end-of-life: A cluster-randomized trial**

M. Hjermland¹, A. Pirnat², N. Aass³, S. Andersen⁴, G. Astrup², O. Dajani¹, H. Garresori⁵, K.V. Guldhav⁶, H.M. Hamre⁷, E. Haukland⁸, F. Jordal⁹, E.T. Lohre¹⁰, T. Lundebj³, S. Mjaaland¹¹, Ø. Paulsen¹², K.A. Semb¹³, E.S. Staff¹⁴, T.E. Wester², S. Kaasa³, ¹Oslo University Hospital - Ullevål Hospital, Oslo, NO, ²Oslo University Hospital, Oslo, NO, ³Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ⁴University Hospital of North Norway, Tromsø, NO, ⁵Helse Stavanger HF, Stavanger, NO, ⁶Health Forde - Forde Central Hospital, Forde, NO, ⁷Akershus University Hospital HF, Lorenskog, NO, ⁸Nordlandssykehuset Bodø, Bodø, NO, ⁹Sykehuset Ostfold, Fredrikstad, NO, ¹⁰St. Olavs Hospital, Trondheim University Hospital, Trondheim, NO, ¹¹Sorlandet Hospital, Kristiansand, NO, ¹²Sykehuset Telemark HF, Skien, NO, ¹³Sykehuset i Vestfold HF, Tonsberg, NO, ¹⁴Helse More og Romsdal HF, Alesund, NO

15:50 - 15:55 **1593MO - Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China**

M. Chen, H. Yu, Chongqing Cancer Hospital, Chongqing, CN

15:55 - 16:00 **2034MO - EAGER: A randomized, controlled, multicenter trial of electroacupuncture in gastric cancer patients undergoing adjuvant chemotherapy**

H.-B. Zhang¹, Y. Zhu¹, J. Mao², X.-S. Chang¹, J.-J. Peng³, X.-Y. Wu⁴, W. Wang⁵, D.-C. Diao¹, Y. Li⁶, H.-Y. Zhang⁷, X.-H. Zhai⁸, J.-L. Yu⁹, W. Wang¹⁰, J.-X. Zhou¹¹, Z.-L. Huang¹², T. Zhang¹³, Y.-H. Liu¹, R. Zhou¹, H.-C. Ma¹, Y.-D. Chen¹, ¹Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, CN, ²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ³The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ⁴Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, CN, ⁵the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, ⁶Guangdong Provincial People's Hospital, Guangzhou, CN, ⁷The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, CN, ⁸The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ⁹Zhujiang Hospital of Southern



Medical University, Guangzhou, CN, ¹⁰Foshan First People's Hospital, Foshan, CN, ¹¹The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, CN, ¹²Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, CN, ¹³Yuebei People's Hospital, Shaoguan, CN

16:00 - 16:15 **Invited Discussant 1592MO, 1593MO and 2034MO**

C. Zimmermann, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

14:45 - 16:15 **Type: Special session** **Oviedo Auditorium - Hall 7**
Title: Management of novel treatments' toxicities
 Chair(s): Lazar Popovic, RS; Alice Indini, IT

14:45 - 15:00 **Toxicities of novel therapies: Why is that important?**

L. Popovic, Oncology Institute of Vojvodina, Sremska Kamenica, RS

15:00 - 15:20 **Toxicity of IO + targeted agents**

E. Grande Pulido, MD Anderson Cancer Center Madrid, Madrid, ES

15:20 - 15:40 **Management of antibody-drug conjugates toxicities**

J. Gligorov, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR

15:40 - 16:00 **Toxicities of TILs, CAR-Ts and bispecific antibodies**

A. Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

16:00 - 16:15 **Discussion and Q&A**

A. Indini, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

14:45 - 16:10 **Type: Mini Oral session** **León Auditorium - Hall 7**
Title: Mini oral session - Melanoma and other skin tumours

Chair(s): Georgina Long, AU; Omid Hamid, US; Caroline Robert, FR

14:45 - 14:50 **1083MO - Brain metastases and survival evaluation in the SECOMBIT trial**

P. Ascierto¹, M. Mandalà², P.F. Ferrucci³, M. Guidoboni⁴, P. Rutkowski⁵, V. Ferraresi⁶, A.M. Arance Fernandez⁷, M. Guida⁸, E. Maiello⁹, H. Gogas¹⁰, E. Richtig¹¹, M.T. Fierro¹², C. Lebbe¹³, H. Helgadottir¹⁴, I. Melero¹⁵, G. Palmieri¹⁶, D. Giannarelli¹⁷, A. Grimaldi¹⁸, R. Dummer¹⁹, V. Chiarion Sileni²⁰, ¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ²Università degli Studi di Perugia, Perugia, IT, ³IEO - Istituto Europeo di Oncologia, Milan, IT, ⁴IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, IT, ⁵Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁶IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT, ⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁸Istituto Tumori Giovanni Paolo II, Bari, IT, ⁹IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni



Rotondo, IT, ¹⁰National and Kapodistrian University of Athens - School of Medicine, Athens, GR, ¹¹Universitätsklinik für Dermatologie und Venerologie, Graz, AT, ¹²University of Turin, Torino, IT, ¹³Hopital Saint Louis AP-HP, Paris, FR, ¹⁴Karolinska Institutet - Cancer Center Karolinska (CCK), Solna, SE, ¹⁵Clinica Universitaria de Navarra, Pamplona, ES, ¹⁶University of Sassari, Sassari, IT, ¹⁷Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ¹⁸AORN "San Pio", Napoli, IT, ¹⁹Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ²⁰IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

14:50 - 14:55 **1084MO - Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial**

A. Di Giacomo¹, V. Chiarion Sileni², M. Del Vecchio³, P.F. Ferrucci⁴, M. Guida⁵, P. Quaglino⁶, M. Guidoboni⁷, P. Marchetti⁸, E. Simonetti⁹, G. Amato¹⁰, A. Covre⁹, R. Camerini¹¹, L. Calabro¹², M. Valente¹⁰, M. Mandalà¹³, D. Giannarelli¹⁴, M. Maio¹, ¹University of Siena, Center for Immuno-Oncology, University Hospital of Siena, Siena, IT, ²Veneto Institute of Oncology IOV-IRCCS, Padova, IT, ³Istituto Nazionale dei Tumori, Milan, IT, ⁴European Institute of Oncology, IRCCS, Milan, IT, ⁵IRCCS Istituto Tumori "Giovanni Paolo II", Bari, IT, ⁶University of Turin, Torino, IT, ⁷Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, ⁸Sapienza University of Rome, Rome, IT, ⁹University of Siena, Siena, IT, ¹⁰Center for Immuno-Oncology, University Hospital of Siena, Siena, IT, ¹¹NIBIT Foundation Onlus, Genova, IT, ¹²University of Ferrara, Ferrara, IT, ¹³University of Perugia, Santa Maria della Misericordia, University Hospital of Perugia, Perugia, IT, ¹⁴Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, IT

14:55 - 15:10 **Invited Discussant 1083MO and 1084MO**

G. Long, University of Sydney, Sydney, AU

15:10 - 15:15 **LBA50 - Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial**

S. Piperno-Neumann¹, J. Hassel², P. Rutkowski³, J.-F. Baurain⁴, M. Schlaak⁵, M. Butler⁶, R. Sullivan⁷, R. Dummer⁸, J. Kirkwood⁹, M. Orloff¹⁰, J. Sacco¹¹, S. Ochsenreither¹², A. Joshua¹³, L. Gastaud¹⁴, B. Curti¹⁵, R. Carvajal¹⁶, O. Hamid¹⁷, L. Collins¹⁸, C. Holland¹⁹, P. Nathan²⁰, ¹Institut Curie, Paris, FR, ²NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ³Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁴Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ⁵Charité - Universitätsmedizin Berlin, Berlin, DE, ⁶UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁷MGH - Massachusetts General Hospital, Boston, US, ⁸Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ⁹UPMC Hillman Cancer Center, Pittsburgh, US, ¹⁰Thomas Jefferson Univ Hospital, Philadelphia, US, ¹¹Clatterbridge Cancer Center - NHS Foundation Trust, Wirral, GB, ¹²Charité - Universitätsmedizin Berlin, Berlin, DE, ¹³The Kinghorn Cancer Centre, Sydney, AU, ¹⁴Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁵Portland Providence Medical Center, Portland, US, ¹⁶Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ¹⁷The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US, ¹⁸Immunocore Limited, Abingdon-on-Thames, GB, ¹⁹Immunocore LLC, Conshohocken, US, ²⁰Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB



- 15:15 - 15:20 **1086MO - Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study**
 G.-U. Grigoleit¹, H. Kluger², S. Thomas³, J. Chesney⁴, E. Domingo-Musibay⁵, M.F. Sanmamed⁶, T. Medina⁷, M. Ziemer⁸, E. Whitman⁹, F. Graf Finckenstein¹⁰, J. Chou¹⁰, X. Wu¹⁰, G. Sultur¹⁰, W. Shi¹⁰, A. Sarnaik¹¹, ¹Helios Klinikum Duisburg, Duisburg, DE, ²Yale Cancer Center, New Haven, US, ³Orlando Health Cancer Institute, Orlando, US, ⁴Brown Cancer Center University of Louisville, Louisville, US, ⁵University of Minnesota, Minneapolis, US, ⁶Clinica Universidad de Navarra, Pamplona, ES, ⁷University of Colorado Cancer Center, Aurora, US, ⁸Universitätsklinikum Leipzig - Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, ⁹Atlantic Health System, Morristown, US, ¹⁰Iovance Biotherapeutics, Inc., San Carlos, US, ¹¹H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US
- 15:20 - 15:25 **LBA51 - Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047**
E. Lipson¹, S. Dolfi², H. Tang², H. Gogas³, H. Tawbi⁴, F.S. Hodi⁵, P. Ascierto⁶, E. Gutierrez⁷, D. Schadendorf⁸, F. Medina Soto⁹, P. Rutkowski¹⁰, E. Murillo Ramirez¹¹, M. Maio¹², Y. Xu², K. Desai², A. Yu², K. Demers², K. Miller-Moslin², G. Long¹³, C. Garnett-Benson², ¹The Sidney Kimmel Comprehensive Cancer Center, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, US, ²Bristol Myers Squibb, Princeton, US, ³National and Kapodistrian University of Athens - School of Medicine, Athens, GR, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵Dana Farber Cancer Institute, Boston, US, ⁶Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, IT, ⁷FAICIC Clinical Research, Veracruz, MX, ⁸University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ⁹Axis Heilsa S. de R.L. de C.V, Monterrey, Nuevo León, MX, ¹⁰Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ¹¹iBiomed Clinical Research, Guadalajara, MX, ¹²Center for Immuno-Oncology, University Hospital of Siena, Siena, IT, ¹³Melanoma Institute Australia, University of Sydney, Royal North Shore and Mater Hospitals, Wollstonecraft, AU
- 15:25 - 15:40 **Invited Discussant LBA50, 1086MO and LBA51**
O. Hamid, The Angeles Clinic and Research Institute - West Los Angeles, Los Angeles, US
- 15:40 - 15:45 **1087MO - A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study**
J. Becker¹, B. Schilling², U. Leiter-Stoppke³, L. Zimmer⁴, J. Hassel⁵, I. Von Wasielewski⁶, M. Ziemer⁷, M. Fluck⁸, F. Meier⁹, A. Spillner¹⁰, A. Gesierich², T. Eigentler¹¹, E. Livingstone¹², M. Albers¹⁰, Y. Angela¹³, R. Gutzmer¹⁴, ¹German Cancer Consortium (DKTK), Essen, DE, ²UKW - University Hospital Würzburg, Würzburg, DE, ³Universitätsklinikum Tuebingen, Tuebingen, DE, ⁴Universitätsklinikum Essen, Essen, DE, ⁵NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ⁶MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁷Universitätsklinikum Leipzig - Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, ⁸Fachklinik Hornheide, Münster, DE, ⁹Universitätsklinikum Carl Gustav Carus Dresden, Dresden, DE, ¹⁰Alcedis GmbH,



Giessen, DE, ¹¹Charité - Universitätsmedizin Berlin, Berlin, DE, ¹²University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE, ¹³Johannes Weseling Klinikum, Minden, DE, ¹⁴Ruhr University Bochum Medizinische Universitätsklinik, Bochum, DE

15:45 - 15:50

1088MO - A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up

N. Gross¹, D.M. Miller², N. Khushalani³, V. Divi⁴, E. Ruiz⁵, E. Lipson⁶, F. Meier⁷, Y.B. Su⁸, P.L. Swiecicki⁹, J.L. Atlas¹⁰, J.L. Geiger¹¹, A. Hauschild¹², J.H. Choe¹³, B. Hughes¹⁴, S.-Y. Yoo¹⁵, M. Mathias¹⁵, H. Han¹⁵, M. Fury¹⁵, D. Rischin¹⁶, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Beth Israel Deaconess Medical Center, Boston, US, ³Moffitt Cancer Centre, Tampa, US, ⁴Stanford University School of Medicine, Stanford, US, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, US, ⁶Johns Hopkins, Baltimore, US, ⁷Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, ⁸Nebraska Cancer Specialists - Midwest Cancer Center-Legacy, Omaha, US, ⁹University of Michigan, Ann Arbor, US, ¹⁰Carolinas HealthCare System/Atrium Health, Charlotte, US, ¹¹Cleveland Clinic, Cleveland, US, ¹²Schleswig-Holstein University Hospital, Kiel, DE, ¹³Duke Cancer Institute, Durham, US, ¹⁴Royal Brisbane and Women's Hospital and University of Queensland, Herston, AU, ¹⁵Regeneron Pharmaceuticals, Inc., Tarrytown, US, ¹⁶Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, AU

15:50 - 15:55

LBA52 - A randomized Phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma

O. Straume¹, C. Schuster¹, S. Aziz², K. Davidsen¹, J. Karlsen³, A.J. Rayford⁴, M.I. Siraji⁴, H. Løvendahl Svendsen², L. Reisæter², B.T. Gjertsen⁴, L. Akslen⁴, J. Lorens⁴, ¹Haukeland Universitetssykehus, Bergen, NO, ²Helse Bergen - Haukeland University Hospital, Bergen, NO, ³NTNU - Norwegian University of Science and Technology, Trondheim, NO, ⁴University of Bergen, Bergen, NO

15:55 - 16:10

Invited Discussant 1087MO, 1088MO and LBA52

C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR

14:45 - 16:15

Type: Proffered Paper session

Title: Proffered paper session: Policy and preventive strategie

Chair(s): Jose Martin-Moreno, ES; Mary Gospodarowicz, CA

Cádiz Auditorium - NCC

14:45 - 14:55

1687O - PRIMCAT: A novel approach to informing health technology assessment decision making in Australia

F. Franchini¹, K. Trapani¹, J. Soon¹, B. Daniels², P. Gillett¹, K. Degeling¹, M. Alexander³, Y.H. To⁴, S. O'Haire⁵, O. Yang³, S. Fox⁶, J. Desai⁵, Y. Zhang³, B. Solomon⁵, P. Gibbs⁴, G. Mearthur⁷, S. Pearson², M. Ijzerman⁸, ¹University of Melbourne, Parkville, AU, ²University of New South Wales, Kensington, AU, ³The University of Melbourne, Parkville, AU, ⁴WEHI - Walter and Eliza Hall Institute of Medical Research, Parkville, AU, ⁵Peter MacCallum Cancer Center, Melbourne, AU, ⁶Peter MacCallum Cancer Centre, Melbourne, AU, ⁷University of Melbourne and Peter MacCallum Cancer Centre, Melbourne, AU, ⁸Erasmus University, Rotterdam, NL



- 14:55 - 15:05 **16880 - Informative censoring of surrogate end-point data in FDA-approved cancer drugs**
T. Meirson¹, J. Ofer², G. Markel¹, Y. Pras³, S. Gilboa⁴, ¹Rabin Medical Center, Petah Tikva, IL, ²Davidoff Cancer Center - Rabin Medical Center, Petah Tikva, IL, ³Tel Aviv University, Tel Aviv, IL, ⁴Tel Aviv University-Sackler Faculty of Medicine, Tel Aviv, IL
- 15:05 - 15:15 **16890 - Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and Digital Health Working Group**
A. Pellat¹, T. Grinda², A. Prelaj³, P. Cresta⁴, A. Valachis⁵, I. Zerdes⁶, D. Martins Branco⁷, L. Provenzano³, A. Spagnoletti³, G. Nader Marta⁷, B. Wilson⁸, F. Montemurro⁹, L. Castelo-Branco¹⁰, G. Pentheroudakis¹⁰, S. Delaloge¹¹, M. Koopman¹², ¹Hôpital Cochin, Paris, FR, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁵Faculty of Medicine & Health, Örebro University, Örebro, SE, ⁶Karolinska Institutet - Bioclinicum, Solna, SE, ⁷Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Brussels, BE, ⁸Queen's University, Kingston, CA, ⁹IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ¹⁰ESMO - European Society for Medical Oncology, Lugano, CH, ¹¹Institut Gustave Roussy, Villejuif, FR, ¹²UMC - University Medical Center Utrecht, Utrecht, NL
- 15:15 - 15:25 **Invited Discussant 16870, 16880 and 16890**
A. Cortellini, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT
- 15:25 - 15:35 **Q&A**
- 15:35 - 15:45 **16900 - Impact of the SARS-CoV-2 outbreak on the initial clinical presentation of new solid cancer diagnoses: A systematic review and meta-analysis**
S. Marty¹, G. Lamé², E. Guével³, S. Priou², G. Chatellier⁴, C. Tournigand¹, E. Kempf¹, ¹Centre Hospitalier Universitaire Henri-Mondor AP-HP, Creteil, FR, ²CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR, ³Assistance Publique - Hopitaux De Paris AP-HP, Paris, FR, ⁴Assistance Publique - Hopitaux De Paris, Paris, FR
- 15:45 - 15:55 **16910 - Trends in new patient consultations during the COVID-19 pandemic at a comprehensive cancer centre in a public healthcare system**
C. Barron¹, T. Pittman², W. Xu², M. Madunic¹, J. Brierley¹, M. Krzyzanowska¹, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²Princess Margaret Cancer Centre, Toronto, CA
- 15:55 - 16:05 **Invited Discussant 16900 and 16910**
L. Castelo-Branco, ESMO - European Society for Medical Oncology, Lugano, CH
- 16:05 - 16:15 **Q&A**



15:00 - 16:00 **Type: Controversy session** **Burgos Auditorium - Hall 3**
Title: Pregnancy after breast cancer: Is it safe?
 Chair(s): Ann H. Partridge, US

15:00 - 15:05 **Welcome and “set the scene”**
A.H. Partridge, Dana Farber Cancer Institute, Boston, US

15:05 - 15:20 **Yes**
P. Neven, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:20 - 15:35 **No**
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

15:35 - 15:40 **First voting**

15:40 - 15:55 **Perspective from the Chair**
A.H. Partridge, Dana Farber Cancer Institute, Boston, US

15:55 - 16:00 **Second voting**

15:00 - 16:00 **Type: Young Oncologists session** **Pamplona Auditorium - Hall 9**
Title: ESMO for medical students and young physicians
 Chair(s): Andres Cervantes, ES; Kok Haw Jonathan Lim, GB

15:00 - 15:15 **ESMO-ESO Medical Students Course**
A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

15:15 - 15:30 **Developing a successful career in medical oncology**
P. Grivas¹, M. Lambertini², ¹University of Washington, Seattle, US, ²IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

15:30 - 16:00 **Guided poster walk**



16:15 - 17:45	Type: EONS Industry Satellite Symposium Title: AstraZeneca - Wellbeing in cancer nursing workforce Chair(s): Virpi Sulosaari, FI	Alicante Auditorium - Hall 10
16:15 - 16:20	Opening remarks V. Sulosaari, Turku University of Applied Sciences, Turku, FI	
16:20 - 16:45	Healthy work environment - what does it stand for in cancer care setting and how to apply the principles into practice V. Sulosaari, Turku University of Applied Sciences, Turku, FI	
16:45 - 17:10	The role of cancer nursing leadership in support of well-being at work H. Ullgren, Karolinska University Hospital-Solna, Solna, SE	
17:10 - 17:35	Factors contributing to well-being at work - cancer nurse's experience M. Cable, University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB	
17:35 - 17:45	Q&A and Conclusion remarks V. Sulosaari ¹ , H. Ullgren ² , M. Cable ³ , ¹ Turku University of Applied Sciences, Turku, FI, ² Karolinska University Hospital-Solna, Solna, SE, ³ University Hospital Coventry - University Hospitals Coventry and Warwickshire NHS Trust, Coventry, GB	
16:30 - 18:10	Type: Mini Oral session Title: Mini oral session 1 - Gastrointestinal tumours, upper digestive Chair(s): Lorenza Rimassa, IT; Hanneke van Laarhoven, NL; Tania Fleitas, ES	Bilbao Auditorium - NCC
16:30 - 16:35	945MO - AdvanTIG-206: Phase II randomized open-label study of ociperlimab (OCI) &#x2b; tislelizumab (TIS) &#x2b; BAT1706 (bevacizumab biosimilar) versus TIS &#x2b; BAT1706 in patients (pts) with advanced hepatocellular carcinoma (HCC) Z. Ren ¹ , Y. Huang ² , Y. Guo ³ , M.M. Hou ⁴ , W. Wang ⁵ , M. Kuang ⁶ , C. Hao ⁷ , W. Wang ⁸ , Y. Zhang ⁹ , T. Song ¹⁰ , C. Dai ¹¹ , K. Hsing-Tao ¹² , V. Li ¹³ , R. Abdrashitov ¹⁴ , L. Wang ¹³ , J. Fan ¹⁵ , ¹ Zhongshan Hospital Fudan University, Shanghai, CN, ² Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, CN, ³ Nanfang Hospital, Southern Medical University, Guangzhou, CN, ⁴ Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital, Taoyuan City, TW, ⁵ Hunan Cancer Hospital, Changsha, CN, ⁶ The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ⁷ Beijing Cancer Hospital, Beijing, CN, ⁸ West China Hospital Sichuan University, Sichuan, CN, ⁹ Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁰ HCC Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ¹¹ Shengjing Hospital of China Medical University - Huaxiang Campus, Shenyang, CN, ¹² Chi Mei Medical Center - Chiali, Tainan City, TW, ¹³ BeiGene (Beijing) Co. Ltd, Beijing, CN, ¹⁴ BeiGene USA, Inc., Fulton, US, ¹⁵ Liver Cancer Institute, Zhongshan Hospital - Fudan University, Shanghai, CN	



- 16:35 - 16:40 **94MO - Advanced extrahepatic cholangiocarcinoma: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials**
A. Lamarca¹, P. Ross², H. Wasan³, R. Hubner⁴, M. Mcnamara⁴, A. Lopes⁵, D. Palmer⁶, J. Valle⁴, J. Bridgewater⁷, ¹Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ²Guy's Hospital, London, GB, ³Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, GB, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵CRUK & UCL Cancer Trials Centre, London, GB, ⁶University of Liverpool - Imaging Centre at Liverpool, ICaL (formerly NiCaL), Liverpool, GB, ⁷UCL Cancer Institute - Paul O'Gorman Building, London, GB
- 16:40 - 16:45 **95MO - Tinengotinib in patients with advanced, fibroblast growth factor receptor (FGFR) inhibitor refractory/relapsed cholangiocarcinoma**
M. Javle¹, L. Kankeu Fonkoua², A. Mahipal³, C.-Y. Liao⁴, C. Fountzilas⁵, D. Li⁶, M. Pelster⁷, S. Goel⁸, P. Peng⁹, C. Sun⁹, H. Wang⁹, K. Hennessy¹⁰, X. Fu¹¹, L. Neo⁹, Y. Shan⁹, P. Huang⁹, D. Wu⁹, F. Wu⁹, J. Fan¹², S.A. Piha-Paul¹³, ¹MD Anderson Cancer Center, Houston, US, ²Mayo Clinic, Rochester, US, ³University Hospitals Cleveland Medical Center, Cleveland, US, ⁴University of Chicago - Department of Medicine, Chicago, US, ⁵Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁶City of Hope Comprehensive Cancer Center, Duarte, US, ⁷Sarah Cannon Research Institute, Tennessee Oncology, Nashville, US, ⁸Rutgers Cancer Institute of New Jersey, New Brunswick, US, ⁹TransThera Sciences (Nanjing), Inc., Nanjing, CN, ¹⁰TransThera Sciences (US), Inc., Gaithersburg, US, ¹¹TransThera Sciences (Nanjing), Inc., nanjing, CN, ¹²TransThera Sciences (US), Inc, Gaithersburg, US, ¹³The University of Texas MD Anderson Cancer Center - Main Building, Houston, US
- 16:45 - 17:00 **Invited Discussant 945MO, 94MO and 95MO**
L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT
- 17:00 - 17:05 **LBA78 - Overall Survival of Perioperative or Postoperative Adjuvant Oxaliplatin with S-1 versus Adjuvant Oxaliplatin with Capecitabine in Locally Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma Undergoing D2 Gastrectomy: An Updated Analysis of RESOLVE Trial**
X. Zhang¹, Z. Li¹, H. Liang², Y. Xue³, Y. Wang⁴, Z. Zhou⁵, J. Yu⁶, L. Chen⁷, Y. Du⁸, G. Li⁹, G. Xiao¹⁰, D. Wu¹¹, Y. Zhou¹², C. Dang¹³, Y. He¹⁴, Z. Zhang¹⁵, Y. Sun¹⁶, Y. Li¹⁷, L. Shen¹, J. Ji¹, ¹Peking University Cancer Hospital-Beijing Cancer Hospital, Beijing, CN, ²Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ³Harbin Medical University Cancer Hospital, Harbin, CN, ⁴Fudan University Shanghai Cancer Center, Shanghai, CN, ⁵Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁶The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, CN, ⁷Chinese PLA General Hospital (301 Military Hospital), Beijing, CN, ⁸Zhejiang Cancer Hospital, Hangzhou, CN, ⁹East theater General Hospital of PLA, Nanjing, CN, ¹⁰Beijing Hospital, Beijing, CN, ¹¹The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ¹²The Affiliated Hospital of Qingdao University, Qingdao, CN, ¹³The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ¹⁴The First Affiliated Hospital, Sun Yat-sen University, Guangdong, CN, ¹⁵Beijing Friendship Hospital, Capital Medical University, Beijing, CN, ¹⁶Zhongshan Hospital Fudan University, Shanghai, CN, ¹⁷The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN



- 17:05 - 17:10 **1512MO - Perioperative camrelizumab (C) combined with rivoceranib (R) and chemotherapy (chemo) versus chemo for locally advanced resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The first interim analysis of a randomized, phase III trial (DRAGON IV)**
- C. Li¹, Y. Zheng¹, Z. Shi², L. Yang³, B. Zhang¹, Z. Wang¹, H. Chen⁴, X. Wang⁵, P. Zhao⁶, J. Dong⁷, C. Lian⁸, Q. Zhao⁹, Z. Zheng¹⁰, A. Zhang¹¹, S. Xu¹², K. Wang¹³, F. Yuan¹, Y. Tian³, K. Yin², Z. Zhu¹, ¹Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, ²Changhai Hospital of Shanghai, Shanghai, CN, ³Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ⁴Lanzhou University Second Hospital, Lanzhou, CN, ⁵Yantai Yuhuangding Hospital, Yantai, CN, ⁶Sichuan Provincial Cancer Hospital, Chengdu, CN, ⁷Shanxi Provincial Cancer Hospital, Taiyuan, CN, ⁸Heping Hospital Affiliated to Changzhi Medical College, Changzhi, CN, ⁹The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ¹⁰Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹¹Affiliated Hospital of Hebei University, Baoding, CN, ¹²Affiliated Hospital of Jiangsu University, Zhenjiang, CN, ¹³Sichuan Provincial People's Hospital, Chengdu, CN
- 17:10 - 17:20 **Invited Discussant LBA78 and 1512MO**
- H. Van Laarhoven, Academic Medical Center, University of Amsterdam, Amsterdam, NL
- 17:20 - 17:25 **LBA79 - GEMSTONE-303: prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase 3 study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma**
- X. Zhang¹, J. Wang², G. Wang³, Y. Zhang⁴, Q. Fan⁵, L. Chuangxin⁶, C. Hu⁷, M.L. Sun⁸, Y. Wan⁹, S. Sun¹⁰, J. Wang¹¹, L. Zhang¹², Y. Shu¹³, J. Luo¹⁴, D. Zhu¹⁴, H. Wang¹⁴, Y. Xu¹⁴, Q. Shi¹⁴, J. Yang¹⁴, L. Shen¹, ¹Beijing Cancer Hospital, Beijing, CN, ²Henan Cancer Hospital, Zhengzhou, CN, ³Anhui Provincial Hospital, Hefei, CN, ⁴Harbin Medical University Cancer Hospital, Harbin, CN, ⁵The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁶Henan Provincial People's Hospital, Zhengzhou, CN, ⁷Anhui Provincial Cancer Hospital, Hefei, CN, ⁸Jinan Central Hospital, Jinan, CN, ⁹Jiangxi Cancer Hospital, Nanchang, CN, ¹⁰Xuzhou Central Hospital, Xuzhou, CN, ¹¹Affiliated Hospital of Jining Medical University, Jining, CN, ¹²Chongqing University Three Gorges Hospital, Chongqing, CN, ¹³Jiangsu Province Hospital, Nanjing, CN, ¹⁴CStone Pharmaceuticals Co. Ltd., Shanghai, CN
- 17:25 - 17:30 **LBA80 - Tislelizumab (TIS) Plus Chemotherapy (Chemo) vs Placebo (PBO) Plus Chemo as First-Line (1L) Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Final Analysis Results of the RATIONALE-305 Study**
- R.-H. Xu¹, D.-Y. Oh², K. Kato³, T. Arkenau⁴, J. Tabernero⁵, M. Cruz-Correa⁶, A. Zimina⁷, Y. Bai⁸, J. Shi⁹, K.-W. Lee¹⁰, H. Hirano³, D.R. Spigel¹¹, L. Wyrwicz¹², R. Pazo Cid¹³, L. Li¹⁴, Y. Xu¹⁵, M.B. Mchenry¹⁶, S. Yang¹⁴, M. Moehler¹⁷, ¹Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, CN, ²Seoul National University Hospital Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ³National Cancer Center Hospital, Tokyo, JP, ⁴Sarah Cannon Research Institute, London, GB, ⁵Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, ES, ⁶University of Puerto Rico, San Juan, PR, ⁷BIH Of Omsk Region, Omsk Oblast, RU, ⁸Harbin Medical University Cancer Hospital, Harbin, CN, ⁹Linyi Cancer Hospital, Linyi, CN, ¹⁰Seoul



National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, ¹¹Tennessee Oncology, Nashville, US, ¹²Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ¹³Hospital Universitario Miguel Servet, Zaragoza, ES, ¹⁴BeiGene (Beijing) Co., Ltd., Beijing, CN, ¹⁵BeiGene (Shanghai) Co., Ltd., Shanghai, CN, ¹⁶BeiGene USA, Inc., Cambridge, US, ¹⁷Johannes Gutenberg-University Clinic, Mainz, DE

17:30 - 17:35 **1513MO - A phase II study of nivolumab plus low dose ipilimumab as first -line therapy in patients with advanced gastric or esophago-gastric junction MSI-H tumor: First results of the NO LIMIT study (WJOG13320G/CA209-7W7)**

K. Muro¹, H. Kawakami², S. Kadowaki¹, A. Makiyama³, M. Tsuda⁴, K. Hirata⁵, N. Sugimoto⁶, N. Machida⁷, H. Hara⁸, H. Hirano⁹, T. Esaki¹⁰, Y. Komatsu¹¹, S. Hironaka¹², ¹Aichi Cancer Center Hospital, Nagoya, JP, ²Kindai University Faculty of Medicine, Osakasayama, JP, ³Gifu University Hospital, Gifu, JP, ⁴Hyogo Cancer Center, Akashi, JP, ⁵Keio University School of Medicine, Shinjuku-ku, JP, ⁶Osaka International Cancer Institute, Osaka, JP, ⁷Kanagawa Cancer Center, Yokohama, JP, ⁸Saitama Cancer Center, Ina, JP, ⁹National Cancer Center Hospital, Chuo-ku, JP, ¹⁰National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹¹Hokkaido University Hospital, Sapporo, JP, ¹²Kyorin University Faculty of Medicine, Mitaka, JP

17:35 - 17:50 **Invited Discussant LBA79, LBA80 and 1513MO**

T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES

17:50 - 17:55 **LBA81 - Updated efficacy and safety results from phase 3 GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma**

F. Lordick¹, M. Shah², K. Shitara³, J. Ajani⁴, Y.-J. Bang⁵, P. Enzinger⁶, D. Ilson⁷, E. Van Cutsem⁸, J. Gallego Plazas⁹, J. Huang¹⁰, L. Shen¹¹, S.C. Oh¹², P. Sunpaweravong¹³, H.H.F. Soo¹⁴, H. Türk¹⁵, J.W. Park¹⁶, D. Moran¹⁶, P. Bhattacharya¹⁶, Y. Cao¹⁷, R.-H. Xu¹⁸, ¹University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, DE, ²Weill Cornell Medical College, New York, US, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵Seoul National University College of Medicine, Seoul, KR, ⁶Dana Farber Cancer Institute, Boston, US, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸University Hospitals Gasthuisberg, Leuven, and KULeuven, Leuven, BE, ⁹Hospital General Universitario de Elche, Elche, ES, ¹⁰National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ¹¹Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, CN, ¹²Korea University Guro Hospital, Seoul, KR, ¹³Prince of Songkla University, Amphoe Hat Yai, TH, ¹⁴Penang Hospital, Penang, MY, ¹⁵BezmialemVakif University, Istanbul, TR, ¹⁶Astellas Pharma Global Development, Inc., Northbrook, US, ¹⁷Astellas Pharma USA, Northbrook, US, ¹⁸Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, CN

17:55 - 18:00 **LBA82 - Updated efficacy and safety results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients**



with claudin-18 isoform 2-positive (CLDN18.2+), HER2–, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

J. Ajani¹, F. Lordick², Y.-J. Bang³, P. Enzinger⁴, D. Ilson⁵, M. Shah⁶, E. Van Cutsem⁷, R.-H. Xu⁸, G. Aprile⁹, J. Xu¹⁰, R. Pazo Cid¹¹, Y.-K. Kang¹², J. Yang¹³, D. Moran¹³, P. Bhattacharya¹³, M. Matsangou¹⁴, A. Arozullah¹³, J.W. Park¹³, K. Shitara¹⁵, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²University Cancer Center Leipzig, University of Leipzig Medical Center, Leipzig, DE, ³Seoul National University College of Medicine, Seoul, KR, ⁴Dana-Farber Cancer Institute, Boston, US, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶Weill Cornell Medical College, New York, US, ⁷University Hospitals Gasthuisberg, Leuven, and KU Leuven, Leuven, BE, ⁸Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁹Azienda ULSS 8 Berica, Vicenza, IT, ¹⁰The Fifth Medical Center of the PLA General Hospital, Beijing, CN, ¹¹Hospital Universitario Miguel Servet, Zaragoza, ES, ¹²Asan Medical Center, University of Ulsan, Seoul, KR, ¹³Astellas Pharma Global Development, Inc., Northbrook, US, ¹⁴Astellas Pharma Inc., Northbrook, US, ¹⁵National Cancer Center Hospital East, Kashiwa, JP

18:00 - 18:10 **Invited Discussant LBA81 and LBA82**

S. Lorenzen, Klinikum Rechts der Isar - Technische Universitaet Muenchen, Munich, DE

16:30 - 18:00	Type: Educational session Title: Biomarkers in metastatic colorectal cancer: What has changed in the last few years? Chair(s): Myriam Chalabi, NL; Hans Prenen, BE	Granada Auditorium - Hall 3
----------------------	--	------------------------------------

16:30 - 16:55 **Clinical data of genomic subtypes of mCRC (MSI, BRAF V600, HER2, KRAS G12C, NTRK)**
M. Chalabi, Netherlands Cancer Institute, Amsterdam, NL

16:55 - 17:20 **Biomarkers in 2023: What, how and when to test?**
H. Prenen, UZA - University Hospital Antwerp, Edegem, BE

17:20 - 17:45 **Biomarkers in the near future: What to expect?**
F. Pietrantonio, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

17:45 - 18:00 **Q&A and Discussion**



16:30 - 17:45 **Type: Multidisciplinary session** **Burgos Auditorium - Hall 3**
Title: Bladder preservation strategies
 Chair(s): Elizabeth Plimack, US; Andrea Necchi, IT

16:30 - 16:35 **Presentation of case/condition: Non-muscle invasive bladder cancer (NMIBC) progressing to MIBC**
A. Necchi, IRCCS Ospedale San Raffaele, Milan, IT

16:35 - 16:55 **Organ preservation for refractory NMIBC: A surgeon's perspective**
J. Boormans, Erasmus MC, Rotterdam, NL

16:55 - 17:15 **Radiotherapy in bladder preservation**
R. Huddart, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB

17:15 - 17:35 **The role of systemic therapy in bladder preservation**
E. Plimack, Fox Chase Cancer Center - Main Campus, Philadelphia, US

17:35 - 17:45 **Discussion**

16:30 - 18:15 **Type: Proffered Paper session** **Madrid Auditorium - Hall 6**
Title: Presidential 1
 Chair(s): Solange Peters, CH; Jean-Yves Blay, FR

16:30 - 16:42 **LBA1 - CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II-IIIb NSCLC**

T. Cascone¹, M. Awad², J. Spicer³, J. He⁴, S. Lu⁵, B. Sepesi¹, F. Tanaka⁶, J. Taube⁷, R. Cornelissen⁸, L. Havel⁹, J. Kuzdzał¹⁰, L. Petruzella¹¹, L. Wu¹², J.-L. Pujol¹³, H. Ito¹⁴, C. Coronado Erdmann¹⁵, P. Sathyanarayana¹⁵, S. Meadows-Shropshire¹⁵, M. Provencio Pulla¹⁶, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Dana-Farber Cancer Institute, Boston, US, ³McGill University Health Center, Montreal, CA, ⁴National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁵Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ⁶University of Occupational and Environmental Health, Kitakyushu, JP, ⁷The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, US, ⁸Erasmus MC Cancer Institute, Rotterdam, NL, ⁹Thomayer Hospital, Prague, CZ, ¹⁰John Paul II Hospital, Krakow, PL, ¹¹Charles University, Prague, CZ, ¹²Hunan Cancer Hospital, Changsha, CN, ¹³Montpellier Regional University Hospital, Montpellier, FR, ¹⁴Kanagawa Cancer Center, Yokohama, JP, ¹⁵Bristol Myers Squibb, Princeton, US, ¹⁶Hospital Universitario Puerta de Hierro, Madrid, ES

16:42 - 16:54 **LBA2 - ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)**
B. Solomon¹, J.S. Ahn², R. Dziadziuszko³, F. Barlesi⁴, M. Nishio⁵, D.H. Lee⁶, J.-S. Lee⁷, W.-



Z. Zhong⁸, H. Horinouchi⁹, W. Mao¹⁰, M. Hochmair¹¹, F. De Marinis¹², M.R. Migliorino¹³, I. Bondarenko¹⁴, T. Lohmann¹⁵, T. Xu¹⁶, A. Cardona Gavaldon¹⁵, W. Bordogna¹⁵, T. Ruf¹⁵, Y.-L. Wu⁸, ¹Peter MacCallum Cancer Center, Melbourne, AU, ²Samsung Medical Center, Seoul, KR, ³Medical University of Gdansk, Gdańsk, PL, ⁴International Center for Thoracic Cancers (CICT), Villejuif, FR, ⁵Japanese Foundation for Cancer Research, Tokyo, JP, ⁶Asan Medical Center, Seoul, KR, ⁷Seoul National University Bundang Hospital, Seongnam, KR, ⁸Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, ⁹National Cancer Center Hospital, Tokyo, JP, ¹⁰Chinese Academy of Sciences, Zhejiang, CN, ¹¹Klinik Floridsdorf, Karl-Landsteiner-Institute for Lung Research and Pulmonary Oncology, Vienna, AT, ¹²European Institute of Oncology (IRCSS), Milan, IT, ¹³San Camillo Forlanini Hospital, Roma, IT, ¹⁴Dnipropetrovsk Medical Academy, Dnipro, UA, ¹⁵F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁶Roche (China) Holding Ltd, Shanghai, CN

16:54 - 17:04 **Invited Discussant LBA1 and LBA2**

M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

17:04 - 17:10 **Q&A**

17:10 - 17:22 **LBA3 - Randomized Phase 3 Study of Selpercatinib versus Cabozantinib or Vandetanib in Advanced, Kinase Inhibitor-Naïve, RET-mutant Medullary Thyroid Cancer**

J. Hadoux¹, R. Elisei², M. Brose³, A. Hoff⁴, B. Robinson⁵, M. Gao⁶, B. Jarzab⁷, P. Isaev⁸, K. Kopeckova⁹, J. Wadsley¹⁰, D. Führer¹¹, B. Keam¹², E. Sherman¹³, M. Tahara¹⁴, M. Hu¹⁵, Y. Lin¹⁶, P. Maeda¹⁶, L. Wirth¹⁷, J. Capdevila Castillon¹⁸, ¹Gustave Roussy, Villejuif, Cedex, FR, ²University of Pisa - DAM, Pisa, IT, ³Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, US, ⁴Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, BR, ⁵University of Sydney, Sydney, AU, ⁶Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ⁷Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, PL, ⁸A. Tsyb MRRC, Obninsk, RU, ⁹Motol University Hospital, Prague, CZ, ¹⁰Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ¹¹University Hospital, Essen, University of Duisburg-Essen, Endocrine Tumour Center at West German Cancer Center, Essen, DE, ¹²Seoul National University Hospital, Seoul, KR, ¹³MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ¹⁴National Cancer Center Hospital East, Kashiwa, JP, ¹⁵The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹⁶Eli Lilly and Company, Indianapolis, US, ¹⁷MGH - Massachusetts General Hospital, Boston, US, ¹⁸Vall Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES

17:22 - 17:30 **Invited Discussant LBA3**

L. Locati, ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano, Milan, IT

17:30 - 17:35 **Q&A**



- 17:35 - 17:47 **LBA4 - Randomized Phase 3 Study of First-line Selpercatinib versus Chemotherapy and Pembrolizumab in RET Fusion-positive NSCLC**
- H.H.F. Loong¹, K. Goto², B. Solomon³, K. Park⁴, M. Pérol⁵, E. Arriola⁶, S. Novello⁷, Y. Cheng⁸, A. Ardizzoni⁹, M. Mak¹⁰, F. Santini¹¹, Y. Elamin¹², A. Drilon¹³, J. Wolf¹⁴, B. Han¹⁵, H. Han¹⁶, M. Uh¹⁶, T. Puri¹⁶, V. Ilaria¹⁷, C. Zhou¹⁸, ¹The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, ²National Cancer Center Hospital East, Kashiwa, JP, ³Peter MacCallum Cancer Center, Melbourne, AU, ⁴Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Centre Léon Bérard, Lyon, FR, ⁶HOSPITAL DEL MAR, BARCELONA, ES, ⁷Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ⁸Jilin Cancer Hospital, Changchun, CN, ⁹University of Bologna - Alma Mater Studiorum, Bologna, IT, ¹⁰ICESP - Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, BR, ¹¹Hospital Sirio Libanes - Complexo Hospitalar Bela Vista, Sao Paulo, BR, ¹²The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹³Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ¹⁴University Hospital of Cologne, Cologne, DE, ¹⁵Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ¹⁶Eli Lilly and Company, Indianapolis, US, ¹⁷Eli Lilly and Company - Global Headquarters, Indianapolis, US, ¹⁸Shanghai Pulmonary Hospital, Shanghai, CN
- 17:47 - 17:59 **LBA5 - Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study**
- N. Girard¹, K. Park², K. Tang³, B.C. Cho⁴, L. Paz-Ares⁵, S. Cheng⁶, S. Kitazono⁷, M. Thiagarajan⁸, J. Goldman⁹, J. Sabari¹⁰, R. Sanborn¹¹, A. Mansfield¹², J.-Y. Hung¹³, S. Popat¹⁴, J. Dias¹⁵, A. Bhattacharya¹⁶, T. Agrawal¹⁷, M. Shreeve¹⁸, R. Knoblauch¹⁷, C. Zhou¹⁹, ¹Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, FR, ²Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, (current affiliation: MD Anderson Cancer Center), Houston, US, ³The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ⁴Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁵Hospital Universitario 12 de Octubre, Madrid, ES, ⁶Sunnybrook Odette Cancer Centre, Toronto, CA, ⁷Japanese Foundation for Cancer Research, Tokyo, JP, ⁸General Hospital Kuala Lumpur, Kuala Lumpur, MY, ⁹University of California Los Angeles, Los Angeles, US, ¹⁰NYU Langone Health, New York, US, ¹¹Providence Cancer Institute, Portland, US, ¹²Mayo Clinic, Rochester, US, ¹³Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TW, ¹⁴The Institute of Cancer Research, London, GB, ¹⁵Barretos Cancer Hospital, Barretos, BR, ¹⁶Janssen R&D, High Wycombe, GB, ¹⁷Janssen R&D, Spring House, US, ¹⁸Janssen R&D, San Diego, US, ¹⁹Tongji University School of Medicine, Shanghai, CN
- 17:59 - 18:09 **Invited Discussant LBA4 and LBA5**
- B. Besse, Institut Gustave Roussy, Villejuif, FR
- 18:09 - 18:15 **Q&A**



16:30 - 18:00 **Type: Special symposium** **Salamanca Auditorium - Hall 3**
Title: New mechanisms and drugs for the treatment of patients with sarcomas
 Chair(s): Kjetil Boye, NO; Marta Sbaraglia, IT

16:30 - 16:35 **Introduction and scientific background**

16:35 - 16:50 **Targeting fusion driven sarcomas**
C. Kadoch, Dana Farber Cancer Institute, Boston, US

16:50 - 17:05 **Targeting proapoptotic pathways: MDM2 and beyond**
S. Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

17:05 - 17:20 **Multi-facets of antiangiogenic agents**
T.W.-W. Chen, NTU - National Taiwan University - College of Medicine, Taipei City, TW

17:20 - 17:35 **Novel combinations**
R. Jones, The Royal Marsden Hospital - Chelsea, London, GB

17:35 - 17:55 **Discussion**

17:55 - 18:00 **Conclusions and perspectives**

16:30 - 17:50 **Type: Mini Oral session** **Málaga Auditorium - Hall 10**
Title: Mini oral session - Investigational immunotherapy
 Chair(s): Alessandra Curioni-Fontecedro, CH; María José De Miguel, ES

16:30 - 16:35 **1020MO - AdvanTIG-203: Phase II randomized, multicenter study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with unresectable, locally advanced, recurrent/metastatic esophageal squamous cell carcinoma (ESCC) and programmed cell death-ligand 1 (PD-L1) positivity**

F. Wang¹, C.-Y. Lin², J.-M. Sun³, C.-H. Lu⁴, X. Zhu⁵, Z. Chen⁶, I.-H. Kim⁷, Y. Pan⁸, J. Zhang⁹, Z. Chen¹⁰, D. Tougeron¹¹, S.-B. Kim¹², E. Van Cutsem¹³, R. Abdrashitov¹⁴, R. Ge¹⁵, J. Sun¹⁵, J. Zhou¹⁵, R.-H. Xu¹, ¹Sun Yat-Sen University Cancer Center, Guangzhou, CN, ²China Medical University Hospital, Taiwan, CN, ³Samsung Medical Center, Seoul, KR, ⁴Chiayi Chang Gung Memorial Hospital, Taiwan, CN, ⁵Sichuan Provincial People's Hospital, Chengdu, CN, ⁶The Second Affiliated Hospital of Anhui Medical University, Hefei, CN, ⁷Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, KR, ⁸Anhui Provincial Hospital, Hefei, CN, ⁹Liaoning Cancer Hospital & Institute, Shenyang, CN, ¹⁰People's Hospital of Deyang City, Deyang, CN, ¹¹Poitiers University Hospital, Poitiers, FR, ¹²Asan Medical Center, Seoul, KR, ¹³University Hospitals Gasthuisberg Leuven and University of Leuven (KUL), Leuven, BE, ¹⁴BeiGene USA, Inc., Fulton, US,



15BeiGene (Beijing) Co., Ltd., Beijing, CN

- 16:35 - 16:40 **1021MO - Safety and efficacy of etigilimab (anti-TIGIT) with nivolumab (anti-PD1) in recurrent/advanced solid tumors**
M. Mckean¹, E. Dumbrava², O. Hamid³, P. Merriam⁴, J. Call⁵, W. Feely⁶, A. Green⁷, U. Vaishampayan⁸, K. Moore⁹, S. Weroha¹⁰, S. Krishnan⁶, A. George¹¹, ¹Sarah Cannon Research Institute, Nashville, US, ²M. D. Anderson Cancer Center, Houston, US, ³The Angeles Clinic and Research Institute, Los Angeles, US, ⁴Dana Farber Cancer Institute, Boston, US, ⁵START Mountain Region, West Valley City, US, ⁶OncoMed Pharmaceuticals, Inc. - Mereo BioPharma Group plc, Redwood City, US, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸Michigan Medicine University of Michigan, Ann Arbor, US, ⁹Oklahoma University, Oklahoma City, US, ¹⁰Mayo Clinic, Rochester, US, ¹¹The Royal Marsden Foundation Trust, London, GB
- 16:40 - 16:55 **Invited Discussant 1020MO and 1021MO**
A. Curioni-Fontecedro, Cantonal Hospital Fribourg, Villar sur Glane, CH
- 16:55 - 17:00 **1022MO - Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy using AI combining total tumor volume and tumor heterogeneity on CT-Scans**
L. Dawi¹, S. Ammari², Y. Belkouchi³, J. Hadchiti⁴, L. Lawrance², F. Wirth⁴, A. Bertin⁴, S. Morer⁴, N. Billet⁴, C. Balleyguier⁵, P.-H. Cournede², H. Talbot³, N. Lassau², ¹Gustave Roussy, Bourg-la-reine, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR, ⁴Gustave Roussy, Paris, FR, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR
- 17:00 - 17:05 **1023MO - Decoding immunotherapy resistance: A novel multiparametric magnetic resonance imaging approach to stratify cancer patient outcomes**
K. Bernatowicz¹, F. Grussu¹, C. Tozzi¹, A. Voronova¹, M. Sanz², M. Vieito Villar², G. Alonso Casal², V. Galvao², A. Oberoi², I. Braña², O. Saavedra Santa Gadea², E. Muñoz Couselo², G. Serna¹, A.B. Moreno¹, M. Rotxes², J. Tabernero², R. Toledo¹, P. Nuciforo¹, E. Garralda², R. Perez Lopez¹, ¹Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ²Vall d'Hebron University Hospital, Barcelona, ES
- 17:05 - 17:10 **1024MO - Interpretable AI-identified spatial tumor microenvironment (TME) neighborhoods associate with severe immune-related adverse events (irAE) and progressive disease (PD) in patients with melanoma treated with anti-PD-1-based therapy**
D. Jimenez-Sanchez¹, E.M. Will¹, J. Lai¹, G. Warriar², E. Lipson², J. Deutsch¹, A.S. Szalay¹, J. Taube³, ¹Johns Hopkins Hospital, Baltimore, US, ²Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ³Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US
- 17:10 - 17:25 **Invited Discussant 1022MO, 1023MO and 1024MO**
M. Donia, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK
- 17:25 - 17:30 **1025MO - Preliminary safety, pharmacokinetics and immunomodulatory activity**



of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors

T. Marron¹, J. Misleh², C. Chen³, Z. Wainberg⁴, J. Powderly⁵, R. Boccia⁶, M. Gordon⁷, J. Segar⁸, I. Csiki⁹, J. Schanzer⁹, L. O'Toole⁹, N. Huang⁹, J. Seppa⁹, J. Glenn¹⁰, K. Klumpp¹¹, A. Spira¹², ¹The Mount Sinai Hospital - Icahn School of Medicine, New York, US, ²Christiana Care Health System - Helen F. Graham Cancer Center and Research Institute, Newark, US, ³Stanford Cancer Center Palo Alto, Palo Alto, US, ⁴UCLA - David Geffen School of Medicine, Los Angeles, US, ⁵Carolina BioOncology Institute, Huntersville, US, ⁶AOP, Bethesda, US, ⁷HonorHealth Research Institute, Scottsdale, US, ⁸The University of Arizona, Tucson, US, ⁹Riboscience LLC, Sunnyvale, US, ¹⁰Stanford Health Care, Stanford, US, ¹¹Riboscience, Sunnyvale, US, ¹²Virginia Cancer Specialist, Fairfax, US

17:30 - 17:35

1026MO - A phase Ib/II study of SHR-1701 (a bifunctional anti-PD-L1/TGF- β 2;RII agent) in combination with bevacizumab (BEV) in patients with advanced solid tumors

R.-H. Xu¹, L. Huiyan¹, H. Zhao¹, W. Wei¹, D. Ma², X. Yin³, Y. Ni⁴, Y. Wang⁵, Y. Zhang⁶, J. Zhou⁷, H. Pan⁸, Z. Niu⁹, J. Zhang¹⁰, H. Ren¹¹, M. Kang¹², W. Jia¹³, S. Gu¹⁴, P. Liu¹⁵, Z. Zhang¹⁵, S. Wang¹⁶, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ³Hunan Cancer Hospital, Changsha, CN, ⁴Shanxi Provincial Hospital of Traditional Chinese Medicine, Taiyuan, CN, ⁵Shanxi Provincial Cancer Hospital, Taiyuan, CN, ⁶Harbin Medical University Cancer Hospital, Harbin, CN, ⁷Sichuan Cancer Hospital, Chengdu, CN, ⁸Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁹Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ¹⁰Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, ¹¹The Second Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ¹²Affiliated Hospital of Guilin Medical University, Guilin, CN, ¹³The First Affiliated Hospital of USTC/Anhui Provincial Hospital, Hefei, CN, ¹⁴Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ¹⁵Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN, ¹⁶Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shenyang, CN

17:35 - 17:50

Invited Discussant 1025MO and 1026MO

M.J. De Miguel Luken, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES



16:30 - 18:00	Type: Patient Advocacy session Title: The importance of secondary prevention: Early detection and screening programmes Chair(s): Eva-Maria Strömsholm, FI; Barbara Moss, GB	Cádiz Auditorium - NCC
16:30 - 16:45	Improving early diagnosis through screening programme guidelines: The case of lung cancer <u>J. Van Meerbeeck</u> , UZA - University Hospital Antwerp, Edegem, BE	
16:45 - 17:00	The importance of harmonizing screening programmes across different levels of healthcare systems: Europe, national, regional <u>R. Giuliani</u> , The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB	
17:00 - 17:15	Cancer screening, another ground of health equity <u>G. Gorgoni</u> , Agenzia Strategica Regionale per la Salute e il Sociale, Bari, IT	
17:15 - 17:30	The case of colon cancer <u>B. Moss</u> , DiCE - Digestive Cancers Europe - EuropaColon LTD, Salisbury, GB	
17:30 - 17:45	The case of dental screening programmes <u>M. Heffernan</u> , Dr. Heffs, London, GB	
17:45 - 17:55	Discussion	
17:55 - 18:00	Conclusion	



18:30 - 20:00 **Type: Industry Satellite Symposium** **Burgos Auditorium - Hall 3**
Title: GSK - Convergence of evidence and experience in first-line advanced ovarian cancer Experts debate considerations and options for optimized clinical management
 Chair(s): Antonio Gonzalez Martin, ES

18:30 - 18:40 **The evidence nexus: Treatment evolution in first-line advanced ovarian cancer**
A. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES

18:40 - 19:25 **Not too little, not too much: What is the best 1L maintenance treatment approach for patients with HRd tumors?**
A. Leary¹, J. Ledermann², ¹Institut Gustave Roussy, Villejuif, FR, ²UCL Cancer Institute - UCL - London's Global University, London, GB

19:25 - 19:50 **What's next: Novel strategies to address unmet needs in advanced ovarian cancer**
A. Leary¹, J. Ledermann², ¹Institut Gustave Roussy, Villejuif, FR, ²UCL Cancer Institute - UCL - London's Global University, London, GB

19:50 - 19:55 **Conclusions and thoughts**
A. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES



18:30 - 20:00	Type: Industry Satellite Symposium Title: Pfizer Oncology - Understanding novel PARPi combination mechanisms in mCRPC Chair(s): Josep M. Piulats, ES	Valencia Auditorium - Hall 10
18:30 - 18:35	Introduction <u>J.M. Piulats</u> , ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES	
18:35 - 19:00	Molecular rationale behind PARPi and ARPi combinations in mCRPC <u>J.M. Piulats</u> , ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES	
19:00 - 19:20	Novel PARPi + ARPi therapeutic combinations in 1L mCRPC: Findings from Clinical Trials <u>A. Azad</u> , Peter MacCallum Cancer Centre, Melbourne, AU	
19:20 - 19:40	Role of novel PARPi + ARPi therapeutic combinations in evolving clinical practice <u>P. Barthélémy</u> , ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR	
19:40 - 19:55	Q&A <u>J.M. Piulats</u> , ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES	
19:55 - 20:00	Conclusion <u>J.M. Piulats</u> , ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES	



18:30 - 20:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Eisai Europe Ltd.: Optimising outcomes for patients with advanced renal cancer Chair(s): Toni Choueiri, US; Thomas Powles, GB	Salamanca Auditorium - Hall 3
18:30 - 18:40	Welcome and introduction <u>T. Choueiri</u> , Dana Farber Cancer Institute, Boston, US	
18:40 - 18:55	Current and emerging clinicopathologic and molecular prognostic schemes for patients with advanced renal cell carcinoma <u>V. Gruenwald</u> , University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	
18:55 - 19:10	State-of-the-art combination therapies for patients with advanced RCC <u>L. Albiges</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
19:10 - 19:25	Do all patients need combination therapy? De-escalation and patient selection <u>T. Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB	
19:25 - 19:40	Research insights in enhancing treatment efficacy: Escalation, sequencing and prediction <u>T. Choueiri</u> , Dana Farber Cancer Institute, Boston, US	
19:40 - 19:55	Q&A and discussion	
19:55 - 20:00	Concluding remarks <u>T. Powles</u> , St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB	



18:30 - 20:00	Type: Industry Satellite Symposium Title: AstraZeneca - Keeping abreast of a dynamic disease: Considerations in HR+ mBC Chair(s): Rebecca Dent, SG	Málaga Auditorium - Hall 10
18:30 - 18:35	Welcome and brief introduction to a dynamic disease <u>R. Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
18:35 - 19:00	Adapting to a dynamic disease: Optimising endocrine therapy and the role for genomic medicine <u>F.C. Bidard</u> , Institut Curie, Paris, FR	
19:00 - 19:25	Responding to a dynamic disease: Utilising ADCs <u>I. Krop</u> , Yale University School of Medicine - Yale Cancer Center, New Haven, US	
19:25 - 19:50	Managing a dynamic disease: Tailoring treatment strategies <u>K. Jhaveri</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
19:50 - 19:58	The future of a dynamic disease: What's on the horizon for HR+ mBC? <u>R. Dent</u> ¹ , <u>F.C. Bidard</u> ² , <u>I. Krop</u> ³ , <u>K. Jhaveri</u> ⁴ , ¹ NCCS - National Cancer Centre Singapore, Singapore, SG, ² Institut Curie, Paris, FR, ³ Yale University School of Medicine - Yale Cancer Center, New Haven, US, ⁴ Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
19:58 - 20:00	Meeting summary and close <u>R. Dent</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	



18:30 - 20:00	Type: Industry Satellite Symposium Title: MSD - Oncologists at the Helm of Translating Biomarker Insights into Actionable Patient Care Chair(s): Maria Alsina Maqueda, ES	Santander Auditorium - Hall 9
18:30 - 18:35	Welcome and Introductions <u>M. Alsina Maqueda</u> , Hospital Universitario de Navarra, Pamplona, ES	
18:35 - 18:55	How have clinical Biomarkers changed the treatment of cancer patients and what may the future look like? <u>M. Alsina Maqueda</u> , Hospital Universitario de Navarra, Pamplona, ES	
18:55 - 19:05	Q&A <u>M. Alsina Maqueda</u> ¹ , <u>K. Pantel</u> ² , <u>C. Eloy</u> ³ , ¹ Hospital Universitario de Navarra, Pamplona, ES, ² UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ³ IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT	
19:05 - 19:30	Emerging role of NGS and ctDNA in transforming the clinical utility of biomarkers <u>K. Pantel</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	
19:30 - 19:45	How will the use of Digital pathology and AI tools lead to better patient care (Panel discussion) <u>C. Eloy</u> , IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT	
19:45 - 19:55	Q&A <u>M. Alsina Maqueda</u> ¹ , <u>K. Pantel</u> ² , <u>C. Eloy</u> ³ , ¹ Hospital Universitario de Navarra, Pamplona, ES, ² UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ³ IPATIMUP - Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Porto, PT	
19:55 - 20:00	Closing Remarks <u>M. Alsina Maqueda</u> , Hospital Universitario de Navarra, Pamplona, ES	



18:30 - 20:00	Type: Industry Satellite Symposium	Toledo Auditorium - Hall 3
	Title: Ipsen - aRCC and mCRPC: is your decision-making up-to-date?	
	Chair(s): Joaquim Bellmunt, US	
18:30 - 18:37	Welcome & introduction	
	<u>J. Bellmunt</u> , Harvard Medical School, Boston, US	
18:37 - 18:49	Keeping pace in aRCC Description: A presentation highlighting the rapid advances in treatment landscape as well as biological understanding of aRCC, and what this means for patients in the real world.	
	<u>D. Heng</u> , Tom Baker Cancer Centre, Calgary, CA	
18:49 - 19:01	Spoilt for choice in 1L aRCC? Or not Really? Description: A presentation discussing the clinical endpoints that are considered when selecting first-line treatment for patients with aRCC.	
	<u>S. Pal</u> , City of Hope Comprehensive Cancer Center, Duarte, US	
19:01 - 19:10	Panel Discussion	
	<u>J. Bellmunt</u> ¹ , <u>S. Pal</u> ² , <u>D. Heng</u> ³ , <u>C. Suarez Rodriguez</u> ⁴ , <u>A. Merseburger</u> ⁵ , ¹ Harvard Medical School, Boston, US, ² City of Hope Comprehensive Cancer Center, Duarte, US, ³ Tom Baker Cancer Centre, Calgary, CA, ⁴ Vall d'Hebron University Hospital, Barcelona, ES, ⁵ UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE	
19:10 - 19:35	Putting theory into practice Description: A simulated multi-disciplinary tumour board considering the first- and second-line treatment choices for a patient with aRCC.	
	<u>C. Suarez Rodriguez</u> ¹ , <u>D. Heng</u> ² , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² Tom Baker Cancer Centre, Calgary, CA	
19:35 - 19:55	Direction of travel in mCRPC Description: A presentation reflecting on the similar rapid changes that are occurring in mCRPC and changes anticipated in the near-term, and considering the data available to help clinicians select and sequence treatments.	
	<u>A. Merseburger</u> , UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE	
19:55 - 20:00	Closing Remarks	
	<u>J. Bellmunt</u> , Harvard Medical School, Boston, US	



18:30 - 19:58 **Type: Industry Satellite Symposium** **Oviedo Auditorium - Hall 7**
Title: Merck - Exploring SCCHN: insight into an evolving treatment landscape
 Chair(s): Hisham Mehanna, GB

18:30 - 18:35 **Welcome and Introduction**
H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB

18:35 - 18:47 **Treatment of LA SCCHN: challenges and unmet needs**
S. Rieken, Universitätsmedizin Göttingen, Goettingen, DE

18:47 - 18:59 **A matter of life and cell death: resistance to apoptosis in SCCHN**
J. Schoenfeld, Dana-Farber Cancer Institute, Boston, US

18:59 - 19:11 **Looking ahead: ongoing developments in LA SCCHN**
C. Le Tourneau, Institut Curie, Paris, FR

19:11 - 19:26 **Panel discussion**
H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB

19:26 - 19:38 **Reviewing the evidence: treatment sequencing in R/M SCCHN**
N. Baste Rotllan, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

19:38 - 19:53 **Panel discussion**
H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB

19:53 - 19:58 **Closing remarks**
H. Mehanna, The University of Birmingham - Institute for Cancer Studies, Birmingham, GB



18:30 - 20:00	Type: Industry Satellite Symposium Title: Gilead Sciences Europe Ltd - Lines of progress: Continuing to improve outcomes in metastatic breast cancer	León Auditorium - Hall 7
	Chair(s): Eva Ciruelos, ES	
18:30 - 18:45	Metastatic Breast Cancer: A journey of progress through innovations	
	<u>E. Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
18:45 - 19:10	Expanding possibilities in HR+/HER2- mBC	
	<u>H. Rugo</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US	
19:10 - 19:35	Improving outcomes for patients with metastatic TNBC	
	<u>A. Schneeweiss</u> , German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE	
19:35 - 19:55	Audience Q&A	
	<u>A. Schneeweiss</u> ¹ , <u>H. Rugo</u> ² , <u>S. Tolaney</u> ³ , ¹ German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE, ² UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ³ Dana Farber Cancer Institute, Boston, US	
19:55 - 20:00	Closing Remarks	
	<u>E. Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	



22.10.2023

08:30 - 10:00 **Type: Special symposium** **Barcelona Auditorium - Hall 9**
Title: Circulating tumour DNA: A perfect fit?
 Chair(s): Clara Montagut Viladot, ES; Julien Taieb, FR

08:30 - 08:35 **Introduction and scientific background**
J. Taieb, Hopital European George Pompidou, Paris, FR

08:35 - 08:50 **ctDNA assessment: How and when?**
K. Pantel, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

08:50 - 09:05 **ctDNA in mCRC: Monitoring response and guiding treatment**
C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

09:05 - 09:20 **ctDNA in early-stage CRC: Tailoring the adjuvant therapy**
J. Taieb, Hopital European George Pompidou, Paris, FR

09:20 - 09:35 **ctDNA clearance: Surrogacy for cure and organ-sparing approaches**
J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**
C. Montagut Viladot, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

08:30 - 10:00 **Type: Mini Oral session** **Sevilla Auditorium - Hall 9**
Title: Mini oral session 2 - NSCLC, metastatic
 Chair(s): Martin Reck, DE; Jessica Lin, US; Tetsuya Mitsudomi, JP

08:30 - 08:35 **1317MO - Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)**
 Y. Ma¹, H. Zhao¹, Y. Zhao², Y. Cheng³, J. Cui⁴, G. Liu⁵, D. Xiong⁵, J. Zhang⁵, L. Xu⁵, J. Yu⁵, L. Men⁵, E. Liang⁶, D. Yang⁵, L. Zhang¹, Y. Zhai⁶, ¹State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ³Jilin Cancer Hospital, Changchun, CN, ⁴The First Hospital of Jilin University, Changchun, CN, ⁵Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, CN, ⁶Ascentage Pharma Group, Inc., Rockville, US

08:35 - 08:40 **1318MO - First-in-human study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting antibody-drug conjugate combined with osimertinib (OSI) in relapsed/refractory, EGFR-mutated non-small cell lung cancer (NSCLC)**
J. Rotow¹, S.N. Waqar², K. Papadopoulos³, J.-Y. Hung⁴, A. Spira⁵, H. Gan⁶, T. Yoshida⁷, C.-



H.S. Kuo⁸, B. Doger De Spéville⁹, E. Felip¹⁰, K. Yoh¹¹, G. Morrison-Thiele¹², R. Robinson¹³, N. Rudraganguly¹³, R. Saab¹³, B.C. Cho¹⁴, ¹The Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, Boston, US, ²Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ³South Texas Accelerated Research Therapeutics (START), San Antonio, US, ⁴Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung City, TW, ⁵Virginia Cancer Specialists, US Oncology Research, Fairfax, US, ⁶Austin Health - Austin Hospital, Heidelberg, AU, ⁷National Cancer Center Hospital, Tokyo, JP, ⁸Chang Gung Memorial Hospital, Chang Gung University, Taipei, TW, ⁹START Madrid Hospital Universitario, Madrid, ES, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹National Cancer Center Hospital East, Kashiwa, JP, ¹²Abbvie Inc. - Headquarters, North Chicago, US, ¹³AbbVie, Inc., San Francisco, US, ¹⁴Yonsei University, Seoul, KR

08:40 - 08:45

1320MO - Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088

H.H.F. Loong¹, G. Daniele², T.-Y. Yang³, T. Leal⁴, K. Goto⁵, Y. Shinno⁶, K. Nishino⁷, T. Sakamoto⁸, E. Felip⁹, J.C. Ruffinelli¹⁰, N. Gallot¹¹, Z. Wang¹², C. Chen¹³, B. Brennan¹⁴, S.-F. Pu¹⁴, M. Kornacker¹⁵, P. Grassi¹⁶, X. Le¹⁷, D.S.W. Tan¹⁸, B.-C. Goh¹⁹, ¹The Chinese University of Hong Kong, Hong Kong, CN, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³Taichung Veterans General Hospital, Taichung City, TW, ⁴Emory University, Atlanta, US, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶National Cancer Center Hospital, Tokyo, JP, ⁷Osaka International Cancer Institute, Osaka, JP, ⁸Tottori University, Yonago, JP, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹¹ClinBAY Ltd., Limassol, CY, ¹²Bayer HealthCare Pharmaceuticals, Inc., Cambridge, US, ¹³Bayer HealthCare Pharmaceuticals Inc., Whippany, US, ¹⁴Bayer HealthCare Pharmaceuticals, Inc., Whippany, US, ¹⁵Bayer Consumer Care, Basel, CH, ¹⁶Bayer S.p.A., Milan, IT, ¹⁷MD Anderson Cancer Center, Houston, US, ¹⁸National Cancer Centre Singapore, Singapore, SG, ¹⁹National University Cancer Institute, Singapore, SG

08:45 - 09:00

Invited Discussant 1317MO, 1318MO and 1320MO

M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

09:00 - 09:05

1319MO - Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01

M. Johnson¹, P. Jänne², Y. Goto³, K. Yoh⁴, S.-H. Lee⁵, L. Paz-Ares⁶, B. Besse⁷, S. Novello⁸, H. Hayashi⁹, D.-W. Kim¹⁰, T. John¹¹, S. Kao¹², E. Felip¹³, J.C.-H. Yang¹⁴, M. Reck¹⁵, Q. Dong¹⁶, A. Sporchia¹⁶, D. Sternberg¹⁶, H.A. Yu¹⁷, ¹Sarah Cannon Research Institute, Nashville, US, ²Dana-Farber Cancer Institute, Boston, US, ³National Cancer Center Hospital, Chuo-ku, JP, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, KR, ⁶Spanish National Cancer Research Center, Universidad Complutense and Ciberonc, Madrid, ES, ⁷Gustave Roussy, Villejuif, FR, ⁸University of Turin, Orbassano, IT, ⁹Kindai University, Osaka, JP, ¹⁰Seoul National University College of Medicine and Seoul National University Hospital, Seoul, KR, ¹¹Peter MacCallum Cancer Centre, Melbourne, AU, ¹²Sydney Medical School,



The University of Sydney, Sydney, AU, ¹³Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁴National Taiwan University Hospital, Taipei City, TW, ¹⁵Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ¹⁶Daiichi Sankyo, Inc, Basking Ridge, US, ¹⁷Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, US

09:05 - 09:10

1321MO - Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

B. Li¹, D. Planchard², K. Goto³, E. Smit⁴, J. De Langen⁵, Y. Goto⁶, K. Ninomiya⁷, T. Kubo⁷, M. Pérol⁸, E. Felip⁹, H. Hayashi¹⁰, K. Nakagawa¹⁰, J. Shimizu¹¹, M. Nagasaka¹², K. Pereira¹³, A. Taguchi¹⁴, A. Ali¹⁵, M. Karnoub¹³, R. Yonemochi¹³, P. Jänne¹⁶, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Gustave Roussy, Villejuif, Cedex, FR, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴LUMC-Leiden University Medical Center, Leiden, NL, ⁵Netherlands Cancer Institute, Amsterdam, NL, ⁶National Cancer Center Hospital, Tokyo, JP, ⁷Okayama University Hospital, Okayama, JP, ⁸Léon Bérard Cancer Center, Lyon, FR, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Kindai University Hospital, Osakasayama, JP, ¹¹Aichi Cancer Center Hospital, Nagoya, JP, ¹²University of California Irvine School of Medicine, Orange, US, ¹³Daiichi Sankyo, Inc., Basking Ridge, US, ¹⁴Daiichi Sankyo Co., Ltd., Chuo-ku, JP, ¹⁵Daiichi Sankyo Europe GmbH, Munich, DE, ¹⁶Dana-Farber Cancer Institute, Boston, US

09:10 - 09:15

1324MO - CNS outcomes of lazertinib vs gefitinib in EGFR-mutated advanced NSCLC: A LASER301 subset analysis

R. Soo¹, B.C. Cho², J.-H. Kim³, M.-J. Ahn⁴, K.H. Lee⁵, A. Zimina⁶, S. Orlov⁷, I. Bondarenko⁸, Y.-G. Lee⁹, L. Yueh Ni¹⁰, S.S. Lee¹¹, K.H. Lee¹², Y.K. Pang¹³, C.H. Fong¹⁴, J.H. Kang¹⁵, C.S. Lim¹⁶, P. Danchaivijitr¹⁷, H. Lee¹⁸, S. Park¹⁸, I. Cicin¹⁹, ¹National University Cancer Institute Singapore, Singapore, SG, ²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ³CHA Bundang Medical Center, Seongnam, KR, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, KR, ⁶State Budgetary Healthcare Institution of Omsk Region, Omsk, RU, ⁷Pavlov State Medical University, Saint-Petersburg, RU, ⁸Dnipropetrovsk Medical Academy, Dnipro, UA, ⁹Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁰Hospital Umum Sarawak, Sarawak, MY, ¹¹Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, KR, ¹²Yeungnam University Medical Center, Daegu, KR, ¹³University Malaya Medical Centre, Kuala Lumpur, MY, ¹⁴Hospital Pulau Pinang, Georgetown, MY, ¹⁵Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KR, ¹⁶Hospital Sultan Ismail, Johor Bahru, MY, ¹⁷Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, ¹⁸Yuhan Corporation, Seoul, KR, ¹⁹Trakya University Medical Faculty, Edirne, TR

09:15 - 09:30

Invited Discussant 1319MO, 1321MO and 1324MO

J. Lin, MGH - Massachusetts General Hospital, Boston, US

09:30 - 09:35

1322MO - Insights into tumour dissemination and progression using



longitudinal Imaging and ctDNA in the TRACERx lung cancer study

W.K. Liu¹, B. Ding², S. Hessey¹, C. Martinez Ruiz³, J. Kittel¹, C. Lombardelli¹, H. Lee², C. Veiga², C. Richard¹, A. Huebner³, A. Hackshaw⁴, C. Abbosh⁵, G. Royle², A. Frankell⁶, C. Swanton⁶, M. Jamal-Hanjani¹, ¹University College London Cancer Institute, London, GB, ²UCL - University College London, London, GB, ³UCL Cancer Institute - Paul O'Gorman Building, London, GB, ⁴Cancer Research UK & University College London Cancer Trials Centre, London, GB, ⁵Cancer Research UK, London, GB, ⁶Francis Crick Institute, London, GB

09:35 - 09:40

LBA72 - DARWIN II: Deciphering Anti-tumour Response and Resistance to immunotherapy With Intratumour Heterogeneity in NSCLC

C. Hiley¹, S. Saghafinia¹, T. Ahmad², M. Krebs³, D. Fennell⁴, S. Baijal⁵, N. Steele⁶, G. Price⁷, C. Lombardelli⁸, W.K. Liu⁹, C. Castignani¹⁰, K. Enfield¹⁰, B. Chain⁸, S. Quezada¹¹, G. Kassiotis¹², K. Litchfield¹³, N. Mcgranahan⁹, A. Hackshaw¹⁴, M. Jamal-Hanjani¹, C. Swanton¹⁰, ¹UCL Cancer Institute - Paul O'Gorman Building, London, GB, ²University College London Hospitals NHS Foundation Trust, London, GB, ³The Christie NHS Foundation Trust, Manchester, GB, ⁴Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, ⁵Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB, ⁶BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁷Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB, ⁸UCL - University College London, London, GB, ⁹University College London Cancer Institute, London, GB, ¹⁰Francis Crick Institute, London, GB, ¹¹UCL Cancer Institute, London, GB, ¹²The Francis Crick Institute, London, GB, ¹³UCL Cancer Institute - UCL - London's Global University, London, GB, ¹⁴Cancer Research UK & University College London Cancer Trials Centre, London, GB

09:40 - 09:45

1323MO - Immune evasion across space and time in patients with lung cancer enrolled in the PEACE autopsy study

S. Hessey¹, W.K. Liu¹, O. Pich², A. Huebner¹, A. Bunkum¹, C. Richard¹, C. Puttick², C. Lombardelli¹, D. Moore¹, N. Mcgranahan¹, S. Zaccaria¹, C. Hiley², C. Swanton², M. Jamal-Hanjani¹, ¹University College London Cancer Institute, London, GB, ²Francis Crick Institute, London, GB

09:45 - 10:00

Invited Discussant 1322MO, LBA72 and 1323MO

T. Mitsudomi, Kindai University - Faculty of Medicine, Osaka, JP

08:30 - 09:55

Type: Mini Oral session

Bilbao Auditorium - NCC

Title: Mini oral session - Breast cancer, metastatic

Chair(s): Barbara Pistilli, FR; Christoph Thomssen, DE; Hervé Bonnefoi, FR

08:30 - 08:35

379MO - Datopotamab deruxtecan (Dato-DXd) & durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

P. Schmid¹, P. Wysocki², C. Ma³, Y.H. Park⁴, R. Fernandes⁵, S. Lord⁶, R. Baird⁷, C. Prady⁸, K. Jung⁹, J. Asselah¹⁰, R. Huisden¹¹, R. Stewart¹¹, K. Heider¹¹, P. Vukovic¹¹, N. Denduluri¹², Z. Nowecki¹³, ¹Barts Cancer Institute, Queen Mary University of London, London, GB, ²Jagiellonian University Medical College, Krakow, PL, ³Washington



University School of Medicine, St. Louis, US, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Schulich School of Medicine & Dentistry, Western University, London Health Sciences Centre, London, CA, ⁶University of Oxford, Oxford, GB, ⁷Cancer Research UK Cambridge Centre, Cambridge, GB, ⁸Sherbrooke University, Centre intégré de Cancérologie de la Montérégie, CISSS Montérégie Centre, Greenfield Park, Quebec, CA, ⁹Asan Medical Center, University of Ulsan, College of Medicine, Seoul, KR, ¹⁰McGill University Health Centre, Montreal, CA, ¹¹AstraZeneca, Cambridge, GB, ¹²AstraZeneca, Gaithersburg, US, ¹³Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

08:35 - 08:40

380MO - SKB264 (MK-2870) in previously treated hormone receptor-positive (HR⁺)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial

Q. Ouyang¹, Y. Yin², L. Song³, M. Yan⁴, X. Wu⁵, Z. Tong⁶, Y. Liu⁷, X. Wang⁸, X. Jin⁹, Y. Diao⁹, G. Liu⁹, J. Ge⁹, J. Li¹⁰, ¹Hunan Cancer Hospital, Changsha, CN, ²Jiangsu Province Hospital/The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ³Shandong Cancer Hospital and Institute, Jinan, CN, ⁴Henan Cancer Hospital, Zhengzhou, CN, ⁵Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology and Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan, CN, ⁶TMUCIH - Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁷The First Hospital of China Medical University, Shenyang, CN, ⁸Sir Run Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ⁹Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, CN, ¹⁰Shanghai East Hospital, Shanghai, CN

08:40 - 08:55

Invited Discussant 379MO and 380MO

B. Pistilli, Institut Gustave Roussy, Villejuif, Cedex, FR

08:55 - 09:00

382MO - Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer

N. Lin¹, V. Borges², M.R. Patel³, M. Okera⁴, J. Meisel⁵, R. Wesolowski⁶, T. Pluard⁷, K. Miller⁸, N. Mccarthy⁹, A. Conlin¹⁰, R. Mahtani¹¹, D. Sabanathan¹², K. Mccann¹³, E. Roesch¹⁴, G. Mathauda-Sahota¹⁵, J. Schroeder¹⁵, E. Hamilton¹⁶, ¹Dana Farber Cancer Institute, Boston, US, ²UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ³Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, US, ⁴Cancer Research SA, Adelaide, AU, ⁵Winship Cancer Institute, Emory University, Atlanta, US, ⁶The Ohio State University Comprehensive Cancer Center, Columbus, US, ⁷Saint Luke's Hospital of Kansas City - Saint Luke's Health System, Kansas City, US, ⁸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, US, ⁹ICON Cancer Center - Wesley Medical Centre, Auchenflower, AU, ¹⁰Providence Cancer Institute, Portland, US, ¹¹Miami Cancer Institute - Baptist Health South Florida, Miami, US, ¹²Macquarie University, Macquarie Park, AU, ¹³Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, US, ¹⁴Cleveland Clinic, Taussig Cancer Center, Cleveland, US, ¹⁵Olema Pharmaceuticals, Inc., San Francisco, US, ¹⁶Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US

09:00 - 09:05

383MO - Imlunestrant with or without everolimus or alpelisib, in ER⁺, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study



K. Jhaveri¹, R. Jeselsohn², C. Ma³, E. Lim⁴, K. Yonemori⁵, E. Hamilton⁶, K. Harnden⁷, S.-A. Im⁸, T. Beck⁹, S. Sammons¹⁰, M. Bhave¹¹, P. Kaufman¹², C. Saura Manich¹³, T. Meniawy¹⁴, F. Bacchion¹⁵, R. Ismail-Khan¹⁵, Y. Li¹⁶, S. Estrem¹⁵, B. Nguyen¹⁵, M. Beeram¹⁷, ¹Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ²Dana Farber Cancer Institute, Boston, US, ³Washington University School of Medicine, St. Louis, US, ⁴Garvan Institute of Medical Research, Darlinghurst, AU, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶Sarah Cannon Research Institute, Nashville, US, ⁷Inova Schar Cancer Institute, Fairfax, US, ⁸Seoul National University Hospital, Seoul, KR, ⁹Highlands Oncology Group - Rogers, Fayetteville, US, ¹⁰Duke Cancer Institute, Boston, US, ¹¹Winship Cancer Institute of Emory University, Atlanta, US, ¹²University of Vermont - Larner College of Medicine, Burlington, US, ¹³Vall d'Hebron University Hospital, Barcelona, ES, ¹⁴Sir Charles Gairdner Hospital and Linear Research Institute, Subiaco, AU, ¹⁵Loxo@Lilly, Lilly Corporate Center, Indianapolis, US, ¹⁶Eli Lilly and Company, New York, US, ¹⁷South Texas Accelerated Research Therapeutics (START), San Antonio, US

09:05 - 09:10

384MO - Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)

J. Robertson¹, Z. Shao², S. Noguchi³, S. Singh⁴, S. Subramaniam⁵, M. Ellis⁶, ¹University of Nottingham, School of Medicine, Nottingham, GB, ²University Shanghai Cancer Center, Shanghai, CN, ³Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, JP, ⁴AstraZeneca Netherlands, Zoetermeer, NL, ⁵AstraZeneca India, Bangalore, IN, ⁶AstraZeneca Pharmaceuticals LP, Gaithersburg, US

09:10 - 09:25

Invited Discussant 382MO, 383MO and 384MO

C. Thomssen, MLU - Martin-Luther-University Halle-Wittenberg, Halle, DE

09:25 - 09:30

385MO - A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors

J. Zhang¹, X. Hu¹, Y. Du¹, Y. Meng¹, Y. Liu², Y. Shi³, J. Wang⁴, A. Zang⁵, S. Gu⁶, T. Liu⁷, H. Zhou⁸, H. Guo⁹, S. Xiang¹⁰, X. Zhang¹¹, S. Wu¹⁰, M. Li¹², ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²The First Hospital of China Medical University, Shenyang, CN, ³Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ⁴Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁵Affiliated Hospital of Hebei University, Baoding, CN, ⁶Hunan Cancer Hospital & The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁷Zhongshan Hospital Fudan University, Shanghai, CN, ⁸The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ⁹Nanjing Drum Tower Hospital, Nanjing, CN, ¹⁰CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Beijing, CN, ¹¹CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Shijiazhuang, CN, ¹²CSPC Zhongqi Pharmaceutical Technology Co., Ltd., Shanghai, CN

09:30 - 09:35

386MO - Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial

P. Aftimos¹, N. Turner², J. O'Shaughnessy³, E. Van Den Tweel⁴, M. Oesterholt⁴, S. Escrivá-De-Romaní⁵, N. Quenel Tueux⁶, T. Tan⁷, J. Lim⁸, S. Ladoire⁹, A. Armstrong¹⁰, A. Stradella¹¹, G. Bianchi¹², M. Colleoni¹³, E. Kaczmarek¹⁴, K. Punie¹⁵, X. Song¹⁶, N.



Koper⁴, C. Saura Manich⁵, ¹Institute Jules Bordet, Anderlecht, BE, ²The Royal Marsden Hospital - Chelsea, London, GB, ³Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ⁴Byondis B.V., Nijmegen, NL, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶Institute Bergonié, Bordeaux, FR, ⁷NCCS - National Cancer Centre Singapore, Singapore, SG, ⁸NUHS - National University Health System, Singapore, SG, ⁹Centre Georges-François Leclerc (Dijon), Dijon, FR, ¹⁰The Christie NHS Foundation Trust, Manchester, GB, ¹¹ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹²SC Oncologia Medica 1 Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, IT, ¹³IEO - Istituto Europeo di Oncologia, Milan, IT, ¹⁴Centre Oscar Lambret, Lille, FR, ¹⁵Leuven Cancer Institute, University Hospitals Leuven, Leuven, BE, ¹⁶The Ottawa Hospital Regional Cancer Centre, Ottawa, CA

09:35 - 09:40 **387MO - First results of the SOLTI-1903 HOPE's patient-centric molecular screening program in advanced breast cancer**

T. Pascual¹, E. Seguí Solís², R. Olivera-Salguero³, J.M. Cejalvo⁴, M. Oliveira⁵, P. Tolosa Ortega⁶, M.J. Vidal Losada⁷, M. Malumbres⁸, J. Gavilá-Gregori⁹, C. Saura Manich⁵, S. Pernas Simon¹⁰, M. Margeli Vila¹¹, E. Ciruelos⁶, E. Galve-Calvo¹², P. Galván¹³, E. Sanfeliu Torres⁷, R. Olmos¹⁴, M. Forn¹⁵, A. Casas Fernandez Tejerina¹⁶, A. Prat¹⁷, ¹SOLTI/Hospital Clinic y Provincial de Barcelona/IDIBAPS, Barcelona, ES, ²Hospital Clinic y Provincial de Barcelona/SOLTI/IDIBAPS, Barcelona, ES, ³SOLTI Cancer Research Group, Barcelona, ES, ⁴Hospital Clinico Universitario de Valencia/INCLIVA/SOLTI, Valencia, ES, ⁵Vall d'Hebron University Hospital, Barcelona, ES, ⁶Hospital Universitario 12 de Octubre, Madrid, ES, ⁷Hospital Clinic of Barcelona, Barcelona, ES, ⁸Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁹IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, ¹⁰ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ¹¹ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ¹²Hospital Universitario de Basurto, Bilbao, ES, ¹³IDIBAPS - Fundació de Recerca Clinic Barcelona - Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, ES, ¹⁴Asociación Española de Cáncer de Mama Metastásico (CMM), Oviedo, ES, ¹⁵Asociación Española de Cáncer de Mama Metastásico, Oviedo, ES, ¹⁶Fundación Actitud Frente al Cáncer, Seville, ES, ¹⁷Hospital Clinic y Provincial de Barcelona, Barcelona, ES

09:40 - 09:55 **Invited Discussant 385MO, 386MO and 387MO**

H. Bonnefoi, Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR

08:30 - 09:35 Type: Mini Oral session Granada Auditorium - Hall 3
Title: Mini oral session - Genitourinary tumours, prostate

Chair(s): Boris Hadaschik, DE; Himisha Beltran, US

08:30 - 08:35 **1766MO - Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study**

S. Freedland¹, M. Gleave², U. De Giorgi³, A. Rannikko⁴, C. Pieczonka⁵, R. Tutrone⁶, B. Venugopal⁷, H. Woo⁸, M. Ramirez Backhaus⁹, S. Supiot¹⁰, A. Lantz¹¹, A. Ganguli¹², J. Ivanova¹³, P. Kral¹⁴, S.-P. Huang¹⁵, F. Saad¹⁶, N. Shore¹⁷, ¹Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, US,



²University of British Columbia Faculty of Medicine, Vancouver, CA, ³IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, IT, ⁴Helsingin yliopistollinen keskussairaala, Helsinki, FI, ⁵PLLC, Syracuse, US, ⁶Chesapeake Urology Research Associates, Towson, US, ⁷BWSSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ⁸Australian National University, Canberra, AU, ⁹Instituto Valenciano de Oncologia IVO, Valencia, ES, ¹⁰ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹¹Karolinska University Hospital, Solna, SE, ¹²Astellas Pharma USA, Northbrook, US, ¹³Pfizer, New York, US, ¹⁴IQVIA, Bratislava, SK, ¹⁵Kaohsiung Medical University Hospital, Kaohsiung City, TW, ¹⁶Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Montreal, CA, ¹⁷Carolina Urologic Research Center/GenesisCare US, Myrtle Beach, US

08:35 - 08:40

1767MO - External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived model in high-risk localized (M0)/metastatic (M1) prostate cancer (PCa) starting androgen deprivation therapy (ADT) in the docetaxel (Doc) or abiraterone (AAP) phase III STAMPEDE trials

C. Parker¹, L. Mendes¹, E. Grist¹, V. Liu², D. Van Der Wal², J. Griffin², E. Chen², P. Tran³, D. Spratt⁴, L. Murphy⁵, A. Sachdeva⁶, S. Lall¹, M. Parmar⁵, M. Sydes⁷, L. Brown⁵, A. Esteva², F. Feng⁸, N. Clarke⁶, N. James⁹, G. Attard¹⁰, ¹UCL Cancer Institute - Paul O'Gorman Building, London, GB, ²ArteraAI, Los Altos, US, ³Maryland Proton Treatment Center, Baltimore, US, ⁴Case Western Reserve University / University Hospitals, Cleveland, US, ⁵MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB, ⁶The Christie & Salford NHS Foundation Trust, Manchester, GB, ⁷Medical Research Council Clinical Trials Unit, London, GB, ⁸UCSF Medical Center at Mission Bay, San Francisco, US, ⁹Institute of Cancer Research and Royal Marsden Hospital, London, GB, ¹⁰University College London, London, GB

08:40 - 08:45

1768MO - Incidence of fracture related hospitalisations in men with de novo high risk localised and metastatic hormone sensitive prostate cancer: Analysis of routinely collected healthcare data from the STAMPEDE docetaxel and zoledronic acid comparisons

C. Jones¹, P. Dutey-Magni², L. Murphy², M. Murray², J. Brown³, E. McCloskey³, M. Parmar⁴, N. James⁵, M. Sydes⁶, L. Brown², N. Clarke⁷, A. Sachdeva¹, ¹The Christie NHS Foundation Trust, Manchester, GB, ²MRC - Medical Research Council Clinical Trials Unit - University College London (UCL), London, GB, ³University of Sheffield Medical School, Sheffield, GB, ⁴Institute of Clinical Trials and Methodology-UCL, London, GB, ⁵ICR - Institute of Cancer Research, London, GB, ⁶Medical Research Council Clinical Trials Unit, London, GB, ⁷The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB

08:45 - 09:00

Invited Discussant 1766MO, 1767MO and 1768MO

B. Hadaschik, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

09:00 - 09:05

1771MO - Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study

J. Graff¹, M. Burotto², P. Fong³, D. Pook⁴, B. Zurawski⁵, R. Manneh Kopp⁶, J. Salinas⁷, K. Bylow⁸, G. Kramer⁹, R. Ratta¹⁰, M. Kwiatkowski¹¹, M. Retz¹², C. Kwak¹³, J. Arranz Arijia¹⁴, H. Gurney¹⁵, N. Matsubara¹⁶, L.W. Liang¹⁷, J. Todoric¹⁷, K. Imai¹⁷, A. Stenzl¹⁸,



¹OHSU - Oregon Health Science University, Portland, US, ²Bradford Hill-Clinical Center, Recoleta, CL, ³Auckland City Hospital, Auckland, NZ, ⁴Monash Health - Monash Medical Centre, Clayton, AU, ⁵Prof. Franciszek Łukaszczyk Oncology Centre, Bydgoszcz, PL, ⁶Sociedad de Oncología y Hematología Del Cesar, Valledupar, CO, ⁷Hospital Provincial de Córdoba, Córdoba, ES, ⁸Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, ⁹Medical University of Vienna, Vienna, AT, ¹⁰Hopital Foch, Suresnes, FR, ¹¹Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie, Koszalin, PL, ¹²Rechts der Isar Medical Center, Technical University Munich, Munich, DE, ¹³Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR, ¹⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹⁵Macquarie University - Faculty of Medicine, Health and Human Sciences, Sydney, AU, ¹⁶National Cancer Center Hospital East, Kashiwa, JP, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸Crona Kliniken - Universitätsklinikum Tübingen, Tübingen, DE

09:05 - 09:10

1772MO - Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study

C. Gratzke¹, M. Ozguroglu², A. Peer³, M.A.N. Sendur⁴, M. Retz⁵, J. Goh⁶, W.C. Loidl⁷, G. Jayram⁸, S.-S. Byun⁹, C. Kwak¹⁰, M. Kwiatkowski¹¹, R. Manneh Kopp¹², J.C. Vazquez Limon¹³, J.F. Escobar Penagos¹⁴, U. De Giorgi¹⁵, K.M.D. Trindade¹⁶, C. Niu¹⁷, Y. Liu¹⁸, C. Poehlein¹⁹, J.M. Piulats²⁰, ¹University Medical Center Freiburg, Freiburg im Breisgau, DE, ²Istanbul University Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, TR, ³Rambam Health Care Center, Haifa, IL, ⁴Ankara Yıldırım Beyazıt University Faculty of Medicine and Ankara Bilkent City Hospital, Ankara, TR, ⁵Rechts der Isar Medical Center, Technical University Munich, Munich, DE, ⁶Fiona Stanley Hospital, Murdoch, AU, ⁷Ordensklinikum Linz Barmherzige Schwestern, Linz, AT, ⁸Urology Associates, P.C, Nashville, US, ⁹Seoul National University Bundang Hospital, Seongnam, KR, ¹⁰Seoul National University - College of Medicine - Yeongeon Medical Campus, Seoul, KR, ¹¹Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie, Koszalin, PL, ¹²Sociedad de Oncología y Hematología Del Cesar, Valledupar, CO, ¹³Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, MX, ¹⁴Hospital San Lucas Cardiológica del Sureste, Tuxtla Gutierrez, MX, ¹⁵IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, ¹⁶Oncocentro Ceara, Fortaleza, BR, ¹⁷MSD China - One Merck Campus Beijing, Beijing, CN, ¹⁸Merck & Co. Inc., Rahway, US, ¹⁹Merck & Co., Inc., Rahway, US, ²⁰ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES

09:10 - 09:15

LBA85 - Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE

K.N. Chi¹, E. Castro², G. Attard³, M.R. Smith⁴, S. Sandhu⁵, E. Efstathiou⁶, G. Roubaud⁷, E.J. Small⁸, A.J. Gomes⁹, D. Rathkopf¹⁰, M. Saad¹¹, H. Gurney¹², W. Jung¹³, G. Mason¹⁴, S. Dibaj¹⁴, D. Wu¹⁴, B. Diorio¹⁴, A. Lopez-Gitlitz¹⁴, W. Kim¹⁴, D. Olmos², ¹University of British Columbia, Vancouver, CA, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³UCL Cancer Institute, London, GB, ⁴Harvard Medical School, Boston, US, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Houston Methodist Cancer Center, Houston, US, ⁷Institute Bergonié, Bordeaux, FR, ⁸University of California San Francisco Medical



Center, San Francisco, US, ⁹Liga Norte Riograndense Contra o Câncer, Natal, BR, ¹⁰Memorial Sloan Kettering Cancer Center, New York, US, ¹¹University of Malaya Medical Centre, Kuala Lumpur, MY, ¹²Macquarie University, Sydney, AU, ¹³Keimyung University Dongsan Hospital, Daegu, KR, ¹⁴Research & Development, Raritan, US

09:15 - 09:20 **LBA86 - Androgen receptor pathway inhibitors or taxanes for patients with metastatic castration-resistant prostate cancer: A direct comparison in ProBio, a randomized, outcome-adaptive, biomarker-driven platform trial**

H. Grönberg¹, J. Lindberg¹, B. De Laere¹, A. Crippa¹, A. Discacciati¹, C. Karlsson², A. Ullén³, E. Jänes⁴, A. Mortezaei⁵, P. Ost⁶, G. Enblad⁷, J. Oldenburg⁸, J. Sandzén⁹, L. Pettersson¹⁰, M. Vigmostad¹¹, M. Hjälml-Eriksson¹², M. Olsson¹³, P. Schatteman¹⁴, C. Ghysel¹⁵, M. Eklund¹, ¹Karolinska Institutet, Stockholm, SE, ²Umea University, Umea, SE, ³Karolinska University Hospital-Solna, Solna, SE, ⁴Sundsvall Hospital, Sundsvall, SE, ⁵University Hospital Basel, Basel, CH, ⁶UZ Gent - University Hospital Ghent, Gent, BE, ⁷Akademiska Sjukhuset Uppsala, Uppsala, SE, ⁸Akershus University Hospital (Ahus), Lorenskog, NO, ⁹Centralsjukhuset i Karlstad, Karlstad, SE, ¹⁰Ryhov County Hospital, Jonkoping, SE, ¹¹Stavanger University Hospital - Helse Stavanger HF, Stavanger, NO, ¹²Capio St. Görans Hospital, Stockholm, SE, ¹³Växjö lasarett, xx, SE, ¹⁴Onze-Lieve-Vrouw Clinic - Campus Aalst, Aalst, BE, ¹⁵AZ Sint-Jan Brugge-Oostende AV, Brugge, BE

09:20 - 09:35 **Invited Discussant 1771MO, 1772MO, LBA85 and LBA86**

H. Beltran, Dana Farber Cancer Institute, Boston, US

08:30 - 10:00 Type: Proffered Paper session Valencia Auditorium - Hall 10
Title: Proffered Paper session - Sarcoma
 Chair(s): Silvia Stacchiotti, IT; Sebastian Bauer, DE

08:30 - 08:40 **19130 - A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study**

P. Pautier¹, A. Italiano², S. Piperno-Neumann³, C. Chevreau⁴, N. Penel⁵, N. Firmin⁶, P. Boudou Rouquette⁷, F. Bertucci⁸, V. Le Brun-Ly⁹, I. Ray-Coquard¹⁰, E. Kalbacher¹¹, E. Bompas¹², O. Collard¹³, N. Isambert¹⁴, C. Guillemet¹⁵, M. Rios¹⁶, A. Le Cesne¹⁷, B. Archambaud¹⁷, F. Duffaud¹⁸, ¹Gustave Roussy Cancer Campus, VILLEJUIF, FR, ²Institute Bergonié, Bordeaux, FR, ³Institut Curie, Paris, FR, ⁴Institut Universitaire du Cancer - Toulouse- Oncopole, Toulouse, FR, ⁵Centre Oscar Lambret, Lille, FR, ⁶Icm Val D Aurelle, Montpellier, FR, ⁷Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, ⁸IPC - Institut Paoli-Calmettes, Marseille, FR, ⁹CHU Limoges - Hopital Dupuytren, Limoges, FR, ¹⁰Centre Léon Bérard, Lyon, FR, ¹¹CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹²ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹³Institute de Cancerologie de la Loire, Saint-Priest-en-Jarez, FR, ¹⁴CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ¹⁵Centre Henri Becquerel, Rouen, FR, ¹⁶Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹⁷Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁸CHU La Timone Adultes, Marseille, FR

08:40 - 08:50 **Invited Discussant 19130**

D. Callegaro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT



08:50 - 08:55 **Q&A**

08:55 - 09:05 **LBA89 - Efficacy and safety findings from MANTRA - a global, randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas**

R. Jones¹, R. Sanfilippo², S. Schuetze³, A. Sebio⁴, R. Alvarez⁵, N. Bui⁶, A. Wagner⁷, S. Chawla⁸, T.W.-W. Chen⁹, D. Pink¹⁰, A. Le Cesne¹¹, A. Italiano¹², B. Vincenzi¹³, I. Kiladze¹⁴, S. Patel¹⁵, R. Bryce¹⁶, F. Xu¹⁷, R. Doebele¹⁷, G. Schwartz¹⁸, M. Gounder¹⁹,
¹The Royal Marsden Hospital and Institute of Cancer Research, London, GB, ²Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ³University Hospital - Michigan Medicine, Ann Arbor, US, ⁴Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁵Hospital General Universitario Gregorio Marañon, Madrid, ES, ⁶Stanford Cancer Center Palo Alto, Palo Alto, US, ⁷Dana-Farber Cancer Institute, Boston, US, ⁸Keck Medical Center of USC, Santa Monica, US, ⁹NTU - National Taiwan University - College of Medicine, Taipei City, TW, ¹⁰HELIOS Klinikum Bad Saarow, Bad Saarow, DE, ¹¹Gustave Roussy - Cancer Campus, Villejuif, FR, ¹²Institute Bergonié, Bordeaux, FR, ¹³Policlinico Universitario Campus Bio-Medico, Rome, IT, ¹⁴CMC - Caucasus Medical Centre, Tbilisi, GE, ¹⁵The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹⁶Rain Oncology, Inc., Newark, US, ¹⁷Rain Oncology Inc, Newark, US, ¹⁸Case Comprehensive Cancer Center, Cleveland, US, ¹⁹Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

09:05 - 09:15 **Invited Discussant LBA89**

S. Bauer, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

09:15 - 09:20 **Q&A**

09:20 - 09:30 **LBA90 - A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-ST5-0415)**

V. Gruenwald, University Hospital Essen, Essen, DE

09:30 - 09:40 **LBA91 - TOMAS2: a randomized phase 2 study from the Italian Sarcoma Group (ISG) of trabectedin plus olaparib (T+O) or trabectedin (T) in advanced, metastatic, or unresectable soft tissue sarcomas (STS) after failure of standard treatments.**

L. D'Ambrosio¹, A. Merlini¹, A. Brunello², V. Ferraresi³, A. Paioli⁴, B. Vincenzi⁵, M. Pantaleo⁶, T. De Pas⁷, L. Gurrieri⁸, R. Sanfilippo⁹, A. Buonadonna¹⁰, G.G. Baldi¹¹, G. Badalamenti¹², C. Marchiò¹³, Y. Pignochino¹, G. Manessi¹, S. Aliberti¹⁴, A.P. Dei Tos¹⁵, S. Stacchiotti⁹, G. Grignani¹⁶,
¹University of Turin, Torino, IT, ²IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³IRCCS Regina Elena National Cancer Institute (IRE), Rome, IT, ⁴IOR - Istituto Ortopedico Rizzoli - IRCCS, Bologna, IT, ⁵Policlinico Universitario Campus Bio-Medico, Rome, IT, ⁶University of Bologna - Alma Mater Studiorum, Bologna, IT, ⁷IEO - Istituto Europeo di Oncologia, Milan, IT, ⁸IRST - Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRCCS S.r.l., Meldola, IT, ⁹Fondazione IRCCS - Istituto



Nazionale dei Tumori, Milan, IT, ¹⁰CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ¹¹Nuovo Ospedale di Prato Santo Stefano - Azienda Usl Toscana Centro, Prato, IT, ¹²University of Palermo, Palermo, IT, ¹³IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ¹⁴Istituto di Candiolo - FPO, Candiolo, IT, ¹⁵University of Padua - School of Medicine, Padua, IT, ¹⁶Istituto di Candiolo - FPO, IRCCS, Candiolo, IT

09:40 - 09:50 **Invited Discussant LBA90 and LBA91**

B. Wilky, UCHHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US

09:50 - 10:00 **Q&A**

08:30 - 10:00 **Type: Special symposium** **Salamanca Auditorium**
Title: Immunotherapy for head and neck cancer: What, when and how long? **- Hall 3**
 Chair(s): Sjoukje Oosting, NL; Melvin Lee Kiang Chua, SG

08:30 - 08:35 **Introduction and scientific background**

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

08:35 - 08:50 **Perioperative immunotherapy for head and neck squamous cell carcinoma (HNSCC)**

A. Argiris, Hygeia Hospital, Marousi, GR

08:50 - 09:05 **Incorporating immunotherapy into the approach to locally advanced HNSCC**

K. Harrington, ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB

09:05 - 09:20 **Novel combinations in the non-curative HNSCC setting**

B. Ma, The Chinese University of Hong Kong, Sha Tin, HK

09:20 - 09:35 **Patient selection is crucial to improve immunotherapy effectiveness**

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

08:30 - 10:00 **Type: Proffered Paper session** **Málaga Auditorium - Hall**
Title: Proffered Paper session - Developmental **10**
therapeutics
 Chair(s): Lillian Siu, CA; Elena Garralda, ES



- 08:30 - 08:40 **6520 - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)**
K. Arbour¹, S. Puneekar², I. Garrido-Laguna³, D. Hong⁴, B. Wolpin⁵, M. Pelster⁶, M. Barve⁷, A. Starodub⁸, D. Sommerhalder⁹, S. Chang¹⁰, Y. Zhang¹⁰, Z. Salman¹⁰, X. Wang¹⁰, C. Gustafson¹⁰, A. Spira¹¹, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²New York University Medical Center, New York, US, ³University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ⁴The University of Texas MD Anderson Cancer Center, Houston, US, ⁵Dana Farber Cancer Institute, Boston, US, ⁶Sarah Cannon Research Institute, Nashville, US, ⁷Mary Crowley Cancer Research Center, Dallas, US, ⁸The Christ Hospital - Hematology & Oncology, Cincinnati, US, ⁹NEXT Oncology™, San Antonio, US, ¹⁰Revolution Medicines, Inc., Redwood City, US, ¹¹Virginia Cancer Specialists, Fairfax, US
- 08:40 - 08:50 **6530 - Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors**
J. Wang¹, J. Zhao², J. Zhong¹, X. Li³, J. Fang², Y. Yu⁴, X. Li⁵, X. Fang⁶, J. Chang⁷, Z. Liu⁸, Y. Zhao⁹, Q. Song¹⁰, C. Bai¹¹, A. Wang-Gillam¹², Y. Ding¹³, Z. Rao¹³, C. Bi¹³, ¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²Beijing Cancer Hospital, Beijing, CN, ³Beijing Tiantan Hospital, Capital Medical University, Beijing, CN, ⁴Harbin Medical University Cancer Hospital, Harbin, CN, ⁵The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁶The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, CN, ⁷Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, CN, ⁸Beijing Chest Hospital, Capital Medical University, Beijing, CN, ⁹Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ¹⁰Renmin Hospital of Wuhan University/ Hubei General Hospital, Wuhan, CN, ¹¹Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ¹²Jacobio (US) Pharmaceuticals, Inc, Boston, US, ¹³Jacobio Pharmaceuticals Co., Ltd., Beijing, CN
- 08:50 - 09:00 **LBA33 - A first-in-human phase 1 study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation**
C. Zhou¹, W. Li¹, Z. Song², Y. Zhang², Y. Zhang³, D. Huang⁴, Z. Yang⁵, M. Zhou⁶, R. Mao⁷, C. Huang⁷, X. Li⁷, J. Wang⁷, ¹Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³West China Hospital, Sichuan University, Chengdu, CN, ⁴Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ⁵The Second Affiliated Hospital of Chongqing Medical University, Chongqing, CN, ⁶Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, CN, ⁷Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, CN
- 09:00 - 09:10 **Invited Discussant 6520, 6530 and LBA33**
E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES
- 09:10 - 09:20 **Q&A**



- 09:20 - 09:30 **6540 - Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study**
- B. Li¹, F. Meric-Bernstam², A. Bardia³, Y. Naito⁴, S. Siena⁵, P. Aftimos⁶, I. Anderson⁷, G. Curigliano⁸, M.J. De Miguel Luken⁹, M. Kalra¹⁰, D.-Y. Oh¹¹, J.O. Park¹², S. Postel-Vinay¹³, S.Y. Rha¹⁴, T. Satoh¹⁵, I. Spanggaard¹⁶, F. Micheli¹⁷, A. Smith¹⁸, K. Kalil Machado¹⁹, C. Saura Manich²⁰, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²MD Anderson Cancer Center, University of Texas, Houston, US, ³Massachusetts General Hospital Cancer Center, Boston, US, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵Università degli Studi di Milano, Milan, IT, ⁶Institute Jules Bordet, Anderlecht, BE, ⁷Providence Medical Group, Santa Rosa, US, ⁸European Institute of Oncology IRCCS, Division of New Drugs and Early Drug Development for Innovative Therapies., Milan, IT, ⁹Centro Integral Oncológico Clara Campal, Hospital Madrid Norte Sanchinarro, Madrid, ES, ¹⁰LifeBridge Health, Baltimore, US, ¹¹Seoul National University Hospital, Seoul, KR, ¹²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ¹³Institut Gustave Roussy, Villejuif, FR, ¹⁴Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ¹⁵Osaka University, Suita, JP, ¹⁶Rigshospitalet, Copenhagen, DK, ¹⁷AstraZeneca, Waltham, US, ¹⁸AstraZeneca UK, Royston, GB, ¹⁹AstraZeneca, Gaithersburg, US, ²⁰SOLTI/Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology, Barcelona, ES
- 09:30 - 09:40 **6550 - Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)**
- B.C. Cho¹, M. Johnson², J. Bar³, E. Schaefer⁴, K. Yoh⁵, A. Zer⁶, M. Moskovitz⁷, S.-H. Lee⁸, V. Moreno Garcia⁹, M.J. De Miguel Luken¹⁰, Y. Okuma¹¹, J.-H. Kim¹², C.-H. Lee¹³, P. Ansell¹⁴, C. Biesdorf De Almeida¹⁵, R. Saab¹⁵, K. Freise¹⁵, D. Ramies¹⁶, E. Jeng¹⁷, D. Camidge¹⁸, ¹Yonsei University, Seoul, KR, ²Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ³Chaim Sheba Medical Center, Ramat Gan, IL, ⁴HOG - Highlands Oncology Group, Rogers, US, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶Rambam Health Care Campus, Haifa, IL, ⁷Rambam Health Care Campus, Haifa, IL, ⁸Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, and Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, KR, ⁹Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES, ¹⁰Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ¹¹NCCH - National Cancer Center Hospital, Chuo-ku, JP, ¹²CHA Bundang Medical Center, Seongnam, KR, ¹³NCKUH - National Cheng Kung University Hospital, Tainan City, TW, ¹⁴AbbVie Inc USA, North Chicago, US, ¹⁵Abbvie Inc. - Headquarters, North Chicago, US, ¹⁶AbbVie, Inc., North Chicago, US, ¹⁷Abbvie, Mettawa, US, ¹⁸University of Colorado Denver - Anschutz Medical Campus, Aurora, US
- 09:40 - 09:50 **Invited Discussant 6540 and 6550**
- A.A. Adjei, Cleveland Clinic Main Campus, Cleveland, US
- 09:50 - 10:00 **Q&A**

08:30 - 10:00



Type: Mini Oral session
Title: Mini oral session - Basic science & translational research

Santander Auditorium - Hall 9

Chair(s): Caterina Marchiò, IT; Sanjay Aneja, US; Luis Montuenga, ES

- 08:30 - 08:35 **132MO - Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study**
- M. Morfouace¹, J. Oliveira², N. Penel³, J. Peron⁴, M. Pracht⁵, B. Brasiuniene⁶, A. Capela Marques⁷, C. Gennigens⁸, L. Greillier⁹, M.-S. Robert¹, H.J. Klumpen¹⁰, R. Peeters¹¹, L. Licitra¹², N. Girard¹³, J. Gietema¹⁴, W. De Herder¹⁵, E. Kapiteijn¹⁶, A. Idbaih¹⁷, I. Ray-Coquard¹⁸, J.-Y. Blay¹⁸, ¹EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE, ²Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, PT, ³Centre Oscar Lambret, Lille, FR, ⁴Ch Lyon Sud, Pierre Benite, FR, ⁵Centre Eugene - Marquis, Rennes, FR, ⁶National Cancer Institute, Vilnius, LT, ⁷CHVNG/E - Centro Hospitalar de Vila Nova de Gaia/Espinho - Unidade 1 - EPE-SNS, Vila Nova de Gaia, PT, ⁸Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ⁹Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ¹⁰Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ¹¹Erasmus MC - University Medical Center, Rotterdam, NL, ¹²Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ¹³Institut Curie, Paris, FR, ¹⁴UMCG - University Medical Center Groningen, Groningen, NL, ¹⁵Erasmus MC - Erasmus University Rotterdam, Rotterdam, NL, ¹⁶Leiden University Medical Center (LUMC), Leiden, NL, ¹⁷Hopital Pitié Salpêtrière AP-HP, Paris, FR, ¹⁸Centre Léon Bérard, Lyon, FR
- 08:35 - 08:40 **LBA100 - CUP-ONE Trial: A prospective double-blind validation of molecular classifiers in the diagnosis of Cancer of Unknown Primary and clinical outcomes**
- H. Wasan¹, J. Wang², E.M. Elaine McCartney³, H. Soifer⁴, K. Treuner⁴, Y. Zhang⁴, C. Schnabel⁴, K. Carty³, L. McMahon³, T.R.J. Evans³, M. Nicolson⁵, H. Thygesen³, J.R. Roche³, K. Oien³, ¹Hammersmith Hospital - Imperial College Healthcare, London, GB, ²UCLH - University College London Hospital, London, GB, ³University of Glasgow, Glasgow, GB, ⁴Biotheranostics, A Hologic Company, San Diego, US, ⁵NHS Highland, Inverness, GB
- 08:40 - 08:45 **1208MO - A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary**
- Z. Luo¹, X. Liu¹, X. Zhang¹, S. Jiang¹, M. Mo¹, Q. Wang¹, Y. Wang¹, L. Zhou¹, S. Hu¹, H. Yang¹, Y. Hou¹, Y. Chen¹, X. Lu¹, X. Zhou¹, W. Li¹, X. Yang¹, K. Chen¹, J. Cao¹, Q. Xu², X. Hu¹, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²The Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd., Hangzhou, China, 311000, Shanghai, CN
- 08:45 - 08:50 **LBA101 - BRCA-DIRECT: A randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer.**
- B. Torr¹, S. Choi¹, S. Allen¹, M. Hamill¹, G. Kavanaugh¹, S. Macmahon², E. Poyastro-Pearson², L. Yuan², M. Valganon-Petrizan², A. George³, V. Jenkins⁴, L. Fallowfield⁴, R. Manchanda⁵, A. Gandhi⁶, G. Evans⁶, Z. Kemp⁷, M. Hubank¹, C. Turnbull¹, ¹ICR - The Institute of Cancer Research - North Site, Sutton, GB, ²The Royal Marsden Hospital



(Sutton), Sutton, GB, ³The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, ⁴Brighton and Sussex Medical School - University of Sussex, Brighton, GB, ⁵Wolfson Institute of Population Health, London, GB, ⁶Manchester University NHS Foundation Trust, Manchester, GB, ⁷The Royal Marsden Hospital - NHS Foundation Trust, London, GB

08:50 - 09:05 **Invited Discussant 132MO, LBA100, 1208MO and LBA101**

C. Marchiò, IRCCS - Istituto di Candiolo - FPO, Candiolo, IT

09:05 - 09:10 **1209MO - Computer-aided HCC lesion detection based on deep learning and CT images**

O. Lucidarme¹, T. Broussaud¹, S. Bodard², V. Paradis³, I. Brocheriou¹, C. Guettier⁴, L. Ayache⁵, C. Bougharka¹, A. O'Keane², S. Poullot⁶, J. Shen⁶, V.K. Le⁶, E. Geremia⁶, V. Groza⁶, Q. Renault⁶, M. Macrez⁶, T. Foriel⁶, Y. Liu⁶, M. Lewin-Zeitoun⁴, V. Vilgrain⁷, ¹Sorbonne Université, Paris, FR, ²GH Necker - Enfants Malades, Paris, FR, ³Campus hospitalo-universitaire Grand Paris-Nord, Paris, FR, ⁴CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR, ⁵Institut Necker Enfant Malades, Paris, FR, ⁶Median Technologies, Valbonne, FR, ⁷Beaujon Hospital APHP, Clichy, FR

09:10 - 09:15 **1210MO - Comparison of clinical and radiological features-based and radiomics features-based models for pulmonary nodule malignancy prediction on CT images**

F. Zeng¹, B. Wang², M. Peng², J. Tao², X. Tu², H. Lu³, X. Qiu², Y. Yang², Q. Zeng¹, J.-B. Fan⁴, Q. Liu¹, ¹The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ²AnchorDX Medical Co., Ltd, Guangzhou, CN, ³AnchorDX Medical Co., Ltd, Guangzhou, CN, ⁴Southern Medical University, Guangzhou, CN

09:15 - 09:25 **Invited Discussant 1209MO and 1210MO**

S. Aneja, Yale University School of Medicine, New Heaven, US

09:25 - 09:30 **2233MO - CDC7 inhibition constrains lineage plasticity and prevents resistance and neuroendocrine transformation in the lung and prostate**

Á. Quintanal-Villalonga¹, S. Zaidi¹, W.R. Karthaus¹, Y.A. Zhan¹, M. Shafer¹, J. Qiu¹, E. De Stanchina¹, M.C. Haffner², C.L. Sawyers¹, C. Rudin¹, ¹MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ²Fred Hutchinson Cancer Research Center, Seattle, US

09:30 - 09:35 **133MO - Differentiation of malignant and benign lung nodules using epigenetically modified nucleosomes in plasma**

P.-H. Chen¹, T.-M. Tsai², D. Pamart³, T. Bygott³, M. Herzog³, J. Micallef³, J.-S. Chen², ¹National Taiwan University Hospital Hsin - Chu Branch, Hsinchu City, TW, ²NTUCC - National Taiwan University Cancer Center, Taipei City, TW, ³Belgian Volition SRL, Isnes, BE

09:35 - 09:45 **Invited Discussant 2233MO and 133MO**

L. Montuenga, FIMA-UNAV-CUN, PAMPLONA, ES



08:30 - 10:00 **Type: Proffered Paper session** **Toledo Auditorium - Hall 3**
Title: Proffered Paper session - NETs and endocrine tumours
 Chair(s): Marianne Pavel, DE; Jaume Capdevila Castillon, ES

08:30 - 08:40 **7230 - Cabozantinib plus atezolizumab in advanced and progressive neoplasms of the endocrine system: A multi-cohort basket phase II trial (CABATEN/GETNET1914)**

J. Capdevila Castillon¹, J. Molina-Cerrillo², M. Benavent Viñuales³, R. Garcia-Carbonero⁴, A. Teule⁵, A. Custodio⁶, P. Jimenez-Fonseca⁷, C. López⁸, C. Hierro⁹, A. Carmona-Bayonas¹⁰, J. Martínez-Trufero¹¹, M. Llanos¹², I. Sevilla¹³, J. Hernando¹, T. Alonso-Gordoa², I. Gallego Jimenez³, J. Gallego¹⁴, B. Antón Pascual⁴, E. Grande Pulido¹⁵, ¹Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, ES, ²Hospital Universitario Ramón y Cajal, Madrid, ES, ³University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Seville, ES, ⁴Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, ES, ⁵Institut Català d'Oncologia (ICO) - IDIBELL, L'Hospitalet de Llobregat, ES, ⁶Hospital Universitario La Paz, IdiPAZ, Madrid, ES, ⁷Hospital Universitario Central de Asturias, ISPA, Oviedo, ES, ⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, ES, ⁹Catalan Institute of Oncology (ICO-Badalona) Germans Trias i Pujol University Hospital, Badalona, ES, ¹⁰Hospital Universitario Morales Meseguer. UMI. IMIB., Murcia, ES, ¹¹Instituto Aragonés de Investigación Sanitaria, Hospital Universitario Miguel Servet, Zaragoza, ES, ¹²Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹³Investigación Clínica y Traslacional en Cáncer / Instituto de Investigaciones Biomédicas de Málaga (IBIMA) / Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, ES, ¹⁴General Universitario de Elche Hospital, Alicante, ES, ¹⁵MD Anderson Cancer Center Madrid, Madrid, ES

08:40 - 08:50 **LBA53 - Alliance A021602: Phase III, Double-Blinded Study of Cabozantinib Versus Placebo for Advanced Neuroendocrine Tumors (NET) After Progression on Prior Therapy (CABINET)**

J. Chan¹, S. Geyer², F.-S. Ou², M. Knopp³, S. Behr⁴, T. Zemla², J. Acoba⁵, A. Shergill⁶, E. Wolin⁷, T. Halfdanarson⁸, N. Trikalinos⁹, B. Konda¹⁰, N. Vijayvergia¹¹, N.A. Dasari¹², J. Strosberg¹³, E. Kohn¹⁴, M. Kulke¹⁵, E. O'Reilly¹⁶, J. Meyerhardt¹, ¹Dana-Farber Cancer Institute, Boston, US, ²Mayo Clinic, Rochester, US, ³University of Cincinnati, Cincinnati, US, ⁴UCSF - University of California San Francisco, San Francisco, US, ⁵University of Hawaii Cancer Center, Honolulu, US, ⁶University of Chicago, Chicago, US, ⁷Icahn School of Medicine at Mount Sinai, New York, US, ⁸Mayo Clinic - Rochester, Rochester, US, ⁹Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ¹⁰The Ohio State University Comprehensive Cancer Center, Columbus, US, ¹¹Fox Chase Cancer Center - Main Campus, Philadelphia, US, ¹²MD Anderson Cancer Center, Houston, US, ¹³H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ¹⁴National Cancer Institute, Bethesda, US, ¹⁵Boston University and Boston Medical Center, Boston, US, ¹⁶Memorial Sloan Kettering Cancer Center, New York, US

08:50 - 09:00 **Invited Discussant 7230 and LBA53**
M. Pavel, Universitätsklinik Erlangen - Medizinische Klinik 1, Erlangen, DE



09:00 - 09:10 **Q&A**

09:10 - 09:20 **LBA54 - Alkylating agent-based vs oxaliplatin-based chemotherapy in neuroendocrine tumours according to the O6-methylguanine-DNA methyltransferase (MGMT) status: a randomized phase II study (MGMT-NET) on behalf of the French Group of Endocrine Tumors (GTE) and ENDOCAN-RENATEN network**

T. Walter¹, T. Lecomte², J. Hadoux³, P. Niccoli⁴, L. Saban-Roche⁵, E. Gaye⁶, R. Guimbaud⁷, M. Baconnier⁸, V. Hautefeuille⁹, C. Do Cao¹⁰, C. Petorin¹¹, O. Hentic Dhome¹², M. Perrier¹³, T. Aparicio¹⁴, J.-Y. Scoazec¹⁵, C. Lombard Bohas¹⁶, S. Bin¹, V. Hervieu¹, M. Barritault¹, L. Gerard¹⁷, ¹Hospices Civiles de Lyon - HCL - Lyon University Hospital Center, Lyon, FR, ²CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, ³Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁵Institut cancerologie de la Loire, Saint Etienne, FR, ⁶Centre Oscar Lambret, Lille, FR, ⁷Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse, FR, ⁸CH Annecy Genevois, Annecy, FR, ⁹CHU Amiens-Picardie - Site Nord, Amiens, FR, ¹⁰Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ¹¹CHU Estaing, Clermont-Ferrand, FR, ¹²Beaujon Hospital APHP, Clichy, FR, ¹³Reims University Hospital, Reims, FR, ¹⁴Hopital Saint Louis AP-HP, Paris, FR, ¹⁵Institut Gustave Roussy, Villejuif, FR, ¹⁶Hopital Edouard Herriot Pav. E bis, Lyon, FR, ¹⁷Hospices Civils de Lyon, Bron, FR

09:20 - 09:30 **11820 - Temozolomide treatment induces an MMR-dependent hypermutator phenotype in well differentiated pancreatic neuroendocrine tumors**

L. De Mestier Du Bourg¹, D. Cohen², J. Masliah-Planchon³, S. Sivakumar⁴, O. De Rycke⁵, O. Hentic Dhome¹, Z. Fleischmann⁶, E. Sokol⁶, B. Decker⁷, A. Couvelard¹, P. Ruzniewski¹, I. Bieche³, J. Cros⁸, ¹Beaujon Hospital APHP, Clichy, FR, ²INSERM, Paris, FR, ³Institut Curie, Paris, FR, ⁴Foundation Medicine, Inc., Morrisville, US, ⁵Assistance Publique - Hopitaux De Paris AP-HP, Paris, FR, ⁶Foundation Medicine, Inc., Cambridge, US, ⁷Foundation Medicine, Boston, US, ⁸Beaujon Hospital APHP, Saint Maur des Fosses, FR

09:30 - 09:40 **7240 - EO2401 (E) peptide immunotherapy + nivolumab (N) in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP): EOADR1-19/SPENCER**

E. Baudin¹, S. Grisanti², C. Menke-Van Der Houven Van Oordt³, H. Haak⁴, J. Capdevila Castillon⁵, M. Fassnacht⁶, V. Subbiah⁷, C. Jimenez⁷, C. De La Fouchardiere⁸, J. Yachnin⁹, D. Granberg⁹, M. Kroiss¹⁰, K.G. Daugaard¹¹, D. Cosentini², L. Lamartina¹, J.-M. Paillarse¹², L. Aubergeon¹², J. Fagerberg¹², L. Chêne¹², A. Berruti², ¹Gustave Roussy, Villejuif, FR, ²Università degli Studi di Brescia, Azienda Ospedaliera Spedali Civili, Brescia, IT, ³Amsterdam UMC, Amsterdam, NL, ⁴Maxima Medisch Centrum, Eindhoven, NL, ⁵Hospital Universitari Vall d'Hebron, Barcelona, ES, ⁶University Hospital Würzburg, Würzburg, DE, ⁷The University of Texas MD Anderson Cancer Center (MDACC), Houston, US, ⁸Centre Léon Bérard, Lyon, FR, ⁹Karolinska Institutet, Karolinska University Hospital, Stockholm, SE, ¹⁰LMU - Ludwig Maximilians University of Munich, Munich, DE, ¹¹Rigshospitalet, Copenhagen, DK, ¹²Enterome, Paris, FR

09:40 - 09:50 **Invited Discussant LBA54, 11820 and 7240**



N. Fazio, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

09:50 - 10:00 **Q&A**

08:30 - 10:00	<p>Type: Educational session Title: Current issues in primary prevention and screening to block the onset or development of cancer Chair(s): Wendy Tse Yared, BE; Mary Gospodarowicz, CA</p>	Cádiz Auditorium - NCC
----------------------	--	-------------------------------

08:30 - 08:50 **Processed meat, sugar, exercise: Prevention opportunities for oncologists**
E. Weiderpass, International Agency for Research on Cancer, Lyon, FR

08:50 - 09:10 **Structural and behavioural interventions: Applying the latest insights from implementation science to cancer prevention**
J. Martin-Moreno, Hospital Clinico Universitario de Valencia, Valencia, ES

09:10 - 09:30 **Commercial drivers of cancer medicines and non-pharmaceutical technologies in cancer care**
R. Sullivan, Institute of cancer policy, London, GB

09:30 - 09:50 **False dichotomies and going beyond screening**
M. Gospodarowicz, University of Toronto - St. George Campus, Toronto, CA

09:50 - 10:00 **Q&A and Discussion**



08:30 - 10:00 **Type: Young Oncologists session** **Ávila**
Title: YO Fellowship Session: Fellowships in Europe: Educational opportunities for young oncologists **Auditorium - NCC**
 Chair(s): Teresa Amaral, DE; Alexios Matikas, SE

08:30 - 08:45 **Introduction to the ESMO Fellowship Programme**
T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

08:45 - 09:00 **Practical tips from a former fellow**
A. Matikas, Karolinska Institutet, Huddinge, SE

09:00 - 09:15 **Best Fellowship Project**
F. Papaccio, University of Salerno, Naples, IT

09:15 - 09:30 **Best Publication from a Fellowship**
M.-J. Devlin, QMUL - Queen Mary University of London - Charterhouse Square, London, GB

09:30 - 09:40 **Conclusions**
T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

09:40 - 10:00 **Awards: Presentation of the 2023 Fellows and Best Exam**
G. Awada¹, P. Baxevanos², M. Chalabi³, P. Lombardi⁴, M. Mair⁵, N. Ngoi⁶, N. Saoudi Gonzalez⁷, ¹UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ²NNA - Naval and Veterans Hospital of Athens, Athens, GR, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ⁵MedUni Wien - Medical University of Vienna, Vienna, AT, ⁶The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁷Vall d'Hebron University Hospital, Barcelona, ES



08:30 - 10:00 **Type: EONS Industry Satellite Symposium** **Alicante Auditorium - Hall 10**
Title: Pfizer - Perspectives on adverse events and healthcare needs management in kidney cancer
 Chair(s): Daniel Kelly, GB

08:30 - 08:35 **Opening remarks**

D. Kelly, Cardiff University - School of Healthcare Sciences, Cardiff, GB

08:35 - 08:55 **Anticancer therapies and adverse events profile in kidney cancer - A medic's perspective**

F. Schlürmann, CHRU Brest - Hopital Augustin Morvan, Brest, FR

08:55 - 09:15 **Adverse events management in kidney cancer: Seeing the whole person - A nurse's perspective**

S. Smith, East & North Hertfordshire NHS Trust, Stevenage, GB

09:15 - 09:35 **Living with and being treated for kidney cancer - A patient's perspective**

S. Pointon, Action Kidney Cancer, Manchester, GB

09:35 - 09:50 **RCC4Nurses - interactive education program**

G. Kotronoulas, University of Glasgow, Glasgow, GB

09:50 - 10:00 **Q&A and Conclusion remarks**

D. Kelly, Cardiff University - School of Healthcare Sciences, Cardiff, GB



09:00 - 10:00 **Type: Controversy session** **Burgos Auditorium - Hall 3**
Title: All patients with resected stage IIB/IIC should be treated with adjuvant anti-PD1 therapy
 Chair(s): Georgina Long, AU

09:00 - 09:05 **Welcome and “set the scene”**
G. Long, University of Sydney, Sydney, AU

09:05 - 09:20 **Yes**
D. Schadendorf, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

09:20 - 09:35 **No**
R. Lee, The University of Manchester, Manchester, GB

09:35 - 09:40 **First voting**

09:40 - 09:55 **Perspective from the Chair**
G. Long, University of Sydney, Sydney, AU

09:55 - 10:00 **Second voting**

09:00 - 09:45 **Type: Challenge your Expert** **Oviedo Auditorium - Hall 7**
Title: Management of IMDC favourable-risk patients in metastatic renal cell carcinoma (RCC)
 Chair(s): Laurence Albiges, FR

09:00 - 09:20 **Presentation by Expert**
M. Schmidinger, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

09:20 - 09:45 **Discussion led by Chair**
L. Albiges, Institut Gustave Roussy, Villejuif, Cedex, FR



09:00 - 10:00 **Type: Special session** **León Auditorium**
Title: Emerging issues in Adolescent and Young Adult (AYA)
patients with malignant diseases **- Hall 7**
 Chair(s): Andrea Ferrari, IT; Ivana Bozovic Spasojevic, RS

09:00 - 09:02 **Introduction**
I. Bozovic Spasojevic, Institute for Oncology and Radiology of Serbia, Belgrade, RS

09:02 - 09:17 **Setting priorities for AYA patients with sarcoma**
A. Ferrari, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

09:17 - 09:32 **Short- and long-term side effects in AYA patients, with a focus on patients with breast cancer**
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

09:32 - 09:47 **AYA oncology: The importance of research, with a focus on patients with melanoma**
K. Young, The Royal Marsden Hospital - Chelsea, London, GB

09:47 - 10:00 **Discussion**

10:00 - 11:00 **Type: Special session** **Pamplona Auditorium - Hall 9**
Title: Resilience Task Force - Caring for caregivers: How to build a sustainable oncology workforce
 Chair(s): Kok Haw Jonathan Lim, GB

10:00 - 10:10 **Introduction**
K.H.J. Lim, The Francis Crick Institute, London, GB

10:10 - 11:00 **Moderated discussion and Q&A**
K. Punie¹, M. O'Connor², M.E. Elez Fernandez³, C. Hardy⁴, I. Vaz Luis⁵, J.-Y. Blay⁶, ¹UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ²University Hospital Waterford, Waterford, IE, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴Lancaster University Division of Health Research, Lancaster, GB, ⁵Institut Gustave Roussy, Villejuif, Cedex, FR, ⁶Centre Léon Bérard, Lyon, FR

10:15 - 11:45 **Type: Proffered Paper session** **Barcelona Auditorium**
Title: Proffered Paper session 2 - Gastrointestinal tumours, upper digestive **- Hall 9**
 Chair(s): Radka Obermannova, CZ; Andrew Ko, US

10:15 - 10:25 **1616O - Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial**



A. Ohba¹, M. Ozaka², G. Ogawa¹, T. Okusaka¹, S. Kobayashi³, T. Yamashita⁴, M. Ikeda⁵, I. Yasuda⁶, K. Sugimori⁷, N. Sasahira², K. Ikezawa⁸, I. Miki⁹, N. Okano¹⁰, N. Mizuno¹¹, M. Furukawa¹², H. Shirakawa¹³, Y. Sano¹, H. Katayama¹, J. Furuse³, M. Ueno³, ¹National Cancer Center Hospital, Tokyo, JP, ²Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, ³Kanagawa Cancer Center, Yokohama, JP, ⁴Kanazawa University, Kanazawa, JP, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶University of Toyama, Toyama, JP, ⁷Yokohama City University Medical Center, Yokohama, JP, ⁸Osaka International Cancer Institute, Osaka, JP, ⁹Hyogo Cancer Center, Hyogo, JP, ¹⁰Kyorin University Faculty of Medicine, Tokyo, JP, ¹¹Aichi Cancer Center Hospital, Nagoya, JP, ¹²National Hospital Organization, Kyushu Cancer Center, Fukuoka, JP, ¹³Tochigi Cancer Center, Utsunomiya, JP

10:25 - 10:35

LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial

B. Groot Koerkamp¹, Q. Janssen¹, J. Van Dam¹, B. Bonsing², H. Bos³, K. Bosscha⁴, B. Haberkorn⁵, I. De Hingh⁶, T. Karsten⁷, M. Van Der Kolk⁸, M. Liem⁹, O. Loosveld¹⁰, G. Patijn¹¹, H.C. Van Santvoort¹², J. De Vos-Geelen¹³, B. Van Der Holt¹⁴, M. Homs¹, G. Van Tienhoven¹⁵, M.G. Besselink¹⁵, H. Wilmink¹⁵, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²LUMC-Leiden University Medical Center, Leiden, NL, ³Ziekenhuis De Tjongerschans, Heerenveen, NL, ⁴Jeroen Bosch Hospital, 's-Hertogenbosch, NL, ⁵Maastad Ziekenhuis, Rotterdam, NL, ⁶Catharina Hospital Eindhoven, Eindhoven, NL, ⁷OLVG Hospital, Amsterdam, NL, ⁸Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁹Medisch Spectrum Twente, Enschede, NL, ¹⁰Amphia Ziekenhuis-location Molengracht, Breda, NL, ¹¹Isala Hospital, Zwolle, NL, ¹²UMC - University Medical Center Utrecht, Utrecht, NL, ¹³Maastricht University Medical Center (MUMC), Maastricht, NL, ¹⁴Erasmus MC Cancer Institute, Rotterdam, NL, ¹⁵Amsterdam UMC - University of Amsterdam, Amsterdam, NL

10:35 - 10:50

Invited Discussant 16160 and LBA83

A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

10:50 - 11:05

Q&A

11:05 - 11:15

LBA76 - The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).

S. Kadowaki¹, D. Sakai², R. Kawabata³, H. Hara⁴, H. Yasui⁵, M. Takahashi⁶, M. Hirao⁷, H. Imai⁸, K. Minashi⁹, T. Kawakami¹⁰, H. Satake¹¹, J. Matsuyama¹², Y. Sakamoto¹³, K. Sawada¹⁴, M. Kataoka¹⁵, H. Kawakami¹⁶, T. Shimokawa¹⁷, N. Boku¹⁸, T. Satoh¹⁹, ¹Aichi Cancer Center Hospital, Nagoya, JP, ²Osaka International Cancer Institute, Osaka, JP, ³Osaka Rosai Hospital, Sakai, JP, ⁴Saitama Cancer Center, Saitama, JP, ⁵Kobe City Medical Center General Hospital, Kobe, JP, ⁶Yokohama Municipal Citizen's Hospital, Yokohama, JP, ⁷National Hospital Organization Osaka National Hospital, Osaka, JP, ⁸Tohoku University Hospital, Sendai, JP, ⁹Chiba Cancer Center Hospital, Chiba, JP, ¹⁰Shizuoka Cancer Center, Shizuoka, JP, ¹¹Kansai Medical University Hospital, Hirakata, JP, ¹²Higashiosaka City Medical Center, Higashiosaka, JP, ¹³Osaki Citizen Hospital, Osaki,



JP, ¹⁴Kushiro Rosai Hospital, Kushiro, JP, ¹⁵National Hospital Organization, Nagoya Medical Center, Nagoya, JP, ¹⁶Kindai University Faculty of Medicine, Osakasayama, JP, ¹⁷Wakayama Medical University, Faculty of Medicine, Wakayama, JP, ¹⁸IMS Hospital, Institute of Medical Science, University of Tokyo, Tokyo, JP, ¹⁹Osaka University Hospital, Suita, JP

11:15 - 11:25 **LBA77 - 5-fluorouracil and oxaliplatin with or without docetaxel in the first-line treatment of HER2 negative locally advanced (LA) unresectable or metastatic gastric or gastro-esophageal junction (GEJ) adenocarcinoma (GASTFOX-PRODIGE 51): a randomized phase 3 trial sponsored by the FFCD**

A. Zaanan¹, O. Bouche², C. De La Fouchardiere³, E. Samalin-Scalzi⁴, K. Le Malicot⁵, S. Pernot⁶, P. Artru⁷, V. Ly Lebrun⁸, K. Aldabbagh⁹, F. Khemissa Akouz¹⁰, H. Castanie¹¹, M. Laly¹², D. Botsen¹³, M. Muller¹⁴, G. Roth¹⁵, T. Lecomte¹⁶, J.M. Phelip¹⁷, C. Lepage¹⁸, C. Louvet¹⁹, ¹Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ²CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR, ³Centre Léon Bérard, Lyon, FR, ⁴ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ⁵Fédération Francophone de Cancérologie Digestive, Dijon, FR, ⁶Institut Bergonié, Bordeaux, FR, ⁷Hôpital privé Jean Mermoz, Lyon, FR, ⁸CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁹Polyclinique Saint Côte, Compiègne, FR, ¹⁰Centre Hospitalier de Perpignan - Hôpital Saint Jean, Perpignan, Cedex, FR, ¹¹Centre Catherine de Sienne, Nantes, FR, ¹²CHD Vendee - Hopital Les Oudairies, La Roche-sur-Yon, FR, ¹³Institut Jean Godinot, Reims, FR, ¹⁴CHRU Nancy, Nancy, FR, ¹⁵CHU Grenoble-Alpes - Le site nord à La Tronche - Hopital Michallon, La Tronche, FR, ¹⁶CHU de Tours, Hôpital Trousseau, Chambray-lès-Tours, FR, ¹⁷CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, ¹⁸CHU Dijon, Dijon, FR, ¹⁹IMM - Institut Mutualiste Montsouris, Paris, FR

11:25 - 11:40 **Invited Discussant LBA76 and LBA77**

R. Obermannova, Masaryk Memorial Cancer Institute, Brno, CZ

11:40 - 11:55 **Q&A**

10:15 - 11:45 **Type: Mini Oral session** **Sevilla Auditorium - Hall 9**
Title: Mini oral session - Genitourinary tumours, non-prostate

Chair(s): Patrizia Giannatempo, IT; Ursula Vogl, CH; Deborah Mukherji, AE

10:15 - 10:20 **2361MO - Impact of positron emission tomography (PET) imaging on staging of muscle-invasive bladder cancer (MIBC) [PET-MUSE]**

S. Sridhar¹, S. Mukherjee², N. Power³, R. Breau⁴, S. Cheng⁵, P. Chung⁶, G. Pond⁷, U. Metser⁶, M. Levine⁸, ¹Princess Margaret Cancer Center, Toronto, CA, ²JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA, ³London Health Sciences Centre (LHSC) - London Regional Cancer Program (LRCP), London, CA, ⁴University of Ottawa Faculty of Medicine, Ottawa, CA, ⁵Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, ⁶Princess Margaret Cancer Centre, Toronto, CA, ⁷McMaster University Medical Centre - Hamilton Health Sciences, Hamilton, CA, ⁸McMaster University, Hamilton, CA



- 10:20 - 10:25 **2362MO - Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study**
 Y. Loriot¹, N. Matsubara², R. Huddart³, N. Houede⁴, B. Laguerre⁵, V. Guadalupi⁶, J.H. Ku⁷, S. Triantos⁸, S. Akapame⁸, K. Deprince⁹, S. Mukhopadhyay¹⁰, A. Siefker-Radtke¹¹,
 1INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, Cedex, FR, 2National Cancer Center Hospital East, Chiba, JP, 3Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, GB, 4Institut de Cancérologie du Gard - CHU Caremeau, Nîmes, France and Montpellier University, Nimes, FR, 5Centre Eugene Marquis, Rennes, FR, 6Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, IT, 7Seoul National University Hospital, Seoul, KR, 8Janssen Research & Development, Spring House, US, 9Janssen Research & Development, Beerse, BE, 10Janssen Research & Development, Lexington, US, 11The University of Texas MD Anderson Cancer Center, Houston, US
- 10:25 - 10:35 **Invited Discussant 2361MO and 2362MO**
 P. Giannatempo, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT
- 10:35 - 10:40 **2363MO - A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in non-urothelial, muscle invasive bladder cancer (ABACUS-2)**
 B. Szabados¹, E. Nogueron Martinez², F.J. Alvarez Marquez³, D. Castellano Gauna⁴, A. Rodriguez-Vida⁵, M.C. Garcias De Espana⁶, S. Hussain⁷, C. Alvarez Fernandez⁸, M. Lynch⁹, T. Bonfill Abella¹⁰, M. Gross Goupil¹¹, J. Kelly¹², R. Jones¹³, S. Crabb¹⁴, L. Beltran¹⁵, R. Garonce-Hediger¹⁶, N.J. Rakebrandt¹⁷, R. Georgescu^{18,18}, C. Ackerman¹⁸, T. Powles¹⁹, 1Barts Cancer Institute, London, GB, 2Complejo Hospitalario Universitario de Albacete, Albacete, ES, 3Hospital General Juan Ramon Jimenez, Huelva, ES, 4Hospital Universitario 12 de Octubre, Madrid, ES, 5Hospital del Mar IMIM Research Institute, Barcelona, ES, 6Hospital Universitario Son Espases, Palma de Mallorca, ES, 78. Sheffield Teaching Hospitals NHS Trust, Sheffield, GB, 8Hospital Universitario Central de Asturias, Oviedo, ES, 9UCL Cancer Institute - Paul O'Gorman Building, London, GB, 10Hospital de Sabadell Corporacis Parc Tauli, Sabadell, ES, 11CHU Bordeaux - Hopital St. André, Bordeaux, FR, 12UCLH - University College London Hospitals NHS Foundation Trust, London, GB, 13MVLS - Medical, Veterinary and Life Sciences College - University of Glasgow, Glasgow, GB, 14Southampton General Hospital, Southampton, GB, 15Barts Hospital NHS Trust, London, GB, 16F. Hoffmann-La Roche AG, Basel, CH, 17Oncology Biomarker Development, F. Hoffmann-La Roche Ltd, Basel, CH, 18Barts ECMC, London, GB, 19St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB
- 10:40 - 10:45 **2364MO - Durvalumab (D) +/- tremelimumab (T) in combination with dose-dense MVAC (ddMVAC) as neoadjuvant treatment in patients with muscle-invasive bladder carcinoma (MIBC): Results of NEMIO, a randomized phase I-II trial**
 C. Thibault¹, M. Bennamoun², A. Flechon³, G. Gravis⁴, D. Pouessel⁵, P.-F. Combe⁶, D. Borchiellini⁷, Y. Loriot⁸, B. Laguerre⁹, P. Barthélémy¹⁰, M. Gross Goupil¹¹, C. Helissey¹², O. Huillard¹³, M. Cancel¹⁴, L. Campedel¹⁵, F. Audenet¹, H. Belhouari¹⁶, S. Kotti¹⁶, Y. Tran¹⁶, S. Oudard¹, 1HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, 2Institute Mutualiste Montsouris, Paris, FR, 3Centre Leon Berard, Lyon, FR, 4IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, 5Oncopole Claudius Regaud - Institut Universitaire du Cancer Toulouse, Toulouse, FR, 6Pôle Santé Léonard de Vinci,



Chambray-lès-Tours, FR, ⁷Centre Anticancer Antoine Lacassagne, Nice, FR, ⁸Institut Gustave Roussy, Paris Saclayrsité ar, Villejuif, Cedex, FR, ⁹Centre Eugene - Marquis, Rennes, FR, ¹⁰ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹¹CHU Bordeaux - Hopital St. André, Bordeaux, FR, ¹²Military Hospital Begin, Saint-Mandé, FR, ¹³Hopital Cochin AP-HP, Paris, FR, ¹⁴University hospital of Tours, Tours, cedex, FR, ¹⁵Hôpital Pitié Salpêtrière, Paris, FR, ¹⁶ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, cedex, FR

10:45 - 10:50 **2365MO - Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)**

S. Sridhar¹, P. O'Donnell², T. Flaig³, J. Rosenberg⁴, C. Hoimes⁵, M. Milowsky⁶, S. Srinivas⁷, S. George⁸, R. Mckay⁹, D. Petrylak¹⁰, P.M. Coelho Barata¹¹, C. Hwang¹², M. Cruz-Correa¹³, M. Iafolla¹⁴, M. Mckean¹⁵, R. Dreicer¹⁶, S. Brancato¹⁷, J. Lukas¹⁸, Y. Yu¹⁸, H. Moon¹⁹, ¹Princess Margaret Cancer Center, Toronto, CA, ²The University of Chicago, Chicago, US, ³UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center, Aurora, US, ⁴MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ⁵Duke Cancer Institute, Durham, US, ⁶University of North Carolina - Chapel Hill, Chapel Hill, US, ⁷Stanford Comprehensive Cancer Institute, Stanford, US, ⁸Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁹University of California San Diego - UCSD, La Jolla, US, ¹⁰Yale University School of Medicine, New Haven, US, ¹¹Case Western Reserve University / University Hospitals, Cleveland, US, ¹²Henry Ford Cancer Institute-Henry Ford Health, Detroit, US, ¹³Hospital Oncologico Isaac Gonzalez Martinez, San Juan, PR, ¹⁴University Health Network - Princess Margaret Cancer Center, Toronto, CA, ¹⁵Sarah Cannon Research Institute, Nashville, US, ¹⁶University of Virginia Cancer Center, Charlottesville, US, ¹⁷Astellas Pharma USA, Northbrook, US, ¹⁸Seagen Inc., Bothell, US, ¹⁹Kaiser Permanente - Riverside Medical Center, Riverside, US

10:50 - 11:05 **Invited Discussant 2363MO, 2364MO and 2365MO**

U. Vogl, IOSI - Istituto Oncologico della Svizzera Italiana, Bellinzona, CH

11:05 - 11:10 **LBA104 - First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non-muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)**

A. Vilaseca¹, G. Jayram², C. Raventos³, N. Shore⁴, D. Zainfeld⁵, T.W. Kang⁶, J.H. Ku⁷, J. Meeks⁸, Ó. Rodríguez Faba⁹, F. Roghmann¹⁰, S. Daneshmand¹¹, N. Beeharry¹², C. Cost¹², A. Kalota¹², J. Lauring¹², M. Peterson¹³, M. Quiroz¹², N. Stone¹², W. Zhu¹³, F. Guerrero-Ramos¹⁴, ¹Hospital Clínic de Barcelona, Barcelona, ES, ²Urology Associates, Nashville, US, ³Vall d'Hebron, Barcelona, ES, ⁴Carolina Urologic Research Center, Myrtle Beach, US, ⁵Urology San Antonio, San Antonio, US, ⁶Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, KR, ⁷Seoul National University Hospital, Seoul National University College of Medicine, Seoul, KR, ⁸Northwestern University, Feinberg School of Medicine, Chicago, US, ⁹Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, ES, ¹⁰Ruhr-University Bochum, Marien Hospital, Herne, DE, ¹¹University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ¹²Janssen Research & Development, Spring House, US, ¹³Janssen Research & Development, Raritan, US, ¹⁴University Hospital 12 de Octubre, Madrid, ES



- 11:10 - 11:15 **LBA105 - Results From SunRISe-1 in Patients (Pts) With Bacillus Calmette-Guérin (BCG)-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (HR NMIBC) Receiving TAR-200 Monotherapy**
- A. Necchi¹, J. Jacob², S. Daneshmand³, G. Simone⁴, E. Xylinas⁵, D. Morris⁶, P. Spiegelhalder⁷, D. Zainfeld⁸, T.W. Kang⁹, J. Matulay¹⁰, L. Belkoff¹¹, K. Decaestecker¹², H. Arentsen¹³, S. Hampras¹⁴, C. Cutie¹⁵, H. Sweiti¹⁶, K. Stromberg¹⁴, J. Martin¹⁷, A. Shukla¹⁵, M. Van Der Heijden¹⁸, ¹Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Milan, IT, ²Upstate Medical University, Syracuse, US, ³University of Southern California Norris Comprehensive Cancer Center, Los Angeles, US, ⁴'Regina Elena' National Cancer Institute, Rome, IT, ⁵Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris Cité, Paris, FR, ⁶Urology Associates, Nashville, US, ⁷Urologie Neandertal, Gemeinschaftspraxis für Urologie, Mettmann, DE, ⁸Urology San Antonio, San Antonio, US, ⁹Chonnam National University Medical School, Chonnam National University Hospital, Gwangju, KR, ¹⁰Atrium Health Levine Cancer Institute, Charlotte, US, ¹¹MidLantic Urology/Solaris Health, Bala Cynwyd, US, ¹²Ghent University Hospital; AZ Maria Middelaes, Ghent, BE, ¹³AZ Sint-Jan Hospital Brugge-Oostende, Oostende, BE, ¹⁴Janssen Research & Development, Raritan, US, ¹⁵Janssen Research & Development, Lexington, US, ¹⁶Janssen Research & Development, Spring House, US, ¹⁷Janssen Research & Development, High Wycombe, GB, ¹⁸Netherlands Cancer Institute, Amsterdam, NL
- 11:15 - 11:25 **Invited Discussant LBA104 and LBA105**
- J. Boormans, Erasmus MC, Rotterdam, NL
- 11:25 - 11:30 **1883MO - MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)**
- M. Voss¹, B. Garmezzy², S.H. Kim³, J.P. Maroto Rey⁴, A. Mansinho⁵, A. Rodriguez-Vida⁶, J. Oliveira⁷, M. Van Dongen⁸, L. Medina Rodríguez⁹, S. Negrier¹⁰, B. Tran¹¹, B. Carneiro¹², E. Castanon Alvarez¹³, S.Y. Rha¹⁴, Y. Wang¹⁵, S. Gainer¹⁵, Z. Tang¹⁵, I. Achour¹⁵, J. Asare¹⁵, L. Albiges¹⁶, ¹Memorial Sloan Kettering Cancer Center and Weill Medical College, New York, US, ²Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US, ³Seoul National University Bundang Hospital, Seongnam, KR, ⁴Santa Creu i Sant Pau Hospital, Barcelona, ES, ⁵Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon, PT, ⁶Hospital del Mar, IMIM Research Institute, Barcelona, ES, ⁷Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), Porto, PT, ⁸The Netherlands Cancer Institute, Amsterdam, NL, ⁹Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, ES, ¹⁰Centre Léon Bérard, Lyon I University, Lyon, FR, ¹¹Peter MacCallum Cancer Centre, Melbourne, AU, ¹²Legorreta Cancer Center at Brown University, The Warren Alpert Medical School, Lifespan Cancer Institute, Providence, US, ¹³Clínica Universidad de Navarra, Madrid, ES, ¹⁴Yonsei Cancer Center, Yonsei University Health System, Seoul, KR, ¹⁵AstraZeneca, Gaithersburg, US, ¹⁶Institut Gustave Roussy, Villejuif, Cedex, FR
- 11:30 - 11:35 **1884MO - Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study**



R. Iacovelli¹, C. Ciccarese¹, M. Bersanelli², P. Zucali³, E. Fantinel⁴, D. Bimbatti⁵, E. Verzoni⁶, C. Accettura⁷, L. Bonomi⁸, C. Buttigliero⁹, G. Fornarini¹⁰, S. Pipitone¹¹, F. Atzori¹², C. Masini¹³, F. Massari¹⁴, F. Primi¹⁵, S. Buti¹⁶, M. Perrino¹⁷, S. Pafumi¹⁸, G. Tortora¹, ¹Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ²University Hospital of Parma, Parma, IT, ³Humanitas University, Pieve Emanuele, IT, ⁴AOU Integrata di Verona - Ospedale Borgo Trento, Verona, IT, ⁵IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁷Ospedale Vito Fazzi - ASL Lecce, Lecce, IT, ⁸ASST Papa Giovanni XXIII, Bergamo, IT, ⁹Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT, ¹⁰IRCCS Ospedale Policlinico San Martino, Genova, IT, ¹¹Azienda Ospedaliero - Universitaria Policlinico di Modena, Modena, IT, ¹²Azienda Ospedaliero Universitaria di Cagliari, Monserrato, IT, ¹³Azienda Ospedaliera - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ¹⁴AOU Policlinico S. Orsola-Malpighi, Bologna, IT, ¹⁵Ospedale Belcolle - ASL Viterbo, Viterbo, IT, ¹⁶University of Parma, Parma, IT, ¹⁷IRCCS Humanitas Research Hospital, Rozzano, IT, ¹⁸AOU Integrata di Verona - University of Verona, Verona, IT

11:35 - 11:45

Invited Discussant 1883MO and 1884MO

D. Mukherji, Clemenceau Medical Center, Dubai, AE



10:15 - 11:45	Type: Special session Title: ESMO Clinical Practice Guidelines 1 Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR	Bilbao Auditorium - NCC
10:15 - 10:25	Early breast cancer case presentation <u>F. Giugliano</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
10:25 - 10:35	Early breast cancer case discussion <u>S. Loibl</u> , German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE	
10:35 - 10:45	Q&A	
10:45 - 10:55	Oncogene-addicted metastatic NSCLC case presentation <u>M. Brandão</u> , Institute Jules Bordet, Brussels, BE	
10:55 - 11:05	Oncogene-addicted metastatic NSCLC discussion <u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
11:05 - 11:15	Q&A	
11:15 - 11:25	Advanced pancreatic cancer case presentation <u>E. Mariamidze</u> , Todua Clinic, Tbilisi, GE	
11:25 - 11:35	Advanced pancreatic cancer discussion <u>T. Conroy</u> , Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR	
11:35 - 11:45	Q&A and Discussion	



10:15 - 11:45 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Dissecting metastatic castration-sensitive prostate cancer (mCSPC) for optimal patient benefit
 Chair(s): Karim Fizazi, FR; Dana Rathkopf, US

10:15 - 10:35 **Evidence from trials: Summary of a fantastic decade**
D. Rathkopf, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

10:35 - 10:55 **Next generation imaging: How does it change the evidence seen in trials?**
B. Tombal, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE

10:55 - 11:15 **How to best integrate biology**
G. Attard, University College London, London, GB

11:15 - 11:35 **Tolerance and long-term side-effects**
A. Morgans, Dana Farber Cancer Institute, Boston, US

11:35 - 11:45 **Discussion**

10:15 - 11:45 **Type: Educational session** **Burgos Auditorium - Hall 3**
Title: Liquid biopsies development and application: Where do we stand?
 Chair(s): Scott Bratman, CA; Naureen Starling, GB

10:15 - 10:32 **Detection of HPV circulating tumour DNA**
S. Bratman, Princess Margaret Cancer Centre, Toronto, CA

10:32 - 10:49 **Incorporating liquid biopsies into clinical trials**
S. Marsoni, IFOM-IEO Campus, Milan, IT

10:49 - 11:06 **Standardisation of liquid biopsy approaches**
E. Heitzer, Medical University of Graz, Graz, AT

11:06 - 11:23 **Genome-wide cell-free DNA fragmentation in cancer**
V. Velculescu, Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US

11:23 - 11:45 **Q&A and Discussion**

10:15 - 11:55 **Type: Mini Oral session** **Valencia Auditorium**
Title: Mini oral session - Gynaecological cancers



Chair(s): Christian Marth, AT; Alexandra Leary, FR; Kosei Hasegawa, JP

10:15 **LBA43 - Updated Response Data and Analysis of Progression Free Survival by Mechanism of Repair Loss in Endometrial Cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG GY018 trial**

R. Eskander¹, M. Sill², A. Miller², L. Beffa³, R. Moore⁴, J. Hope⁵, F. Musa⁶, R. Mannel⁷, M. Shahin⁸, C. Canturia⁹, E. Girda¹⁰, C. Mathews¹¹, J. Kavecansky¹², C. Leath Iii¹³, L. Gien¹⁴, E. Hinchcliff¹⁵, S. LeL Powell¹⁷, C. Aghajanian¹⁸, ¹University of California San Diego - UCSD, La Jolla, US, ²NRG Oncology and Data Management Center, Philadelphia, US, ³Case Western Reserve University / University Hospital Cleveland, US, ⁴URMC - University of Rochester Medical Center, Rochester, US, ⁵Alaska Women's Cancer Anchorage, US, ⁶Pacific Cancer Care, Monterey, US, ⁷Stephenson Cancer Center, Oklahoma University Science Center, Oklahoma City, US, ⁸Sidney Kimmel Cancer Center - Thomas Jefferson University, Philadelphia, US, ⁹Georgia Cancer Specialists affiliated with Northside Hospital Cancer Institute, Atlanta, US, ¹⁰Roswell Park Cancer Institute of New Jersey, New Brunswick, US, ¹¹Women & Infants Hospital - Warren Alpert Medical School of Brown Univ, Providence, US, ¹²The Permanente Medical Group, San Jose, US, ¹³University of Alabama at Birmingham, Birmingham, US, ¹⁴Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, Canada, ¹⁵Northwestern Medical Group, Chicago, US, ¹⁶Roswell Park Comprehensive Cancer Center, Buffalo, NY, ¹⁷National Cancer Institute Sponsored NRG Oncology, Washington University School of Medicine, Philadelphia, US, ¹⁸Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

10:20 **740MO - Dostarlimab & chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial**

M.R. Mirza¹, S. Sharma², J. Herrstedt³, M. Shahin⁴, D. Cibula⁵, E. Fleming⁶, F. Raspagliesi⁷, J. Busceti⁸, R. Coleman¹⁰, I. Boere¹¹, K. Schneider¹², L. Gilbert¹³, B. Slomovitz¹⁴, M.G. Teneriello¹⁵, M. Powell¹⁶, S. Ghosh¹⁷, S. Stevens¹⁸, K. Ring¹⁹, A. Stuckey²⁰, ¹Rigshospitalet, Copenhagen University Hospital, Copenhagen, and Nordic Society of Gynaecologic Oncology-Clinical Trial Unit, Copenhagen, DK, ²Adventist Hinsdale Hospital, Hinsdale, US, ³Zealand University Hospital Roskilde, Roskilde, DK, ⁴Harvard Medical School, Brigham Young University, Abington Hospital-Jefferson Health, Asplundh Cancer Pavilion, Sidney Kimmel Medical College of Thomas Jefferson University, Willow Grove, US, ⁵General University Hospital, Prague, First Faculty of Medicine, Charles University, Prague, CZ, ⁶Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, US, ⁷Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT, ⁸Arizona Cancer Center, Tucson, US, ⁹University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, and AGO Study Group, Wiesbaden, DE, ¹⁰Sarah Cannon Research Institute, Nashville, US, ¹¹Erasmus MC Cancer Centre, Rotterdam, NL, ¹²Norvant Health Cancer Institute - Elizabeth, Charlotte, US, ¹³McGill University Health Centre, Vancouver, BC, CA, ¹⁴Mount Sinai Medical Center, and the Department of Obstetrics and Gynecology, Florida International University, Miami Beach, US, ¹⁵US Oncology Research, The Woodlands, US, ¹⁶National Cancer Institute Sponsored NRG Oncology, Washington University School of Medicine, St. Louis, US, ¹⁷GSK, Waltham, MA, ¹⁸GSK, London, GB, ¹⁹University of Virginia, Charlottesville, US, ²⁰Women and Infants Hospital, Providence, RI, US

10:25 **742MO - Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer**

M. De Bruyn¹, A. Eerkens¹, K. Brummel¹, A. Vledder¹, S. Paijens², M. Requesens¹, D. Loiero³, N. Van Plat¹, P. Klok¹, F.-J. Haan¹, D. Church⁴, R. Wardenaar¹, F. Fojjer¹, V. Koelzer³, T. Bosse⁵, J. Bart¹, M. J. Reyners¹, H. Nijman¹, ¹UMCG - University Medical Center Groningen, Groningen, NL, ²Erasmus MC Cancer Center, Rotterdam, NL, ³USZ - Universitätsspital Zürich, Zurich, CH, ⁴University of Oxford, Oxford, GB, ⁵Leiden University Medical Center, Leiden, NL



10:30 **741MO - Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolR α 3b1) antibody drug conjugate (ADC), demonstrates clinical activity in recurrent/progressive epithelial endometrial cancer (EEC): STRO-002-GM1 phase I dose expansion**

B. Pothuri¹, R. Naumann², L. Martin³, D. O'Malley⁴, D. Uyar⁵, J. Moroney⁶, J. Diaz⁷, J. Garcia-Donas⁸, Redondo⁹, A. Gonzalez Martin¹⁰, D. Illescas¹¹, L. Liu¹², C. Berman¹³, A. Oaknin¹¹, ¹NYU Langone Lauder Center for Cancer and Immunology, New York, US, ²Levine Cancer Institute, Charlotte, US, ³Fox Chase Cancer Center - Main Campus, Philadelphia, US, ⁴OSUCCC - The Ohio State University Comprehensive Cancer Center, Columbus, US, ⁵Froedtert Hospital & Medical College of Wisconsin, Milwaukee, US, ⁶University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ⁷Miami Cancer Institute at Baptist Health South Florida, Miami, US, ⁸Hospital Madrid Norte San Chinarro - Centro Integral Oncológico Clara Campal, Madrid, ES, ⁹Hospital Universitario La Paz, Madrid, ES, ¹⁰Clinica Universidad de Navarra, Madrid, ES, ¹¹Vall d'Hebron University Hospital, Barcelona, ES, ¹²Sutro Biopharma - Headquarters, South San Francisco, US, ¹³Sutro Biopharma, Inc., South San Francisco, US

10:35 **Invited Discussant LBA43, 740MO, 742MO and 741MO**

10:50

C. Marth, Innsbruck Medical University, Innsbruck, AT

10:50 **743MO - Efficacy and safety of QL1706 plus paclitaxel and cisplatin/carboplatin +/- bevacizumab (Bev) as 1L treatment in recurrent or metastatic cervical cancer (r/mCC): A single-arm, multicenter, phase II study**

N. Liu¹, Z. Yang², D. Tang³, H. Lou⁴, K. Zhang³, H. Cao⁵, D. Zou⁶, X. Zhang⁷, S. Xue⁷, X. Kang⁷, D. Wang⁷, ¹Shandong Cancer Hospital Affiliated to Shandong University, Jinan, CN, ²Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, CN, ³The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, CN, ⁴Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN, ⁵Guizhou Provincial People's Hospital, College of Guizhou University, Guiyang, CN, ⁶Chongqing University Cancer Hospital, Chongqing, CN, ⁷Pharmaceutical Co., Ltd., Jinan, CN

10:55 **744MO - AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic cervical cancer (CC)**

J.-Y. Lee¹, L. Wu², S. Boonyapipat³, H.S. Kim⁴, J.-W. Lee⁵, L. Wang⁶, T. Wang⁷, D. Wang⁸, D. Yao⁹, H. I. Andabekov¹¹, X. Zhang¹², W. Wang¹³, Y.M. Kim¹⁴, K. Wang¹⁵, Y. Gao¹⁵, X. Mu¹⁶, I. Volodymyrovych Sinielnikov¹⁷, ¹Severance Hospital Yonsei University Health System, Seoul, KR, ²Cancer Hospital China Academy of Medical Sciences, Beijing, CN, ³Songklanagarind Hospital (Prince of Songkhla University Hospital), Songkhla, TH, ⁴Seoul National University Hospital, Seoul, KR, ⁵Samsung Medical Center, Seoul, KR, ⁶Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ⁷The Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ⁸Liaoning Cancer Hospital & Institute, Xi'an, CN, ⁹Tumor Hospital Affiliated to Guangxi Medical University, Nanning, CN, ¹⁰Anhui Provincial Cancer Hospital West Branch of Anhui Province Hospital, Hefei City, CN, ¹¹Oncological Scientific Center LLC, Moscow, Russia, ¹²Zhejiang Cancer Hospital, Hangzhou, CN, ¹³Second Hospital of Shanxi Medical University, Taiyuan, CN, ¹⁴Asan Medical Center, Seoul, KR, ¹⁵BeiGene (Beijing) Co. Ltd, Beijing, CN, ¹⁶BeiGene (Shanghai) Co. Ltd, Shanghai, CN, ¹⁷Volyn Regional Medical Center of Oncology, Lutsk, UA

11:00 **LBA44 - Camrelizumab plus famitinib versus camrelizumab alone and investigator's choice chemotherapy in women with recurrent or metastatic cervical cancer**



11:05

X. Wu¹, L. Xia¹, K. Zhang², Y. Tang³, G.N. Zhang⁴, D. Wang⁵, H. Lou⁶, N. Liu⁷, H. Zhang⁸, H. Chen⁹, S. Wei¹¹, L. Wang¹², K. Gao¹³, G. Li¹⁴, H. Zhang¹⁵, Y. Hu¹⁶, X. Zhou¹⁷, Y. Wang¹⁷, Q. Wang¹⁷, ¹Fudan Shanghai Cancer Center, Shanghai, CN, ²Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ³Chongqing University Cancer Hospital, Chongqing, CN, ⁴Sichuan Cancer Hospital & Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, CN, ⁵Liaoning Cancer Hospital & Institute, Shenyang, CN, ⁶Zhejiang Cancer Hospital, Hangzhou, CN, ⁷Shandong Cancer Hospital & Institute, Jinan, CN, ⁸Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University, Kunming, CN, ⁹The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ¹⁰Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ¹¹Shanxi Cancer Hospital, Taiyuan, CN, ¹²The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ¹³Guangxi Medical University Cancer Hospital, Nanning, CN, ¹⁴Cancer Center Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, CN, ¹⁵Hubei Cancer Hospital, Wuhan, CN, ¹⁶Central Hospital of Gynecology Obstetrics, Tianjin, CN, ¹⁷Jiangsu Hengrui Pharmaceuticals Co., Ltd., Suzhou, CN

11:05 **Invited Discussant 743MO, 744MO and LBA44**

-

11:15

A. Leary, Institut Gustave Roussy, Villejuif, FR

11:15 **LBA45 - Overall Survival (OS) Outcomes from NRG-GY004, a Phase III Study Comparing Sirtaximab or Olaparib or Combination Cediranib and Olaparib to Platinum (Plat) Based Chemotherapy in Platinum Sensitive Ovarian Cancer (OvCa)**

11:20

J. Liu¹, M. Brady², U. Matulonis¹, A. Miller², E. Kohn³, E. Swisher⁴, W. Tew⁵, N. Cloven⁶, C. Muller⁷, R. Moore⁹, D. Michelin¹⁰, S. Waggoner¹¹, M. Geller¹², K. Fujiwara¹³, S. D'Andre¹⁴, M. Carney¹⁵, A. S. Walker¹⁷, M. Bookman¹⁸, ¹Dana Farber Cancer Institute, Boston, US, ²Roswell Park Comprehensive Cancer Center, Buffalo, US, ³National Cancer Institute, Bethesda, US, ⁴University of Washington, Seattle, US, ⁵Sloan Kettering Cancer Center, New York, US, ⁶Texas Oncology, Fort Worth, US, ⁷University of New Mexico, Albuquerque, US, ⁸University of Iowa Hospitals and Clinics, Iowa City, US, ⁹URMC - University of Rochester Medical Center, Rochester, US, ¹⁰Cancer Research Consortium of West Michigan, Grand Rapids, US, ¹¹Western Reserve University / University Hospitals, Cleveland, US, ¹²University of Minnesota, Minneapolis, US, ¹³Saitama Medical University International Medical Center, Saitama, JP, ¹⁴Sutter Institute for Medical Science, Sacramento, US, ¹⁵University of Hawaii Cancer Center, Honolulu, US, ¹⁶Duke University, Durham, US, ¹⁷University of Oklahoma Health Sciences Center, Oklahoma City, US, ¹⁸Kaiser Permanente Medical Center, San Francisco, US

11:20 **746MO - Randomized phase II trial of durvalumab in combination with olaparib and cediranib compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY004)**

11:25

J.-M. Lee¹, A. Miller², P. Rose³, M. Alhilli³, C. Washington⁴, V. John⁵, C. Shah⁶, K. Matsuo⁷, J. Siedel⁸, J. Chan¹⁰, E. Hopp¹¹, E. Kohn¹, K. Moore⁴, J. Liu¹², ¹National Cancer Institute, Bethesda, US, ²NRG Oncology, Buffalo, US, ³Case Western Reserve University / University Hospitals, Cleveland, US, ⁴Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ⁵Northwell Health Cancer Institute, Lake Success, US, ⁶Swedish Cancer Institute - Medical Oncology - First Hill, Seattle, US, ⁷Keck School of Medicine - University of Southern California USC, Los Angeles, US, ⁸University of Michigan Hospital, Ann Arbor, US, ⁹UTSW Medical Center, University of Texas Southwestern Medical Center, Dallas, US, ¹⁰Sutter Cancer Center, Sacramento, US, ¹¹Froed Hospital & Medical College of Wisconsin, Milwaukee, US, ¹²Dana Farber Cancer Institute, Boston, US



11:25 **Invited Discussant LBA45 and 746MO**

-

11:35

K. Hasegawa, Saitama Medical University International Medical Center, Saitama, JP

11:35 **745MO - Raludotatug deruxtecan (R-DXd; DS-6000) monotherapy in patients with previous ovarian cancer (OVC): Subgroup analysis of a first-in-human phase I study**

11:40

K. Moore¹, A. Philipovskiy², K. Harano³, B. Rini⁴, K. Sudo⁵, S. Kitano⁶, D.R. Spigel⁷, J. Lin⁸, M. Kundt Bensmaine⁹, Y. Myobatake⁸, E. Hamilton¹⁰, ¹Oklahoma University, Oklahoma City, US, ²Florida Cancer Specialists, Lake Mary, US, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Vanderbilt-Ingram Cancer Center, Nashville, US, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶Japanese Foundation for Cancer Tokyo, JP, ⁷Tennessee Oncology, PLLC, Nashville, US, ⁸Daiichi Sankyo, Inc., Basking Ridge, US, ⁹Daiichi France SAS, Rueil-Malmaison, FR, ¹⁰Sarah Cannon Research Institute, Nashville, US

11:40 **747MO - First results from the ENGOT-GYN2/GOG-3051/BOUQUET phase II biomarker-directed platform study: Cobimetinib (cobi) or atezolizumab (atezo) + bevacizumab (bev) for persistent/recurrent rare epithelial ovarian cancer (eOC)**

11:45

I. Ray-Coquard¹, S. Pignata², J.-Y. Lee³, R. Coleman⁴, J. Brown⁵, J.-W. Kim⁶, F. Selle⁷, D. Lorusso⁸, M.J. Pérez⁹, P. Pautier¹⁰, C. Gourley¹¹, A. Ayhan¹², G. Richardson¹³, D. Cibula¹⁴, L. Yauch¹⁵, M. Dieterich Krishnan¹⁵, O. Calas-Zeroug¹⁷, P. Harter¹⁸, D. Gershenson¹⁹, ¹Centre Léon Bérard and University of Lyon, France, ²Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ³Yonsei University College of Medicine, Seoul, KR, ⁴The US Oncology Network, The Woodlands, US, ⁵Levine Cancer Institute at Atrium Health, Charlotte, US, ⁶Seoul National University College of Medicine, Seoul, KR, ⁷Groupe Hospitalier Diaconesses Croix Saint-Simon, Paris, FR, ⁸Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Catholic University of Sacred Heart, Rome, IT, ⁹Hospitales Universitarios Regional y Virgen Victoria, Málaga, ES, ¹⁰Gustave Roussy, Villejuif, FR, ¹¹Cancer Research UK Edinburgh Centre, Western General Hospital, Edinburgh, GB, ¹²Baskent University Hospital, Ankara, TR, ¹³Cabrini Hospital, Malvern, AU, ¹⁴Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, CZ, ¹⁵Genentech, South San Francisco, US, ¹⁶F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁷Cytel Inc - Clinical Research Services, Geneva, CH, ¹⁸Evang. Kliniken Essen-Mitte, Essen, DE, ¹⁹The University of Texas MD Anderson Cancer Center, Houston, US

11:45 **Invited Discussant 745MO and 747MO**

-

11:55

M.R. Mirza, Rigshospitalet, Copenhagen, DK



10:15 - 11:45	Type: Special symposium Title: Cutting edge diagnostics and innovation in the treatment of brain tumours Chair(s): Roger Stupp, US; Slavka Lukacova, DK	Salamanca Auditorium - Hall 3
10:15 - 10:20	Introduction and scientific background <u>S. Lukacova</u> , Aarhus University Hospital, Aarhus, DK	
10:20 - 10:35	New treatment targets: From bench to bedside <u>M. Sanson</u> , Hopital Pitié Salpêtrière AP-HP, Paris, FR	
10:35 - 10:50	Immunotherapy <u>M. Platten</u> , Heidelberg University - Faculty of Medicine in Mannheim, Mannheim, DE	
10:50 - 11:05	Opening the blood-brain barrier (BBB) <u>A. Sonabend</u> , Northwestern University Feinberg School of Medicine, Chicago, US	
11:05 - 11:20	Methylation profiling: Hype or progress? <u>H.-K. Ng</u> , The Chinese University of Hong Kong - Sino Building, Sha Tin, HK	
11:20 - 11:40	Discussion	
11:40 - 11:45	Conclusions and perspectives <u>R. Stupp</u> , Northwestern University Feinberg School of Medicine, Chicago, US	



10:15 - 11:45	Type: Multidisciplinary session Title: A young female with limited stage classic Hodgkin's lymphoma and large mediastinal mass Chair(s): Olivier Casasnovas, FR; Ramon Garcia-Sanz, ES	Toledo Auditorium - Hall 3
10:15 - 10:20	Presentation of case/condition <u>O. Casasnovas</u> , CHU Dijon, Dijon, FR	
10:20 - 10:40	How to select the chemotherapy <u>P. Borchmann</u> , University Hospital Cologne, Köln, DE	
10:40 - 11:00	How to guide treatment with PET <u>O. Casasnovas</u> , CHU Dijon, Dijon, FR	
11:00 - 11:20	When or when not to irradiate <u>U. Ricardi</u> , Azienda Ospedaliero Universitaria San Giovanni Battista di Torino, Torino, IT	
11:20 - 11:40	Preserving fertility in female patients <u>R. Garcia-Sanz</u> , University Hospital of Salamanca, Salamanca, ES	
11:40 - 11:45	Discussion	



10:15 - 11:45	Type: Special session Title: More intelligent trial design Chair(s): Mahesh Parmar, GB; Ian Tannock, CA	León Auditorium - Hall 7
10:15 - 10:20	Introduction and scientific background <u>I. Tannock</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
10:20 - 10:35	Multi-arm multi-stage (MAMS) trials <u>M. Parmar</u> , Institute of Clinical Trials and Methodology-UCL, London, GB	
10:35 - 10:50	Pragmatic trials <u>J. Bogaerts</u> , EORTC AISBL/IVZW - European Organisation for Research and Treatment of Cancer, Brussels, BE	
10:50 - 11:05	De-escalation trials <u>L. Carey</u> , UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US	
11:05 - 11:20	Trials in low-and middle-income countries (LMIC) <u>C. Pramesh</u> , Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN	
11:20 - 11:40	Discussion	
11:40 - 11:45	Conclusions and perspectives <u>M. Parmar</u> , Institute of Clinical Trials and Methodology-UCL, London, GB	



10:15 - 11:45	Type: Educational session Title: Transnational cancer policies: EU and WHO projects driving improvements in national cancer plans Chair(s): Bente Mikkelsen, CH; Tit Albreht, SI	Cádiz Auditorium - NCC
10:15 - 10:35	EBCP and implementation plans at the EU level <u>P. Roux</u> , European Commission - Directorate General Health and Food Safety, Luxembourg City, LU	
10:35 - 10:55	The joint development of policies through Joint Actions as policy projects, and the arising EU guide for National Cancer Control Programmes <u>T. Albreht</u> , National Institute of Public Health of Slovenia - Nacionalni institut za javno zdravje, Ljubljana, SI	
10:55 - 11:15	The Youth Cancer Europe's perspective <u>S. Narbutas</u> , Lithuanian Cancer Patient Coalition, Kaunas, LT	
11:15 - 11:35	WHO/IARC national cancer control plan tool and case studies <u>B. Mikkelsen</u> , WHO - World Health Organization, Geneva, CH	
11:35 - 11:45	Q&A and Discussion	



10:15 - 11:45	Type: EONS session Title: EONS16: Symptom management Chair(s): Tugba Pehlivan Saribudak, TR	Alicante Auditorium - Hall 10
10:15 - 10:30	Prevalence and predictors of unmet needs among lymphoma cancer survivors <u>V. Boland</u> , Trinity College Dublin, Dublin, IE	
10:30 - 10:45	PROMS in patients with advanced RCC and advanced hepatocellular carcinoma <u>G. Kotronoulas</u> , University of Glasgow, Glasgow, GB	
10:45 - 11:00	Digital innovation in cancer care: Symptom assessment and management <u>E. Furlong</u> , National University of Ireland - University College Dublin, Dublin, IE	
11:00 - 11:15	Evaluation of the ABC4Nurses education programme <u>A. Drury</u> , DCU - Dublin City University, Dublin, IE	
11:15 - 11:25	CN3 - Patient adherence to digital patient-reported outcome monitoring (PROM) in cancer immunotherapies <u>J. Lijnsvelt</u> ¹ , <u>S.G. Aanes</u> ² , <u>S. Iivanainen</u> ³ , <u>M.G. Vitale</u> ⁴ , <u>S. Mentu</u> ⁵ , <u>R. Arokoski</u> ⁵ , <u>P. Mohr</u> ⁶ , <u>A. Addeo</u> ⁷ , <u>P. Ascierto</u> ⁴ , <u>J. Koivunen</u> ³ , <u>E. Haukland</u> ⁸ , <u>C. Blank</u> ¹ , ¹ NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ² Nordlandsykehuset HF, Bodoe, NO, ³ OYS - Oulu University Hospital, Oulu, FI, ⁴ Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵ Kaiku Health, Helsinki, FI, ⁶ Elbe-Kliniken, Buxtehude, DE, ⁷ HUG - Hopitaux Universitaires de Geneve, Geneva, CH, ⁸ University of Stavanger, Stavanger, NO	
11:25 - 11:35	CN59 - The comparison between two types of educational information in reducing nausea and vomiting in patients undergoing chemotherapy: Randomized controlled trial <u>C. Mazzega Fabbro</u> ¹ , <u>J. Polesel</u> ¹ , <u>M. Manicone</u> ¹ , <u>L. Brusutti</u> ¹ , <u>E. Malnis</u> ¹ , <u>F. Puglisi</u> ² , ¹ CRO Aviano - Centro di Riferimento Oncologico - IRCCS, Aviano, IT, ² Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, IT	
11:35 - 11:45	Q&A and discussion	



10:30 - 11:45 **Type: Multidisciplinary session** **Málaga Auditorium - Hall 10**
Title: Is stereotactic radiotherapy a valid alternative to surgery for patients with stage I NSCLC?
 Chair(s): Matthias Guckenberger, CH; Gaetano Rocco, US

10:30 - 10:45 **Characteristics and treatment outcomes of screening-detected early NSCLC**
W. Rzyman, Medical University of Gdansk, Gdansk, PL

10:45 - 11:00 **A radiation oncologist's perspective**
M. Guckenberger, USZ - University Hospital Zürich, Zurich, CH

11:00 - 11:15 **A surgeon's perspective**
G. Rocco, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

11:15 - 11:30 **Opportunities for immunotherapy in stage I NSCLC**
S. Novello, Università Degli Studi Di Torino - Orbassano, Orbassano, IT

11:30 - 11:45 **Discussion**

10:30 - 11:15 **Type: Challenge your Expert** **Santander Auditorium - Hall 9**
Title: How do we manage patients with complicated toxicity to immunotherapy?
 Chair(s): John Haanen, NL

10:30 - 10:50 **Presentation by Expert**
M. Postow, Memorial Sloan Kettering 60th Street Outpatient Center, New York, US

10:50 - 11:15 **Discussion led by Chair**
J. Haanen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL



10:30 - 11:45 **Type: Multidisciplinary session** **Oviedo Auditorium - Hall 7**
Title: Management of retroperitoneal sarcoma
 Chair(s): Winan Van Houdt, NL; Claudia María Valverde Morales, ES

10:30 - 10:35 **Presentation of case/condition**
H. Kosela Paterczyk, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL

10:35 - 10:50 **A pathologist's perspective**
M. Sbaraglia, Ospedale Regionale di Treviso S.Maria di Cà Foncello - ULSS2, Treviso, IT

10:50 - 11:05 **A surgeon's perspective**
D. Callegaro, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

11:05 - 11:20 **A radiation oncologist's perspective**
A. Miah, The Royal Marsden Hospital - Chelsea, London, GB

11:20 - 11:35 **A medical oncologist's perspective**
C.M. Valverde Morales, Vall d'Hebron University Hospital, Barcelona, ES

11:35 - 11:45 **Discussion**

11:00 - 11:45 **Type: Young Oncologists session** **Ávila Auditorium - NCC**
Title: YO Brunch 2: How to tell a compelling story in scientific articles and presentations
 Chair(s): Rille Pihlak, GB

11:00 - 11:15 **How to tell a compelling story in scientific articles and presentations**
P. Sobczuk, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

11:15 - 11:45 **Discussion led by Chair**
R. Pihlak, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

12:00 - 12:30 **Type: Keynote lecture** **Barcelona Auditorium - Hall 9**
Title: Healthcare in times of crises
 Chair(s): Jose Martin-Moreno, ES

12:00 - 12:05 **Introduction by the Chair**
J. Martin-Moreno, Hospital Clinico Universitario de Valencia, Valencia, ES

12:05 - 12:30 **Healthcare in times of crises**
B. Mikkelsen, WHO - World Health Organization, Geneva, CH



12:00 - 13:30	Type: EONS Industry Satellite Symposium Title: MSD - The Role of Cancer Nurses in the Management of gBRCAm HER2- Breast Cancer Chair(s): Julio de la Torre-Montero, ES	Alicante Auditorium - Hall 10
12:00 - 12:05	Welcome and Introduction <u>J. De La Torre-Montero</u> , Universidad Pontificia Comillas, Madrid, ES	
12:05 - 12:20	Genetic risk/surgical management <u>S. González-Santiago</u> , Hospital San Pedro De Alcantara, Caceres, ES	
12:20 - 12:25	Q&A <u>J. De La Torre-Montero</u> ¹ , <u>S. González-Santiago</u> ² , <u>Y. Hanhauser</u> ³ , <u>E. Schumacher-Wulf</u> ⁴ , ¹ Universidad Pontificia Comillas, Madrid, ES, ² Hospital San Pedro De Alcantara, Caceres, ES, ³ St James's Hospital, Dublin, IE, ⁴ Mamma MIA - The Breast Cancer Magazine, Köln, DE	
12:25 - 12:40	Decision-making in BRCA+ risk management <u>Y. Hanhauser</u> , St James's Hospital, Dublin, IE	
12:40 - 12:45	Q&A <u>J. De La Torre-Montero</u> ¹ , <u>S. González-Santiago</u> ² , <u>Y. Hanhauser</u> ³ , <u>E. Schumacher-Wulf</u> ⁴ , ¹ Universidad Pontificia Comillas, Madrid, ES, ² Hospital San Pedro De Alcantara, Caceres, ES, ³ St James's Hospital, Dublin, IE, ⁴ Mamma MIA - The Breast Cancer Magazine, Köln, DE	
12:45 - 13:00	Nursing considerations related to PARP inhibitors <u>S. González-Santiago</u> , Hospital San Pedro De Alcantara, Caceres, ES	
13:00 - 13:05	Q&A <u>J. De La Torre-Montero</u> ¹ , <u>S. González-Santiago</u> ² , <u>E. Schumacher-Wulf</u> ³ , <u>Y. Hanhauser</u> ⁴ , ¹ Universidad Pontificia Comillas, Madrid, ES, ² Hospital San Pedro De Alcantara, Caceres, ES, ³ Mamma MIA - The Breast Cancer Magazine, Köln, DE, ⁴ St James's Hospital, Dublin, IE	
13:05 - 13:20	Patient experience of care <u>E. Schumacher-Wulf</u> , Mamma MIA - The Breast Cancer Magazine, Köln, DE	
13:20 - 13:25	Q&A <u>J. De La Torre-Montero</u> ¹ , <u>S. González-Santiago</u> ² , <u>Y. Hanhauser</u> ³ , <u>E. Schumacher-Wulf</u> ⁴ , ¹ Universidad Pontificia Comillas, Madrid, ES, ² Hospital San Pedro De Alcantara, Caceres, ES, ³ St James's Hospital, Dublin, IE, ⁴ Mamma MIA - The Breast Cancer Magazine, Köln, DE	
13:25 - 13:30	Conclusions	



J. De La Torre-Montero, Universidad Pontificia Comillas, Madrid, ES

13:00 - 14:30	Type: Industry Satellite Symposium Title: AstraZeneca - Transforming care in Early stage Lung cancer Chair(s): Sanjay Popat, GB	Burgos Auditorium - Hall 3
13:00 - 13:05	Welcome and introduction <u>S. Popat</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
13:05 - 13:20	Optimising resectable NSCLC outcomes in patients with actionable mutations <u>R.S. Herbst</u> , Yale University School of Medicine, New heaven, US	
13:20 - 13:35	Improving outcomes in unresectable NSCLC: from clinical trial to clinical practice <u>S. Formenti</u> , Weill Cornell Medicine - Gastrointestinal (GI) Oncology, New York, US	
13:35 - 13:50	Leveraging the MDT to navigate early-stage disease <u>J. Naidoo</u> , Beaumont Hospital, Dublin, IE	
13:50 - 14:25	Panel discussion and audience Q&A <u>S. Popat</u> ¹ , <u>R.S. Herbst</u> ² , <u>S. Formenti</u> ³ , <u>J. Naidoo</u> ⁴ , ¹ The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ² Yale University School of Medicine, New heaven, US, ³ Weill Cornell Medicine - Gastrointestinal (GI) Oncology, New York, US, ⁴ Beaumont Hospital, Dublin, IE	
14:25 - 14:30	Summary and Close <u>S. Popat</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	



13:00 - 14:30	Type: Industry Satellite Symposium Title: Novartis - Expanding Horizons: Clinical and Patient Perspectives on CDK4/6 Inhibitors in HR+/HER2- Early Breast Cancer Chair(s): Michael Gnant, AT	Valencia Auditorium - Hall 10
13:00 - 13:10	Unmet Need in HR+/HER2- Early Breast Cancer <u>M. Gnant</u> , MedUni Wien - Medical University of Vienna, Vienna, AT	
13:10 - 13:20	Efficacy of CDK4/6i in HR+/HER2- Early Breast Cancer <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
13:20 - 13:30	Discussion <u>M. Gnant</u> ¹ , <u>M. Piccart</u> ² , ¹ MedUni Wien - Medical University of Vienna, Vienna, AT, ² Institute Jules Bordet, Brussels, BE	
13:30 - 13:40	Safety and QoL with CDK4/6i in HR+/HER2- Early Breast Cancer <u>M. Gnant</u> , MedUni Wien - Medical University of Vienna, Vienna, AT	
13:40 - 13:50	Discussion <u>M. Gnant</u> ¹ , <u>M. Piccart</u> ² , ¹ MedUni Wien - Medical University of Vienna, Vienna, AT, ² Institute Jules Bordet, Brussels, BE	
13:50 - 14:00	Key Takeaways and Live Q&A <u>M. Gnant</u> ¹ , <u>M. Piccart</u> ² , ¹ MedUni Wien - Medical University of Vienna, Vienna, AT, ² Institute Jules Bordet, Brussels, BE	
14:00 - 14:10	QOL and Treatment Adherence in Early Breast Cancer: The Patient Perspective <u>R. Haidinger</u> , Brustkrebs Deutschland e.V., Hohenbrunn, DE	
14:10 - 14:20	Discussion <u>M. Gnant</u> ¹ , <u>M. Piccart</u> ² , ¹ MedUni Wien - Medical University of Vienna, Vienna, AT, ² Institute Jules Bordet, Brussels, BE	
14:20 - 14:30	Live Q&A and Closing <u>M. Gnant</u> ¹ , <u>M. Piccart</u> ² , <u>R. Haidinger</u> ³ , ¹ MedUni Wien - Medical University of Vienna, Vienna, AT, ² Institute Jules Bordet, Brussels, BE, ³ Brustkrebs Deutschland e.V., Hohenbrunn, DE	



13:00 - 14:30 **Type: Industry Satellite Symposium** **Salamanca Auditorium - Hall 3**
Title: MSD - Treatment Modalities in Early-Stage Resectable NSCLC
 Chair(s): Delvys Rodriguez Abreu, ES

13:00 - 13:05 **Welcome & opening comments**

D. Rodriguez Abreu, Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES

13:05 - 13:25 **Current early-stage resectable disease data**

H. Wakelee, Stanford University, Stanford, US

13:25 - 13:45 **Surgical considerations in early-stage disease**

J. Spicer, McGill University, Montreal, CA

13:45 - 14:05 **Integrating treatment strategies into practice**

B. Besse, Institut Gustave Roussy, Villejuif, FR

14:05 - 14:25 **Panel Q&A**

D. Rodriguez Abreu¹, H. Wakelee², J. Spicer³, B. Besse⁴, ¹Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES, ²Stanford University, Stanford, US, ³McGill University, Montreal, CA, ⁴Institut Gustave Roussy, Villejuif, FR

14:25 - 14:30 **Closing Remarks**

D. Rodriguez Abreu, Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES



13:00 - 14:30	Type: Industry Satellite Symposium Title: Janssen Pharmaceutica N.V. - Transforming treatment approaches for patients with EGFR-mutant NSCLC Chair(s): Luis Paz-Ares, ES; Natasha Leighl, CA	Málaga Auditorium - Hall 10
13:00 - 13:05	Welcome and introductions <u>L. Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
13:05 - 13:20	Strategies for overcoming EGFR resistance in NSCLC patient management <u>A. Passaro</u> , IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT	
13:20 - 13:32	Discussion <u>L. Paz-Ares</u> ¹ , <u>N. Leighl</u> ² , <u>N. Girard</u> ³ , <u>J. Sabari</u> ⁴ , <u>A. Passaro</u> ⁵ , ¹ Hospital Universitario 12 de Octubre, Madrid, ES, ² UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ³ Institut Curie, Paris, FR, ⁴ NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, ⁵ IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT	
13:32 - 13:47	Expanding our horizons: Novel frontline approaches in EGFR-mutant NSCLC <u>N. Girard</u> , Institut Curie, Paris, FR	
13:47 - 13:59	Discussion <u>L. Paz-Ares</u> ¹ , <u>N. Leighl</u> ² , <u>N. Girard</u> ³ , <u>J. Sabari</u> ⁴ , <u>A. Passaro</u> ⁵ , ¹ Hospital Universitario 12 de Octubre, Madrid, ES, ² UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ³ Institut Curie, Paris, FR, ⁴ NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, ⁵ IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT	
13:59 - 14:14	Current and future directions for EGFR exon 20 insertion mutations in NSCLC <u>J. Sabari</u> , NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US	
14:14 - 14:26	Discussion <u>L. Paz-Ares</u> ¹ , <u>N. Leighl</u> ² , <u>N. Girard</u> ³ , <u>J. Sabari</u> ⁴ , <u>A. Passaro</u> ⁵ , ¹ Hospital Universitario 12 de Octubre, Madrid, ES, ² UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ³ Institut Curie, Paris, FR, ⁴ NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US, ⁵ IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT	
14:26 - 14:30	Key learnings/closing remarks <u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	



13:00 - 14:00	<p>Type: Industry Satellite Symposium Title: Astellas Pharma Europe Ltd - Putting the patient first: Considering treatment choice and maximising quality of life in mHSPC</p>	<p>Santander Auditorium - Hall 9</p>
	<p>Chair(s): Christopher Sweeney, AU</p>	
13:00 - 13:05	<p>Welcome and introduction <u>C. Sweeney</u>, The University of Adelaide, Adelaide, AU</p>	
13:05 - 13:20	<p>Reinforcing standard of care: The benefits of early treatment intensification in patients with mHSPC <u>H. Payne</u>¹, <u>C. Sweeney</u>², <u>J. Puente</u>³, ¹University College London Hospitals NHS Foundation Trust, London, GB, ²The University of Adelaide, Adelaide, AU, ³Hospital Clinico Universitario San Carlos, Madrid, ES</p>	
13:20 - 13:35	<p>The importance of first-line treatment choice in patients with mHSPC <u>H. Payne</u>¹, <u>C. Sweeney</u>², <u>J. Puente</u>³, ¹University College London Hospitals NHS Foundation Trust, London, GB, ²The University of Adelaide, Adelaide, AU, ³Hospital Clinico Universitario San Carlos, Madrid, ES</p>	
13:35 - 13:50	<p>Maintaining quality of life: Holistic approaches in the management of patients with mHSPC <u>H. Payne</u>¹, <u>C. Sweeney</u>², <u>J. Puente</u>³, ¹University College London Hospitals NHS Foundation Trust, London, GB, ²The University of Adelaide, Adelaide, AU, ³Hospital Clinico Universitario San Carlos, Madrid, ES</p>	
13:50 - 13:55	<p>Q&A <u>H. Payne</u>¹, <u>C. Sweeney</u>², <u>J. Puente</u>³, ¹University College London Hospitals NHS Foundation Trust, London, GB, ²The University of Adelaide, Adelaide, AU, ³Hospital Clinico Universitario San Carlos, Madrid, ES</p>	
13:55 - 14:00	<p>Closing remarks <u>C. Sweeney</u>, The University of Adelaide, Adelaide, AU</p>	



13:00 - 14:30	Type: ESMO Colloquium Title: ESMO Colloquium supported by Daiichi Sankyo, Europe in collaboration with AstraZeneca: The impact of antibody-drug conjugates (ADCs) in the changing treatment landscape of advanced NSCLC Chair(s): Enriqueta Felip, ES; Pasi Jänne, US	Toledo Auditorium - Hall 3
13:00 - 13:10	Welcome and introduction <u>E. Felip</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:10 - 13:30	Emerging data on the role of ADCs in the clinical care pathways for advanced NSCLC patients <u>P. Jänne</u> , Dana Farber Cancer Institute, Boston, US	
13:30 - 13:50	Improving the safety profiles of ADCs: Early detection and optimal management of toxicities <u>M. Pérol</u> , Centre Léon Bérard, Lyon, FR	
13:50 - 14:10	Antibody-drug conjugates: Novel combinations with precision therapeutics and the quest for biomarkers <u>A.-M. Dingemans</u> , Erasmus MC - University Medical Center, Rotterdam, NL	
14:10 - 14:25	Q&A and discussion	
14:25 - 14:30	Concluding remarks <u>P. Jänne</u> , Dana Farber Cancer Institute, Boston, US	



13:00 - 14:30	Type: Industry Satellite Symposium Title: F. Hoffmann-La Roche LTD - Redefining Lung Cancer Together: A New Era for Patients Chair(s): Stephen Liu, US	Oviedo Auditorium - Hall 7
13:00 - 13:05	Welcome and introduction <u>S. Liu</u> , Lombardi Cancer Center Georgetown University, Washington, US	
13:05 - 13:25	Optimising the patient journey: from lung cancer detection to biomarker testing <u>S. Liu</u> ¹ , <u>L. Pijuan</u> ² , ¹ Lombardi Cancer Center Georgetown University, Washington, US, ² Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES	
13:25 - 13:45	Evolving treatment decisions in resectable NSCLC <u>M. Reck</u> ¹ , <u>N. Altorki</u> ² , ¹ Krankenhaus Grosshansdorf, Grosshansdorf, DE, ² NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US	
13:45 - 13:55	A look at the patient journey through the lens of the nurse <u>A. Silverio Pons</u> , Vall d'Hebron Institut de Recerca (VHIR), Barcelona, ES	
13:55 - 14:25	Panel discussion and Q&A <u>S. Liu</u> ¹ , <u>M. Reck</u> ² , <u>N. Altorki</u> ³ , <u>L. Pijuan</u> ⁴ , <u>A. Silverio Pons</u> ⁵ , ¹ Lombardi Cancer Center Georgetown University, Washington, US, ² Krankenhaus Grosshansdorf, Grosshansdorf, DE, ³ NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ⁴ Hospital Universitari de Bellvitge, Hospitalet de Llobregat, ES, ⁵ Vall d'Hebron Institut de Recerca (VHIR), Barcelona, ES	
14:25 - 14:30	Conclusion <u>S. Liu</u> , Lombardi Cancer Center Georgetown University, Washington, US	



13:00 - 14:30	Type: Industry Satellite Symposium Title: GSK - The breakthrough era in endometrial cancer treatment	León Auditorium - Hall 7
	Chair(s): Ana Oaknin, ES	
13:00 - 13:10	Three ways EC management is changing <u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:10 - 13:35	Anti-PD-(L)1s plus chemotherapies continue to evolve: Updates from 2023 congresses <u>I. Colombo</u> , EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH	
13:35 - 13:55	Synergy: Is it more than a buzzword for IO plus PARPi or TKI? <u>K. Moore</u> , Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US	
13:55 - 14:15	Surge in molecular-based targets brings new hope for EC treatment <u>A. Oaknin</u> ¹ , <u>I. Colombo</u> ² , <u>K. Moore</u> ³ , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH, ³ Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US	
14:15 - 14:30	Full discussion/Q&A <u>A. Oaknin</u> ¹ , <u>K. Moore</u> ² , <u>I. Colombo</u> ³ , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ³ EOC - Ospedale Regionale di Bellinzona e Valli, San Giovanni, Bellinzona, CH	



13:00 - 14:30	Type: Patient Advocacy session Title: Living with and after cancer Chair(s): André Deschamps, BE; Natacha Bolanos Fernandez, ES	Cádiz Auditorium - NCC
13:00 - 13:15	Resilience is key after diagnosis, during treatment, and after treatment <u>N. Bolanos Fernandez</u> , Lymphoma Coalition, Madrid, ES	
13:15 - 13:30	Behavioural changes in daily life: A cross-cutting approach for daily wellbeing <u>J. Kufel-Grabowska</u> , Wielkopolskie Centrum Onkologii, Poznan, PL	
13:30 - 13:45	Quality of life and survivorship <u>M. Die-Trill</u> , Atrium: Psycho-Oncology & Clinical Psychology, Madrid, ES	
13:45 - 14:00	Palliative and supportive care <u>C. Ostgathe</u> , Universität Erlangen-Nürnberg, Nürnberg, DE	
14:00 - 14:15	Reducing inequalities in Europe through robust national cancer control plans that include palliative care <u>T. Albreht</u> , National Institute of Public Health of Slovenia - Nacionalni institut za javno zdravje, Ljubljana, SI	
14:15 - 14:25	Discussion	
14:25 - 14:30	Conclusion	



14:45 - 16:15	Type: Special symposium Title: Finding the positive in triple negative breast cancer Chair(s): Andrew Tutt, GB; Eva Ciruelos, ES	Barcelona Auditorium - Hall 9
14:45 - 14:50	Introduction and scientific background <u>E. Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
14:50 - 15:05	Integrative multiomics analysis to dissect TNBC <u>S.J. Sammut</u> , CRUK - Cancer Research UK Cambridge Institute - University of Cambridge, Cambridge, GB	
15:05 - 15:20	Targeting DNA damage response <u>A. Tutt</u> , ICR - Institute of Cancer Research, London, GB	
15:20 - 15:35	Predicting response or resistance to IO <u>G. Bianchini</u> , IRCCS Ospedale San Raffaele, Milan, IT	
15:35 - 15:50	Emerging targets in TNBC <u>M. Arnedos</u> , Institute Bergonié, Bordeaux, FR	
15:50 - 16:10	Discussion	
16:10 - 16:15	Conclusions and perspectives <u>A. Tutt</u> , ICR - Institute of Cancer Research, London, GB	



14:45 - 16:15	Type: Special symposium Title: Molecular profiling of gynaecological cancers for therapeutic stratification Chair(s): David SP Tan, SG; Clare Scott, AU	Sevilla Auditorium - Hall 9
14:45 - 14:50	Introduction and scientific background <u>D.S. Tan</u> , NUHS - National University Health System, Singapore, SG	
14:50 - 15:05	Molecular profiling of gynaecological cancers: A pathologist's view <u>G. Mccluggage</u> , Royal Victoria Hospital - Belfast Health and Social Care Trust HSC, Belfast, GB	
15:05 - 15:20	Endometrial cancer <u>V. Makker</u> , Memorial Sloan-Kettering Cancer Center, New York City, US	
15:20 - 15:35	Ovarian and rare gynaecological cancers <u>C. Scott</u> , Walter and Eliza Hall Institute WEHI, Parkville, AU	
15:35 - 15:50	Cervical cancer <u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, ES	
15:50 - 16:10	Discussion	
16:10 - 16:15	Conclusions and perspectives <u>D.S. Tan</u> , NUHS - National University Health System, Singapore, SG	



14:45 - 16:15	Type: Special session Title: ESMO Clinical Practice Guidelines 2 Chair(s): Giuseppe Curigliano, IT; Emanuela Romano, FR	Bilbao Auditorium - NCC
14:45 - 14:55	Non-oncogene-addicted metastatic NSCLC case presentation <u>M. Tagliamento</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
14:55 - 15:05	Non-oncogene-addicted metastatic NSCLC discussion <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
15:05 - 15:15	Q&A	
15:15 - 15:25	Recurrent/metastatic squamous cell carcinoma of the head and neck case presentation <u>C. Gurizzan</u> , Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT	
15:25 - 15:35	Recurrent/metastatic squamous cell carcinoma of the head and neck discussion <u>C. Even</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
15:35 - 15:45	Q&A	
15:45 - 15:55	Prostate cancer case presentation <u>C. Oing</u> , Newcastle University, Newcastle upon Tyne, GB	
15:55 - 16:05	Prostate cancer discussion <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
16:05 - 16:15	Q&A and Discussion	



14:45 - 16:15 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Managing stage III NSCLC in the era of IO
 Chair(s): Kersti Oselin, EE; Rafal Dziadziuszko, PL

14:45 - 14:50 **Presentation of case/condition**
J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

14:50 - 15:15 **Who should and shouldn't get surgery?**
J. Spicer, McGill University, Montreal, CA

15:15 - 15:40 **IO and chemotherapy before or after surgery?**
L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

15:40 - 16:05 **IO after or with chemoradiotherapy? For how long?**
J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:05 - 16:15 **Q&A and Discussion**

14:45 - 16:20 **Type: Mini Oral session** **Burgos Auditorium - Hall 3**
Title: Mini oral session - Gastrointestinal tumours, lower digestive
 Chair(s): Gunnar Folprecht, DE; Raghav Sundar, SG; Jeanne Tie, AU

14:45 - 14:50 **LBA30 - Panitumumab (P) + FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA). First results of the randomised phase II PANIRINOX-UCGI28 study**

T. Mazard¹, F. Ghiringhelli², A. Winter¹, C. De La Fouchardiere³, D. Botsen⁴, T. André⁵, J. Vanboeckstael⁶, M. Dos Santos⁷, J. Martin-Babau⁸, Y. Rinaldi⁹, L. Evesque¹⁰, S. Ellis¹¹, C. Gavaille¹², D. Smith¹³, M. Fonck¹⁴, D. Sefrioui¹⁵, V. Pezzella¹⁶, S. Nougaret¹, A.R. Thierry¹, O. Bouche¹⁷, ¹ICM - Institut du Cancer de Montpellier, Montpellier, Cedex, FR, ²Centre Georges-François Leclerc (Dijon), Dijon, FR, ³IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR, ⁴Institut Jean Godinot, Reims, FR, ⁵Hopital Saint-Antoine, Paris, FR, ⁶ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, ⁷Centre Francois Baclesse, Caen, FR, ⁸Hôpital Privé des Côtes d'Armor, Plérin, FR, ⁹Marseille European Hospital, Marseille, FR, ¹⁰Centre Anticancer Antoine Lacassagne, Nice, FR, ¹¹Centre Catalan d'Oncologie Clinique St. Pierre, Perpignan, FR, ¹²Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, ¹³Hopital Haut Leveque, Pessac, FR, ¹⁴Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, ¹⁵Hopital Charles-Nicolle - CHU de Rouen, Rouen, FR, ¹⁶Unicancer, Paris, Cedex, FR, ¹⁷CHU de Reims - Hôpital Robert Debré, Reims, Cedex, FR

14:50 - 14:55 **554MO - Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX in RAS wild-type patients with initially unresectable colorectal liver metastases: The TRICE randomized clinical trial**



Y. Li¹, D. Wang¹, C. Ren¹, S.-S. Li², W. Pat Fong¹, X. Wu¹, J. Xiao², Y. Yuan¹, B.-K. Li¹, P.-R. Ding¹, Z. Wang¹, F. Wang¹, Z. Pan¹, G. Chen¹, X.-Z. Wang³, L.-Y. Wang⁴, T. Chen⁴, T. Liu⁵, Y. Yuan⁶, R.-H. Xu¹, ¹Sun Yat-sen University Cancer Center, Guangzhou, CN, ²The 6th Affiliated Hospital of Sun Yat-Sen University, Guangzhou, CN, ³Shantou Central Hospital, Shantou, CN, ⁴Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN, ⁵Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ⁶The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, CN

14:55 - 15:00

555MO - Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13)

Y. Sunakawa¹, M. Shiozawa², T. Watanabe³, H. Ota⁴, H. Yasui⁵, M. Kochi⁶, D. Manaka⁷, H. Ohori⁸, T. Yamaguchi⁹, M. Matsuura¹⁰, Y. Shinohara¹¹, T. Miyake¹², T. Sagawa¹³, C. Tanaka¹⁴, S. Okamura¹⁵, M. Takeuchi¹⁶, W. Ichikawa¹⁷, M. Fujii¹⁸, A. Tsuji¹⁹, ¹St. Marianna University School of Medicine, Kawasaki, JP, ²Kanagawa Cancer Center, Yokohama, JP, ³Japanese Red Cross Society Himeji Hospital, Himeji, JP, ⁴Ikeda City Hospital, Ikeda, JP, ⁵Kobe City Medical Center General Hospital, Kobe, JP, ⁶Nihon University School of Medicine, Tokyo, JP, ⁷Kyoto-Katsura Hospital, Kyoto, JP, ⁸Japanese Red Cross Ishinomaki Hospital, Miyagi, Miyagi, JP, ⁹Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, JP, ¹⁰Kobe City Nishi-Kobe Medical Center, Kobe, JP, ¹¹JCHO - Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu, JP, ¹²Shiga University of Medical Science, Otsu, JP, ¹³Hokkaido Cancer Center, Sapporo, JP, ¹⁴Gifu Prefectural General Medical Center, Gifu, JP, ¹⁵Suita Municipal Hospital, Suita, JP, ¹⁶The University of Tokyo, Tokyo, JP, ¹⁷Showa University Fujigaoka Hospital, Yokohama, JP, ¹⁸Japan Clinical Cancer Research Organization, TOKYO, JP, ¹⁹Kagawa University Faculty of Medicine/Graduate School of Medicine, Miki, JP

15:00 - 15:15

Invited Discussant LBA30, 554MO and 555MO

G. Folprecht, Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE

15:15 - 15:20

LBA31 - Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: the NICHE-3 study

Y. Verschuur¹, J. Van Den Berg¹, S. Balduzzi¹, J. Van Blijderveen¹, S. Oosterling², P. Burger³, T. Aukema⁴, T. Vogten⁵, S. Dokter¹, R. Beets-Tan⁶, A. Lent⁷, G. Beets¹, M. Van Leerdam¹, J. Haanen¹, M. Chalabi¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Spaarne Hospital Hoofddorp, Hoofddorp, NL, ³Catharina Hospital Eindhoven, Eindhoven, NL, ⁴Hagaziekenhuis, Den Haag, NL, ⁵Tergooi Ziekenhuizen, Blaricum, NL, ⁶Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, ⁷OLVG Hospital, Amsterdam, NL

15:20 - 15:25

556MO - A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer

F. Wang¹, Y. Jin¹, H.-Y. Luo¹, W.-L. Guan¹, Y. Li¹, F. Wang¹, M. Qiu¹, L.-L. Liu², X. Hu³, Y. Zhang⁴, W. Fang², Z.-X. Wang¹, C. Ren¹, D. Wang¹, R.-H. Xu¹, ¹Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, CN, ²The First Affiliated Hospital, Zhejiang University School Of Medicine, Hangzhou, CN, ³The First Affiliated Hospital of



Guangxi Medical University, Nanning, CN, ⁴Cancer Hospital Affiliated to Harbin Medical University, Harbin, CN

- 15:25 - 15:30 **LBA32 - Pembrolizumab versus chemotherapy in microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): 5-year follow-up of the randomized phase 3 KEYNOTE-177 study**
- K.-K. Shiu¹, T. André², T.W. Kim³, B. Vittrup Jensen⁴, L.H. Jensen⁵, C. Punt⁶, D. Smith⁷, R. Garcia-Carbonero⁸, J. Alcaide-Garcia⁹, P. Gibbs¹⁰, C. De La Fouchardiere¹¹, F. Rivera¹², M.E. Elez Fernandez¹³, D. Le¹⁴, T. Yoshino¹⁵, Y. Zuo¹⁶, D. Fogelman¹⁷, D. Adelberg¹⁷, L. Diaz¹⁸, ¹University College Hospital, NHS Foundation Trust, London, GB, ²Sorbonne University, Saint-Antoine Hospital, AP-HP, INSERM 938, SIRIC CURAMUS, Paris, FR, ³Asan Medical Center, University of Ulsan, Seoul, KR, ⁴Herlev and Gentofte Hospital, Herlev, DK, ⁵University Hospital of Southern Denmark, Vejle, DK, ⁶Amsterdam University Medical Center, University of Amsterdam, Amsterdam Netherlands, and Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, NL, ⁷Bordeaux University Hospital, Bordeaux, FR, ⁸Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, ES, ⁹Hospitales Universitarios Regional y Virgen de la Victoria IBIMA, Malaga, ES, ¹⁰Western Health, St. Albans, AU, ¹¹Centre Léon Bérard, Lyon, FR, ¹²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, ES, ¹³Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁴Sydney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, US, ¹⁵National Cancer Center Hospital East, Kashiwa, JP, ¹⁶MSD China, Beijing, CN, ¹⁷Merck & Co., Inc., Rahway, US, ¹⁸Memorial Sloan Kettering Cancer Center, New York, US
- 15:30 - 15:35 **557MO - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial**
- C. Coutzac¹, F. Bigot², D. Vansteene³, M. Dos Santos⁴, F. Ghiringhelli⁵, B. You⁶, A. Lambert⁷, C. Gomez-Roca⁸, C. Abdeddaim⁹, C. Neuzillet¹⁰, E. Jeannot¹⁰, E. Guerini Rocco¹¹, G. Frige¹², L. Mazzarella¹², C. Dupain¹⁰, M. Kamal¹⁰, F. Legrand¹³, M. Jimenez¹⁴, T. Filleron¹⁵, C. Le Tourneau², ¹Centre Léon Bérard, Lyon, FR, ²ICO - Institut de Cancerologie de l'Ouest - Site Paul Papin, Angers, FR, ³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁴Centre Francois Baclesse, Caen, FR, ⁵Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁶Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ⁷Capsule Corp, Nancy, FR, ⁸Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR, ⁹Centre Oscar Lambret, Lille, FR, ¹⁰Institut Curie, Paris, FR, ¹¹IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, ¹²IEO - Istituto Europeo di Oncologia, Milan, IT, ¹³Unicancer, Paris, Cedex, FR, ¹⁴Unicancer, Paris, FR, ¹⁵Institut Claudius Regaud - IUCT Oncopole, Toulouse, Cedex, FR
- 15:35 - 15:50 **Invited Discussant LBA31, 556MO, LBA32 and 557MO**
- R. Sundar, NUHS - National University Health System, Singapore, SG
- 15:50 - 15:55 **558MO - Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)**
- Y. Nakamura¹, D. Kotani², M. Saori², H. Yukami³, J. Watanabe⁴, N. Akazawa⁵, K.



Kataoka⁶, K. Hirata⁷, K. Yamazaki⁸, K.-H. Yeh⁹, G. Laliotis¹⁰, V. Aushev¹⁰, A. Jurdi¹⁰, M. Kotaka¹¹, H. Bando², H. Taniguchi¹², I. Takemasa¹³, T. Kato¹⁴, T. Yoshino¹, E. Oki¹⁵,
¹National Cancer Center Hospital East, 柏市柏の葉--, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³Osaka Medical and Pharmaceutical University Hospital, Takatsuki, JP, ⁴Yokohama City University Medical Center, Yokohama, JP, ⁵Sendai City Medical Center Sendai Open Hospital, Sendai, JP, ⁶Hyogo College of Medicine, Nishinomiya, JP, ⁷University of Occupational and Environmental Health, Kitakyushu, JP, ⁸Shizuoka Cancer Center, Shizuoka, JP, ⁹NTUH - National Taiwan University Hospital, Taipei City, TW, ¹⁰Natera, Inc., San Carlos, US, ¹¹Sano Hospital-Gastrointestinal Cancer Centre, Kobe, JP, ¹²Aichi Cancer Center Hospital, Nagoya, JP, ¹³Sapporo Medical University School of Medicine, Sapporo, JP, ¹⁴National Hospital Organization Osaka National Hospital, Osaka, JP, ¹⁵Kyushu University - Graduate School of Medical Sciences - Faculty of Medical Sciences, Fukuoka, JP

15:55 - 16:00

559MO - Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: Individual patients' data pooled analysis from 4 phase II trials

D. Ciardiello¹, G. Mauri², D. Rossini³, V. Famiglietti⁴, G. Martini⁵, S. Napolitano⁵, S. Del Tufo⁴, M.G. Zampino⁶, A. Avallone⁷, F. Pietrantonio⁸, S. Lonardi⁹, D. Santini¹⁰, G. Masi¹¹, S. Siena¹², A. Bardelli¹³, F. Ciardiello⁵, C. Cremolini¹¹, A. Sartore Bianchi¹⁴, T. Troiani⁵, E. Martinelli⁵, ¹IEO, Milan, IT, ²IFOM, Milan, IT, ³Università di Pisa, Pisa, IT, ⁴Università degli Studi della Campania Luigi Vanvitelli, Caserta, IT, ⁵Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁶IEO - Istituto Europeo di Oncologia, Milan, IT, ⁷Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁸Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁹IIOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁰Università degli Studi di Roma la Sapienza - Facoltà di Medicina, Latina, IT, ¹¹AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ¹²UNIMI - Università degli Studi di Milano Statale, Milan, IT, ¹³IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ¹⁴Università degli Studi di Milano, Milan, IT

16:00 - 16:05

560MO - Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial

P. García Alfonso¹, M.E. Elez Fernandez², J. Soto Alsar¹, D. Paez³, A. Fernandez Montes⁴, B. Grana Suarez⁵, A. Salud⁶, A. Yubero Esteban⁷, M.A. Gomez España⁸, I. Macias Declara⁹, G.A. Quintero Aldana¹⁰, C. Lopez Lopez¹¹, T. Fernandez Rodriguez¹², M.C. Gravalos Castro¹³, E. González-Flores¹⁴, M. Guix Arnau¹⁵, B. García Paredes¹⁶, J.J. Reina Zoilo¹⁷, J. Sastre Varela¹⁶, E. Aranda Aguilar⁸, ¹Gregorio Marañón General University Hospital, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, Madrid, ES, ²Vall d'Hebron Barcelona Hospital Campus, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, ES, ³Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁴Complexo Hospitalario Universitario de Ourense, Ourense, ES, ⁵Hospital Universitario de A Coruña. Instituto Investigación Biomédica INIBIC, A Coruña, ES, ⁶Hospital de Lleida Arnau de Vilanova, Lleida, ES, ⁷Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ⁸Universidad de Córdoba, CIBERONC, Instituto de Salud Carlos III. Hospital Universitario Reina Sofía, Cordoba, ES, ⁹Hospital Parc Taulí de Sabadell, Barcelona, ES, ¹⁰Hospital Universitario Lucus Augusti (HULA), Lugo, ES, ¹¹Hospital Marqués de Valdecilla, IDIVAL, UNICAN, Santander, ES, ¹²Hospital Son Llatzer, Palma de Mallorca, ES, ¹³Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁴Hospital Universitario Virgen



de las Nieves, Granada, ES, ¹⁵Hospital del Mar, Barcelona, ES, ¹⁶Hospital Clínico San Carlos. Instituto de Investigación Hospital Clínico San Carlos (IdISSC), Universidad Complutense, Madrid, ES, ¹⁷Complejo Hospitalario Virgen de la Macarena, Seville, ES

16:05 - 16:20 **Invited Discussant 558MO, 559MO and 560MO**
J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU

14:45 - 16:15 **Type: Multidisciplinary session** **Valencia**
Title: Pancreatic cancer: Evidence based options to improve Auditorium - Hall
quality of life and extend survival 10
 Chair(s): Stephen Chan, HK; Radka Obermannova, CZ

14:45 - 14:50 **Case/Condition presentation**
S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

14:50 - 15:05 **Endoscopic management of obstructive jaundice: What clinicians should know?**
R. Tang, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

15:05 - 15:20 **Pain management and palliative care**
A. Epstein, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

15:20 - 15:35 **Malignant ascites**
J. Herre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB

15:35 - 15:50 **Nutrition and exercise**
R. Obermannova, Masaryk Memorial Cancer Institute, Brno, CZ

15:50 - 16:05 **Radiotherapy**
L. Dawson, Princess Margaret Cancer Centre, Toronto, CA

16:05 - 16:15 **Discussion**



14:45 - 16:15	Type: Educational session Title: Neoadjuvant and adjuvant therapy in genitourinary cancers Chair(s): Srikala Sridhar, CA; Axel Bex, GB	Salamanca Auditorium - Hall 3
14:45 - 15:05	State-of-the-art in adjuvant treatment of renal cell carcinoma <u>G.A. De Velasco Oria</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
15:05 - 15:25	State-of-the-art in adjuvant treatment of urothelial cancer <u>M. De Santis</u> , Charité - Universitätsmedizin Berlin, Berlin, DE	
15:25 - 15:45	Interpretation of current peri-operative trial designs and endpoints <u>S. Sridhar</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
15:45 - 16:05	Global access considerations in systemic treatment of genitourinary cancers <u>F.A. Barros Schutz</u> , Beneficencia Portuguesa de Sao Paulo - BP Mirante, Sao Paulo, BR	
16:05 - 16:15	Discussion	



14:45 - 16:15 **Type: Multidisciplinary session** **Málaga Auditorium - Hall 10**
Title: Early-stage (II/III) melanoma: Risk stratification and treatment decisions
 Chair(s): Mathilde Jalving, NL; Dirk Schadendorf, DE

14:45 - 14:50 **Presentation of case/condition**
P. Sobczuk, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

14:50 - 15:05 **A pathologist's perspective: What to look for and how to report it**
B. Bastian, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

15:05 - 15:20 **A dermatologist's perspective: Secondary prevention and risk stratifications strategies**
D. Schadendorf, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

15:20 - 15:35 **Further development of the clinical case: A surgeon's perspective - Do we still need surgery in the era of risk scores stratification and systemic therapy?**
A. Van Akkooi, Melanoma Institute Australia, Wollstonecraft, AU

15:35 - 15:50 **Further development of the clinical case: A medical oncologist's perspective - Do all patients need adjuvant systemic therapy and how does this influences therapy in advanced setting?**
M. Jalving, UMCG - University Medical Center Groningen, Groningen, NL

15:50 - 16:15 **Discussion**

14:45 - 16:15 **Type: Educational session** **Santander Auditorium - Hall 9**
Title: Intensification vs deescalation of therapy in H&N cancer: When and for whom?
 Chair(s): Amanda Psyrrri, GR; Jens Peter Klussmann, DE

14:45 - 15:10 **Novel strategies to de-escalate surgery**
R. Ferris, University of Pittsburgh Cancer Institute, Pittsburgh, US

15:10 - 15:35 **De-escalation in radiation and systemic therapy**
A. Psyrrri, Attikon University Hospital, Haidari, GR

15:35 - 16:00 **Which patients need more intensive treatment?**
J. Bourhis, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

16:00 - 16:15 **Q&A and Discussion**



14:45 - 16:15 **Type: Special symposium** **Oviedo Auditorium - Hall 7**
Title: Advances in our understanding of paraganglioma / pheochromocytoma
 Chair(s): Margot Tesselaar, NL; Patricia Dahia, US

- 14:45 - 14:50 **Introduction and scientific background**
M. Tesselaar, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 14:50 - 15:05 **The genetics of paraganglioma (PPGL) and implications for testing and screening**
M. Robledo, CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES
- 15:05 - 15:20 **Perioperative considerations and management of localised disease**
M. Tesselaar, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 15:20 - 15:35 **Targeted radionuclide therapy for advanced disease/theranostics**
J. Kunikowska, University of Warsaw, Warsaw, PL
- 15:35 - 15:50 **The treatment landscape for metastatic PPGL: Are we making progress?**
P. Dahia, UTHSCSA - University of Texas Health Science Center at San Antonio, San Antonio, US
- 15:50 - 16:10 **Discussion**
- 16:10 - 16:15 **Conclusions and perspectives**
P. Dahia, UTHSCSA - University of Texas Health Science Center at San Antonio, San Antonio, US



14:45 - 16:15 **Type: Special session** **León Auditorium - Hall 7**
Title: In collaboration with the MASCC - The multiple faces of fatigue in the cancer ecosystem
 Chair(s): Christina Ruhlmann, DK; Florian Scotté, FR

14:45 - 15:05 **The epidemiology, biology and aetiology of cancer-related fatigue**
F. Scotté, Institut Gustave Roussy, Villejuif, FR

15:05 - 15:25 **Fatigue in health care professionals: Another term for burnout?**
K. Punie, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:25 - 15:45 **Systemic anticancer therapy-related fatigue: Causes and management**
C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

15:45 - 16:05 **Fatigue related to emerging targeted anticancer therapeutics**
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

16:05 - 16:15 **Panel discussion / Q&A**

14:45 - 16:15 **Type: Educational session** **Cádiz Auditorium - NCC**
Title: Oncology drug trials: How can we bring true value for patients?
 Chair(s): Ian Tannock, CA; E.G. Elisabeth de Vries, NL

14:45 - 15:05 **Challenges, pitfalls and the way forward: Investigator's perspective**
I. Tannock, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

15:05 - 15:25 **Walking the tightrope without losing sight of the patient**
K. Yonemori, National Cancer Center - Tsukiji Campus, Chuo-ku, JP

15:25 - 15:40 **Clinical trials in oncology: What really matters to patients?**
T. Lang, Myeloma Patients Europe AISBL, Brussels, BE

15:40 - 16:00 **"Value" and what it really means for new cancer drugs**
A. Fojo, Columbia University, New York, US

16:00 - 16:15 **Q&A and Discussion**



14:45 - 17:45	Type: Young Oncologists session Title: YO Masterclass: Tackling new challenges facing young investigators Chair(s): Kok Haw Jonathan Lim, GB; Elizabeth Connolly, AU	Ávila Auditorium - NCC
14:45 - 15:10	Bridging the gap between basic science and clinical research <u>C. Serrano</u> , Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES	
15:10 - 15:25	Discussion	
15:25 - 15:50	Investigator-initiated trials: From design to activation <u>N. Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, DE	
15:50 - 16:05	Discussion	
16:05 - 16:25	Coffee break	
16:25 - 16:50	Preprints from medRxiv and bioRxiv: Should I trust them? <u>L. Rowett</u> , ESMO - European Society for Medical Oncology, Lugano, CH	
16:50 - 17:05	Discussion	
17:05 - 17:30	Interpreting clinical trial data: How to understand subgroup analyses <u>S. Brown</u> , University of Leeds - Leeds Institute of Molecular Medicine (LIMM), Leeds, GB	
17:30 - 17:45	Discussion	



15:00 - 15:45 **Type: Challenge your Expert** **Toledo**
Title: The control centre in immune defence: The tertiary **Auditorium - Hall**
lymphoid structure in tumours **3**
Chair(s): Daniela Thommen, NL

15:00 - 15:20 **Presentation by Expert**
C. Sautes-Fridman, Centre de Recherche des Cordeliers, Paris, FR

15:20 - 15:45 **Discussion led by Chair**
D. Thommen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL



15:00 - 16:30 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: Palliative and end-of-life care
 Chair(s): Tugba Pehlivan Saribudak, TR

15:00 - 15:15 **Co-design of a web-based resource for head and neck cancer patients using the person-based approach**
C. Semple, Ulster Hospital - South Eastern Health and Social Care Trust, Dundonald, GB

15:15 - 15:30 **Managing Cancer and Living Meaningfully (CALM) for oncology nurses**
M. Van Klinken, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

15:30 - 15:45 **The journey of persons with genitourinary malignancies: Nurses' perspective on supportive and palliative care**
S. Terzoni, Ospedale San Paolo - ASST Santi Paolo e Carlo, Milan, IT

15:45 - 15:55 **CN25 - Psycho-education and telephone counselling on the quality of life of advanced cancer patients undergoing chemotherapy in Indonesia**
N. Huda, W.N. Dewi, H. Deli, Universitas Riau, Pekanbaru, ID

15:55 - 16:05 **CN26 - Healthcare professionals' perceptions on palliative care in onco-haematological area: Validation of the palliative care perception instrument**
 T. Buttiron Webber¹, G. Pegoraro², I. Lima², G. Catania², M. Calzolari², M. Zanini², L. Sasso², A. Bagnasco², ¹Ente Ospedaliero Ospedali Galliera, Genova, IT, ²University of Genoa, Genova, IT

16:05 - 16:15 **CN27 - Pain in men with metastatic castration-resistant prostate cancer (mCRPC) starting their first-line of life prolonging treatment: A cross sectional study in Sweden**
U. Rönningås¹, M. Holm², P. Fransson³, L. Beckman⁴, A. Wennman-Larsen¹, ¹Karolinska Institutet, Stockholm, SE, ²Sophiahemmet Universty, Stockholm, SE, ³Umea University, Umea, SE, ⁴Sundsvalls sjukhus, Sundsvall, SE

16:15 - 16:30 **Q&A and discussion**

16:30 - 18:00 **Type: Mini Oral session** **Burgos Auditorium - Hall 3**
Title: Mini oral session - NETs and endocrine tumours
 Chair(s): Mauro Cives, IT; Sara De Dosso, CH; Jaydira Del Rivero, US

16:30 - 16:35 **2211MO - Uncovering the mechanisms of persistent disease in RET-altered thyroid cancers: Insights from patient-derived xenograft models treated with selective RET inhibitors**
A. Garcia Alvarez¹, J. Hernando², I. Chicote², J. Martínez-Quintanilla³, A. Carmona³, C. Iglesias¹, X. Serres Créixams¹, J. Jimenez⁴, P. Nuciforo⁴, S. Aguilar Izquierdo¹, J. Gonzalo⁴, A. Vivancos¹, H.G. Palmer³, J. Capdevila Castillon¹, ¹Vall d'Hebron University



Hospital, Barcelona, ES, ²Hospital Universitario Vall d'Hebron, Vall d'Hebron Institut of Oncology (VHIO), Barcelona, ES, ³VHIO - Vall d'Hebron Institute of Oncology, Barcelona, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

- 16:35 - 16:40 **1183MO - Molecular characterization of rectal neuroendocrine tumors (NETs) with unfavorable prognosis by multiomics analysis: A multicenter retrospective cohort study (GARNET)**
- T. Shibuki¹, N. Mizuno², N. Kobayashi³, H. Hirano⁴, T. Tsuchikawa⁵, S. Matsumoto⁶, H. Okuyama⁷, E. Sasaki⁸, K. Shinjo⁹, R. Yamaguchi¹⁰, T. Kawata¹¹, W. Hosoda², ¹National Cancer Center Hospital East, Chiba, JP, ²Aichi Cancer Center Hospital, Aichi, JP, ³Yokohama City University Hospital, Kanagawa, JP, ⁴National Cancer Center Hospital, Tokyo, JP, ⁵Hokkaido University Hospital, Hokkaido, JP, ⁶Kyoto University Hospital, Kyoto, JP, ⁷Kagawa University Hospital, Kagawa, JP, ⁸Fukushima Medical University Hospital, Fukushima, JP, ⁹Nagoya University Graduate School of Medicine, Aichi, JP, ¹⁰Aichi Cancer Center Research Institute, Aichi, JP, ¹¹Novartis Pharma K.K., Tokyo, JP
- 16:40 - 16:55 **Invited Discussant 2211MO and 1183MO**
- M. Cives, Università degli Studi di Bari Aldo Moro, Bari, IT
- 16:55 - 17:00 **1184MO - Safety and efficacy of everolimus (EVE) as second-line treatment in neuroendocrine neoplasms G3 (NEN G3): An AIO phase II study (EVINEC)**
- M. Pavel¹, L. Fischer Von Weikersthal², G. Klöppel³, K. Krause⁴, L. Apostolidis⁵, ¹Universitätsklinik Erlangen, Erlangen, DE, ²Klinikum St. Marien Amberg, Amberg, DE, ³Technical University Munich, München, DE, ⁴AIO-Studien-gGmbH, Berlin, DE, ⁵National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE
- 17:00 - 17:05 **1185MO - Activity and safety of avelumab alone or in combination with cabozantinib in patients with advanced high grade neuroendocrine neoplasias (NEN G3) progressing after chemotherapy. The phase II, open-label, multicenter AVENEC and CABOAVENEC trials**
- M.M. Weber¹, L. Apostolidis², S. Krug³, A. Rinke⁴, B. Gruen², P. Michl⁵, T. Gress⁴, D. Wagner¹, W. Roth¹, E. Mettler¹, C. Ruckes¹, P. Galle¹, C. Fottner⁶, ¹Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ²National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, DE, ³UKH - Universitätsklinikum Halle (Saale), Halle (Saale), DE, ⁴UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ⁵UKHD - Universitätsklinikum Heidelberg, Heidelberg, DE, ⁶Universitätsmedizin Mainz, Mainz, DE
- 17:05 - 17:10 **725MO - Phase I trial of the DLL3/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumours: Focus on neuroendocrine carcinomas**
- V. Gambardella¹, J. Capdevila Castillon², Y. Kuboki³, O. Alese⁴, D. Morgensztern⁵, C.M. Sayehli⁶, M.F. Sanmamed⁷, E. Arriola⁸, Z. Oum'Hamed⁹, E. Song¹⁰, M. Studeny¹¹, M. Wermke¹², ¹Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, ES, ²Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ³National Cancer Center Hospital East, Kashiwa, JP, ⁴Winship Cancer Institute of Emory University, Atlanta, US, ⁵Washington University School of Medicine, St. Louis, US, ⁶Medical Clinic and Polyclinic II of the



University Hospital, Würzburg, DE, ⁷Clínica Universidad de Navarra, Pamplona, ES, ⁸Hospital del Mar - CIBERONC (Centro de Investigación Biomédica en Red de Oncología), Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, ES, ⁹Boehringer Ingelheim France SAS, Paris, FR, ¹⁰Boehringer Ingelheim (China) Investment Co., Shanghai, CN, ¹¹Boehringer Ingelheim International GmbH, Ingelheim, DE, ¹²NCT/UCC Early Clinical Trial Unit, Dresden, DE

- 17:10 - 17:25 **Invited Discussant 1184MO, 1185MO and 725MO**
S. De Dosso, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH
- 17:25 - 17:30 **1186MO - A prospective phase II single-arm trial on neoadjuvant peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE followed by surgery for pancreatic neuroendocrine tumors (NeoLuPaNET)**
S. Partelli¹, L. Landoni², M. Bartolomei³, A. Zerbi⁴, C. Grana⁵, U. Boggi⁶, G. Butturini⁷, R. Casadei⁸, C. Bassi², M. Falconi⁹, ¹UniSR - Università Vita e Salute San Raffaele Milano, Milan, IT, ²AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT, ³Arcispedale Sant'Anna - AOU di Ferrara, Ferrara, IT, ⁴Department of Biomedical Sciences, Humanitas University, Milan, IT, ⁵IEO - Istituto Europeo di Oncologia, Milan, IT, ⁶Azienda Ospedaliero-Universitaria Pisana, Pisa, IT, ⁷Ospedale P. Pederzoli Casa di Cura Privata Spa, Peschiera Del Garda, IT, ⁸University of Bologna - Alma Mater Studiorum, Bologna, IT, ⁹IRCCS Ospedale San Raffaele, Milan, IT
- 17:30 - 17:35 **2212MO - Major secondary outcomes in the multicentre noninferiority randomised trial IoN: Is ablative radioiodine necessary for low-risk differentiated thyroid cancer patients?**
A. Hackshaw¹, K. Newbold², M. Beasley³, K. Garcez⁴, J. Wadsley⁵, S. Johnson⁶, T. Stephenson⁷, M. Gaze⁸, A. Goodman⁹, S. Jeffries¹⁰, D. Wilkinson¹¹, E. Macias¹², D. Power¹³, T. Roques¹⁴, L. Speed¹⁵, G. Gerrard¹⁶, S. Forsyth¹, E. Chang¹, K. Farnell¹⁷, U. Mallick¹⁸, ¹Cancer Research UK & University College London Cancer Trials Centre, London, GB, ²The Royal Marsden Hospital (Sutton), Sutton, GB, ³BHOC - Bristol Haematology and Oncology Centre, Bristol, GB, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ⁶Newcastle General Hospital Northern Centre for Cancer Treatment, Newcastle-upon-Tyne, GB, ⁷Northern General Hospital-Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ⁸University College London Hospitals NHS Foundation Trust, London, GB, ⁹RD&E - Royal Devon and Exeter Hospital (Wonford), Exeter, GB, ¹⁰Addenbrooke's Hospital, Cambridge, GB, ¹¹The James Cook University Hospital, Middlesbrough, GB, ¹²Kent and Canterbury Hospital, Canterbury, GB, ¹³St. Mary's Hospital Imperial College Healthcare NHS Trust, London, GB, ¹⁴Norfolk and Norwich University Hospital NHS Foundation Trust, Norwich, GB, ¹⁵Leicester Royal Infirmary, Leicester, GB, ¹⁶Leeds Cancer Centre, Leeds, GB, ¹⁷Butterfly Thyroid Cancer Trust, Newcastle, GB, ¹⁸Newcastle Freeman Hospital - Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, GB
- 17:35 - 17:40 **1187MO - Does the ENDOCAN-COMETE network improves the survival of adrenocortical carcinomas in France?**
R. Libe¹, G. Coureau², A.-S. Foucan², M. Haissaguerre³, D. Drui⁴, S. Grunenwald⁵, F.



Castinetti⁶, S. Laboureaux⁷, C. Docao⁸, F. Borson-Chazot⁹, B. Goichot¹⁰, L. Lamartina¹¹, O. Chabre¹², S. Moog¹¹, J. Bertherat¹³, A. Tabarin¹⁴, M. Faron¹⁵, E. Baudin¹¹, ¹Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, ²CHU - Centre Universitaire Hospitalier de Bordeaux, Bordeaux, FR, ³CHU de Bordeaux-Hôpital Haut-Lévêque, Pessac, FR, ⁴CHU de Nantes, Hôtel Dieu, Nantes, FR, ⁵Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ⁶Aix-Marseille University - Faculté de Médecine - Timone, Marseille, FR, ⁷CHU Angers, Angers, Cedex, FR, ⁸CHU Lille - Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ⁹Hospices Civils de Lyon, Bron, FR, ¹⁰Hopital de Hautepierre - Hopitaux Universitaires de Strasbourg, Strasbourg, FR, ¹¹Gustave Roussy - Cancer Campus, Villejuif, FR, ¹²CHU Grenoble Alpes - Site Nord (La Tronche), La Tronche, FR, ¹³Institut Cochin, Paris, FR, ¹⁴University of Bordeaux, Bordeaux, FR, ¹⁵Institut Gustave Roussy, Villejuif, FR

17:40 - 17:55 **Invited Discussant 1186MO, 2212MO and 1187MO**

J. Del Rivero, NIH - National Institutes of Health, Bethesda, US

**16:30 - 18:15 Type: Proffered Paper session
Title: Presidential 2**

Madrid Auditorium - Hall 6

Chair(s): Andres Cervantes, ES; Silke Gillessen, CH

16:30 - 16:42 **LBA6 - EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV+P) Vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced Metastatic Urothelial Carcinoma (la/mUC)**

T. Powles¹, B. Perez Valderrama², S. Gupta³, J. Bedke⁴, E. Kikuchi⁵, J. Hoffman-Censits⁶, G. Iyer⁷, C. Vulsteke⁸, S.H. Park⁹, S.J. Shin¹⁰, D. Castellano Gauna¹¹, G. Fornarini¹², J.-R. Li¹³, M. Gumus¹⁴, N. Mar¹⁵, S. Narayanan¹⁶, X. Yu¹⁶, S. Gorla¹⁷, B. Homet Moreno¹⁸, M. Van Der Heijden¹⁹, ¹Saint Barts Cancer Institute, Queen Mary University of London,, London, GB, ²Hospital Universitario Virgen del Rocio, Seville, ES, ³Taussig Cancer Center-Cleveland Clinic, Cleveland, US, ⁴Klinikum Stuttgart Katharinenhospital (KH), Stuttgart, DE, ⁵St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, JP, ⁶Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, ⁷Memorial Sloan Kettering Cancer Center, New York, US, ⁸AZ Maria Middelaes AZMMSJ, Gent, BE, ⁹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ¹⁰Yonsei University College of Medicine, Seoul, KR, ¹¹Hospital Universitario 12 de Octubre, Madrid, ES, ¹²Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, IT, ¹³Taichung Veterans General Hospital, Taichung City, TW, ¹⁴Istanbul Medeniyet University, Yalcin City Hospital, Istanbul, TR, ¹⁵UCI Health - University of California Irvine, Orange, US, ¹⁶Seagen Inc., Bothell, US, ¹⁷Astellas Pharma USA, Northbrook, US, ¹⁸Merck, Rahway, US, ¹⁹Netherlands Cancer Institute, Amsterdam, NL

16:42 - 16:54 **LBA7 - Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial**

M. Van Der Heijden¹, G. Sonpavde², T. Powles³, A. Necchi⁴, M. Burotto⁵, M. Schenker⁶, J.P. Sade⁷, A. Bamias⁸, P. Beuzeboc⁹, J. Bedke¹⁰, J. Oldenburg¹¹, Y. Urun¹², D. Ye¹³, Z. He¹⁴, B. Perez Valderrama¹⁵, Y. Tomita¹⁶, J. Filian¹⁷, D. Purcea¹⁸, F. Nasroulah¹⁷, M. Galsky¹⁹, ¹Netherlands Cancer Institute, Amsterdam, NL, ²Dana-Farber Cancer Institute,



Harvard Medical School, Boston, US, ³Barts Cancer Institute, Queen Mary University of London, London, GB, ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ⁵Bradford Hill-Clinical Center, Santiago, CL, ⁶Sf. Nectarie Oncology Center Craiova, Craiova, RO, ⁷Alexander Fleming Institute, Buenos Aires, AR, ⁸National & Kapodistrian University of Athens, ATTIKON University Hospital, Athens, GR, ⁹Hopital Foch, Suresnes, FR, ¹⁰Eberhard Karls University Tübingen, Tübingen, DE, ¹¹Akershus University Hospital (Ahus), Lorenskog, NO, ¹²Ankara University, Ankara, TR, ¹³Fudan University Shanghai Cancer Center, Shanghai, CN, ¹⁴Peking University First Hospital, Beijing, CN, ¹⁵Hospital Universitario Virgen del Rocío, Seville, ES, ¹⁶Niigata University Graduate School of Medical and Dental Sciences, Niigata, JP, ¹⁷Bristol Myers Squibb, Princeton, US, ¹⁸Bristol Myers Squibb, Boudry, CH, ¹⁹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US

16:54 - 17:04 **Invited Discussant LBA6 and LBA7**

A. Apolo, National Cancer Institute, Bethesda, US

17:04 - 17:10 **Q&A**

17:10 - 17:22 **LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial**

M. McCormack¹, D. Gallardo Rincón², G. Eminowicz³, P. Diez⁴, L. Farrelly⁵, C. Kent⁶, E. Hudson⁷, M. Panades⁸, T. Mathews⁹, A. Anand¹⁰, M. Persic¹¹, J. Forrest¹², R. Bhana¹³, N. Reed¹⁴, A. Drake¹⁵, H. Stobart¹⁶, A. Mukhopadhyay¹⁷, A.M. Hacker¹⁸, A. Hackshaw⁵, J. Ledermann¹⁹, ¹University College London Hospital, London, GB, ²The National Cancer Institute, Ciudad de Mexico, MX, ³UCH - University College Hospital, London, GB, ⁴Mount Vernon Cancer Centre, Northwood, GB, ⁵Cancer Research UK & University College London Cancer Trials Centre, London, GB, ⁶Leicester Royal Infirmary - University Hospitals of Leicester NHS Trust, Leicester, GB, ⁷Velindre Cancer Centre - Velindre NHS University Trust - NHS Wales, Cardiff, GB, ⁸United Lincolnshire Hospitals - Lincoln County Hospital, Lincoln, GB, ⁹Northern General Hospital-Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, ¹⁰Nottingham City Hospital, Nottingham, GB, ¹¹Royal Derby Hospital - University Hospitals of Derby and Burton NHS Foundation Trust, Derby, GB, ¹²Royal Devon and Exeter NHS Hospital (Wonford) - Royal Devon and Exeter Foundation Trust, Exeter, GB, ¹³Royal Stoke University Hospital, Stoke-on-Trent, GB, ¹⁴BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, ¹⁵Belfast City Hospital - Belfast Health & Social Care Trust, Belfast, GB, ¹⁶Independent Cancer Patients Voice, London, GB, ¹⁷CNCI - Chittaranja National Cancer Institute, Kolkata, IN, ¹⁸UCL - University College London, London, GB, ¹⁹UCL Cancer Institute - UCL - London's Global University, London, GB

17:22 - 17:34 **LBA9 - innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator's Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer**

I. Vergote¹, A. Gonzalez Martin², K. Fujiwara³, E. Kalbacher⁴, A. Bagameri⁵, S. Ghamande⁶, J.-Y. Lee⁷, S. Banerjee⁸, F. Maluf⁹, D. Lorusso¹⁰, K. Yonemori¹¹, E. Van



Nieuwenhuysen¹, L. Manso¹², L. Woelber¹³, A. Westermann¹⁴, A. Covens¹⁵, E. Whalley¹⁶, M.S.L. Teng¹⁶, I. Soumaoro¹⁷, B. Slomovitz¹⁸, ¹Universitaire Ziekenhuizen Leuven, Katholieke Universiteit Leuven, and Belgium and Luxembourg Gynaecological Oncology Group, Belgium, European Union, Leuven, BE, ²Cancer Center Clinica Universidad de Navarra, Madrid, Spain and GEICO, Madrid, ES, ³Saitama Medical University International Medical Center, Saitama, JP, ⁴Centre Hospitalier Universitaire de Besançon, Besançon, FR, ⁵Országos Onkológiai Intézet, Budapest, HU, ⁶Georgia Cancer Center, August University, Augusta, US, ⁷Yonsei University College of Medicine, Seoul, KR, ⁸The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, ⁹Hospital Beneficencia Portuguesa of Sao Paulo, Sao Paulo, BR, ¹⁰Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome and Catholic University of Sacred Heart, Rome, IT, ¹¹National Cancer Center - Tsukiji Campus, Chuo-ku, JP, ¹²Hospital Universitario 12 de Octubre, Madrid, ES, ¹³Arbeitsgemeinschaft Gynäkologische Onkologie Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, DE, ¹⁴Amsterdam University Medical Centres, Amsterdam, NL, ¹⁵Sunnybrook Research Institute, Toronto, CA, ¹⁶Seagen Inc., Bothell, US, ¹⁷Genmab, Princeton, US, ¹⁸Mount Sinai Medical Center, Miami Beach, US

17:34 - 17:44 **Invited Discussant LBA8 and LBA9**

K. Tewari, UC Irvine Medical Center, Orange, US

17:44 - 17:50 **Q&A**

17:50 - 18:02 **LBA10 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase 3 study**

F. Pietrantonio¹, L. Salvatore², T. Esaki³, D. Modest⁴, D. Paez⁵, J. Taieb⁶, M. Karamouzis⁷, E. Ruiz⁸, T.W. Kim⁹, Y. Kuboki¹⁰, F. Meriggi¹¹, D. Cunningham¹², K.-H. Yeh¹³, E. Chan¹⁴, J. Chao¹⁵, N. Strydom¹⁶, Y. Saportas¹⁷, Q. Tran¹⁷, C. Cremolini¹⁸, M. Fakih¹⁹, ¹Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, ³National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ⁴Charité - Universitaetsmedizin Berlin, Berlin, DE, ⁵Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁶Hopital European George Pompidou, Paris, FR, ⁷National and Kapodistrian University of Athens - School of Medicine, Athens, GR, ⁸INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX, ⁹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ¹⁰National Cancer Center Hospital East, Kashiwa, JP, ¹¹Fondazione Poliambulanza Istituto Ospedaliero, Brescia, IT, ¹²The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, ¹³NTUH - National Taiwan University Hospital, Taipei City, TW, ¹⁴Amgen, Thousand Oaks, US, ¹⁵AMGEN - USA, Seattle, US, ¹⁶Amgen Inc - SSF, South San Francisco, US, ¹⁷AMGEN (Headquarters) - USA, Thousand Oaks, US, ¹⁸AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT, ¹⁹City of Hope Comprehensive Cancer Center, Duarte, US

18:02 - 18:10 **Invited Discussant LBA10**

M. Koopman, UMC - University Medical Center Utrecht, Utrecht, NL



18:10 - 18:15 **Q&A**

16:30 - 18:00 **Type: Educational session** **Valencia Auditorium - Hall 10**
Title: ESMO Guideline updates on supportive and palliative care
 Chair(s): Florian Scotté, FR; Christina Ruhlmann, DK

16:30 - 16:55 **Antiemetics**
J. Herrstedt, ZUH - Zealand University Hospital Roskilde - Region Sjælland, Roskilde, DK

16:55 - 17:20 **Anxiety, depression and insomnia**
R. Ródenas, Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES

17:20 - 17:45 **Prognostication in advanced cancer: Navigating the uncertainty**
P. Stone, University College London, London, GB

17:45 - 18:00 **Q&A and Discussion**

16:30 - 18:00 **Type: Proffered Paper session** **Toledo Auditorium - Hall 3**
Title: Proffered paper session - Haematological malignancies
 Chair(s): Davide Rossi, CH; Alessandra Tedeschi, IT

16:30 - 16:40 **8220 - Activation of CD39^{hi} CD4⁺ T cells by ICT01 as a novel immunotherapeutic approach for relapsed/refractory hematologic cancers (EVICTION trial)**
S. Garciaz¹, S. Champiat², P. Peterlin³, K. Lemmens⁴, A. De Gassart⁴, P. Brune⁴, E. Valentin⁴, C. Leparquier⁵, M. Iche⁵, D. Olive⁶, N. Vey⁷, P. Frohna⁴, ¹Institut Paoli-Calmettes, Aix-Marseille University, Marseille, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³University Hospital of Nantes (Hôtel-Dieu - CHU de Nantes), Nantes, FR, ⁴ImCheck Therapeutics SAS, Marseille, Cedex, FR, ⁵Ilife Consulting, Argenteuil, FR, ⁶Centre de Recherche en Cancérologie de Marseille, Marseille, FR, ⁷IPC - Institut Paoli-Calmettes, Marseille, Cedex, FR

16:40 - 16:50 **8230 - Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)**
M. Jongen-Lavrencic¹, A. Bajel², S. Garciaz³, A. Maiti⁴, S. Fleming⁵, S. De Button⁶, G. A. Huls⁷, K. Jensen⁸, S. Ziti-Ljajic⁹, D. Draganov⁸, F. Rotolo¹⁰, C. Palu¹¹, J. Courta⁹, W. Passe-Coutrin⁹, K. Traudtner¹², T. Wagenaar⁸, G. Abbadessa⁸, A. Selwyn Stein¹³, ¹Erasmus University Medical Center, Rotterdam, NL, ²Peter MacCallum Cancer Center and Royal Melbourne Hospital, Melbourne, AU, ³Institut Paoli-Calmettes, Aix-Marseille University, Marseille, FR, ⁴MD Anderson Cancer Center, Houston, US, ⁵Alfred Health, Melbourne, AU, ⁶Institut Gustave Roussy, Paris, FR, ⁷University Medical Center



Groningen, Groningen, NL, ⁸Sanofi, Cambridge, US, ⁹Sanofi, Chilly-Mazarin, FR, ¹⁰Sanofi, Montpellier, FR, ¹¹Sanofi, Cambridge, GB, ¹²Sanofi, Amsterdam, NL, ¹³City of Hope National Medical Center, Duarte, US

- 16:50 - 17:00 **Invited Discussant 8220 and 8230**
D. Rossi, EOC - Amministrazione IOSI, Bellinzona, CH
- 17:00 - 17:10 **Q&A**
- 17:10 - 17:20 **8240 - Treatment and survival in patients with localized primary ocular adnexal MALT lymphoma: A large bicentric cohort study**
L.-R. Gao¹, X. Li², X. Wang¹, Y. Wu¹, L. Wang², S. Qi¹, Y. Li¹, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Beijing TongRen Hospital, Capital Medical University, Beijing, CN
- 17:20 - 17:30 **8250 - Genomic traits of therapeutic response to anti-PD-1 therapy in peripheral T cell lymphoma**
N. Lou¹, M. Yang¹, X. Han², ¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²CAMS-PUMC - Chinese Academy of Medical Sciences and Peking Union Medical College - Dongdan Campus, Dongcheng-qu, CN
- 17:30 - 17:40 **8260 - A single-arm, multicenter clinical study of radiotherapy combined with toripalimab in stage I/II extranodal NK/T cell lymphoma**
M. Jiang, L. Liang, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN
- 17:40 - 17:50 **Invited Discussant 8240, 8250 and 8240**
O. Casasnovas, CHU Dijon, Dijon, FR
- 17:50 - 18:00 **Q&A**



16:30 - 18:00	Type: Patient Advocacy session Title: How does digitalisation help personalised care throughout the patient journey? Chair(s): Tanja Spanic, SI; Gregor Cuzak, SI	Cádiz Auditorium - NCC
16:30 - 16:45	Patients at the centre of the new digital solutions: HealthDay and personalised care <u>T. Spanic</u> , Europa Donna Slovenia, Ljubljana, SI	
16:45 - 17:00	New solutions for cancer patients <u>G. Cuzak</u> , Trokot d.o.o., Ljubljana, SI	
17:00 - 17:15	Saving life trough tracking symptoms and early detection of cancer recurrence: The importance of collecting data in registries <u>R. Cordoba Mascunano</u> , Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES	
17:15 - 17:30	Virtual nursing services: Data for healthier patient lives <u>H. Ullgren</u> , Karolinska University Hospital-Solna, Solna, SE	
17:30 - 17:45	New technologies in hospitals, improving patient experience <u>L. Kornowska</u> , Polish Federation of Hospitals, Warsaw, PL	
17:45 - 17:55	Discussion	
17:55 - 18:00	Conclusion	



16:45 - 17:45 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: ECL/EONS collaborative session - Let's break the taboo around cancer and sexuality: Improving communication and care
 Chair(s): Johan De Munter, BE

16:45 - 17:00 **How to improve communication and care for sexual wellbeing? Recommendations and tools for oncology professionals**
H. Neefs, Kom op tegen Kanker, Brussels, BE

17:00 - 17:15 **Cancer and sexuality in adolescents and young adults (AYAs)**
S. Sleeman, Association of European Cancer Leagues, Brussels, BE

17:15 - 17:25 **CN37 - Perceptions and attitudes of healthcare providers towards discussing sexuality and sexual problems in cancer patients (from LGBTQ+ backgrounds)**
C. Beyts¹, J. Verhelle¹, E. Pape², G. Van Ramshorst², ¹Ghent University - Campus Ufo, Gent, BE, ²UZ Gent - Universitair Ziekenhuis Gent, Gent, BE

17:25 - 17:45 **Q&A and discussion**

17:00 - 18:00 **Type: Controversy session** **Málaga Auditorium - Hall 10**
Title: PARP inhibitors for castration-resistant prostate cancer combined with an AR pathway inhibitor: One approach for all
 Chair(s): Elena Castro, ES

17:00 - 17:05 **Welcome and "set the scene"**
E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

17:05 - 17:20 **Pro**
N. Clarke, The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB

17:20 - 17:35 **Contra**
J. Mateo, Vall d'Hebron University Hospital, Barcelona, ES

17:35 - 17:40 **First voting**

17:40 - 17:55 **Perspective from the Chair**
E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

17:55 - 18:00 **Second voting**



18:30 - 20:00	Type: Industry Satellite Symposium Title: Sanofi Regeneron - Overcoming Therapeutic Challenges in Non-melanoma Skin Cancer: A Multidisciplinary Approach	Burgos Auditorium - Hall 3
	Chair(s): Paolo Ascierto, IT	

- 18:30 - 18:35 **Welcome and Introduction**
P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT
- 18:35 - 18:55 **Multidisciplinary management of non-melanoma skin cancer: Dermatological Standpoint**
C. Robert, Institut Gustave Roussy, Villejuif, Cedex, FR
- 18:55 - 19:15 **Multidisciplinary management of non-melanoma skin cancer: Oncological Approach**
P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT
- 19:15 - 19:35 **Multidisciplinary management of non-melanoma skin cancer: Surgical Perspective**
W. Van Houdt, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL
- 19:35 - 19:55 **Multidisciplinary management of non-melanoma skin cancer: Radiological Viewpoint**
S. Billan, Rambam Health Care Campus, Haifa, IL
- 19:55 - 20:00 **Summary and Close**
P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT



18:30 - 20:00 **Type: Industry Satellite Symposium** **Valencia Auditorium - Hall 10**
Title: Seagen - ADCs' Potential Across Tumors
Chair(s): Josep Tabernero, ES

18:30 - 18:33 **Welcome and Introduction**

J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

18:33 - 18:43 **ADC Technologies in Oncology**

J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES

18:43 - 19:13 **Emerging ADCs in Non-Small Cell Lung Cancer**

D. Planchard, Institut Gustave Roussy, Villejuif, Cedex, FR

19:13 - 19:28 **Advances in ADCs for Head and Neck Cancer**

L. Locati, ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano, Milan, IT

19:28 - 19:48 **Future Directions for ADCs in Urothelial Cancer**

T. Powles, St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

19:48 - 19:58 **Panel Discussion and Audience Q&A**

J. Tabernero¹, D. Planchard², L. Locati³, T. Powles⁴, ¹Vall d'Hebron University Hospital, Barcelona, ES, ²Institut Gustave Roussy, Villejuif, Cedex, FR, ³ICS Maugeri: Pazienti e Famiglie Istituti Clinici Scientifici - IRCCS Milano, Milan, IT, ⁴St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB

19:58 - 20:00 **Closing Remarks**

J. Tabernero, Vall d'Hebron University Hospital, Barcelona, ES



18:30 - 20:00	Type: Industry Satellite Symposium Title: AstraZeneca - Assessing therapeutic options for patients with hepatobiliary cancers: the role of immunotherapy-based regimens Chair(s): Stephen Chan, HK	Salamanca Auditorium - Hall 3
18:30 - 18:35	Welcome and introductions <u>S. Chan</u> , The Chinese University of Hong Kong - Sino Building, Sha Tin, HK	
18:35 - 18:55	Plenary: Integration of immunotherapy-based approaches in HCC and BTC <u>B. Sangro</u> , Clinica Universidad de Navarra, Pamplona, ES	
18:55 - 19:10	Panel discussion 1: Assessing long-term survivorship and prognostic factors in patients with hepatobiliary cancers <u>S. Chan</u> , The Chinese University of Hong Kong - Sino Building, Sha Tin, HK	
19:10 - 19:25	Case study discussion 1: Assessing patient outcomes in unresectable / advanced HCC <u>S. Chan</u> , The Chinese University of Hong Kong - Sino Building, Sha Tin, HK	
19:25 - 19:40	Case study discussion 2: Navigating clinical decision-making in advanced BTC <u>A. Casadei Gardini</u> , IRCCS Ospedale San Raffaele, Milan, IT	
19:40 - 19:55	Panel discussion 2: Current management of immune-mediated adverse events in patients with hepatobiliary cancers <u>S.P. Choo</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
19:55 - 20:00	Audience Q&A <u>S. Chan</u> ¹ , <u>S.P. Choo</u> ² , <u>B. Sangro</u> ³ , <u>A. Casadei Gardini</u> ⁴ , ¹ The Chinese University of Hong Kong - Sino Building, Sha Tin, HK, ² NCCS - National Cancer Centre Singapore, Singapore, SG, ³ Clinica Universidad de Navarra, Pamplona, ES, ⁴ IRCCS Ospedale San Raffaele, Milan, IT	



18:30 - 20:00	Type: Industry Satellite Symposium Title: Illumina - Detection of homologous recombination deficiency (HRD): Role of HRD testing and impact on patient management Chair(s): Frederique Penault-Llorca, FR	Málaga Auditorium - Hall 10
18:30 - 18:35	Introduction & Welcome <u>F. Penault-Llorca</u> , Jean Perrin Center, Clermont-Ferrand, FR	
18:35 - 18:55	The clinical value of HRD testing in ovarian cancer <u>D. Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT	
18:55 - 19:15	The value of biomarker testing for homologous recombination deficiency in prostate cancer <u>D. Olmos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
19:15 - 19:35	The role of HRD and related tests in cancer care <u>F. Penault-Llorca</u> , Jean Perrin Center, Clermont-Ferrand, FR	
19:35 - 19:55	The utility of HRD testing - current status and future trends <u>F. Barve</u> ¹ , <u>F. Penault-Llorca</u> ² , <u>D. Lorusso</u> ³ , <u>D. Olmos</u> ⁴ , ¹ CRUK - Cancer Research UK Cambridge Institute - University of Cambridge, Cambridge, GB, ² Jean Perrin Center, Clermont-Ferrand, FR, ³ Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, ⁴ Hospital Universitario 12 de Octubre, Madrid, ES	
19:55 - 20:00	Closing remarks <u>F. Penault-Llorca</u> , Jean Perrin Center, Clermont-Ferrand, FR	



18:30 - 20:00	Type: Industry Satellite Symposium Title: PeerVoice - The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualisation of Treatment Chair(s): Karim Fizazi, FR	Santander Auditorium - Hall 9
18:30 - 18:33	Welcome and Introduction <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
18:33 - 19:03	State of the Science, State of the Art: Are We Implementing Individualised and Evidence-Based Treatment Plans for mHSPC? <u>C. Gratzke</u> ¹ , <u>A. Morgans</u> ² , <u>K. Fizazi</u> ³ , ¹ University Medical Center Freiburg, Freiburg im Breisgau, DE, ² Dana Farber Cancer Institute, Boston, US, ³ Institut Gustave Roussy, Villejuif, Cedex, FR	
19:03 - 19:15	Audience Q&A: What's on Your Mind in mHSPC? <u>K. Fizazi</u> ¹ , <u>A. Morgans</u> ² , <u>C. Gratzke</u> ³ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Dana Farber Cancer Institute, Boston, US, ³ University Medical Center Freiburg, Freiburg im Breisgau, DE	
19:15 - 19:45	Mastering the Science and the Art: Are We Taking Advantage of Opportunities to Optimise Care and Outcomes in nmCRPC? <u>K. Fizazi</u> ¹ , <u>A. Morgans</u> ² , <u>C. Gratzke</u> ³ , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Dana Farber Cancer Institute, Boston, US, ³ University Medical Center Freiburg, Freiburg im Breisgau, DE	
19:45 - 19:57	Audience Q&A: Sharing Challenges and Solutions in nmCRPC <u>A. Morgans</u> ¹ , <u>K. Fizazi</u> ² , <u>C. Gratzke</u> ³ , ¹ Dana Farber Cancer Institute, Boston, US, ² Institut Gustave Roussy, Villejuif, Cedex, FR, ³ University Medical Center Freiburg, Freiburg im Breisgau, DE	
19:57 - 20:00	Final Remarks and Closing <u>K. Fizazi</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	



18:30 - 20:00	Type: Industry Satellite Symposium Title: Takeda - Navigating Treatment Choices In ALK+ mNSCLC: A Focus on Patient-Centered Decision Making Chair(s): Stephen Liu, US	Toledo Auditorium - Hall 3
18:30 - 18:35	Chair Introduction <u>S. Liu</u> , Lombardi Cancer Center Georgetown University, Washington, US	
18:35 - 18:55	Optimizing Molecular Testing and Diagnosis of NSCLC <u>R. Califano</u> , The Christie NHS Foundation Trust, Manchester, GB	
18:55 - 19:15	Quality of Life and Impact on Individuals Living With ALK+ mNSCLC <u>L. Mezquita</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
19:15 - 19:35	Current and Emerging Treatment Landscape in ALK+ mNSCLC <u>S. Liu</u> , Lombardi Cancer Center Georgetown University, Washington, US	
19:35 - 19:45	Panel Q&A <u>S. Liu</u> ¹ , <u>R. Califano</u> ² , <u>L. Mezquita</u> ³ , ¹ Lombardi Cancer Center Georgetown University, Washington, US, ² The Christie NHS Foundation Trust, Manchester, GB, ³ Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
19:45 - 20:00	A Conversation With an Individual Living With Lung Cancer: Perspectives on Testing and Quality of Life <u>S. Liu</u> ¹ , <u>Y. Diaz</u> ² , ¹ Lombardi Cancer Center Georgetown University, Washington, US, ² ALK+ International, London, GB	



18:30 - 20:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Eli Lilly and Company: Integrating molecular oncology in the care of patients with rare oncogene-driven non-small cell lung cancer Chair(s): Noemi Reguart Aransay, ES; Jürgen Wolf, DE	Oviedo Auditorium - Hall 7
18:30 - 18:40	Welcome and introduction <u>N. Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
18:40 - 19:00	The importance of next-generation sequencing (NGS) testing in non-small cell lung cancer: Science, implementation and timing <u>A. Stenzinger</u> , University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE	
19:00 - 19:20	The availability of molecular testing in Europe and its implications for state-of-the-art care for patients with lung cancer <u>A. Bayle</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
19:20 - 19:40	Targeting molecular aberrations beyond EGFR, ALK: Clinical evidence for efficacy and ongoing research <u>J. Wolf</u> , University Hospital of Cologne, Cologne, DE	
19:40 - 19:55	Q&A and discussion	
19:55 - 20:00	Concluding remarks <u>J. Wolf</u> , University Hospital of Cologne, Cologne, DE	



18:30 - 20:00 **Type: Industry Satellite Symposium** **León Auditorium - Hall 7**
Title: Daiichi Sankyo - The Multi-Tumor Toolkit: ADCs in Cancer Therapy
 Chair(s): Benjamin Levy, US

18:30 - 18:40 **ADC technology in cancer therapy**
B. Levy, Johns Hopkins University, Baltimore, US

18:40 - 19:05 **The role of ADCs in the lung treatment landscape**
M. Thomas, Thoraxklinik Heidelberg gGmbH, Heidelberg, DE

19:05 - 19:25 **The impact of ADCs on the breast cancer treatment landscape**
C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

19:25 - 19:40 **The current state and future potential of ADCs in other tumor types**
K. Shitara, National Cancer Center Hospital East, Kashiwa, JP

19:40 - 20:00 **Multi-tumor panel roundtable discussion and Q&A**
B. Levy¹, M. Thomas², C. Saura Manich³, K. Shitara⁴, ¹Johns Hopkins University, Baltimore, US, ²Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ³Vall d'Hebron University Hospital, Barcelona, ES, ⁴National Cancer Center Hospital East, Kashiwa, JP



23.10.2023

08:30 - 10:00 **Type: Proffered Paper session** **Barcelona Auditorium**
Title: Proffered Paper session 2 - Gastrointestinal **- Hall 9**
tumours, lower digestive

Chair(s): Dominik Modest, DE; Clara Montagut Viladot, ES

- 08:30 - 08:40 **5520 - FOxTROT: Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel**
- J. Seligmann¹, D. Morton², M. Seymour³, F. Elliott³, K. Handley⁴, B. Glimelius⁵, C. Williams³, G. Hemmings⁶, D. Bottomley⁷, R. Gray⁸, P. Quirke³, L. Magill⁴, A. Beggs², N. West⁹, ¹University of Leeds, leeds, GB, ²The University of Birmingham - Medical School, leeds, GB, ³UL - University of Leeds, leeds, GB, ⁴The University of Birmingham - Institute for Cancer Studies, leeds, GB, ⁵Akademiska Sjukhuset Uppsala, leeds, GB, ⁶University of Leeds - Institute of Cancer and Pathology (LICAP), Leeds, GB, ⁷UL - University of Leeds, Leeds, GB, ⁸University of Oxford, leeds, GB, ⁹St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, leeds, GB
- 08:40 - 08:50 **LBA27 - First-line systemic treatment in patients with initially unresectable colorectal cancer liver metastases (CRLM): overall survival of the phase III CAIRO5 study of the Dutch Colorectal Cancer Group**
- C. Punt¹, M. Bond¹, K. Bolhuis², O. Loosveld³, J.W. De Groot⁴, H. Droogendijk⁵, H. Helgason⁶, M. Hendriks⁷, J. Klaase⁸, G. Kazemier⁹, M. Liem¹⁰, A. Rijken³, C. Verhoef¹¹, J. De Wilt¹², K. De Jong⁸, M. Van Amerongen¹³, B. De Valk¹⁴, E. Kerver¹⁵, A. Komurcu¹⁶, R.-J. Swijnenburg⁹, ¹University Medical Center Utrecht, Utrecht, NL, ²The Netherlands Cancer Institute, Amsterdam, NL, ³Amphia Ziekenhuis, Breda, NL, ⁴Isala, Zwolle, NL, ⁵Bravis Ziekenhuis, Roosendaal, NL, ⁶Haaglanden Medisch Centrum, Den Haag, NL, ⁷Noordwest Ziekenhuisgroep, Alkmaar, NL, ⁸University Medical Center Groningen, Groningen, NL, ⁹Amsterdam UMC, Amsterdam, NL, ¹⁰Medisch Spectrum Twente, Enschede, NL, ¹¹Erasmus MC, Rotterdam, NL, ¹²Radboud University Medical Center, Nijmegen, NL, ¹³Sint Maartenskliniek, Woerden, NL, ¹⁴Spaarne Gasthuis, Hoofddorp, NL, ¹⁵OLVG Hospital, Amsterdam, NL, ¹⁶IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL
- 08:50 - 09:00 **Invited Discussant 5520 and LBA27**
- D. Modest, Charité - Universitaetsmedizin Berlin, Berlin, DE
- 09:00 - 09:10 **Q&A**
- 09:10 - 09:20 **LBA28 - The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients**
- S. Lonardi¹, F. Pietrantonio², N. Tarazona Llaverro³, C. Montagut Viladot⁴, A. Sartore Bianchi⁵, M.G. Zampino⁶, M.E. Elez Fernandez⁷, C. Santos Vivas⁸, M. Mandalà⁹, S. Tamberi¹⁰, M.S. Sciallero¹¹, S. Muñoz¹², L. Lazzari¹³, P. Luraghi¹³, V. Torri¹⁴, A. Cervantes³, A. Bardelli¹³, J. Tabernero⁷, S. Siena⁵, S. Marsoni¹³, ¹IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ²Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ³INCLIVA Biomedical Research Institute, University of Valencia,



Valencia, ES, ⁴Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ⁵Università degli Studi di Milano "La Statale", ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ⁶IEO - Istituto Europeo di Oncologia, Milan, IT, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ⁹University of Perugia, Santa Maria della Misericordia, University Hospital of Perugia, Perugia, IT, ¹⁰Ospedale degli Infermi - AUSL Romagna, Faenza, IT, ¹¹IRCCS Ospedale Policlinico San Martino, Genova, IT, ¹²Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, ¹³IFOM - the AIRC Institute of Molecular Oncology, Milan, IT, ¹⁴Istituto Di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, IT

09:20 - 09:30

LBA29 - Aspirin After Standard Adjuvant Therapy for Colorectal Cancers (ASCOLT) - An International, Phase III, Randomised, Placebo-controlled Trial

J. Chia¹, E. Segelov², Y. Deng³, W. Wang⁴, G.F. Ho⁵, A. Sharma⁶, K. Ding⁷, G. Chen⁸, G.M. Jeffery⁹, L. Nott¹⁰, R. Zielinski¹¹, J.B. Ahn¹², T.-Y. Chao¹³, T. Yau¹⁴, S. Nabilah¹⁵, M. Gandhi¹⁵, P. Rothwell¹⁶, J. Simes¹⁷, R. Ali¹⁸, H.C. Toh¹⁹, ¹CURIE Oncology, Singapore, SG, ²University of Bern, Bern, CH, ³The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, CN, ⁴Foshan First People's Hospital, Foshan, CN, ⁵Pusat Perubatan Universiti Malaya (PPUM), Kuala Lumpur, MY, ⁶AIIMS - All India Institute of Medical Sciences, New Delhi, IN, ⁷The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, ⁸Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁹Christchurch Hospital, Christchurch, NZ, ¹⁰Department of Health - Australia, Canberra, AU, ¹¹Orange Health Service, Orange, AU, ¹²Yonsei University, Seoul, KR, ¹³Shuang Ho hospital, New Taipei City, CN, ¹⁴The University of Hong Kong - Queen Mary Hospital, Hong Kong, HK, ¹⁵CRIS - Consortium for Clinical Research and Innovation Singapore, Singapore, SG, ¹⁶Wolfson Institute of Preventive Medicine - Barts and The London School of Medicine, London, GB, ¹⁷University of Sydney, Sydney, AU, ¹⁸Cambridge Clinical Trials Unit - Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB, ¹⁹NCCS - National Cancer Centre Singapore, Singapore, SG

09:30 - 09:40

5530 - Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials

J. Taieb¹, L. Pederson², F. Sinicrope³, S. Lonardi⁴, S. Alberts², T. George⁵, L. Saltz⁶, G. Yothers⁷, R. Goldberg⁸, R. Kerr⁹, T. Yoshino¹⁰, E. Van Cutsem¹¹, S. Ogino¹², T. André¹³, P. Laurent-Puig¹⁴, Q. Shi³, ¹Hopital European George Pompidou, Paris, FR, ²Mayo Clinic - Rochester, Rochester, US, ³Mayo Clinic, Rochester, US, ⁴IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁵UF - University of Florida Health, Gainesville, US, ⁶Memorial Sloan Kettering Cancer Center, New York, US, ⁷University of Pittsburgh, Pittsburgh, US, ⁸West Virginia University, Morgantown, US, ⁹Churchill Hospital, Oxford, GB, ¹⁰National Cancer Center Hospital East, Kashiwa, JP, ¹¹UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹²Harvard Medical School, Boston, US, ¹³Hopital Saint-Antoine, Paris, FR, ¹⁴Université Paris Cité, Paris, FR

09:40 - 09:50

Invited Discussant LBA28, LBA29 and 5530

C. Cremolini, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

09:50 - 10:00

Q&A



08:30 - 10:00 **Type: Multidisciplinary session** **Sevilla Auditorium - Hall 9**
Title: Management of oligometastatic disease in NSCLC
 Chair(s): Anne-Marie Dingemans, NL; Giulia Veronesi, IT

08:30 - 08:45 **Introduction and definition of oligometastatic disease(s) + Case presentation**
A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL

08:45 - 09:05 **The role of systemic therapy in patients with or without molecular alterations**
R. Soo, NCIS - National University Cancer Institute Singapore, Singapore, SG

09:05 - 09:25 **The role of surgery**
G. Veronesi, IRCCS Ospedale San Raffaele, Milan, IT

09:25 - 09:45 **The role of radiation therapy**
C. Le Pechoux, Institut Gustave Roussy, Villejuif, Cedex, FR

09:45 - 10:00 **Q&A and Discussion**

08:30 - 10:00 **Type: Educational session** **Bilbao Auditorium - NCC**
Title: How to navigate the different treatment options for hepatobiliary cancers
 Chair(s): Angela Lamarca, ES; Jeroen Dekervel, BE

08:30 - 08:50 **Immunotherapy for liver cancer**
A. Vogel, University Health Network - Toronto General Hospital Research Institute (TGHRI), Toronto, CA

08:50 - 09:10 **Immunotherapy for biliary cancer**
A. Lamarca, Hospital Universitario Fundacion Jimenez Diaz, Madrid, ES

09:10 - 09:30 **Personalised medicine and targeted agents for biliary tract cancer**
L. Rimassa, IRCCS Humanitas Research Hospital, Rozzano, IT

09:30 - 09:50 **Personalised treatment for HCC: Where are we now?**
S. Chan, The Chinese University of Hong Kong - Sino Building, Sha Tin, HK

09:50 - 10:00 **Q&A and Discussion**



08:30 - 10:00 **Type: Special symposium** **Granada Auditorium - Hall 3**
Title: Molecular targets and related treatments
 Chair(s): Himisha Beltran, US; Daniel Heinrich, NO

08:30 - 08:45 **How to interpret a genomic testing report**
H. Beltran, Dana Farber Cancer Institute, Boston, US

08:45 - 09:00 **PSMA targeting**
D. Heinrich, Sykehuset Innlandet HF, Brumunddal, NO

09:00 - 09:15 **PARP inhibition**
E. Castro, Hospital Universitario 12 de Octubre, Madrid, ES

09:15 - 09:30 **Third generation AR targeting**
A. Bernard-Tessier, Institut Gustave Roussy, Villejuif, Cedex, FR

09:30 - 09:45 **Checkpoint inhibitors and Pi3K inhibitors**
N. Mehra, Radboud University Medical Center, Nijmegen, Nijmegen, NL

09:45 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**

08:30 - 09:55 **Type: Proffered Paper session** **Burgos Auditorium - Hall 3**
Title: Proffered Paper session - Head and neck cancer
 Chair(s): Silke Tribius, DE; Paolo Bossi, IT

08:30 - 08:40 **8530 - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase II trial**
J. Thariat¹, M. Bosset², A. Falcoz³, D. Vernerey⁴, Y. Pointreau⁵, S. Racadot⁶, J.C. Faivre⁷, J. Castelli⁸, S. Guihard⁹, F. Huguet¹⁰, S. Chapet¹¹, Y. Tao¹², J. Bourhis¹³, X.S. Sun¹⁴,
 1Centre Francois Baclesse, caen, FR, 2Marie Curie Radiotherapy Center, valence, FR, 3CHRU Besancon - Hopital Jean Minjoz, besancon, FR, 4MSD, besancon, FR, 5Jean Bernard Center, Le Mans, FR, 6Centre Léon Bérard, Lyon, FR, 7Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR, 8Centre Eugene - Marquis, Rennes, FR, 9Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, 10Hopital Tenon AP-HP, Paris, Cedex, FR, 11CHRU Bretonneau, Tours, FR, 12Institut Gustave Roussy, Villejuif, Cedex, FR, 13CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, 14Hôpital Nord Franche-Comté - HNFC, Belfort, FR

08:40 - 08:45 **8570 - MACH-EGFR: Individual patient data (IPD) meta-analysis of anti-EGFR**



monoclonal antibodies (Ab) in patients (pts) with locally advanced (LA) squamous cell carcinomas of head and neck (SCCHN)

P. Blanchard¹, M. Cheugoua-Zanetsie², I. Deneche², D. Rosenthal³, M. Gillison⁴, J. Eriksen⁵, K. Prabhash⁶, J. Giralt⁷, J.A. Bonner⁸, M.G. Ghi⁹, H. Mehanna¹⁰, L. Siu¹¹, M. Gebre Medhin¹², D. Rischin¹³, A. Dietz¹⁴, R. Mesia Nin¹⁵, Y. Pointreau¹⁶, T. Crombet¹⁷, A. Auperin¹⁸, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy, Villejuif, FR, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴University of Texas MD Anderson Cancer Center, Houston, US, ⁵Aarhus University Hospital, Aarhus, DK, ⁶Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, ⁷Vall d'Hebron University Hospital, Barcelona, ES, ⁸University of Alabama at Birmingham Hospital, Birmingham, US, ⁹IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁰The University of Birmingham - Institute for Cancer Studies, Birmingham, GB, ¹¹Princess Margaret Cancer Centre, Toronto, CA, ¹²Lund University, Lund, SE, ¹³Peter MacCallum Cancer Centre, Melbourne, AU, ¹⁴Universitätsklinikum Leipzig, Leipzig, DE, ¹⁵ICO - Institut Català d'Oncologia - Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ¹⁶Centre Jean Bernard, Le Mans, FR, ¹⁷Center of Molecular Immunology, Havana, CU, ¹⁸Gustave Roussy - Cancer Campus, Villejuif, FR

08:45 - 08:55 **Invited Discussant 8530 and 8570**

S. Tribius, Asklepios Klinik St. Georg, Hamburg, DE

08:55 - 09:05 **Q&A**

09:05 - 09:10 **8580 - Minimal residual disease (MRD) diagnosed by a plasma tumor-agnostic circulating tumor DNA (ctDNA) assay after curative therapy in locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) predicts disease relapse and survival**

N. Honoré¹, C. Van Marcke De Lummen², R. Galot², R. Helaers³, A. Van Maanen⁴, J. Ambroise⁵, A. Mendola¹, H. Dahou¹, E. Marbaix², P. Van Eeckhout², E. Longton², M. Magremanne², S. Schmitz², N. Limaye³, J.-P. Machiels², ¹UCLouvain -IREC/MIRO, Woluwe-Saint-Lambert, BE, ²Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ³De Duve Institute UCLouvain, Woluwe-Saint-Lambert, BE, ⁴Institut Roi Albert II - Cliniques universitaires St-Luc, Brussels, BE, ⁵UCLouvain - Université Catholique de Louvain, Woluwe-Saint-Lambert, BE

09:10 - 09:25 **Invited Discussant 8580**

J.P. Klussmann, Universitätsklinikum Köln (AöR), Köln, DE

09:25 - 09:30 **Q&A**

09:30 - 09:40 **8540 - INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)**



J. Fayette¹, L. Licitra², K. Harrington³, R. Haddad⁴, L. Siu⁵, Y.C. Liu⁶, M. Tahara⁷, J.-P. Machiels⁸, D. Rischin⁹, T. Seiwert¹⁰, R. Ferris¹¹, U. Keilholz¹², A. Psyrri¹³, B. Keam¹⁴, P. Bossi¹⁵, R. Metcalf¹⁶, O. Serrano¹⁷, P. Kaur¹⁸, D. Ruscica¹⁹, R. Cohen²⁰, ¹Lyon-I University, Lyon, FR, ²Milan and University of Milan, Milan, IT, ³The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre, London, GB, ⁴Dana-Farber Cancer Institute, Boston, US, ⁵Princess Margaret Cancer Centre, Toronto, CA, ⁶Taichung Veterans General Hospital, Taichung City, TW, ⁷Hospital East, Kashiwa, JP, ⁸Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institute for Experimental and Clinical Research (IREC, pôle MIRO), Université Catholique de Louvain, Brussels, BE, ⁹Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, AU, ¹⁰Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, US, ¹¹University of Pittsburgh Cancer Institute, Pittsburgh, US, ¹²Charité Comprehensive Cancer Center, Berlin, DE, ¹³Attikon University Hospital, National Kapodistrian University of Athens, Athens, GR, ¹⁴Seoul National University Hospital, Seoul, KR, ¹⁵Radiological Sciences and Public Health, University of Brescia, Brescia, IT, ¹⁶The Christie NHS Foundation Trust, Manchester, GB, ¹⁷AstraZeneca & Cytel Inc, Paris, FR, ¹⁸Formerly AstraZeneca, Cambridge, GB, ¹⁹AstraZeneca, Cambridge, GB, ²⁰University of Pennsylvania School of Medicine, Philadelphia, US

09:40 - 09:50 **Invited Discussant 854MO**
C. Le Tourneau, Institut Curie, Paris, FR

09:50 - 09:55 **Q&A**

08:30 - 10:00	Type: Proffered Paper session Title: Proffered Paper session - Melanoma and other skin tumours Chair(s): Teresa Amaral, DE; Enrique Espinosa, ES	Valencia Auditorium - Hall 10
----------------------	--	--------------------------------------

08:30 - 08:40 **LBA48 - Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801**

S. Patel¹, M. Othus², P. Wright³, J. Hyngstrom⁴, C. Lao⁵, T.-G. Truong⁶, S. Chandra⁷, K. Kendra⁸, C. Devoe⁹, A. Hegde¹⁰, A. Mangla¹¹, M. Lowe¹², E. Buchbinder¹³, J. Kirkwood¹⁴, E. Sharon¹⁵, L. Korde¹⁵, J. Moon², V. Sondak¹⁶, A. Ribas¹⁷, V. Prieto¹, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²Fred Hutchinson Cancer Research Center, Seattle, US, ³Spectrum Health, Grand Rapids, US, ⁴University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US, ⁵University of Michigan Comprehensive Cancer Center, Ann Arbor, US, ⁶Kaiser Permanente Vallejo Medical Center, Vallejo, US, ⁷Robert. H. Lurie Cancer Center of Northwestern University, Chicago, US, ⁸OSUCCC - The Ohio State University Comprehensive Cancer Center - James, Columbus, US, ⁹Northwell Health Cancer Institute, Lake Success, US, ¹⁰The University of Alabama at Birmingham, Birmingham, US, ¹¹Case Western Reserve University / University Hospitals, Cleveland, US, ¹²Emory University, Atlanta, US, ¹³Dana Farber Cancer Institute, Boston, US, ¹⁴UPMC Hillman Cancer Center, Pittsburgh, US, ¹⁵National Cancer Institute, Bethesda, US, ¹⁶H. Lee Moffitt Cancer Center & Research Institute - Magnolia Campus, Tampa, US, ¹⁷Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US



08:40 - 08:50 **LBA49 - mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: clinical efficacy and correlates of response**

J. Weber¹, A. Khattak², M. Carlino³, R. Sullivan⁴, J. Luke⁵, T. Meniawy⁶, M. Taylor⁷, G. Ansstas⁸, K. Kim⁹, M. Mckean¹⁰, M. Faries¹¹, T. Tran¹², C.L. Cowey¹³, A. Pecora¹⁴, T. Medina¹⁵, V. Atkinson¹⁶, G. Gibney¹⁷, E. Buchbinder¹⁸, R. Meehan¹⁹, G. Long²⁰, ¹Laura and Isaac Perlmutter Cancer Center, New York City, US, ²Hollywood Private Hospital & Edith Cowan University, Perth, AU, ³Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ⁴MGH - Massachusetts General Hospital, Boston, US, ⁵University of Pittsburgh Cancer Institute, Pittsburgh, US, ⁶Saint John of God Subiaco Hospital, Subiaco, AU, ⁷Providence Cancer Institute, Southfield, US, ⁸Washington University School of Medicine in St. Louis - Siteman Cancer Center, St. Louis, US, ⁹California Pacific Medical Center Research Institute, San Francisco, US, ¹⁰Sarah Cannon Research Institute, Nashville, US, ¹¹The Angeles Clinic and Research Institute, Los Angeles, US, ¹²Yale University School of Medicine - Yale Cancer Center, New Haven, US, ¹³Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ¹⁴John Theurer Cancer Center - Hackensack University Medical Center, Hackensack, US, ¹⁵University of Colorado Cancer Center Anschutz Cancer Pavilion, Aurora, US, ¹⁶Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU, ¹⁷Georgetown Lombardi Comprehensive Cancer Center, Washington DC, US, ¹⁸Dana Farber Cancer Institute, Boston, US, ¹⁹Moderna, Inc. - Global Headquarters, Cambridge, US, ²⁰Melanoma Institute Australia, Wollstonecraft, AU

08:50 - 09:00 **10810 - ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM)**

M. Mckean¹, B. Chmielowski², M. Butler³, R. Carvajal⁴, J. Rodon⁵, M. Carlino⁶, K. Kim⁷, T. Wise-Draper⁸, S. Khan⁹, A. Salama¹⁰, J. Moser¹¹, J. Reeves¹², K. Wilner¹³, M. Maurer¹⁴, M. Abed¹⁴, B. Mitchell¹⁴, D. Beaupre¹⁵, M. Orloff¹⁶, ¹Sarah Cannon Research Institute, Nashville, US, ²Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, US, ³UHN - University Health Network - Princess Margaret Cancer Centre, Toronto, CA, ⁴Northwell Health Cancer Institute, Lake Success, US, ⁵The University of Texas MD Anderson Cancer Center, Houston, US, ⁶Crown Princess Mary Cancer Centre Westmead, Westmead, AU, ⁷California Pacific Medical Center Research Institute, San Francisco, US, ⁸Vontz Center for Molecular Studies, Cincinnati, US, ⁹HICCC - Herbert Irving Comprehensive Cancer Center - Columbia University, New York, US, ¹⁰Duke University, Durham, US, ¹¹HonorHealth Research Institute, Scottsdale, US, ¹²Sarah Cannon Research Institute at Florida Cancer Specialists, Cape Coral, US, ¹³Pfizer Inc., San Diego, US, ¹⁴IDEAYA Biosciences, South San Francisco, US, ¹⁵Biosplice Therapeutics, Inc., San Diego, US, ¹⁶Thomas Jefferson Univ Hospital, Philadelphia, US

09:00 - 09:10 **Invited Discussant LBA48, LBA49 and 10810**

T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

09:10 - 09:20 **Q&A**



- 09:20 - 09:30 **10820 - Concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for melanoma (MM) patients (pts) with leptomeningeal disease (LMD)**
I. Glitza¹, S. Phillips¹, I. John¹, R. Bassett², R. Lin², M. Rohlf¹, J. Richard¹, M. Iqbal¹, T. Hennegan¹, I. Mccutcheon³, S. Ferguson³, B. O'Brien³, S. Tummala³, N. Guha-Thakurta¹, M. Debnam¹, H. Tawbi¹, E. Burton¹, M. Davies¹, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US, ³The University of Texas MD Anderson Cancer Center, Houston, US
- 09:30 - 09:40 **10850 - Atezolizumab, bevacizumab, and cobimetinib (TACo) in patients (pts) with PD1 refractory melanoma brain metastases (MBM)**
E. Burton¹, V. Honaker², D. Milton³, I. Glitza¹, R. Amaria⁴, S. Patel², A. Diab³, M. Wong³, J. Mcquade¹, C. Chung², J. Wefel³, J. Li⁵, M. Davies³, H. Tawbi³, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴The M.D. Anderson Cancer Center, Houston, US, ⁵The University of Texas MD Anderson Cancer Center - Main Building, Houston, US
- 09:40 - 09:50 **Invited Discussant 10820 and 10850**
R. Dummer, USZ - University Hospital Zürich, Zurich, CH
- 09:50 - 10:00 **Q&A**
- 08:30 - 10:00** **Type: Special session** **Salamanca Auditorium - Hall 3**
Title: Women for Oncology - How is the progress towards gender equity? 10 years of ESMO W4O advocating for the cause
 Chair(s): Pilar Garrido Lopez, ES; Duncan Hart, GB
- 08:30 - 08:35 **Welcome**
D. Hart, Cameron Communications, Glasgow, GB
- 08:35 - 08:50 **10 years of ESMO W4O advocating for gender equity**
P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES
- 08:50 - 10:00 **Live discussion, Q&A and wrap-up**
P. Garrido Lopez¹, S. Peters², G. Curigliano³, H. Linardou⁴, D. Mukherji⁵, ¹Hospital Universitario Ramon y Cajal, Madrid, ES, ²CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ³IEO - Istituto Europeo di Oncologia, Milan, IT, ⁴Metropolitan Hospital, Athens, GR, ⁵Clemenceau Medical Center, Dubai, AE



08:30 - 10:00 **Type: Educational session** **Santander Auditorium - Hall 9**
Title: Diffuse large B-cell lymphoma
 Chair(s): Hervé Tilly, FR; Laurie Sehn, CA

08:30 - 08:55 **Molecular classification**
P. Johnson, University of Southampton, Southampton, GB

08:55 - 09:20 **First-line therapy**
H. Tilly, Centre Henri Becquerel, Rouen, FR

09:20 - 09:45 **Therapy at relapse**
L. Sehn, UBC - The University of British Columbia, Vancouver, CA

09:45 - 10:00 **Q&A and Discussion**

08:30 - 10:00 **Type: Special symposium** **León Auditorium - Hall 7**
Title: Cancer-related central and peripheral neuropathy
 Chair(s): Maryam Lustberg, US; Jorn Herrstedt, DK

08:30 - 08:35 **Introduction and scientific background**
M. Lustberg, Yale University School of Medicine, New Haven, US

08:35 - 08:50 **Antineoplastic drug-induced central neuropathy**
A. Argyriou, University Hospital Patras, Patras, GR

08:50 - 09:05 **Preventive strategies for chemotherapy-induced peripheral neuropathy (CIPN)**
S. Nielsen, Sjællands Universitets Hospital, Naestved, DK

09:05 - 09:20 **Treatment of established CIPN**
R. Geva, Tel Aviv Sourasky Medical Center-(Ichilov), Tel Aviv, IL

09:20 - 09:35 **Unmet needs**
M. Lustberg, Yale University School of Medicine, New Haven, US

09:35 - 09:55 **Discussion**

09:55 - 10:00 **Conclusions and perspectives**
J. Herrstedt, ZUH - Zealand University Hospital Roskilde - Region Sjælland, Roskilde, DK



08:30 - 10:00	Type: Educational session Title: ESMO-WHO review of innovation in cancer therapeutics: Does the pipeline meet the need? Chair(s): Rosa Giuliani, GB; André Ilbawi, CH	Cádiz Auditorium - NCC
08:30 - 08:35	Introduction <u>A. Ilbawi</u> , WHO - World Health Organization, Geneva, CH	
08:35 - 08:50	Evaluating innovative products in breast cancer: Characteristics, impact and market share <u>R. Giuliani</u> , The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB	
08:50 - 09:05	Horizon scanning of emerging therapeutics in the next decade: What does the future hold? <u>D. Trapani</u> , Università degli Studi di Milano, Milan, IT	
09:05 - 09:20	Innovation in the EU Cancer Mission: Delivering solutions? <u>C. Chomienne</u> , Hopital Saint Louis AP-HP, Paris, FR	
09:20 - 09:50	Panel Discussion <u>R. Giuliani</u> ¹ , <u>A. Ilbawi</u> ² , <u>W. Tse Yared</u> ³ , <u>D. Trapani</u> ⁴ , <u>C. Chomienne</u> ⁵ , ¹ The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB, ² WHO - World Health Organization, Geneva, CH, ³ Association of European Cancer Leagues, Brussels, BE, ⁴ Università degli Studi di Milano, Milan, IT, ⁵ Hopital Saint Louis AP-HP, Paris, FR	
09:50 - 10:00	Q&A and closing remarks <u>R. Giuliani</u> , The Clatterbridge Cancer Centre - Liverpool, Liverpool, GB	



08:30 - 10:00	Type: Young Oncologists session Title: YO Forum: Preparing future-proof (young) oncologists Chair(s): Maria Kfoury, FR; Rodrigo Sanchez Bayona, ES	Ávila Auditorium - NCC
08:30 - 08:50	How to put together a great CV and make a standout application <u>F. André</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
08:50 - 09:10	How to write a successful research grant/protocol <u>R. Plummer</u> , Newcastle University, Newcastle-upon-Tyne, GB	
09:10 - 09:30	The dos and don'ts of research project management <u>A.S. Berghoff</u> , Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT	
09:30 - 09:50	Empowerment and resilience: A toolbox to foster your well-being and personal development <u>C. Hardy</u> , Lancaster University Division of Health Research, Lancaster, GB	
09:50 - 10:00	Discussion	



08:30 - 09:50	Type: EONS session Title: EONS16: Person centred care in cancer Chair(s): Paz Fernández Ortega, ES	Alicante Auditorium - Hall 10
08:30 - 08:30	Novice Research Dissemination Award <u>A. Kolstrøm</u> , Home nursing care, Kristiansund, NO	
08:30 - 08:40	CN28 - From difficulty to meaning: Palliative cancer patients experience on advance care planning conversation and having a palliative plan <u>A. Kolstrøm</u> , Kristiansund Municipality/ NTNU, Kristiansund, NO	
08:40 - 09:00	Person-centred care for older people with cancer <u>N. Farrington</u> , Southampton General Hospital Southampton University Hospitals NHS Trust, Southampton, GB	
09:00 - 09:25	Survivorship through the eyes of a cancer nurse <u>V. Sulosaari</u> ¹ , <u>J. De Munter</u> ² , ¹ Turku University of Applied Sciences, Turku, FI, ² UZ Gent - Universitair Ziekenhuis Gent, Gent, BE	
09:25 - 09:35	CN4 - Enabling patient empowerment through digital symptom monitoring <u>E. Haukland</u> ¹ , S.G. Aanes ¹ , V. Kataja ² , L. Lang ² , ¹ Nordlandssykehuset HF, Bodoe, NO, ² Kaiku Health, Helsinki, FI	
09:35 - 09:50	Q&A and discussion	



08:45 - 10:00 **Type: Multidisciplinary session** **Málaga Auditorium - Hall 10**
Title: The positive sentinel lymph node: What does it mean for treatment?
 Chair(s): Evandro de Azambuja, BE; Shani Paluch-Shimon, IL

08:45 - 08:50 **Case presentation: 50-year-old woman HR+ HER2+ EBC with 1/2 positive sentinel nodes**
S. Paluch-Shimon, Hadassah University Hospital - Ein Kerem, Jerusalem, IL

08:50 - 09:10 **A medical oncologist's perspective**
E. De Azambuja, Institute Jules Bordet, Brussels, BE

09:10 - 09:30 **A surgeon's perspective**
P. Dubsy, Onkozentrum Luzern Hirslanden-Klinik St. Anna, Luzern, CH

09:30 - 09:50 **A radiation oncologist's perspective**
P. Poortmans, AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE

09:50 - 10:00 **Discussion**

08:45 - 09:30 **Type: Challenge your Expert** **Toledo Auditorium - Hall 3**
Title: Antibody drug conjugates: Current data and future role in drug development
 Chair(s): Sarat Chandarlapaty, US

08:45 - 09:05 **Presentation by Expert**
I. Braña, Vall d'Hebron University Hospital, Barcelona, ES

09:05 - 09:30 **Discussion led by Chair**
S. Chandarlapaty, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

08:45 - 09:30 **Type: Challenge your Expert** **Oviedo Auditorium - Hall 7**
Title: Molecular evolution of brain metastases and therapeutic implications
 Chair(s): Giuseppe Minniti, IT

08:45 - 09:05 **Presentation by Expert**
S. Formenti, Weill Cornell Medicine - Gastrointestinal (GI) Oncology, New York, US

09:05 - 09:30 **Discussion led by Chair**
G. Minniti, Sapienza Università di Roma, Rome, IT



10:15 - 11:45	Type: Special symposium Title: Novel targets, therapies and toxicities in genitourinary cancers Chair(s): Yohann Loriot, FR; Debbie Robbrecht, NL	Sevilla Auditorium - Hall 9
10:15 - 10:20	Introduction and scientific background D. Robbrecht, Erasmus MC Cancer Institute, Rotterdam, NL	
10:20 - 10:35	Screening new agents in “window of opportunity” neoadjuvant trials A. Necchi, IRCCS Ospedale San Raffaele, Milan, IT	
10:35 - 10:50	Antibody drug conjugates and FGFR-directed therapies: New toxicities Y. Loriot, Institut Gustave Roussy, Villejuif, Cedex, FR	
10:50 - 11:05	Prediction of toxicity in current systemic treatment of genitourinary cancers S. Gusev, Dana Farber Cancer Institute, Boston, US	
11:05 - 11:20	Advances in the molecular understanding of GU cancers: The next generation of therapeutic targets S. Turajlic, The Royal Marsden Hospital - Chelsea, London, GB	
11:20 - 11:40	Discussion	
11:40 - 11:45	Conclusions and perspectives D. Robbrecht, Erasmus MC Cancer Institute, Rotterdam, NL	
10:15 - 11:45	Type: Mini Oral session Title: Mini oral session - Breast cancer, early stage Chair(s): Ines Vaz Luis, FR; Carsten Denkert, DE; Ava Kwong, HK	Bilbao Auditorium - NCC
10:15 - 10:20	238MO - Long-term residential and workplace exposure to air pollution and breast cancer risk: A case-control study nested in the French E3N cohort from 1990 to 2011 B. Fervers ¹ , M. Duboeuf ¹ , A. Amadou ¹ , T. Coudon ¹ , L. Grassot ¹ , E. Faure ² , G. Severi ² , F. Mancini ² , P. Salizzoni ³ , J. Gulliver ⁴ , D. Praud ¹ , ¹ Centre Léon Bérard, Lyon, FR, ² Gustave Roussy, Villejuif, FR, ³ Ecole Centrale, Ecully, FR, ⁴ University of Leicester, Leicester, GB	
10:20 - 10:25	LBA22 - Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: results from the DISCO randomized trial B. Fervers ¹ , B. Fournier ¹ , T. Durand ¹ , D. Perol ¹ , C. Schiffler ¹ , A. Maire ¹ , L. Perrier ¹ , M. Préau ² , T. Bachelot ¹ , P.-E. Heudel ¹ , C. Faure ¹ , M. Heinemann ¹ , S. Kingler ¹ , D. Mouttet ¹ , L. Rossi ¹ , P. Toussaint ¹ , J. Grenier ³ , O. Tredan ¹ , J.-Y. Blay ¹ , O. Pérol ¹ , ¹ Centre Léon Bérard, Lyon, FR, ² Université Lyon 2, Lyon, FR, ³ Institut Ste Catherine, Avignon, FR	



- 10:25 - 10:30 **239MO - Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials**
H. Chen¹, X. Qian², Y. Tao³, D. Wang⁴, Y. Wang¹, Y. Yu¹, H. Yao¹, ¹Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, ²Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, CN, ³The Affiliated Hospital of Xuzhou Medical University, Xuzhou, CN, ⁴State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, CN
- 10:30 - 10:45 **Invited Discussant 238MO, LBA22 and 239MO**
I. Vaz Luis, Institut Gustave Roussy, Villejuif, Cedex, FR
- 10:45 - 10:50 **240MO - Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR⁺, HER2-, early breast cancer (EBC)**
M. Goetz¹, N. Turner², H. Sasano³, C. Arteaga⁴, S. Chandarlapaty⁵, S. Loi⁶, J. Reis-Filho⁵, H. Kreipe⁷, N. Harbeck⁸, P. Fasching⁹, C. Rubenstein¹⁰, S. Wijayawardana¹⁰, M. Muñoz¹⁰, L. Litchfield¹⁰, S. Johnston², ¹Mayo Clinic, Rochester, US, ²Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London, GB, ³Tohoku University Hospital, Sendai, JP, ⁴University of Texas Southwestern Medical Center, Dallas, US, ⁵Memorial Sloan Kettering Cancer Center, New York, US, ⁶Peter MacCallum Cancer Centre, Melbourne, AU, ⁷Hannover Medical School, Hannover, DE, ⁸Ludwig Maximilians University Hospital, Munich, DE, ⁹Universitätsklinikum Erlangen, Erlangen, DE, ¹⁰Eli Lilly and Company, Indianapolis, US
- 10:50 - 10:55 **LBA23 - Invasive disease-free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC)**
A. Bardia¹, G. Hortobagyi², O. Lipatov³, N. McAndrew⁴, A. Lacko⁵, J. Sohn⁶, L. Hart⁷, J. Crown⁸, S.-A. Im⁹, N. Harbeck¹⁰, J. O'Shaughnessy¹¹, B. Xu¹², C. Barrios¹³, R. Moroese¹⁴, V. Gonzalez¹⁵, R. Fresco¹⁶, F. Ghaznawi¹⁷, S. Waters¹⁸, A. Chakravarty¹⁹, D. Slamon²⁰, ¹Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³Bashkirian Republican Oncology Center, Bashkortostan, RU, ⁴UCLA Santa Monica Hematology / Oncology Regulatory-2, Santa Monica, US, ⁵Dolnoslaskie Centrum Onkologii, Wrocław, PL, ⁶Yonsei Cancer Center, Seoul, KR, ⁷Florida Cancer Specialists, Fort Myers, US, ⁸St Vincent's University Hospital, Dublin, IE, ⁹SNUH - Seoul National University Hospital, Seoul, KR, ¹⁰LMU University Hospital, Munich, DE, ¹¹Texas Oncology-Baylor University Medical Center and The US Oncology Research Network, Dallas, US, ¹²Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ¹³Latin American Cooperative Oncology Group (LACOG), Porto Alegre, BR, ¹⁴Orlando Health Cancer Institute, Orlando, US, ¹⁵TRIO - Translational Research in Oncology, Montevideo, UY, ¹⁶TRIO-Translational Research in Oncology, Montevideo, UY, ¹⁷Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁸Novartis Ireland Limited, Dublin, IE, ¹⁹Novartis Pharmaceuticals Corp.,



East Hanover, US, ²⁰UCLA - David Geffen School of Medicine, Los Angeles, US

- 10:55 - 11:00 **241MO - Patient characteristics and real-world outcomes in HER2 negative/ ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020**
I. Fredriksson¹, B. Acs¹, J. Hartman¹, D. Sönmez², H. Lindman³, ¹Karolinska Institutet & Karolinska University Hospital, Comprehensive Cancer Center, Stockholm, SE, ²MSD - Merck Sharp & Dohme (Sweden) AB, Stockholm, SE, ³University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE
- 11:00 - 11:05 **242MO - Association of tumor-infiltrating lymphocytes (TILs) with recurrence score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC): A translational analysis of four prospective multicentric studies**
F. Miglietta¹, M.V. Dieci², T. Giarratano³, V. Torri⁴, M. Giuliano⁵, F. Zustovich⁶, M. Mion⁷, C. Tondini⁸, E. Bria⁹, M. Franchi¹⁰, L. Merlini¹¹, R. Giannatiempo¹², D. Russo¹³, V. Fotia⁸, P. Poletti⁸, E. Rota Caremoli⁸, G. Arpino¹⁴, G. De Salvo³, A. Zambelli¹⁵, V. Guarneri², ¹IOV - Istituto Oncologico Veneto IRCCS; Unipd, Padova, IT, ²University of Padua, Padova, IT, ³IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ⁴Istituto Di Ricerche Farmacologiche Mario Negri - IRCCS, Milan, IT, ⁵AOU "Federico II", Napoli, IT, ⁶Ospedale di Belluno, Belluno, IT, ⁷Camposampiero-Cittadella, AULSS6,, Camposampiero, IT, ⁸ASST Papa Giovanni XXIII, Bergamo, IT, ⁹Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy, Rome, IT, ¹⁰FROM Fondazione per la Ricerca Ospedale Maggiore, Bergamo, IT, ¹¹UOSD Montecchio Maggiore, Vicenza, IT, ¹²Ospedale Evangelico Betania, Napoli, IT, ¹³University of Naples Federico II, Napoli, IT, ¹⁴Università degli Studi di Napoli Federico II - Dipartimento di Farmacia, Napoli, IT, ¹⁵Humanitas University, Milan, IT
- 11:05 - 11:10 **LBA24 - Multiparametric prognostic score in early HR+/HER2- breast cancer: impact of Recurrence Score, clinical-pathological factors, gene mutations and histology**
O. Gluz¹, M. Christgen², C. Zu Eulenburg³, U. Nitz³, S. Kummel⁴, M. Braun⁵, B. Aktas⁶, K. Luedtke-Heckenkamp⁷, H. Forstbauer⁸, E.-M. Grischke⁹, C. Schumacher¹⁰, R. Baehner¹¹, R. Kates³, M. Graeser¹², R. Würstlein¹³, H. Kreipe¹⁴, N. Harbeck¹⁵, ¹Evang. Krankenhaus "Bethesda" Klinik, Mönchengladbach, DE, ²MHH - Medizinische Hochschule Hannover, Hannover, DE, ³Westdeutsche Studiengruppe GmbH, Mönchengladbach, DE, ⁴Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ⁵Rotkreuzklinikum München - Frauenklinik, Munich, DE, ⁶Universitätsklinikum Leipzig - Klinik und Poliklinik für Frauenheilkunde, Leipzig, DE, ⁷Franziskus-Hospital Harderberg - Niels-Stensen-Kliniken GmbH, Georgsmarienhütte, DE, ⁸Praxisnetzwerk Onkologie, Troisdorf, DE, ⁹Universitätsklinikum Tübingen, Tuebingen, DE, ¹⁰St. Elisabeth Krankenhaus Köln-Hohenlind, Köln, DE, ¹¹Exact Sciences Corporation, Redwood City, US, ¹²Evang. Krankenhaus Johanniter Bethesda, Mönchengladbach, DE, ¹³LMU Klinikum der Universität München, Munich, DE, ¹⁴Hannover Medical School, Hannover, DE, ¹⁵Ludwig Maximilians University - Grosshadern, Munich, DE
- 11:10 - 11:25 **Invited Discussant 240MO, LBA23, 241MO, 242MO and LBA24**
C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE



- 11:25 - 11:30 **243MO - Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial**
- H.M. Kuerer¹, G. Rauch², S. Krishnamurthy¹, E. Diego³, W. Yang¹, Y. Shen², H. Lin⁴, A. Lucci⁴, T. Moseley², D. Ramirez⁵, J. Mouabbi², J. Boughey⁶, S. Shaitelman¹, R. White⁷, K. Hunt², M. Mitchell¹, M. Teshome¹, H. Johnson¹, B. Smith¹, V. Valero⁸, ¹The University of Texas MD Anderson Cancer Center, Houston, US, ²MD Anderson Cancer Center, Houston, US, ³University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, US, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁵The University of Texas MD Anderson Cancer Center - Breast Medical Oncology, Houston, US, ⁶Mayo Clinic, Rochester, US, ⁷Levine Cancer Institute-Concord - Carolinas HealthCare System, Concord, US, ⁸The M.D. Anderson Cancer Center, Houston, US
- 11:30 - 11:35 **244MO - A phase II trial targeting disseminated dormant tumor cells with hydroxychloroquine, everolimus or the combination to prevent recurrent breast cancer (CLEVER)**
- A. Demichele¹, A. Clark¹, L. Bayne¹, K. Rohn¹, I. Nivar¹, P. Wileyto², L. Berry³, S. Deluca¹, J. Savage¹, I. Makhlin¹, T.C. Pan², J. Graves², G. Belka², J. Wang², N. Shih¹, D. Berry³, A. Nayak¹, M. Feldman⁴, L. Chodosh², ¹University of Pennsylvania, Philadelphia, US, ²University Of Pennsylvania, Philadelphia, US, ³Berry Consultants, Austin, US, ⁴Indiana University, Indianapolis, US
- 11:35 - 11:45 **Invited Discussant 243MO and 244MO**
- A. Kwong, The University of Hong Kong - Li Ka Shing Faculty of Medicine, Hong Kong, HK



10:15 - 11:45 **Type: Special symposium** **Granada Auditorium - Hall 3**
Title: Challenging the status quo of early phase clinical trial design: Project Optimus
 Chair(s): Emiliano Calvo, ES; Mirat Shah, US

10:15 - 10:20 **Introduction and scientific background**
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

10:20 - 10:35 **Project Optimus update**
M. Ratain, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

10:35 - 10:50 **Investigator perspective**
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

10:50 - 11:00 **Regulatory perspective: FDA**
M. Shah, U.S. Food and Drug Administration, Silver Spring, US

11:00 - 11:10 **Pharmaceutical industry perspective**
S. Arora, AstraZeneca Pharmaceuticals LP, Gaithersburg, US

11:10 - 11:25 **Patient advocacy perspective**
J. Feldman, EGFR Resisters, Deerfield, US

11:25 - 11:40 **Discussion**

11:40 - 11:45 **Conclusions and perspectives**
M. Shah, U.S. Food and Drug Administration, Silver Spring, US

10:15 - 11:40 **Type: Proffered Paper session** **Burgos Auditorium - Hall 3**
Title: Proffered Paper session - Investigational immunotherapy
 Chair(s): Gary Middleton, GB; Alessandra Curioni-Fontecedro, CH

10:15 - 10:25 **10160 - Autoimmunity against surfactant protein B drives immune checkpoint inhibitor-related pneumonitis in patients with NSCLC**
L. Flatz¹, M. Frueh², V. Walter³, A.-K. Jochum², S. Diem⁴, E. Jaeger⁵, C. Antonio⁶, C. Schürch³, C. Driessen⁴, M. Brutsche⁶, J. Walz⁷, H.-G. Rammensee³, B. Becher⁸, A. Tufman⁹, N. Nunez¹⁰, M. Joerger⁴, L. Zender⁷, H. Läubli¹¹, F. Berner⁴, N. Wyss²,
¹Universitätsklinikum Tübingen, Tuebingen, DE, ²Cantonal Hospital, St. Gallen, CH, ³Universität Tübingen, Tübingen, DE, ⁴Kantonsspital St. Gallen, St. Gallen, CH, ⁵KHNW - Krankenhaus Nordwest GmbH, Frankfurt am Main, DE, ⁶Cantonal Hospital, St.Gallen,



CH, ⁷University Clinic Tübingen, Tuebingen, DE, ⁸UZH - Universität Zürich, Zurich, CH, ⁹LMU Klinikum der Universität München, Munich, DE, ¹⁰Universidad Nacional de Cordoba, Cordoba, AR, ¹¹Universitatsspital Basel, Basel, CH

10:25 - 10:35 **Invited Discussant 10160**

G. Middleton, Institute of Cancer and Genomic Sciences - University of Birmingham, Birmingham, GB

10:35 - 10:45 **Q&A**

10:45 - 10:55 **10170 - NTC-001: A phase I study to test safety and efficacy of BNT221, a non-engineered neoantigen-specific T cell product, in patients with advanced or metastatic melanoma**

J. Borgers¹, D. Lenkala², B. Mccarthy², V. Kohler², S. Hymson², K. Esaulova², O. Finney², K. Balogh², S. Klobuch¹, C. Nijenhuis³, R. Gaynor², M. Demario², J. Haanen¹, M. Van Buuren², ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²BioNTech US, Cambridge, US, ³Netherlands Cancer Institute, Amsterdam, NL

10:55 - 11:05 **10180 - Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer**

C. Qi¹, L. Chang¹, J. Li¹, J. Gong¹, X. Wang¹, Z. Wang¹, X. Lu², T. He², Y. Ding², F. Wu², D. Liu², L. Shen¹, ¹Peking University Cancer Hospital and Institute, Beijing, CN, ²Beijing Immunopharm Technology Co., Ltd., Beijing, CN

11:05 - 11:15 **10190 - Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors**

V. Moreno Garcia¹, E. Calvo², A. Asch³, M. Butler⁴, J. Zugazagoitia⁵, J. Charlson⁶, A. Cervantes⁷, B. Van Tine⁸, D. Aggen⁹, J. Clarke¹⁰, M. Johnson¹¹, M. Wileman¹², A. Liddle¹², R. Naidoo¹², F. Brophy¹³, M. Rosenberg¹³, D. Jolliffe¹⁴, D. Williams¹⁵, E. Norry¹³, D. Hong¹⁶, ¹START Madrid-FJD, Fundación Jiménez Díaz Hospital, Madrid, ES, ²Centro Integral Oncológico Clara Campal, Madrid, ES, ³Stephenson Cancer Center, Oklahoma University Health Science Center, Oklahoma City, US, ⁴Department of Immunology, University of Toronto, Toronto, CA, ⁵Hospital Universitario 12 de Octubre, Madrid, ES, ⁶Medical College of Wisconsin, Milwaukee, US, ⁷University of Valencia, Valencia, ES, ⁸Washington University School of Medicine, St. Louis, US, ⁹Memorial Sloan Kettering Cancer Center, New York, US, ¹⁰Duke Cancer Center, Durham, US, ¹¹Sarah Cannon Research Institute, Nashville, US, ¹²Adaptimmune Ltd, Abingdon-on-Thames, GB, ¹³Adaptimmune, Philadelphia, US, ¹⁴Adaptimmune, Abingdon, Oxfordshire, GB, ¹⁵Adaptimmune Therapeutics plc, Philadelphia, US, ¹⁶The University of Texas MD Anderson Cancer Center, Houston, US

11:15 - 11:30 **Invited Discussant 10170, 10180 and 10190**

I.-M. Svane, Herlev Hospital - National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DK



11:30 - 11:40 **Q&A**

10:15 - 11:45	<p>Type: Multidisciplinary session Title: What is the optimal therapeutic approach following progression on front line PARP inhibitor maintenance therapy in ovarian cancer? Chair(s): Antonio Gonzalez Martin, ES; Sven Mahner, DE</p>	<p>Salamanca Auditorium - Hall 3</p>
----------------------	---	---

10:15 - 10:20 **Presentation of case/condition**
A. Gonzalez Martin, Clinica Universidad de Navarra, Madrid, ES

10:20 - 10:35 **The role of surgery**
S. Mahner, University Hospital, LMU Munich, München, DE

10:35 - 10:50 **Systemic treatment options following progression on PARPi**
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

10:50 - 11:05 **Novel treatment options for PARPi resistant ovarian cancer**
C. Gourley, Cancer Research UK Edinburgh Centre, Edinburgh, GB

11:05 - 11:20 **Understanding and overcoming resistance to PARP inhibitors: What is the way forward?**
J. Jonkers, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

11:20 - 11:45 **Discussion**



10:15 - 11:45	Type: Special session Title: ESMO/ASCO Global Curriculum: Medical oncology Training: Challenges and opportunities Chair(s): Tanja Cufer, SI; Kalijn Bol, NL	León Auditorium - Hall 7
10:15 - 10:20	Introduction <u>K. Bol</u> , Radboud University Medical Center, Nijmegen, Nijmegen, NL	
10:20 - 10:35	Development and update of the ESMO/ASCO Global Curriculum: Why and how <u>T. Cufer</u> , University of Ljubljana - Faculty of Medicine, Ljubljana, SI	
10:35 - 10:50	Using the ESMO/ASCO Global Curriculum and Log Book to improve educational content: The perspective of the mentor <u>K. Bol</u> , Radboud University Medical Center, Nijmegen, Nijmegen, NL	
10:50 - 11:05	Optimizing learning in a fast-paced training environment: The perspective of the trainee <u>M. Fontes E Sousa</u> , Hospital CUF Tejo, Lisbon, PT	
11:05 - 11:20	Integrating global standards in medical oncology training: The perspective of the trainee <u>K. Sharma</u> , AKUH - Aga Khan University Hospital - Nairobi, Nairobi, KE	
11:20 - 11:35	The role of the Global Curriculum in the era of digital health and artificial intelligence <u>R. Dienstmann</u> , Grupo Oncoclinicas, Sao Paulo, BR	
11:35 - 11:45	Discussion and Q&A	



10:15 - 11:45	Type: Special session Title: In collaboration with the IARC - Cancer prevention: What every oncologist must know Chair(s): Jean-Yves Blay, FR; Elisabete Weiderpass, FR	Cádiz Auditorium - NCC
10:15 - 10:20	Introduction <u>J.-Y. Blay</u> , Centre Léon Bérard, Lyon, FR	
10:20 - 10:35	Presentation of the IARC-ESMO survey results on the educational needs of medical oncologists on cancer <u>J.-Y. Blay</u> , Centre Léon Bérard, Lyon, FR	
10:35 - 10:50	The IARC World Cancer Report Updates Learning Platform - Supported by ESMO <u>E. Weiderpass</u> , International Agency for Research on Cancer, Lyon, FR	
10:50 - 11:05	The present and future of lung cancer screening: What does the scientific evidence show? <u>J. Aerts</u> , Erasmus MC - University Medical Center, Rotterdam, NL	
11:05 - 11:20	IARC's European Code Against Cancer: The EONS-ESMO campaign <u>L. Sharp</u> , RCC - Regionalt cancercentrum Stockholm - Gotland, Stockholm, SE	
11:20 - 11:35	WHO's cancer prevention policy resolutions, best buys, and framework convention on tobacco control <u>A. Ilbawi</u> , WHO - World Health Organization, Geneva, CH	
11:35 - 11:45	Discussion	



10:15 - 11:30	Type: EONS session Title: EONS16: Professional and educational issues in cancer nursing Chair(s): Julio de la Torre-Montero, ES	Alicante Auditorium - Hall 10
10:15 - 10:30	Moral dilemmas of (cancer) nurses <u>W. Oldenmenger</u> , Erasmus MC Cancer Institute, Rotterdam, NL	
10:30 - 10:45	European College of Cancer Nursing: An evaluation of learning <u>W. Mcinally</u> , Open University, Edinburgh, GB	
10:45 - 11:00	Developing cancer nursing services in low- and middle-income countries <u>M. Fowler</u> , Heartlands Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB	
11:00 - 11:10	CN5 - Shared decision making in rectal cancer surgery: The way to go? <u>E. Pape</u> ¹ , <u>J. Dobbelaer</u> ¹ , <u>D. Van De Putte</u> ² , <u>K. Geboes</u> ³ , <u>A. Van Hecke</u> ⁴ , <u>I. Vlerick</u> ⁴ , <u>G. Van Ramshorst</u> ¹ , <u>Y. Van Nieuwenhove</u> ¹ , ¹ UZ Gent - University Hospital Ghent, Ghent, BE, ² UZ Gent - University Hospital Ghent, Ghent, BE, ³ UZ Gent - Universitair Ziekenhuis Gent, Ghent, BE, ⁴ Ghent University - University Centre for Nursing and Midwifery, Ghent, BE	
11:10 - 11:20	CN77 - EONS advocacy toolkit: How to let your voice be heard as a cancer nurse <u>D. Protogiros</u> ¹ , <u>M. Van Klinken</u> ² , <u>G. Suchodolska</u> ³ , <u>T. Theologia</u> ⁴ , <u>G. Catania</u> ⁵ , <u>G. Knötgen</u> ⁶ , ¹ Ministry of Health, Athens, GR, ² Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, ³ Medical University of Gdańsk, Gdansk, PL, ⁴ Cyprus University of Technology - Nursing Science, Limassol, CY, ⁵ University of Genova, Genova, IT, ⁶ German Cancer Nursing Society, Munich, DE	
11:20 - 11:30	Q&A and discussion	
10:30 - 11:15	Type: Challenge your Expert Title: When and from where is tumour DNA sequencing needed for patients with metastatic breast cancer (mBC)? Chair(s): Karen Gelmon, CA	Valencia Auditorium - Hall 10
10:30 - 10:50	Presentation by Expert <u>F. André</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
10:50 - 11:15	Discussion led by Chair <u>K. Gelmon</u> , BC Cancer Agency - Vancouver, Vancouver, CA	



10:30 - 11:15	Type: Challenge your Expert Title: Looking ahead in SCLC: From biology to clinical practice Chair(s): Maurice Pérol, FR	Málaga Auditorium - Hall 10
10:30 - 10:50	Presentation by Expert <u>T. Owonikoko</u> , University of Pittsburgh, Pittsburgh, US	
10:50 - 11:15	Discussion led by Chair <u>M. Pérol</u> , Centre Léon Bérard, Lyon, FR	
10:30 - 11:45	Type: Multidisciplinary session Title: Rectal cancer with oligometastatic disease Chair(s): Thomas Gruenberger, AT; Claudia Cardone, IT	Santander Auditorium - Hall 9
10:30 - 10:35	Case/condition presentation <u>C. Cardone</u> , Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	
10:35 - 10:50	How to perform an accurate staging? <u>R. Beets-Tan</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL	
10:50 - 11:05	Options for the choice of the systemic therapy <u>G. Folprecht</u> , Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE	
11:05 - 11:20	Radiotherapy and timing <u>K. Haustermans</u> , UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
11:20 - 11:35	Timing and modality of surgical intervention <u>T. Gruenberger</u> , Wiener Gesundheitsverbund - Klinik Favoriten, Vienna, AT	
11:35 - 11:45	Discussion	



10:30 - 11:15 **Type: Challenge your Expert** **Toledo Auditorium - Hall 3**
Title: Adrenocortical carcinoma
 Chair(s): Cristina Ronchi, GB

10:30 - 10:50 **Presentation by Expert**
A. Berruti, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

10:50 - 11:15 **Discussion led by Chair**
C. Ronchi, The University of Birmingham - Medical School, Birmingham, GB

10:30 - 11:15 **Type: Challenge your Expert** **Oviedo Auditorium - Hall 7**
Title: When to stop systemic anticancer treatment in patients with advanced malignancy?
 Chair(s): Gudrun Kreye, AT

10:30 - 10:50 **Presentation by Expert**
S. Kaasa, Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO

10:50 - 11:15 **Discussion led by Chair**
G. Kreye, Universitätsklinikum Krems, Krems an der Donau, AT

11:00 - 11:45 **Type: Young Oncologists session** **Ávila Auditorium - NCC**
Title: YO Brunch 3: Establishing successful global research collaborations and network
 Chair(s): Kevin Punie, BE

11:00 - 11:15 **Establishing successful global research collaborations and networks**
A. Awada, Institute Jules Bordet, Brussels, BE

11:15 - 11:45 **Discussion led by Chair**
K. Punie, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

12:00 - 12:30 **Type: Keynote lecture** **Barcelona Auditorium - Hall 9**
Title: Elucidating cancer biology, and transforming cancer care, through academic drug development
 Chair(s): Lillian Siu, CA

12:00 - 12:05 **Introduction by the Chair**
L. Siu, Princess Margaret Cancer Centre, Toronto, CA

12:05 - 12:30 **Elucidating cancer biology, and transforming cancer care, through academic drug development**
J. De Bono, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB



12:00 - 13:30 **Type: EONS Industry Satellite Symposium** **Alicante Auditorium - Hall 10**
Title: MSD - Treatment and management of IO +/- TKi in advanced and recurrent endometrial cancer

Chair(s): Silvia Mazzanti, IT

12:00 - 12:05 **Introductions and Objectives**

S. Mazzanti, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

12:05 - 12:25 **Current landscape in the treatment and management of endometrial cancer patients**

V. Makker, Memorial Sloan-Kettering Cancer Center, New York City, US

12:25 - 12:50 **Understanding the AE management of patients receiving the IO +/- TKI treatments**

S. Mazzanti, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT

12:50 - 13:15 **Challenges in endometrial cancer patient education and preparation prior to treatment**

J. Serra López, Hospital de la Santa Creu i Sant Pau, Barcelona, ES

13:15 - 13:25 **Q&A**

S. Mazzanti¹, V. Makker², J. Serra López³, ¹IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, ²Memorial Sloan-Kettering Cancer Center, New York City, US, ³Hospital de la Santa Creu i Sant Pau, Barcelona, ES

13:25 - 13:30 **Conclusions**

S. Mazzanti, IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT



13:00 - 14:30	Type: Industry Satellite Symposium Title: Exact Sciences - Shifting the Paradigm in Cancer Screening: Multi-cancer Early Detection (MCED) Testing Chair(s): Elizabeth O'Donnell, US; Tomasz Beer, US	Burgos Auditorium - Hall 3
----------------------	--	-----------------------------------

13:00 - 13:05 **Welcome and Introductions**
E. O'Donnell, Dana Farber Cancer Institute, Boston, US

13:05 - 13:15 **Meeting the Unmet Needs in Cancer Screening**
C. Marinac, Dana Farber Cancer Institute, Boston, US

13:15 - 13:30 **Advancements in Tumor Biology and Circulating Biomarkers: Application in Early Cancer Detection**
N. Papadopoulos, Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US

13:30 - 13:45 **A Multi-Biomarker Approach to MCED Test Design: Optimizing Performance to Help Enhance Future Clinical Impact**
F. Diehl, Exact Sciences Corporation, Madison, US

13:45 - 14:00 **Demonstrating the Potential Clinical Value of MCED Testing**
T. Beer, Exact Sciences Corporation, Madison, US

14:00 - 14:10 **The Future Paradigm of Cancer Screening**
E. O'Donnell, Dana Farber Cancer Institute, Boston, US

14:10 - 14:30 **Summary and Q&A**
C. Marinac, Dana Farber Cancer Institute, Boston, US



13:00 - 14:30	Type: Industry Satellite Symposium Title: Mirati Therapeutics, Inc. - New horizons in the treatment of KRAS-driven NSCLC and GI cancers Chair(s): Luis Paz-Ares, ES	Valencia Auditorium - Hall 10
----------------------	---	--------------------------------------

13:00 - 13:05 **Welcome & Introduction**
L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

13:05 - 13:30 **Recent advances in targeting KRASG12C-mutated NSCLC**
L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

13:30 - 13:55 **Targeting KRAS in GI cancers: where are we now?**
A. Parikh, MGH - Massachusetts General Hospital, Boston, US

13:55 - 14:15 **The key role of biomarker testing in precision medicine**
K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB

14:15 - 14:30 **Q&A**
L. Paz-Ares¹, A. Parikh², K. Kerr³, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²MGH - Massachusetts General Hospital, Boston, US, ³Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB



13:00 - 14:30	Type: Industry Satellite Symposium Title: Sanofi Regeneron - Considerations for Frontline Immunotherapy in NSCLC: A Case-Based Discussion Chair(s): Martin Reck, DE	Salamanca Auditorium - Hall 3
13:00 - 13:05	Welcome and Introduction <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
13:05 - 13:30	Mono vs combination therapy: identifying if less is more in complex patient cases <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
13:30 - 13:55	Tailoring the approach: selecting the optimal immunotherapy combination regimen <u>D. Rodriguez Abreu</u> , Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES	
13:55 - 14:20	Navigating difficult-to-treat populations: additional considerations for using immunotherapy <u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
14:20 - 14:30	Group Discussion <u>M. Reck</u> ¹ , <u>L. Hendriks</u> ² , <u>D. Rodriguez Abreu</u> ³ , ¹ Krankenhaus Grosshansdorf, Grosshansdorf, DE, ² Maastricht University Medical Center (MUMC), Maastricht, NL, ³ Hospital Universitario Insular de Gran Canaria - Complejo Hospitalario Materno-Insular, Las Palmas de Gran Canaria, ES	



13:00 - 14:30	Type: Industry Satellite Symposium Title: Bristol Myers Squibb - The Changing Paradigm of Melanoma Treatment: A Clinical Update for 2023 Chair(s): Eva Muñoz Couselo, ES	Málaga Auditorium - Hall 10
13:00 - 13:05	Welcome and Introduction <u>E. Muñoz Couselo</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:05 - 13:25	Navigating the Adjuvant Setting: Who, When, and What? <u>E. Muñoz Couselo</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:25 - 13:45	Current and Emerging Neoadjuvant Treatment Options for Resectable Melanoma <u>S. Patel</u> , MD Anderson Cancer Center, Houston, US	
13:45 - 14:05	Panel Discussion: Factors Impacting Treatment Selection for Resectable Melanoma <u>E. Muñoz Couselo</u> ¹ , <u>S. Patel</u> ² , <u>D. Schadendorf</u> ³ , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² MD Anderson Cancer Center, Houston, US, ³ WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE	
14:05 - 14:25	Evidence-Based Considerations for the First-Line Treatment of Metastatic Melanoma <u>D. Schadendorf</u> , WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE	
14:25 - 14:30	Summary and Close <u>E. Muñoz Couselo</u> , Vall d'Hebron University Hospital, Barcelona, ES	



13:00 - 14:30	Type: Industry Satellite Symposium Title: Seagen - Case by Case: Strategic Sequencing Considerations in 3L HER2+ Metastatic Breast Cancer (MBC) Chair(s): Cristina Saura Manich, ES	Santander Auditorium - Hall 9
13:00 - 13:05	Welcome and Introductions <u>C. Saura Manich</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:05 - 13:20	Embracing Change: Uncovering Challenges and Opportunities in the Changing Treatment Landscape of HER2+ MBC <u>C. Saura Manich</u> , Vall d'Hebron University Hospital, Barcelona, ES	
13:20 - 13:40	Decision-making in 3L Following T-DXd Progression (Case-based discussion) <u>J. O'Shaughnessy</u> , Texas Oncology - Baylor Sammons Cancer Center, Dallas, US	
13:40 - 14:00	Decision-making in 3L Progression With CNS Involvement (Case-based discussion) <u>M. De Laurentiis</u> , Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	
14:00 - 14:15	Charting the Course: Navigating the Landscape From Real-world Evidence to Future Studies <u>J. Gligorov</u> , Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR	
14:15 - 14:25	Q&A <u>C. Saura Manich</u> ¹ , <u>J. O'Shaughnessy</u> ² , <u>M. De Laurentiis</u> ³ , <u>J. Gligorov</u> ⁴ , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ³ Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁴ Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR	
14:25 - 14:30	Closing Remarks <u>C. Saura Manich</u> , Vall d'Hebron University Hospital, Barcelona, ES	



13:00 - 14:30	Type: Industry Satellite Symposium Title: Myriad Genetics - Accessing cutting-edge precision oncology through local testing Chair(s): Carsten Denkert, DE; Pascal Pujol, FR	Toledo Auditorium - Hall 3
13:00 - 13:05	HRD round table P. Pujol, Hopital Arnaud de Villeneuve, Montpellier, FR	
13:05 - 13:25	Optimal HRD ovarian cancer treatment - Are genomic tests interchangeable? C. Denkert ¹ , B. You ² , F. Marmé ³ , ¹ UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ² Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ³ UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE	
13:25 - 13:40	How to implement local LoE1A HRD testing: experience of a center of excellence C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE	
13:40 - 13:50	Live Q&A P. Pujol ¹ , C. Denkert ² , B. You ³ , F. Marmé ⁴ , ¹ Hopital Arnaud de Villeneuve, Montpellier, FR, ² UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ³ Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ⁴ UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE	
13:50 - 14:10	Real world prospective data support prognostic and predictive second-generation breast cancer signature performance M. Kiechle, E. Klein, Klinikum Rechts der Isar - Technische Universität München, Munich, DE	
14:10 - 14:20	Live Q&A C. Denkert ¹ , M. Kiechle ² , E. Klein ² , ¹ UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE, ² Klinikum Rechts der Isar - Technische Universität München, Munich, DE	
14:20 - 14:30	Conclusion C. Denkert, UKGM - Uniklinikum Giessen und Marburg - Standort Marburg, Marburg, DE	



13:00 - 14:30	Type: Industry Satellite Symposium Title: Novocure GmbH - The evolving role of TTFIELDS therapy in solid tumors Chair(s): Jalid Sehouli, DE; Joachim Aerts, NL	Oviedo Auditorium - Hall 7
13:00 - 13:05	Welcome <u>J. Sehouli</u> ¹ , <u>J. Aerts</u> ² , ¹ Charité - Universitaetsmedizin Berlin, Berlin, DE, ² Erasmus MC - University Medical Center, Rotterdam, NL	
13:05 - 13:20	Practice changing experience of TTFIELDS therapy in Glioblastoma <u>S. Rieken</u> , Universitätsmedizin Göttingen, Goettingen, DE	
13:20 - 13:35	Evolving role of TTFIELDS therapy in NSCLC <u>J. Aerts</u> , Erasmus MC - University Medical Center, Rotterdam, NL	
13:35 - 13:50	Bringing change with TTFIELDS therapy in ovarian cancer <u>J. Sehouli</u> , Charité - Universitaetsmedizin Berlin, Berlin, DE	
13:50 - 14:30	Fireside chat <u>B. Monk</u> ¹ , <u>J. Aerts</u> ² , <u>J. Sehouli</u> ³ , <u>S. Rieken</u> ⁴ , <u>T. Macarulla</u> ⁵ , ¹ The University of Arizona, Tucson, US, ² Erasmus MC - University Medical Center, Rotterdam, NL, ³ Charité - Universitaetsmedizin Berlin, Berlin, DE, ⁴ Universitätsmedizin Göttingen, Goettingen, DE, ⁵ Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES	



13:00 - 14:30	Type: Industry Satellite Symposium Title: Novartis - Navigating the evolving mCRPC landscape: Your questions, their answers Chair(s): Alicia Morgans, US	León Auditorium - Hall 7
13:00 - 13:10	Welcome, introduction and educational objectives: Treatment landscape evolution in mCRPC <u>A. Morgans</u> , Dana Farber Cancer Institute, Boston, US	
13:10 - 13:29	Treatment of advanced prostate cancer: Frequently asked questions - How do I choose the right treatment for my patient with mCRPC? <u>A. Morgans</u> ¹ , <u>E. Castro</u> ² , <u>B. Hadaschik</u> ³ , <u>I. Burger</u> ⁴ , ¹ Dana Farber Cancer Institute, Boston, US, ² Hospital Universitario 12 de Octubre, Madrid, ES, ³ WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ⁴ KSB - Kantonsspital Baden, Baden, CH	
13:29 - 13:47	Is there a right sequence in advanced prostate cancer? <u>A. Morgans</u> ¹ , <u>E. Castro</u> ² , <u>B. Hadaschik</u> ³ , <u>I. Burger</u> ⁴ , ¹ Dana Farber Cancer Institute, Boston, US, ² Hospital Universitario 12 de Octubre, Madrid, ES, ³ WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ⁴ KSB - Kantonsspital Baden, Baden, CH	
13:47 - 14:05	What is the right approach to interdisciplinary/MDT collaborations? <u>A. Morgans</u> ¹ , <u>E. Castro</u> ² , <u>B. Hadaschik</u> ³ , <u>I. Burger</u> ⁴ , ¹ Dana Farber Cancer Institute, Boston, US, ² Hospital Universitario 12 de Octubre, Madrid, ES, ³ WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ⁴ KSB - Kantonsspital Baden, Baden, CH	
14:05 - 14:25	Patient case discussion <u>A. Morgans</u> ¹ , <u>E. Castro</u> ² , <u>B. Hadaschik</u> ³ , <u>I. Burger</u> ⁴ , ¹ Dana Farber Cancer Institute, Boston, US, ² Hospital Universitario 12 de Octubre, Madrid, ES, ³ WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE, ⁴ KSB - Kantonsspital Baden, Baden, CH	
14:25 - 14:30	Closing remarks <u>A. Morgans</u> , Dana Farber Cancer Institute, Boston, US	



13:00 - 14:30 **Type: Patient Advocacy session** **Cádiz Auditorium - NCC**
Title: People at the centre of cancer care
Chair(s): Stefan Gijssels, BE

13:00 - 13:15 **People at the centre**
S. Gijssels, Patient Expert Center, Brussels, BE

13:15 - 13:30 **Patient satisfaction during treatment and after care**
J. Geissler, Leukemia Patient Advocates Foundation - LeukaNET e.V., Riemerling (Hohenbrunn), DE

13:30 - 13:45 **Personalised treatment: Reflections on CAR-T therapy**
J. Clark, Lymphoma Coalition, Motovun, HR

13:45 - 14:00 **A journalist's approach to advocacy for improved access to diagnosis and treatment**
I. Mantiñan Búa, ASARGA - La Asociación Sarcomas de Galicia, Carballo, ES

14:00 - 14:15 **Advocating for cancer care in Armenia**
H. Martirosyan, "HENARAN" charitable foundation, Yerevan, AM

14:15 - 14:30 **Discussion**



13:45 - 14:45 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: EONS-EBMT collaborative session
Chair(s): Johan De Munter, BE

13:45 - 14:00 **Developing a CAR-T service**

A. Tooley, Southampton General Hospital, Southampton, GB

14:00 - 14:15 **CAR-T therapy and impact to patient outcomes and experience of treatment**

M. Hellberg-Naegele, Kantonsspital St. Gallen, St. Gallen, CH

14:15 - 14:25 **CN7 - The effect of using mobile application on supportive care needs, distress and quality of life in hematopoietic stem cell transplant patients: Randomized controlled study**

D. Başı¹, S. Kav², ¹University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TR, ²Baskent University Faculty of Health Sciences, Ankara, TR

14:25 - 14:35 **CN78 - Chimeric antigen receptor T cell (CAR T) nursing educational pathway: Reporting on participant feedback**

A. O'Halloran¹, S. Impey², D. Byrne¹, M. Gillespie¹, K. Mc Tague², ¹St. James's Hospital, Dublin, IE, ²Trinity College Dublin, Dublin, IE

14:35 - 14:45 **Q&A and discussion**



14:45 - 16:15 **Type: Special symposium** **Barcelona Auditorium - Hall 9**
Title: Controversies in early stage triple negative breast cancer
 Chair(s): Valentina Guarneri, IT; Rebecca Dent, SG

14:45 - 14:50 **Introduction and scientific background**
V. Guarneri, University of Padua, Padova, IT

14:50 - 15:05 **Optimal neo-adjuvant therapy in TNBC: Does one size fit all?**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

15:05 - 15:20 **Individualisation of adjuvant therapy in TNBC: Who gets what?**
V. Guarneri, University of Padua, Padova, IT

15:20 - 15:35 **What to do with stage 1 TNBC: Can we deescalate systemic therapy?**
P. Schmid, Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB

15:35 - 15:50 **Role of biomarkers / ctDNA monitoring in therapy decisions**
A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

15:50 - 16:10 **Discussion**

16:10 - 16:15 **Conclusions and perspectives**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

14:45 - 15:55 **Type: Mini Oral session** **Sevilla Auditorium - Hall 9**
Title: Mini oral session 2 - Non-metastatic NSCLC and other thoracic malignancies
 Chair(s): Edward Garon, US; Matthias Guckenberger, CH

14:45 - 14:50 **LBA57 - Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase 3 CheckMate 816 study: 3-y results by tumor PD-L1 expression**
M. Provencio Pulla¹, P. Forde², J. Spicer³, C. Wang⁴, S. Lu⁵, T. Mitsudomi⁶, M. Awad⁷, E. Felip⁸, S. Broderick², S.J. Swanson⁷, J. Brahmer², K. Kerr⁹, G. Saylor¹⁰, F. Tanaka¹¹, K.-N. Chen¹², M. Tran¹³, J.L. Cai¹³, J. Mahmood¹³, S. Meadows-Shropshire¹³, N. Girard¹⁴,
 1Hospital Universitario Puerta de Hierro, Madrid, ES, 2The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, 3McGill University Health Centre, Montreal, CA, 4Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, 5Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, 6Kindai University Faculty of Medicine, Ohno-Higashi, Osaka-Sayama, JP, 7Dana-Farber Cancer Institute, Boston, US, 8Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, ES, 9Aberdeen Royal Infirmary, Aberdeen, GB, 10Charleston Oncology, Charleston, US, 11University of Occupational and Environmental



Health, Kitakyushu, JP, ¹²Peking University School of Oncology, Beijing Cancer Hospital, Beijing, CN, ¹³Bristol Myers Squibb, Princeton, US, ¹⁴Institut Curie, Paris, FR

- 14:50 - 14:55 **1264MO - IMpower010: Exploratory analysis of disease-free survival (DFS) by TGF β 2; cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)**
- N. Altorki¹, M. Reck², H. Wakelee³, E. Felip⁴, E. Vallieres⁵, R. Liersch⁶, S. Oizumi⁷, H. Tanaka⁸, S. Novello⁹, S. Mccune¹⁰, H. Li¹¹, L. Molinero¹², S. Müller¹², E. Bennett¹², B. Gitlitz¹², V. McNally¹³, M. Ballinger¹², B. Nabet¹², M. Srivastava¹², C. Zhou¹⁴, ¹NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ²Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, DE, ³Stanford University School of Medicine, Stanford Cancer Institute, Stanford, US, ⁴Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵Swedish Cancer Institute, Seattle, US, ⁶Clemenshospital Muenster, Muenster, DE, ⁷National Hospital Organization Hokkaido Cancer Center, Hokkaido University Hospital, Sapporo, JP, ⁸Niigata Cancer Center Hospital, Niigata, JP, ⁹University of Turin, AOU San Luigi Gonzaga, Orbassano, Turin, IT, ¹⁰Northwest Georgia Oncology Centers, Marietta, US, ¹¹Hoffmann-La Roche Limited, Mississauga, CA, ¹²Genentech, Inc., South San Francisco, US, ¹³Roche Products Ltd, Welwyn Garden City, GB, ¹⁴Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, CN
- 14:55 - 15:00 **LBA58 - Pathological Response to Neoadjuvant Tislelizumab (TIS) Plus Platinum-Doublet (PtDb) Chemotherapy (CT) in Resectable Stage II-III A NSCLC Patients (pts) in the Phase 3 (Ph3) RATIONALE-315 Trial**
- D. Yue¹, W. Wang², H. Liu³, Q. Chen⁴, C. Chen⁵, J. Zhang⁶, F. Bai⁷, C. Wang¹, ¹Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, ²Hunan Cancer Hospital, Hunan, CN, ³Liaoning Cancer Hospital and Institute, Shenyang, CN, ⁴Zhejiang Cancer Hospital, Hangzhou, CN, ⁵Fujian Medical University Union Hospital, Fuzhou, CN, ⁶BeiGene USA, Inc., San Mateo, US, ⁷BeiGene (Shanghai) Co., Ltd., Shanghai, CN
- 15:00 - 15:05 **LBA59 - Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase 3 AEGEAN trial**
- M. Reck¹, D. Gale², D. Harpole³, J. Taube⁴, T. Mitsudomi⁵, M. Hochmair⁶, T. Winder⁷, Z. Zhu⁸, Z. Lai⁹, R. Stewart², D. Hodgson², G. Doherty², J. Heymach¹⁰, ¹Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ²AstraZeneca, Cambridge, GB, ³Duke University Medical Center, Durham, US, ⁴Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, US, ⁵Kindai University Faculty of Medicine, Osaka-Sayama, JP, ⁶Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ⁷Landeskrankenhaus Feldkirch, Feldkirch, AT, ⁸AstraZeneca, Gaithersburg, US, ⁹AstraZeneca, Waltham, US, ¹⁰The University of Texas, M.D. Anderson Cancer Center, Houston, US
- 15:05 - 15:20 **Invited Discussant LBA57, 1264MO, LBA58 and LBA59**
- E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US
- 15:20 - 15:25 **LBA61 - Durvalumab (durva) after sequential chemoradiotherapy (CRT) in**



patients (pts) with unresectable Stage III NSCLC: Final analysis from PACIFIC-6

M. Garassino¹, J. Mazieres², M. Reck³, C. Chouaid⁴, H. Bischoff⁵, N. Reinmuth⁶, L. Cove-Smith⁷, T. Mansy⁸, D. Cortinovis⁹, M.R. Migliorino¹⁰, A. Delmonte¹¹, J. García Sanchez¹², L.E. Chara Velarde¹³, R. Bernabe Caro¹⁴, L. Paz-Ares¹⁵, P. Chander¹⁶, I. Diaz Perez¹⁶, K. Foroutanpour¹⁶, C. Faivre-Finn¹⁷, ¹University of Chicago, Chicago, US, ²Institut Universitaire du Cancer de Toulouse, Toulouse, FR, ³Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, DE, ⁴Centre Hospitalier Intercommunal de Créteil, Créteil, FR, ⁵Universitätsklinikum Heidelberg, Heidelberg, DE, ⁶Asklepios Fachkliniken München-Gauting, and German Center for Lung Research (DZL), Gauting, DE, ⁷The Christie NHS Foundation Trust and Manchester University Hospitals Foundation Trust, Manchester, GB, ⁸James Cook University Hospital, Middlesbrough, GB, ⁹Fondazione IRCCS San Gerardo dei Tintori, Monza, IT, ¹⁰San Camillo-Forlanini Hospital, Rome, IT, ¹¹IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, IT, ¹²Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana (FISABIO), Valencia, ES, ¹³Hospital Universitario de Guadalajara, Guadalajara, ES, ¹⁴Hospital Universitario Virgen del Rocío, Seville, ES, ¹⁵Universidad Complutense, Cyberonc, CNIO and Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB

15:25 - 15:30

1292MO - A phase II study of daily carboplatin plus irradiation followed by durvalumab for unresectable III non-small cell lung cancer patients with PS 2 or elderly (≧75 years): NEJ039A

R. Ko¹, A. Mouri², A. Kishohara³, R. Morita⁴, T. Nakagawa⁵, T. Makiguchi⁶, K. Isobe⁷, N. Ishikawa⁸, T. Kondo⁹, M. Akiyama¹⁰, A. Bessho¹¹, R. Honda¹², K. Yoshimura¹³, H. Kagamu², S. Kato¹⁴, K. Kobayashi², K. Kaira², ¹Shizuoka Cancer Center, Shizuoka, JP, ²Saitama Medical University International Medical Center, Hidaka, JP, ³Kasukabe medical center, Kasukabe, Saitama Prefecture, JP, ⁴Akita Kousei Medical Center, Akita, JP, ⁵Omagari Kousei Medical Center, Daisen, JP, ⁶Hirosaki University Graduate School of Medicine, Hirosaki, JP, ⁷Toho university Medical Center Oomori Hospital, Tokyo, JP, ⁸Hiroshima Prefectural Hospital, Hiroshima, JP, ⁹Kanagawa Cancer Center, Yokohama, JP, ¹⁰Iwate Medical University, Shiwa-gun, JP, ¹¹Japanese Red Cross Okayama Hospital, Okayama, JP, ¹²Asahi General Hospital, Asahi, JP, ¹³Hiroshima University Hospital, Hiroshima, JP, ¹⁴International Medical Center, Saitama Medical University, Hidaka, JP

15:30 - 15:35

LBA62 - Durvalumab after radiotherapy (RT) in patients with unresectable Stage III NSCLC ineligible for chemotherapy (CT): Primary results from the DUART study

A.R. Filippi¹, M.R. Garcia Campelo², J.-B. Paoli³, D. Kowalski⁴, C. Bennati⁵, P. Borghetti⁶, D. Cortinovis⁷, A. Delmonte⁸, C. Genova⁹, S. Van Hulst¹⁰, R. Mroz¹¹, S. Nawrocki¹², I. Toledano¹³, G. Tonini¹⁴, I. Diaz Perez¹⁵, N. Georgoulia¹⁵, K. Foroutanpour¹⁵, R. Dziadziuszko¹⁶, ¹Fondazione IRCCS Policlinico San Matteo and University of Pavia, Pavia, IT, ²University Hospital A Coruña, A Coruña, ES, ³Hôpital Privé Clairval, Marseille, FR, ⁴Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁵S Maria delle Croci Hospital, AUSL della Romagna, Ravenna, IT, ⁶ASST Spedali Civili and University of Brescia, Brescia, IT, ⁷Fondazione IRCCS San Gerardo dei Tintori Monza, Monza, IT, ⁸IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, IT, ⁹IRCCS Ospedale Policlinico San Martino/University of Genoa, Genoa, IT,



¹⁰University Hospital of Nîmes, Nîmes, FR, ¹¹Medical University of Bialystok, Bialystok, PL, ¹²University of Warmia and Mazury in Olsztyn, Olsztyn, PL, ¹³CCGM, Clinique Clémentville, Montpellier, FR, ¹⁴Fondazione Policlinico Universitario Campus Bio-Medico/Università Campus Bio-Medico di Roma, Rome, IT, ¹⁵AstraZeneca, Gaithersburg, US, ¹⁶Medical University of Gdansk, Gdansk, PL

15:35 - 15:40

1293MO - Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial

F. Bozorgmehr¹, E. Buchmeier², M. Hammer-Hellmig², U. Nestle³, C. Meyer Zum Bueschenfelde⁴, F. Weykamp⁵, J. Claßen⁶, P. Schuett⁷, T. Riedel⁸, T. Wehler⁹, S. Hey-Koch⁹, T. Overbeck¹⁰, J. Alt¹¹, H. Schmidberger¹², R. Behnisch¹³, I. Chung¹, M. Thomas¹, S. Rieken¹⁴, ¹Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, DE, ²Klinikum Köln-Merheim, Köln, DE, ³Kliniken Maria Hilf, Mönchengladbach, DE, ⁴St. Vincentius Hospital Medizinische Klinik II, Karlsruhe, DE, ⁵University Hospital Heidelberg, Heidelberg University, Heidelberg, DE, ⁶ViDia Karlsruhe Diakonissenkrankenhaus, Karlsruhe, DE, ⁷Onkologische Schwerpunktpraxis, Gütersloh, DE, ⁸Radioonkologische Praxis, Gütersloh, DE, ⁹Sana Klinikum Offenbach GmbH, Offenbach am Main, DE, ¹⁰University Medical Center Göttingen, Göttingen University, Goettingen, DE, ¹¹University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, DE, ¹²Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ¹³Heidelberg University Hospital, Heidelberg, DE, ¹⁴Universitätsmedizin Göttingen, Goettingen, DE

15:40 - 15:55

Invited Discussant LBA61, 1292MO, LBA62 and 1293MO

M. Guckenberger, USZ - University Hospital Zürich, Zurich, CH



14:45 - 16:15 **Type: Special symposium** **Bilbao Auditorium - NCC**
Title: Long term survivors in the era of immunotherapy of cancer
 Chair(s): Teresa Amaral, DE; Michiel van der Heijden, NL

14:45 - 15:05 **Long-term toxicity of immunotherapeutics**
D. Mcdermott, Beth Israel Deaconess Medical Center, Boston, US

15:05 - 15:25 **Quality of life in IO-treated long-term survivors**
L. Van De Poll-Franse, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

15:25 - 15:45 **Cognitive defects in long term IO**
A. Rogiers, CHU Brugmann UVB, Brussels, BE

15:45 - 16:05 **Ideal duration of IT: How to define it and what are the implications**
T. Amaral, Skin Cancer Clinical Trials Center, University of Tuebingen, Tübingen, DE

16:05 - 16:15 **Discussion**

14:45 - 16:15 **Type: Special session** **Granada Auditorium - Hall 3**
Title: Artificial Intelligence in prognostication
 Chair(s): Sanjay Aneja, US; Anne Vincent-Salomon, FR

14:45 - 15:10 **AI for breast cancer prognostication**
A. Vincent-Salomon, Institut Curie, Paris, FR

15:10 - 15:35 **Biomarkers of response to drugs and radiotherapy**
B. Haihe-Kains, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

15:35 - 16:00 **Digital pathology for immuno-oncology**
M. Salto-Tellez, Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, GB

16:00 - 16:15 **Q&A and Discussion**



14:45 - 16:15	Type: Special session Title: How do we best monitor patients during follow-up? Chair(s): Christian Rolfo, US; Paolo Bossi, IT	Valencia Auditorium - Hall 10
14:45 - 14:50	Introduction <u>C. Rolfo</u> , Icahn School of Medicine at Mount Sinai, New York, US	
14:50 - 15:05	Minimalist or maximalist? From literature to real-world data <u>P. Zola</u> , Università di Torino, Torino, IT	
15:05 - 15:20	Radiological imaging vs clinical examination: When less is more <u>R. Maroldi</u> , Università degli Studi di Brescia - Facoltà di Medicina e Chirurgia, Brescia, IT	
15:20 - 15:35	Liquid biopsy may improve a tailored follow up <u>C. Rolfo</u> , Icahn School of Medicine at Mount Sinai, New York, US	
15:35 - 15:50	The patient's perspective and expectations <u>A. Cardone</u> , Cancer Patients Europe, Brussels, BE	
15:50 - 16:05	It is not just survival: Rehabilitation, quality of life and late toxicities <u>F. Jansen</u> , Amsterdam University Medical Centers UMC, Amsterdam, NL	
16:05 - 16:15	Discussion	



14:45 - 16:15	Type: Educational session Title: Bringing together thyroid cancer and neuroendocrine tumours Chair(s): Eric Baudin, FR; Emily Bergsland, US	Salamanca Auditorium - Hall 3
14:45 - 15:05	State-of-the-art in the treatment of advanced neuroendocrine tumours <u>E. Bergsland</u> , UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US	
15:05 - 15:25	State-of-the-art in the treatment of advanced thyroid cancer <u>C. Spitzweg</u> , LMU Klinikum der Universität München, Munich, DE	
15:25 - 15:45	What we could learn from each tumour type to improve the management of both <u>E. Baudin</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
15:45 - 16:05	Future directions on targeted agents and beyond in thyroid and neuroendocrine tumours <u>E. Grande Pulido</u> , MD Anderson Cancer Center Madrid, Madrid, ES	
16:05 - 16:15	Discussion	



14:45 - 16:15	Type: Educational session Title: Genetic predisposition in patients with sarcoma Chair(s): Nadia Hindi, ES; Tom Wei-Wu Chen, TW	Málaga Auditorium - Hall 10
14:45 - 15:05	When and why to test a patient with sarcoma for hereditary predisposition <u>D. Thomas</u> , Garvan Institute of Medical Research, Darlinghurst, AU	
15:05 - 15:20	How to use radiology in patients with hereditary syndromes <u>C. Messiou</u> , The Royal Marsden Hospital - Chelsea, London, GB	
15:20 - 15:35	How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A surgeon's perspective <u>S. Bonvalot</u> , Institut Curie, Paris, FR	
15:35 - 15:50	How to treat bone, soft tissue and GIST patients with a hereditary predisposition: A medical oncologist's perspective <u>W. Van Der Graaf</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL	
15:50 - 16:05	How to treat sarcoma patients with a hereditary predisposition: A radiation oncologist's perspective <u>B. Timmermann</u> , University Hospital Essen - Westdeutsches Protonentherapiezentrum, Essen, DE	
16:05 - 16:15	Discussion	



15:00 - 16:00	Type: Controversy session Title: Can we avoid preoperative (chemo)radio-therapy in locally advanced rectal cancer patients? Chair(s): Andres Cervantes, ES	Burgos Auditorium - Hall 3
15:00 - 15:05	Welcome and "set the scene" <u>A. Cervantes</u> , Hospital Clinico Universitario de Valencia, Valencia, ES	
15:05 - 15:20	Yes <u>S. Lonardi</u> , IOV - Istituto Oncologico Veneto IRCCS, Padova, IT	
15:20 - 15:35	No <u>D. Sebag-Montefiore</u> , St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, GB	
15:35 - 15:40	First voting	
15:40 - 15:55	Perspective from the Chair <u>A. Cervantes</u> , Hospital Clinico Universitario de Valencia, Valencia, ES	
15:55 - 16:00	Second voting	



15:00 - 16:15 **Type: Multidisciplinary session** **Santander Auditorium - Hall 9**
Title: Management of (very) high-risk localised PCA: How hard should you look and how long should we treat?
 Chair(s): Gwenaëlle Gravis, FR; Boris Hadaschik, DE

15:00 - 15:05 **Presentation of case/condition**
B. Hadaschik, WTZ - Westdeutsches Tumorzentrum Essen, Essen, DE

15:05 - 15:15 **Usefulness and limitations of PSMA imaging/PET in high-risk localised disease**
K. Goffin, UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

15:15 - 15:30 **Dose intensification and field expansion of EBRT**
A. Bossi, Gustave Roussy - Cancer Campus, Villejuif, FR

15:30 - 15:45 **Delineating staging pelvic LND before RT and positioning primary prostatectomy**
D. Tilki, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

15:45 - 16:00 **How much systemic treatment is needed and how long?**
G. Gravis, IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

16:00 - 16:15 **Q&A and Discussion**

15:00 - 15:45 **Type: Challenge your Expert** **Toledo Auditorium - Hall 3**
Title: Checkpoint inhibition and beyond: New approaches in advanced gastric oesophageal cancer
 Chair(s): Tania Fleitas, ES

15:00 - 15:20 **Presentation by Expert**
S.-E. Al-Batran, Nordwest-Krankenhaus, Frankfurt am Main, DE

15:20 - 15:45 **Discussion led by Chair**
T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES



15:00 - 15:45 **Type: Challenge your Expert** **Oviedo Auditorium - Hall 7**
Title: Challenges in the management of Waldenström's macroglobulinemia
 Chair(s): Meletios Dimopoulos, GR

15:00 - 15:20 **Presentation by Expert**
A. Tedeschi, ASST Grande Ospedale Metropolitano Niguarda, Milan, IT

15:20 - 15:45 **Discussion led by Chair**
M. Dimopoulos, Alexandra Hospital, Athens, GR

15:00 - 16:15 **Type: Multidisciplinary session** **León Auditorium - Hall 7**
Title: Challenging common problems in neuro-oncology
 Chair(s): Enrico Franceschi, IT; Emma van Kessel, NL

15:00 - 15:15 **Presentation of case: Low-grade glioma**
E. Van Kessel, UMC - University Medical Center Utrecht, Utrecht, NL

15:15 - 15:30 **Upfront and salvage surgery for low grade gliomas: Do tumour mutations need different strategies?**
A. Jakola, University of Gothenburg - The Sahlgrenska Academy, Göteborg, SE

15:30 - 15:45 **Radiotherapy for low grade gliomas with and without mutations: Wait or treat?**
H. Shih, MGH - Massachusetts General Hospital, Boston, US

15:45 - 16:00 **The optimal radiochemotherapeutic combination for low grade gliomas: Lessons from trials**
E. Franceschi, Ospedale Bellaria Carlo Alberto Pizzardi, Bologna, IT

16:00 - 16:15 **Discussion**

15:00 - 15:45 **Type: Challenge your Expert** **Cádiz Auditorium - NCC**
Title: Alcohol consumption and cancer risk: The sobering facts about alcohol and cancer
 Chair(s): Gilberto Morgan, SE

15:00 - 15:20 **Presentation by Expert**
I. Soerjomataram, IARC - International Agency for Research on Cancer, Lyon, FR

15:20 - 15:45 **Discussion led by Chair**
G. Morgan, Skane University Hospital, Lund, SE



15:00 - 16:00 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: YCN/YO collaborative session

Chair(s): Nikolina Dodlek, HR

15:00 - 15:15 **Personalised cancer care: The physician's perspective**

P. Aftimos, Institute Jules Bordet, Anderlecht, BE

15:15 - 15:30 **Nursing in clinical trials**

H. Mccallig, University Hospital Limerick, Limerick, IE

15:30 - 15:40 **CN60 - Dynamics and processes in the perception of colorectal cancer patients facing skin toxicity due to an EGFR-inhibitor**

M. De Kegel¹, K. Geboes², S. De Meyer², P. Vandecandelaere³, E. Pape⁴, ¹Ghent University - Campus Ufo, Gent, BE, ²UZ Gent - University Hospital Ghent, Gent, BE, ³AZ Delta Campus Rumbeke, Roeselare, BE, ⁴UZ Gent - Universitair Ziekenhuis Gent, Gent, BE

15:40 - 15:50 **CN61 - Recognizing and managing immune checkpoint: Related symptoms with expert advice from dedicated oncology nurse**

A. Muratovic, S. Sopaj, U. Janzic, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, SI

15:50 - 16:00 **Q&A and discussion**



16:00 - 17:00 **Type: Young Oncologists session** **Pamplona Auditorium - Hall 9**
Title: YO Clinical Case Discussion sessions

16:00 - 16:00 **Table 1: Immunotherapy in patients with autoimmune disease**

C. Robert¹, A. Starzer², ¹Institut Gustave Roussy, Villejuif, Cedex, FR, ²Medizinische Universitaet Wien, Vienna, AT

16:00 - 16:00 **Table 2: Integration of liquid biopsy in decision making in the management of patients with colon cancer**

A. De Stefano¹, E. Mariamidze², ¹Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ²Todua Clinic, Tbilisi, GE

16:00 - 16:00 **Table 3: HER2+ breast cancer with brain metastases**

E. De Azambuja¹, P. Mando², ¹Institute Jules Bordet, Brussels, BE, ²CEMIC - Centro de Educacion Medica e Investigacones Clinicas Dr Norberto Quirno, Buenos Aires, AR

16:00 - 16:00 **Table 4: Molecular profiling for cancer of unknown primary**

N. Cook¹, K. Punie², ¹The Christie NHS Foundation Trust, Manchester, GB, ²UZ Leuven - University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

16:00 - 16:00 **Table 5: Rare sarcomas and the importance of centralised and multidisciplinary care**

K. Kozak¹, P. Sobczuk², ¹Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL, ²Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

16:15 - 16:30 **Type: EONS session** **Alicante Auditorium - Hall 10**
Title: EONS16: EONS closing session

16:15 - 16:20 **EONS Poster Awards**

16:20 - 16:25 **ECND 2023 winners**

16:25 - 16:30 **Closing remarks and Farewell**



16:30 - 18:00 **Type: Educational session** **Granada Auditorium - Hall 3**
Title: Adjuvant / neoadjuvant therapy of operable NSCLC in 2023
 Chair(s): Heather Wakelee, US; Jarushka Naidoo, IE

16:30 - 16:55 **Current standard of care in adjuvant / neoadjuvant therapy of operable NSCLC**
H. Wakelee, Stanford University, Stanford, US

16:55 - 17:20 **Predictive biomarkers for adjuvant / neoadjuvant IO**
N. Girard, Institut Curie, Paris, FR

17:20 - 17:45 **Management of relapse on/after perioperative IO**
M. Frueh, Kantonsspital St. Gallen, St. Gallen, CH

17:45 - 18:00 **Discussion**

16:30 - 18:05 **Type: Mini Oral session** **Cádiz Auditorium - NCC**
Title: Mini oral session - Policy and preventive strategies
 Chair(s): James McKay, FR; Tit Albrecht, SI; Wendy Tse Yared, BE

16:30 - 16:35 **1692MO - Is project Orbis successful? The Swiss perspective**
M. Pavic, Q. Li, E. Atiek, A. Wolfer, U.-P. Rohr, Swissmedic Swiss Agency for Therapeutic Products, Bern, CH

16:35 - 16:40 **1693MO - The high burden of long-term and late health-related problems among adolescent and young adult cancer survivors: Results of the SURVAYA study**
S. Janssen¹, C. Vlooswijk², R. Van Leeuwen³, S. Kaal⁴, J. Kerst¹, J. Tromp⁵, M. Bos⁶, T. Van Der Hulle⁷, R.I. Lalisang⁸, J. Nuver⁹, M. Kouwenhoven⁵, W. Van Der Graaf¹, O. Husson¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²IKNL - Netherlands Comprehensive Cancer Organisation, Utrecht, NL, ³UMC - University Medical Center Utrecht, Utrecht, NL, ⁴Radboud University Medical Center, Nijmegen, Nijmegen, NL, ⁵Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL, ⁶Erasmus MC - University Medical Center, Rotterdam, NL, ⁷LUMC - Universitair Medisch Centrum, Leiden, NL, ⁸Maastricht University Medical Center (MUMC), Maastricht, NL, ⁹University Medical Center Groningen - umcg, Groningen, NL

16:40 - 16:45 **1694MO - Socio-economic consequences among adolescent and young adult cancer patients: A European perspective**
S. Janssen¹, J. Vancoppenolle¹, N. Franzen¹, W. Van Der Graaf¹, O. Husson¹, V. Retel¹, W. Van Harten², ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²University of Twente, Enschede, NL

16:45 - 16:50 **1695MO - Cancer care during armed conflict: Factors associated with adult**



patient transfer for treatment abroad during the war in Ukraine

I. Huivaniuk¹, D. Kizub², V. Kopetskyi¹, A. Dzhemiliev³, A. Kacharian¹, V. Strilka¹, A. Beznosenko¹, N. Melnitchouk⁴, ¹National Cancer Institute of the Ministry of Health of Ukraine, Kiev, UA, ²MD Anderson Cancer Center, Houston, US, ³Brigham and Women's Hospital, Boston, US, ⁴Harvard Medical School, Boston, US

16:50 - 17:05 **Invited Discussant 1692MO, 1693MO, 1694MO and 1695MO**

J. Mckay, IARC - International Agency for Research on Cancer, Lyon, FR

17:05 - 17:10 **1759MO - Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study**

H. Azim¹, L. Kassem¹, K. Shohdy¹, Y. Safwat¹, E. Khallaf¹, S. Naguib¹, M. Hegazy², A. Selim¹, N. Hussein³, A. Abdelaziz⁴, H. El Ghazaly⁴, M. Hassany³, A. Abdelaziz¹, A. Kandil⁵, B.A. El Sayed³, T. Hashem⁶, S. Eid⁷, A. Morsy³, K. Abdelghaffar³, H. Zaid³, ¹Cairo University, Giza, EG, ²Mansoura University, Mansoura, EG, ³Ministry of Health and Population, Cairo, EG, ⁴Ain Shams University, Cairo, EG, ⁵Alexandria University, Alexandria, EG, ⁶Menoufia University, Shebeen El-Kom, EG, ⁷Assiut University, Assiut, EG

17:10 - 17:15 **1696MO - Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending**

D. Michaeli¹, C. Michaeli², ¹Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, DE, ²UMM - Universitaetsklinikum Mannheim, Mannheim, DE

17:15 - 17:20 **1697MO - Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases**

J.C. Michaeli¹, C. Michaeli², D. Michaeli³, ¹LMU University Hospital, LMU Munich, Munich, DE, ²UMM - Universitaetsklinikum Mannheim, Mannheim, DE, ³Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, DE

17:20 - 17:35 **Invited Discussant 1759MO, 1696MO and 1697MO**

T. Albreht, National Institute of Public Health of Slovenia - Nacionalni inštitut za javno zdravje, Ljubljana, SI

17:35 - 17:40 **1698MO - E-cigarette use among us ever-smoking cancer survivors and its implications on lung cancer screening**

Q. Wang¹, M. Hsu¹, C. Wen², A. Dowlati¹, Y. Zhang³, C. Jiang⁴, D. Bruno¹, Y. Li⁵, L. Deng⁴, L. Chiec¹, G. Dutcher¹, C.Y. Kong², ¹University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, US, ²Icahn School of Medicine at Mount Sinai, New York, US, ³Ascension Providence Hospital, Southfield, US, ⁴Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁵UBC - The University of British Columbia, Vancouver, CA

17:40 - 17:45 **1699MO - Intervening factors for participation and non-participation in colorectal cancer screening in Spain**

M.L. Amador¹, D. De Haro², B. Fernández Sánchez¹, M. Lopez³, M. Blanco Álvarez¹, A.



Fernández Marcos¹, ¹Headquarters Spanish Association Against Cancer (AECC), Madrid, ES, ²AECC - Asociación Española Contra El Cáncer, MADRID, ES, ³Asociación Española Contra el Cáncer, MADRID, ES

17:45 - 17:50 **1700MO - Knowledge of cancer risk factors and risk-reduction in 20 high- and middle-income countries**

P. Carrera, S. Calderazzo, DKFZ - German Cancer Research Center, Heidelberg, DE

17:50 - 18:05 **Invited Discussant 1698MO, 1699MO and 1700MO**

W. Tse Yared, Association of European Cancer Leagues, Brussels, BE

**16:30 - 18:15 Type: Proffered Paper session
Title: Presidential 3**

Madrid Auditorium - Hall 6

Chair(s): Fabrice André, FR; Karin Jordan, DE

16:30 - 16:42 **LBA11 - Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial.**

A. Bardia¹, K. Jhaveri², S.-A. Im³, S. Pernas Simon⁴, M. De Laurentiis⁵, S. Wang⁶, N. Martinez⁷, G. Santos Borges⁸, D. Cescon⁹, M. Hattori¹⁰, Y.-S. Lu¹¹, E. Hamilton¹², Q.Y. Zhang¹³, J. Tsurutani¹⁴, K. Kalinsky¹⁵, L. Xu¹⁶, N. Denduluri¹⁷, H. Rugo¹⁸, B. Xu¹⁹, B. Pistilli²⁰, ¹Massachusetts General Hospital Cancer Center, Boston, US, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ⁴Institut Català d'Oncologia, IDIBELL, L'Hospitalet, L'Hospitalet de Llobregat, ES, ⁵Istituto Nazionale Tumori Napoli IRCCS "Fondazione Pascale", Napoli, IT, ⁶Cancer Center of SunYet-sen University, Guangzhou, CN, ⁷Ramón y Cajal University Hospital, Madrid, ES, ⁸Catarina Pesquisa Clínica, Santa Catarina, BR, ⁹Princess Margaret Cancer Centre/UHN, Toronto, CA, ¹⁰Aichi Cancer Center, Nagoya, JP, ¹¹National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei City, TW, ¹²Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, ¹³Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁴Showa University Hospital, Tokyo, JP, ¹⁵Winship Cancer Institute at Emory University, Atlanta, US, ¹⁶AstraZeneca, New York, US, ¹⁷AstraZeneca, Arlington, US, ¹⁸University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ¹⁹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²⁰Gustave Roussy Cancer Center, Villejuif, FR

16:42 - 16:54 **LBA12 - Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase 3 study TROPION-Lung01**

M.-J. Ahn¹, A. Lisberg², L. Paz-Ares³, R. Cornelissen⁴, N. Girard⁵, E. Pons-Tostivint⁶, D. Vicente Baz⁷, S. Sugawara⁸, M. Cobo Dols⁹, M. Pérol¹⁰, C. Mascaux¹¹, E. Poddubskaya¹², S. Kitazono¹³, H. Hayashi¹⁴, J. Sands¹⁵, R. Hall¹⁶, Y. Zhang¹⁷, H. Zebger-Gong¹⁸, D. Uema¹⁷, I. Okamoto¹⁹, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ²Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, ³Hospital Universitario 12 de Octubre, Madrid, ES, ⁴Erasmus MC Cancer Institute,



Rotterdam, NL, ⁵Institut Curie, Paris, FR, ⁶University Hospital Nantes, Nantes, FR, ⁷Hospital Universitario Virgen Macarena, Seville, ES, ⁸Sendai Kousei Hospital, Sendai, JP, ⁹Regional and Virgen de la Victoria University Hospitals, Malaga, ES, ¹⁰Léon Bérard Cancer Centre, Lyon, FR, ¹¹Hôpitaux Universitaires de Strasbourg (CHRU), Strasbourg, FR, ¹²Vitamed LLC, Moscow, RU, ¹³The Cancer Institute Hospital of JFCR, Tokyo, JP, ¹⁴Kindai University, Osaka, JP, ¹⁵Dana-Farber Cancer Institute, Boston, US, ¹⁶University of Virginia Health System, Charlottesville, US, ¹⁷Daiichi Sankyo, Inc, Basking Ridge, US, ¹⁸Daiichi Sankyo Europe GmbH, Munich, DE, ¹⁹Kyushu University, Fukuoka, JP

16:54 - 17:04 **Invited Discussant LBA11 and LBA12**

S. Chandralapaty, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

17:04 - 17:10 **Q&A**

17:10 - 17:22 **LBA13 - Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)**

O. Sartor¹, D. Castellano Gauna², K. Herrmann³, J. De Bono⁴, N. Shore⁵, K.N. Chi⁶, M. Crosby⁷, J.M. Piulats⁸, A. Flechon⁹, X. Wei¹⁰, H. Mahammedi¹¹, G. Roubaud¹², H. Studentova¹³, S. Ghebremariam¹⁴, E. Kpamegan¹⁴, T. Kreisl¹⁴, N. Delgosaie¹⁵, K. Lehnhoff¹⁵, M. Morris¹⁶, K. Fizazi¹⁷, ¹Mayo Clinic - Rochester, Rochester, US, ²Hospital Universitario 12 de Octubre, Madrid, ES, ³University of Duisburg-Essen and German cancer consortium (DKTK), partner site University Hospital Essen, Essen, DE, ⁴The Institute of Cancer Research and Royal Marsden Hospital, Sutton, GB, ⁵Carolina Urologic Research Center/GenesisCare US, Myrtle Beach, US, ⁶BC Cancer and Vancouver Prostate Centre, Vancouver, CA, ⁷Veterans Prostate Cancer Awareness Inc, Washington DC, US, ⁸ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, ES, ⁹Centre Leon Berard, Lyon, FR, ¹⁰Dana Farber Cancer Institute, Boston, US, ¹¹Centre Jean PERRIN, Clermont-Ferrand, Cedex, FR, ¹²Institute Bergonié, Bordeaux, FR, ¹³FN Olomouc/ University Hospital Olomouc, Olomouc, CZ, ¹⁴Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁵Novartis International AG - Basel, Basel, CH, ¹⁶MSKCC - Memorial Sloan Kettering Cancer Center, New York, US, ¹⁷Gustave Roussy, University Paris Saclay, Villejuif, FR

17:22 - 17:30 **Invited Discussant LBA13**

C. Sweeney, The University of Adelaide, Adelaide, AU

17:30 - 17:35 **Q&A**

17:35 - 17:47 **LBA14 - Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial**

B.C. Cho¹, E. Felip², A. Spira³, N. Girard⁴, J.-S. Lee⁵, S.-H. Lee⁶, Y. Ostapenko⁷, P. Danchaivijitr⁸, B. Liu⁹, A. Alip¹⁰, E. Korbenfeld¹¹, J. Dias¹², T. Sun¹³, M. Martinez¹³, J.



Bauml¹⁴, M. Shreeve¹⁵, S. Sethi¹⁴, R. Knoblauch¹⁴, H. Hayashi¹⁶, S. Lu¹⁷, ¹Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ²Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ³Virginia Cancer Specialists, Fairfax, US, ⁴Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, FR, ⁵Seoul National University Bundang Hospital, Seongnam, KR, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁷National Cancer Institute, Kyiv, UA, ⁸Siriraj Hospital, Mahidol University, Bangkok, TH, ⁹Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁰University Malaya Medical Centre, Kuala Lumpur, MY, ¹¹Hospital Britanico de Buenos Aires, Buenos Aires, AR, ¹²Barretos Cancer Hospital, Barretos, BR, ¹³Janssen R&D, Raritan, US, ¹⁴Janssen R&D, Spring House, US, ¹⁵Janssen R&D, San Diego, US, ¹⁶Kindai University Faculty of Medicine, Osaka, JP, ¹⁷Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN

17:47 - 17:59

LBA15 - Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated Advanced NSCLC After Progression on Osimertinib: MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial

A. Passaro¹, B.C. Cho², Y. Wang³, B. Melosky⁴, R. Califano⁵, S.-H. Lee⁶, N. Girard⁷, K. Reckamp⁸, T. Takahashi⁹, E. Felip¹⁰, R.D. Gentzler¹¹, S. Popat¹², W. Nassib William Junior¹³, T. Sun¹⁴, S. Shah¹⁵, B. Diorio¹⁶, R. Knoblauch¹⁵, J. Bauml¹⁵, M.R. Garcia Campelo¹⁷, J. Wang¹⁸, ¹European Institute of Oncology, IRCCS, Milan, IT, ²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ³West China Hospital, Sichuan University, Chengdu, CN, ⁴British Columbia Cancer Agency, Vancouver, CA, ⁵Christie NHS Foundation Trust and Division of Cancer Sciences, The University of Manchester, Manchester, GB, ⁶Sungkyunkwan University School of Medicine, Seoul, KR, ⁷Institut du Thorax Curie-Montsouris, Paris, France; Paris Saclay University, UVSQ, Versailles, FR, ⁸Cedars-Sinai Medical Center, Los Angeles, US, ⁹Shizuoka Cancer Center, Nagaizumi, JP, ¹⁰Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹¹University of Virginia Cancer Center, Charlottesville, US, ¹²Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, GB, ¹³Beneficência Portuguesa de São Paulo and Grupo Oncoclínicas, São Paulo, BR, ¹⁴Janssen R&D, Raritan, US, ¹⁵Janssen R&D, Spring House, US, ¹⁶Janssen R&D, Titusville, US, ¹⁷University Hospital A Coruña, A Coruña, ES, ¹⁸Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

17:59 - 18:09

Invited Discussant LBA14 and LBA15

Z. Piotrowska, MGH - Massachusetts General Hospital, Boston, US

18:09 - 18:15

Q&A

16:30 - 18:00

Type: Mini Oral session
Title: Mini oral session - Developmental therapeutics

Valencia Auditorium - Hall 10

Chair(s): Pamela Munster, US; Ulrik Lassen, DK; Philippe Cassier, FR

16:30 - 16:35

656MO - The HER2-targeting ADC SHR-A1811 in HER2-expressing/mutated advanced non-breast solid tumors (STs): Results from the global phase I study

H. Yao¹, M.H. Ryu², J. Park³, M. Voskoboynik⁴, J.H. Kim⁵, K. Liu⁶, M. Barve⁷, A. Acuna-



Villaorduna⁸, S.-A. Im⁹, A.C. Roy¹⁰, L.-Y. Bai¹¹, C.-J. Yen¹², J. Zhang¹³, V. Ganju¹⁴, L. Wu¹⁵, M. Yan¹⁶, L. Bao¹⁷, Y. Zhao¹, S. Rong¹⁸, E. Song¹, ¹Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, CN, ²Asan Medical Center, Seoul, KR, ³Macquarie University, Sydney, AU, ⁴Alfred Health, Melbourne, AU, ⁵Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, ⁶Hunan Cancer Hospital, Changsha, CN, ⁷Mary Crowley Cancer Research, Dallas, US, ⁸Montefiore-Einstein Center for Cancer Care, Bronx, US, ⁹Seoul National University, Seoul, KR, ¹⁰Southern Oncology Clinical Research Unit, Adelaide, AU, ¹¹China Medical University Hospital, Taichung, TW, ¹²National Cheng Kung University Hospital, Tainan, TW, ¹³Fudan University Shanghai Cancer Center, Shanghai, CN, ¹⁴PASO Medical, Melbourne, AU, ¹⁵Cancer Hospital Chinese Academy of Medical Sciences, Beijing, CN, ¹⁶Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ¹⁷HuBei Cancer Hospital, Wuhan, CN, ¹⁸Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, CN

16:35 - 16:40

657MO - Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors

B. Li¹, K.-W. Lee², M. Pegram³, M. Sharma⁴, J. Lee⁵, A. Spira⁶, Y.-K. Kang⁷, K. Moore⁸, D. Rasco⁹, G. Hanna¹⁰, B. Weinberg¹¹, T. Yu¹², M. Alonso¹², J. Ptacek¹², M. Yin¹², C. Tapia¹², L. Xu¹², E. Perez¹², E. Dumbrava¹³, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, KR, ³Stanford Comprehensive Cancer Institute, Stanford, US, ⁴START Midwest, Grand Rapids, US, ⁵Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁶Virginia Cancer Specialist, Fairfax, US, ⁷Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ⁸Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ⁹South Texas Accelerated Research Therapeutics (START), San Antonio, US, ¹⁰Dana Farber Cancer Institute, Boston, US, ¹¹Lombardi Cancer Center Georgetown University, Washington, US, ¹²Bolt Biotherapeutics, Inc., Redwood City, US, ¹³The University of Texas M. D. Anderson Cancer Center, Houston, US

16:40 - 16:45

LBA34 - Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: primary analysis from the DESTINY-PanTumor02 (DP-02) study

F. Meric-Bernstam¹, V. Makker², A. Oaknin³, D.-Y. Oh⁴, S. Banerjee⁵, A. Gonzalez Martin⁶, K. Jung⁷, I. Lugowska⁸, L. Manso⁹, A. Manzano¹⁰, B. Melichar¹¹, S. Siena¹², D. Stroyakovskiy¹³, A. Fielding¹⁴, Y. Ma¹⁵, S. Puvvada¹⁴, J.-Y. Lee¹⁶, ¹University of Texas MD Anderson Cancer Center, Houston, US, ²Memorial Sloan-Kettering Cancer Center, New York City, US, ³Vall d'Hebron Institute of Oncology, Hospital Universitari Vall d'Hebron, Barcelona, ES, ⁴Seoul National University Hospital, Seoul, KR, ⁵The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, GB, ⁶Cancer Center Clínica Universidad de Navarra, Madrid, ES, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁸Maria Skłodowska-Curie National Research Institute and Oncology Centre, Warsaw, PL, ⁹Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁰Hospital Clinico San Carlos, Madrid, ES, ¹¹University Hospital, Palacký University Medical School, Olomouc, CZ, ¹²Università degli Studi di Milano, Piazza Ospedale Maggiore, Milan, IT, ¹³Moscow City Oncology Hospital No. 62, Moscow, RU, ¹⁴AstraZeneca, Gaithersburg, MD, US, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶Yonsei University College of Medicine, Seoul, KR



- 16:45 - 16:50 **658MO - Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors**
 Q. Zhou¹, Y.-L. Wu¹, J. Li², A. Liu², J. Cui³, Y. Kuboki⁴, N. Yamamoto⁵, S.-W. Han⁶, G. Lin⁷, J.-M. Sun⁸, L. Wu⁹, Z. Zhu¹⁰, J. Shuang¹⁰, F. Qiu¹⁰, W. Shi¹⁰, ¹Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, CN, ²The Second Affiliated Hospital of Nanchang University, Nanchang, CN, ³The First Hospital of Jilin University, Changchun, CN, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵National Cancer Center Hospital-Tsukiji Campus, Chuo-ku, JP, ⁶Seoul National University Hospital, Seoul, KR, ⁷Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ⁸Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, ⁹Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ¹⁰Jiangsu Hengrui Pharmaceuticals, Co., Ltd, Shanghai, CN
- 16:50 - 17:05 **Invited Discussant 656MO, 657MO, LBA34 and 658MO**
P. Munster, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
- 17:05 - 17:10 **659MO - Preliminary results from a phase I/II study of 9MW2821, an antibody-drug conjugate targeting nectin-4, in patients with advanced solid tumors**
J. Zhang¹, R. Liu¹, S. Gao¹, X. Li², J. Chen³, X. Yao⁴, Y. Fang⁵, R. Li⁶, M. Zhang⁷, F. Qiu⁸, Y. Li⁹, T. Liu¹⁰, H. Huang¹¹, X. Zhang¹², H. Guo¹³, B. Hu¹⁴, J.-Y. Liu¹⁵, Q. Yang¹⁶, P. Zhao¹⁷, P. Wang¹⁸, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ³Yantai Yuhunagding Hospital, Yantai, CN, ⁴Tianjin Cancer Hospital, Tianjin, CN, ⁵Affiliated Cancer Hospital of Chongqing University, Chongqing, CN, ⁶Chongqing University Cancer Hospital, Chongqing, CN, ⁷The Second Hospital of Anhui Medical University, Hefei, CN, ⁸The Second Affiliated Hospital of Zhejiang University School of Medicine - East Gate 1, Hangzhou, CN, ⁹Shenyang Tenth People's Hospital, Shenyang, CN, ¹⁰Zhongshan Hospital Affiliated to Fudan University, Shanghai, CN, ¹¹The First Affiliated Hospital of Wenzhou Medical University - Nanbaixiang Site, Wenzhou, CN, ¹²Wuhan Union Hospital, Wuhan, CN, ¹³The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, CN, ¹⁴Liaoning Cancer Hospital and Institute, Shenyang, CN, ¹⁵West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN, ¹⁶The Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, CN, ¹⁷The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, CN, ¹⁸Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, CN
- 17:10 - 17:15 **660MO - First-in-human study of SGN-B7H4V, a B7-H4-directed vedotin ADC, in patients with advanced solid tumors: Preliminary results of a phase I study (SGNB7H4V-001)**
C. Perez¹, J. Henry², N. Lakhani³, J. Call⁴, E. Hamilton⁵, G. Colon-Otero⁶, J. Diamond⁷, B. O'Neil⁸, A. Kalyan⁹, G. Sonpavde¹⁰, I. Moreno¹¹, A. Awan¹², E. Fontana¹³, P. Xu¹⁴, F. Zhang¹⁴, N. Nazarenko¹⁴, A. Patnaik¹⁵, ¹University of Central Florida Lake Nona Cancer Center, Orlando, US, ²Sarah Cannon Research Institute at HealthONE, Denver, US, ³START Midwest, Grand Rapids, US, ⁴START Mountain Region, West Valley City, US, ⁵Tennessee Oncology, Nashville, US, ⁶Mayo Clinic, Jacksonville, US, ⁷University of Colorado, Aurora, US, ⁸Community Health Network, Indianapolis, US, ⁹Northwestern University, Chicago, US, ¹⁰AdventHealth Cancer Institute, Celebration, US, ¹¹Centro



Integral Oncológico Clara Campal, Madrid, ES, ¹²Ottawa Hospital Research Institute, Ottawa, CA, ¹³Sarah Cannon Research Institute SCRI UK, London, GB, ¹⁴Seagen Inc., Bothell, US, ¹⁵START San Antonio, San Antonio, US

17:15 - 17:30 **Invited Discussant 659MO and 660MO**

U. Lassen, Rigshospitalet, Copenhagen, DK

17:30 - 17:35 **LBA35 - BNT211-01: Interim results from a repeat dose escalation study of CLDN6 CAR-T cells manufactured with an automated process ± a CLDN6-encoding CAR-T cell-Amplifying RNA Vaccine (CARVac)**

J. Haanen¹, W. Alsdorf², C. Koenecke³, E. Wagner-Drouet⁴, P. Borchmann⁵, D. Heudobler⁶, A. Busse⁷, S. Klobuch¹, N. Kutsch⁸, F. Müller⁹, C. Bokemeyer¹⁰, A. Desuki¹¹, F. Lueke⁶, T. Ho¹², K. Vemuri¹², L. Preussner¹³, B. Rengstl¹³, Ö. Türeci¹³, U. Sahin¹³, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²University Medical Center Hamburg-Eppendorf, Hamburg, DE, ³MHH - Medizinische Hochschule Hannover, Hannover, DE, ⁴University Medical Center Mainz, Mainz, DE, ⁵University Hospital Cologne, Köln, DE, ⁶UKR - University Hospital Regensburg, Regensburg, DE, ⁷Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE, ⁸University Hospital of Cologne, Cologne, DE, ⁹Universitätsklinikums Erlangen, Erlangen, DE, ¹⁰UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ¹¹Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, ¹²BioNTech US, Cambridge, US, ¹³BioNTech SE, Mainz, DE

17:35 - 17:40 **661MO - Anti-tumor activity of belvarafenib in combination with cobimetinib in patients with metastatic solid tumors harboring BRAF fusions or BRAF class II/III mutation**

T.W. Kim¹, J. Lee², S.J. Shin³, S.-W. Han⁴, Y.J. Kim⁵, J.-S. Kim⁶, S.Y. Oh⁷, D.H. Lee¹, M.H. Kim³, S. Kim², Y. Hong⁸, S. Kim⁸, T. Kim⁸, B. Lee⁸, J. Eng-Wong⁹, Y. Yan⁹, C. Chou⁹, Y.S. Noh⁸, ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³Yonsei University College of Medicine, Seoul, KR, ⁴Seoul National University Hospital, Seoul, KR, ⁵Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, ⁶Boramae Medical Center, Seoul, KR, ⁷Dong-A University College of Medicine, Busan, KR, ⁸Hanmi Pharmaceutical Co., Ltd, Seoul, KR, ⁹Genentech, Inc., South San Francisco, US

17:40 - 17:45 **662MO - Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors**

C.-C. Lin¹, J. Grewal², J. Baranda³, R. Schneider⁴, J. Zhang⁵, L.-Y. Bai⁶, Y.-M. Yeh⁷, D. Sommerhalder⁸, G. Li⁹, L. Shen¹⁰, H.-C. Hsu¹¹, O. Alese¹², R. Yin¹³, C.-Y. Hsieh¹⁴, S.X. Cai¹⁴, Y.E. Tian¹⁴, H. Xia¹⁵, B. Li¹⁴, M. Zhang¹⁴, C. Zhang¹⁴, ¹NTUH - National Taiwan University Hospital, Taipei City, TW, ²Norton Cancer Institute, Louisville, US, ³University of Kansas Clinical Research Center, Kansas City, US, ⁴Mary Crowley Cancer Research Center, Dallas, US, ⁵Fudan University Shanghai Cancer Center, Shanghai, CN, ⁶China Medical University Hospital, New Taipei City, TW, ⁷NCKUH - National Cheng Kung University Hospital, Tainan City, TW, ⁸NEXT Oncology, San Antonio, US, ⁹Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ¹⁰Beijing Cancer Hospital, Beijing, CN, ¹¹Chang Gung Medical Foundation - Linkou



Chang Gung Memorial Hospital, Taoyuan City, TW, ¹²Emory University Hospital, Atlanta, US, ¹³West China Second University Hospital, Sichuan University/ West China Women's and Children's Hospital, Chengdu, CN, ¹⁴IMPACT Therapeutics, Inc. (Shanghai), Shanghai, CN, ¹⁵Impact Therapeutics, Shanghai, CN

17:45 - 18:00 **Invited Discussant LBA35, 661MO and 662MO**

P. Cassier, Centre Léon Bérard, Lyon, FR

16:30 - 18:00 **Type: Educational session** **Málaga Auditorium - Hall 10**
Title: Advances in the management of locally advanced NPC

Chair(s): Brigette Ma, HK; Lisa Licitra, IT

16:30 - 16:50 **Recent advances in the clinical application of plasma EBV DNA in individualizing treatment of LA-NPC**

M.L.K. Chua, NCCS - National Cancer Centre Singapore, Singapore, SG

16:50 - 17:10 **Navigating the undulating landscape of radiotherapy escalation/ de-escalation in the treatment of LA-NPC**

Q.-T. Le, Stanford University, Stanford, US

17:10 - 17:30 **Induction versus adjuvant chemotherapy in LA-NPC: Deciphering the latest evidence for the practicing oncologist**

P. Blanchard, Institut Gustave Roussy, Villejuif, Cedex, FR

17:30 - 17:50 **How to transfer results from endemic to non-endemic settings**

L. Licitra, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT

17:50 - 18:00 **Q&A and Discussion**



18:30 - 20:00	Type: Industry Satellite Symposium Title: GSK - The Need for Better Patient Outcomes: Latest Investigational Approaches for dMMR/MSI-H CRC Chair(s): Jenny Seligmann, GB	Burgos Auditorium - Hall 3
18:30 - 18:45	The Need for New Approaches in Locally Advanced dMMR/MSI-H CRC <u>J. Seligmann</u> , The University of Leeds, Leeds, GB	
18:45 - 19:05	Locally Advanced dMMR/MSI-H Rectal Cancer: New Approaches Under Investigation <u>A. Parikh</u> , MGH - Massachusetts General Hospital, Boston, US	
19:05 - 19:25	Locally Advanced dMMR/MSI-H Colon Cancer: New Approaches Under Investigation <u>V. Heinemann</u> , LMU Klinikum der Universität München, Munich, DE	
19:25 - 19:45	The Multidisciplinary Approach to Locally Advanced dMMR/MSI-H CRC: Reducing the Patient Burden <u>J. Seligmann</u> , The University of Leeds, Leeds, GB	
19:45 - 20:00	Q&A Panel Discussion <u>J. Seligmann</u> ¹ , <u>V. Heinemann</u> ² , <u>A. Parikh</u> ³ , ¹ The University of Leeds, Leeds, GB, ² LMU Klinikum der Universität München, Munich, DE, ³ MGH - Massachusetts General Hospital, Boston, US	



18:30 - 20:00 **Type: Industry Satellite Symposium** **Valencia**
Title: Stemline. A Menarini Group Company - Current and upcoming **Auditorium**
treatment strategies after CDK4/6 inhibitors for patients with **- Hall 10**
ER+/HER2- advanced breast cancer
Chair(s): Antonio Llombart Cussac, ES

18:30 - 18:40 **Welcome and introductions**
A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES

18:40 - 19:10 **The current and future treatment landscape for ER+/HER2- metastatic breast cancer**
V. Kaklamani, Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center, San Antonio, US

19:10 - 19:30 **Emerging biomarkers in breast cancer: Implementing liquid biopsy ESR1 mutation testing**
V. Mueller, UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE

19:30 - 19:40 **Key takeaways**
A. Llombart Cussac, Hospital Arnau de Vilanova, Valencia, ES

19:40 - 20:00 **Q&A**
A. Llombart Cussac¹, V. Kaklamani², V. Mueller³, ¹Hospital Arnau de Vilanova, Valencia, ES, ²Mays Cancer Center - UT Health San Antonio MD Anderson Cancer Center, San Antonio, US, ³UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE



18:30 - 20:00	Type: Industry Satellite Symposium Title: F. Hoffmann-La Roche LTD - Shaping the future of personalised healthcare for cancer patients Chair(s): Vivek Subbiah, US	Salamanca Auditorium - Hall 3
18:30 - 18:35	Understanding the patient's perspective <u>T. Knott</u> , Sarah Jennifer Knott Foundation, DUBLIN, IE	
18:35 - 18:45	CUPISCO as an innovative example in precision oncology <u>L. Mileshkin</u> , Peter MacCallum Cancer Center, Melbourne, AU	
18:45 - 18:55	Changing the trajectory for cancer patients with liquid biopsy <u>B. Westphalen</u> , LMU Klinikum der Universität München, Munich, DE	
18:55 - 19:10	Panel discussion: including Q&A: Considerations for future clinical decision making <u>T. Knott</u> ¹ , <u>V. Subbiah</u> ² , <u>B. Westphalen</u> ³ , <u>L. Mileshkin</u> ⁴ , <u>A. Krämer</u> ⁵ , ¹ Sarah Jennifer Knott Foundation, DUBLIN, IE, ² The University of Texas M. D. Anderson Cancer Center, Houston, US, ³ LMU Klinikum der Universität München, Munich, DE, ⁴ Peter MacCallum Cancer Center, Melbourne, AU, ⁵ German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, DE	
19:10 - 19:20	Translating scientific evidence into drug approvals <u>V. Subbiah</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
19:20 - 19:30	Shaping public healthcare systems to accelerate treatment access <u>D. Thomas</u> , Garvan Institute of Medical Research, Darlinghurst, AU	
19:30 - 19:55	Panel discussion including Q&A: Considerations for our future healthcare systems <u>V. Subbiah</u> ¹ , <u>D. Thomas</u> ² , <u>V. Muthu</u> ³ , ¹ The University of Texas M. D. Anderson Cancer Center, Houston, US, ² Garvan Institute of Medical Research, Darlinghurst, AU, ³ Marivek LTD, Epsom, GB	
19:55 - 20:00	Call to action <u>V. Subbiah</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	



18:30 - 20:00 **Type: Industry Satellite Symposium** **Málaga Auditorium - Hall 10**
Title: AbbVie Inc. - The Future of ADCs in NSCLC
Chair(s): Federico Cappuzzo, IT

18:30 - 18:35 **Welcome and Introduction**

F. Cappuzzo, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

18:35 - 19:00 **An introduction to ADCs in the treatment of NSCLC**

B. Besse, Institut Gustave Roussy, Villejuif, FR

19:00 - 19:25 **The emerging role for ADCs in the NSCLC treatment landscape**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

19:25 - 19:55 **Panel discussion and Q&A**

F. Cappuzzo¹, B. Besse², E. Felip³, ¹IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ²Institut Gustave Roussy, Villejuif, FR, ³Vall d'Hebron University Hospital, Barcelona, ES

19:55 - 20:00 **Closing**

E. Felip, Vall d'Hebron University Hospital, Barcelona, ES



18:30 - 20:00 **Type: Industry Satellite Symposium** **Santander Auditorium - Hall 9**
Title: F. Hoffmann-La Roche LTD - HER future: Pathways to better care for women with HER2+ breast cancer
 Chair(s): Matteo Lambertini, IT

18:30 - 18:33 **Welcome and introduction**
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

18:33 - 18:53 **Delivering women-centric cancer care for optimal outcomes**
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

18:53 - 19:13 **Changing the SScript: Rewriting the patient experience with subcutaneous formulations of HER2-targeted antibodies**
J. O'Shaughnessy, Texas Oncology - Baylor Sammons Cancer Center, Dallas, US

19:13 - 19:33 **Decentralised cancer care: Providing healthcare closer to home**
S.C. Lee, Cancer Science Institute (CSI) - National University of Singapore (NUS), Singapore, SG

19:33 - 20:00 **Live Q&A, discussion and closing remarks**
M. Lambertini, IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT

18:30 - 20:00 **Type: Industry Satellite Symposium** **Toledo Auditorium - Hall 3**
Title: Pfizer Oncology - ALK+ NSCLC: Maximising the potential for patients throughout their treatment journey
 Chair(s): Geoffrey Liu, CA

18:30 - 18:35 **Welcome and introduction**
G. Liu, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

18:35 - 19:55 **Follow a fictional patient on their ALK+ NSCLC treatment journey: Diagnosis, Treatment selection, 1L treatment, Experiencing adverse events, Beyond progression**
G. Liu¹, M.R. Garcia Campelo², M. Dietrich³, ¹UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ³Florida Cancer Specialists & Research Institute - Lake Mary Cancer Center, Lake Mary, US

19:55 - 20:00 **Meeting close**
G. Liu, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA



18:30 - 20:00	Type: Industry Satellite Symposium Title: MSD - Immune Checkpoint Inhibitors & beyond: Evolving treatment landscape of Kidney Cancer	Oviedo Auditorium - Hall 7
Chair(s): Toni Choueiri, US		
18:30 - 18:35	Welcome <u>T. Choueiri</u> , Dana Farber Cancer Institute, Boston, US	
18:35 - 18:55	Management of post-nephrectomy RCC patients: Adjuvant treatment options and Patient case discussion <u>J. Bedke</u> ¹ , <u>T. Choueiri</u> ² , ¹ Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, ² Dana Farber Cancer Institute, Boston, US	
18:55 - 19:00	Q&A <u>J. Bedke</u> ¹ , <u>T. Choueiri</u> ² , ¹ Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, ² Dana Farber Cancer Institute, Boston, US	
19:00 - 19:20	First line advanced RCC treatment landscape: current standard of care, treatment decision making for both clear-cell and non-clear cell RCC treatment options and Patient Case discussion <u>L. Albiges</u> ¹ , <u>T. Choueiri</u> ² , ¹ Institut Gustave Roussy, Villejuif, Cedex, FR, ² Dana Farber Cancer Institute, Boston, US	
19:20 - 19:35	2L+ treatment options for advanced RCC patients post IO and/or TKI: Current treatment options & Patient case discussion <u>C. Suarez Rodriguez</u> ¹ , <u>T. Choueiri</u> ² , ¹ Vall d'Hebron University Hospital, Barcelona, ES, ² Dana Farber Cancer Institute, Boston, US	
19:35 - 20:00	Expert Panel & Q&A <u>T. Choueiri</u> ¹ , <u>J. Bedke</u> ² , <u>L. Albiges</u> ³ , <u>C. Suarez Rodriguez</u> ⁴ , ¹ Dana Farber Cancer Institute, Boston, US, ² Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, DE, ³ Institut Gustave Roussy, Villejuif, Cedex, FR, ⁴ Vall d'Hebron University Hospital, Barcelona, ES	



18:30 - 20:00	Type: Industry Satellite Symposium Title: Daiichi Sankyo AstraZeneca - From Bench to Bedside: Interdisciplinary Management of HER2-Low Breast Cancer in the Clinic Chair(s): Eva Ciruelos, ES	León Auditorium - Hall 7
18:30 - 18:35	Welcome & Introduction <u>E. Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
18:35 - 18:55	Inside the HER2 Expression Spectrum <u>P. Sinn</u> , University Hospital Heidelberg, Heidelberg, DE	
18:55 - 19:15	Treatment of HR+ Metastatic Breast Cancer: Considerations <u>V. Guarneri</u> , University of Padua, Padova, IT	
19:15 - 19:35	Optimising Patient Management in the Real-World <u>E. Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
19:35 - 19:55	Panel Discussion and Q&A <u>E. Ciruelos</u> ¹ , <u>V. Guarneri</u> ² , <u>P. Sinn</u> ³ , ¹ Hospital Universitario 12 de Octubre, Madrid, ES, ² University of Padua, Padova, IT, ³ University Hospital Heidelberg, Heidelberg, DE	
19:55 - 20:00	Wrap-up and Meeting Close <u>E. Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	



09:00 - 12:40 **Type: Scientific Congress highlights** **Sevilla Auditorium - Hall 9**
Title: Scientific Congress Highlights 2
 Chair(s): Andres Cervantes, ES; Solange Peters, CH

09:00 - 09:20 **Melanoma and other skin tumours**

I. Marquez-Rodas, Hospital General Universitario Gregorio Marañón - Fundación Investigación Biomedica, Madrid, ES

09:20 - 09:40 **Sarcoma**

C.M. Valverde Morales, Vall d'Hebron University Hospital, Barcelona, ES

09:40 - 10:00 **Head and neck cancer**

P. Bossi, IRCCS Humanitas Research Hospital, Rozzano, IT

10:00 - 10:20 **Supportive and palliative care**

C. Ruhlmann, OUH - Odense University Hospital, Odense, DK

10:20 - 10:40 **Haematological malignancies**

D. Rossi, EOC - Amministrazione IOSI, Bellinzona, CH

10:40 - 11:00 **Break**

11:00 - 11:20 **GI, lower digestive**

S.P. Choo, NCCS - National Cancer Centre Singapore, Singapore, SG

11:20 - 11:30 **GI, upper digestive: HPB**

A. Ko, UCSF - University of California San Francisco - Parnassus Campus, San Francisco, US

11:30 - 11:40 **GI, upper digestive: Gastroesophageal**

T. Fleitas, Hospital Clinico Universitario de Valencia, Valencia, ES

11:40 - 12:00 **NETs and endocrine tumours**

C. De La Fouchardiere, IPC - Institut Paoli-Calmettes, Marseille, Cedex 09, FR

12:00 - 12:20 **Non-metastatic NSCLC and other thoracic malignancies**

J. Naidoo, Beaumont Hospital, Dublin, IE

12:20 - 12:40 **NSCLC, metastatic**

G. Pasello, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT